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Background: There is good evidence that therapist-delivered interventions have modest beneficial effects
for people with low back pain (LBP). Identification of subgroups of people with LBP who may benefit from
these different treatment approaches is an important research priority.
Aim and objectives: To improve the clinical effectiveness and cost-effectiveness of LBP treatment by
providing patients, their clinical advisors and health-service purchasers with better information about which
participants are most likely to benefit from which treatment choices. Our objectives were to synthesise
what is already known about the validity, reliability and predictive value of possible treatment moderators
(patient factors that predict response to treatment) for therapist-delivered interventions; develop a
repository of individual participant data from randomised controlled trials (RCTs) testing therapist-delivered
interventions for LBP; determine which participant characteristics, if any, predict clinical response to
different treatments for LBP; and determine which participant characteristics, if any, predict the most
cost-effective treatments for LBP. Achieving these objectives required substantial methodological work,
including the development and evaluation of some novel statistical approaches. This programme of work
was not designed to analyse the main effect of interventions and no such interpretations should be made.
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Methods: First, we reviewed the literature on treatment moderators and subgroups. We initially invited
investigators of trials of therapist-delivered interventions for LBP with > 179 participants to share their data
with us; some further smaller trials that were offered to us were also included. Using these trials we
developed a repository of individual participant data of therapist-delivered interventions for LBP. Using this
data set we sought to identify which participant characteristics, if any, predict response to different
treatments (moderators) for clinical effectiveness and cost-effectiveness outcomes. We undertook an
analysis of covariance to identify potential moderators to apply in our main analyses. Subsequently, we
developed and applied three methods of subgroup identification: recursive partitioning (interaction trees
and subgroup identification based on a differential effect search); adaptive risk group refinement; and an
individual participant data indirect network meta-analysis (NWMA) to identify subgroups defined by
multiple parameters.
Results: We included data from 19 RCTs with 9328 participants (mean age 49 years, 57% females).
Our prespecified analyses using recursive partitioning and adaptive risk group refinement performed well
and allowed us to identify some subgroups. The differences in the effect size in the different subgroups
were typically small and unlikely to be clinically meaningful. Increasing baseline severity on the outcome of
interest was the strongest driver of subgroup identification that we identified. Additionally, we explored
the application of Bayesian indirect NWMA. This method produced varying probabilities that a particular
treatment choice would be most likely to be effective for a specific patient profile.
Conclusions: These data lack clinical effectiveness or cost-effectiveness justification for the use of baseline
characteristics in the development of subgroups for back pain. The methodological developments from
this work have the potential to be applied in other clinical areas. The pooled repository database will serve
as a valuable resource to the LBP research community.
Funding: The National Institute for Health Research Programme Grants for Applied Research programme.
This project benefited from facilities funded through Birmingham Science City Translational Medicine
Clinical Research and Infrastructure Trials Platform, with support from Advantage West Midlands (AWM)
and the Wolfson Foundation.
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Glossary
Adaptive refinement A method to identify subgroups of participants, defined by cut-offs for the
selected covariates, resulting in box-shaped subgroups.
Crosswalking A method of mapping multiple participant-reported outcome measures that measure the
same domain, to a common scale.
Moderators Factors measured prior to randomisation that subsequently influence the effect of
the treatment.
Recursive partitioning A technique that searches all possible binary splits of covariates to identify
subgroups of participants.
Standardised mean difference The score divided by the standard deviation of the baseline score of
all participants.
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Plain English summary
Low back pain is a common and costly disorder for both the patient and the health service, which canbe managed using different treatment approaches, some of which are delivered in a physiotherapy
department. The benefits of treatments delivered by therapists are small, on average, that is, they get small
improvements. If we could predict which patients would be most likely to benefit from different treatments
it would be possible to improve the overall effectiveness of treatments and potentially make better use of
NHS resources. To address this we pooled together data from 19 back pain trials from around the world.
This provided us with a data set of 9328 patients. We developed novel statistical methods to identify
subpopulations (groups of people with similar characteristics) that would be likely to benefit from certain
treatments. Of the three methods developed, two allowed us to identify subpopulations. The additional
benefits for individuals in the subpopulations were modest and unlikely to be of clinical importance.
Our third method was exploratory and allowed us to identify the chance of a particular treatment choice
being effective for a particular patient.
Overall, we did not find any subpopulations that would benefit from treatment. Neither did we find that
such an approach to identifying patients would be cost-effective. We have developed new ways of
identifying subpopulations and would recommend the application of these methods to other clinical
conditions. We have also developed, from prior trials, a data pool that will now become a resource for
back pain researchers to help them answer other questions in the field.
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Scientific summary
Background
Identifying subgroups of people living with low back pain (LBP) who may do better, or worse, with
different treatment choices is a high research priority internationally. Many randomised controlled trials
(RCTs) could be designed to address individual components of this problem. High-quality trials in this area
are very costly and time-consuming (typically requiring a minimum of 700 participants, at a cost of £1M to
£2M, and taking at least 6 years from design to implementation); each will address only one small part of
this complex problem.
Alternative methods can provide complementary information that could add value to our knowledge.
Approaches, that make the best possible use of existing data might produce timely answers to a range of
important research questions and provide substantial added value to the money that is already invested in
this area.
We present a programme of work – using systematic reviews, methodological development, and
secondary analyses of existing data sets – to identify strategies to improve outcomes for people who are
seeking treatment for back pain by improving how patients, clinicians and purchasers choose treatments.
Our programme of work ensures that the maximum information is gleaned from existing substantial trial
data sets. The analysis plan for these data and the modelling of clinical effectiveness and cost-effectiveness
are informed by our literature reviews.
Aims and objectives
The overall aim of this programme grant was to improve the clinical effectiveness and cost-effectiveness of
therapist-delivered treatments for LBP by providing patients, their clinical advisors and health service
purchasers with better information about which patients are most likely to benefit from which treatment
choices. Our objectives were to:
1. synthesise what is already known about the validity, reliability and predictive value of possible treatment
moderators (patient factors that predict response to treatment)
2. develop a repository of individual participant data from RCTs testing therapist-delivered interventions
for LBP
3. determine which participant characteristics, if any, predict clinical response to different treatments
for LBP
4. determine which participant characteristics, if any, predict the most cost-effective treatments for LBP.
Seeking to achieve these objectives required substantial methodological work, including the development
and evaluation of some novel statistical approaches. This programme of work was not designed to analyse
the main effect of interventions and no such interpretations should be made.
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Method and results
To synthesise what is already known about the validity, reliability and
predictive value of possible treatment moderators
We carried out two systematic reviews: one to identify potential moderators of treatment effect from
studies of therapist-delivered interventions to inform our analyses, and, the second, to review the quality of
subgroup analyses in LBP trials.
As the purpose of moderator identification was for future application in our analyses, we identified potential
moderators with strong evidence (p< 0.05) and potential moderators with weaker evidence in one or more
studies (0.05< p≤ 0.20). Data from four trials were included in the review. Potential moderators with strong
evidence included age, employment status and type, back pain status, narcotic medication use, treatment
expectations and education. Potential moderators with weaker evidence included gender, psychological
distress, pain/disability and quality of life. Although the overall data were weak and lacking in rigour to
inform clinical practice, they provided a starting point for application in our analyses.
The second review looked at the quality and reporting of subgroup analyses in LBP. Thirty-nine papers
were included in the final review. The majority of papers provided only exploratory or insufficient findings.
Only three trials provided confirmatory findings (i.e. subgroup analyses were hypothesis driven and
grounded in existing theory or empirical data). The overall quality of reporting was poor and, generally, the
subgroup analyses have been severely underpowered. We concluded the need to develop new approaches
to subgroup identification to identify multiple participant characteristics or clusters of moderators that
would identify who is most or least likely to benefit.
To develop a repository of individual participant data from randomised
controlled trials testing therapist-delivered interventions for low back pain
To allow the identification of subgroups in appropriately powered data sets, we developed a repository of data
from completed trials. We used a systematic approach in identifying trials and approached chief investigators
for their data. Our pool of potential trials came from the search results that were generated in our review of
moderators. As a starting point, we were interested only in RCTs of therapist-delivered interventions with a
sample size of > 179. We were offered data from three smaller trials, which we also included.
The final repository comprises 19 trials, with 9328 participants. No two trials had identical interventions or
controls. Despite the large initial sample, we had to broadly pool interventions into groups for our analyses
in order to draw any meaningful comparisons. As a first step, we identified the control interventions and
classified these as either usual care or as a sham control; furthermore, we have specified the type of sham,
as there may be qualitative differences between sham treatments. To cluster the interventions we first
classified them into core groups (individual physiotherapy, exercise, manipulation, advice/education,
psychological therapy, graded activity, acupuncture, combination therapy, mock transcutaneous electrical
nerve stimulation, sham acupuncture and control). We later looked at the data to explore the scope for
direct and indirect comparisons, and the data available for these comparisons. This indicated that, without
grouping these interventions, it would be difficult to make any meaningful comparisons; therefore, the
collaborative team decided on broader categories: active physical (exercise and graded activity), passive
physical (individual physiotherapy, manipulation and acupuncture) and psychological (advice/education and
psychological therapy). In this programme of work we are not seeking to estimate the true effect size of
any individual intervention. Rather, we are seeking to identify predictors of treatment response making it
reasonable to pool in this manner.
In addition to the challenges of pooling multiple data sets using multiple interventions, there was careful
consideration of how to most accurately map multiple participant-reported outcome measures that
measure the same domain, to a common scale. We concluded that, because of the lack of correlation and
responsiveness in outcomes from two measures in the same individual, it would not be appropriate to map
any physical disability outcome measures to another.
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To determine which participant characteristics, if any, predict clinical
response to different treatments for low back pain
We undertook analysis of covariance analyses comparing all of the intervention groups with all controls to
identify potential moderators to take forward for our main analyses. We were able to take forward the
Hannover Functional Ability score, the Roland–Morris Disability questionnaire (RMDQ), the Short Form
questionnaire-12 items (SF-12)/ Short Form questionnaire-36 items (SF-36) physical and mental component
scores, age, gender, pain, fear avoidance and coping as variables, with a possible signal in one or
more analysis.
In this programme grant we have explored, in considerable detail, new and novel methods for subgroup
identification. We have presented three core methods in this report: recursive partitioning (interaction trees
and subgroup identification based on a differential effect search), adaptive risk group refinement and
individual participant data indirect network meta-analysis (NWMA).
Our prespecified analytical approaches – recursive partitioning and adaptive risk group refinement –
produced identifiable subgroups, the parameter definitions of which were grounded in the data. The
differences in effect sizes, between groups, however, were small, and unlikely to be clinically meaningful.
The effect sizes in the groups who did less well would still justify the use of these interventions. The overall
results point to larger treatment responses in those with higher levels of the outcome of interest at
baseline. The results also suggest that those with greater psychological distress, as measured by the
SF-12/36 mental component score, do not have a greater treatment effect on physical outcomes from any
of the therapist-delivered interventions tested. Targeting low-intensity interventions at those with higher
levels of psychological distress for treatment might not be justified.
We undertook a post hoc exploratory individual participant data indirect NWMA to identify subgroups.
This does not identify subgroups in the traditional manner but rather uses the available data to work out
the probability that a particular treatment choice is most likely to be effective. The outputs from this
method have the potential to inform clinical decision-making but requires further testing and application.
To determine which participant characteristics, if any, predict the most
cost-effective treatments for low back pain
We applied the directed peeling algorithm to the economic and resource-use data. When exploring
interventions compared with control, subgroups were identified. These subgroups comprised patients who
were older, with relatively worse physical functioning at baseline. The gain in treatment effect for the
subgroup was small, therefore, given the relatively low cost of the intervention treatment it is likely to be
cost-effective for the whole patient group. No convincing subgroups were found for active and passive
physical treatment. This may be as a result of lack of power or simply that there is no subgroup to
be found.
Age, SF-12/36 physical component score and RMDQ score were the three potential moderators identified
from the economic analysis. However, the relationship of the quality-adjusted life-years (QALYs) with the
moderators differed in some cases to that of the clinical outcome measures. Subgroups were identified
only in the comparison of treatment with control. Our interpretation is that those who are older, with
worse RMDQ score and SF12/36 physical component score are likely to gain a greater benefit on QALY
outcomes from treatment. Doing this, however, will not improve overall QALY gain and is very unlikely to
be seen as a cost-effective choice if the National Institute for Health and Care Excellence threshold of
£20,000–30,000 per QALY is used to inform treatment choices.
DOI: 10.3310/pgfar04100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Patel et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxxi
Conclusions and recommendations
In this programme of work we have developed advances in methodological developments for subgroup
analyses. We have developed different approaches to the identification of differential subgroup effects that
provide considerable added value compared with conventional analyses that simply test for interactions
between single baseline parameters and treatment allocation. In addition, we have developed advanced
systems for pooling and storing large data sets, highlighted that it is not possible to map different
outcome measures for a meta-analysis, and, finally, we have developed an important resource for back
pain researchers who wish to undertake further analyses on data from multiple trials.
Clinically, the application of the different frequentist methods (recursive partitioning and adaptive design)
has not allowed us to identify subgroups of patients who might benefit from different back pain
treatments. Some of the core outputs and recommendations from this work include:
l application of these methods for the identification of subgroups in other clinical areas
l reanalysis of existing meta-analyses of back pain treatments to separate out results from trials with
different outcome measures
l further development of methods and application to the data that we already have
l making the data set available to other researchers
l adding additional trial data sets to the repository
l developing and testing a web portal to help inform choice of treatments based on our NWMA.
Overall, our results do not provide sufficient clinical effectiveness or cost-effectiveness justification for the
use of baseline characteristics in the development of subgroups for LBP. We would, however, suggest
that such methods should be applied in other clinical areas where subgroups may be important.
The exploratory outputs from our Bayesian NWMA provide some scope for deciding on optimal therapies.
This, however, would need empirical testing before clinical recommendation.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research. This project benefited from facilities funded through Birmingham
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Chapter 1 Overview of the programme
In this chapter we have provided the background and rationale for our programme to improve the clinicaleffectiveness and cost-effectiveness of low back pain (LBP) treatment by identifying groups that may gain
maximum benefit from therapist-delivered treatments.
Background
Chronic non-specific LBP (CNSLBP) is a common problem affecting a large proportion of the population.1–4
In the UK, around 70–80% of adults will experience back pain at some point in their life.5 Some argue
that episodic LBP is a universal part of human experience.6,7 Half of the adult population in the UK (49%)
report LBP lasting at least 24 hours in a 1-year period.5 The 2010 Global Burden of Disease study8
identified LBP as the leading cause of years lived with disability internationally. LBP affects around one-third
of the world’s population.8
Most episodes of back pain are short lived, resolving without the need for any specific treatment. It is the
minority of episodes that develop into CNSLBP which create the greatest health need. The natural history
of LBP is untidy; around 70% of those affected will experience at least one recurrent episode within a
12-month period.9
The true prevalence of CNSLBP is difficult to estimate, as definitions and populations vary between studies
and countries. However, a review of prevalence studies, reported, between 1966 and 1998, a 12–33%
point prevalence; 22–65% 1-year prevalence and up to 84% lifetime prevalence.10
Since this review, further reviews on the prevalence, focusing on older people and adolescents, have been
published.3,11 A 2012 systematic review synthesised the global prevalence of LBP in studies published between
1980 and 2009. The greatest prevalence was in females aged 40–80 years. After adjusting for methodological
variations the point prevalence of back pain lasting for > 1 day was 11.9% [95% confidence interval (CI)
7.98% to 15.82%] and 1-month period prevalence was estimated at 23.2% (95% CI 17.52% to 28.88%).12
Defining low back pain
The International Association of the Study of Pain defines pain as ‘an unpleasant sensory and emotional
experience associated with actual or potential tissue damage, or described in terms of such damage’.13 The
British Pain Society defines acute pain as ‘short term lasting less than 12 weeks’ duration’, whereas chronic
pain is defined as ‘long-term pain of more than 12 weeks or after the time that healing would have been
thought to have occurred in pain after trauma or surgery’.14
Low back pain is diagnosed based on the presence of pain and discomfort in the lumbosacral area.15 Some
people also experience pain in the upper leg as a result of LBP. In the majority of cases it is difficult to
identify a single cause for back pain. A 2013 systematic review16 of studies of new presentations of LBP
found a combined prevalence of 1.5% for fracture and malignancy in primary care; in secondary and
tertiary care, prevalence was 6.5%. Once specific causes for LBP have been excluded [malignancy, fracture,
infection, inflammatory disorders (such as ankylosing spondylitis)] then a diagnosis of non-specific LBP
(NSLBP) is made. This recognises the difficulty in producing robust classification criteria to identify different
populations of people affected by chronic LBP.
There is no evidence for a reduction in the population burden of LBP over time. Between 1990 and 2010, in the
UK, the number of disability-adjusted life-years attributable to LBP increased by 3.7% from 2231 (95% CI 1555
to 3015) of 100,000 to 2313 (95% CI 1574 to 3113) of 100,000 of the age-standardised population.17
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Economic burden of low back pain
Low back pain is a costly condition to society, health care and the individual. It is the leading cause of
sickness absence and health-care use.18–21 In the UK, the direct health-care cost of back pain in 1998 was
£163M. However, the larger burden is that of the indirect costs related to lost production and informal
care, which were estimated to be at least £5018M.22 More up-to-date UK estimates are not available.
The current cost is likely to be substantially larger. It is difficult to make direct comparisons of the cost of
LBP internationally because of varying health and social care systems.23
Low back pain results in approximately 4% of the UK population taking time off work. This translates to
around 90 million working days lost and between 8 and 12 million general practitioner (GP) consultations
per year.22,24 In 2013 the Office for National Statistics reported 131 million lost working days due to
sickness absences in that year in the UK; 30.6 million of these (23%) were lost because of musculoskeletal
conditions including back and neck pain.25
Treatment options for low back pain
People experiencing LBP will often seek medical and drug therapies, as well as therapist-delivered
complementary therapies, such as acupuncture, chiropractic or osteopathy, to help relieve pain.26 Until
comparatively recently there were few robust trials of treatments for LBP, and no convincing evidence for
the effectiveness of any back-pain treatments. Guidance on the management of LBP was based largely on
expert opinion, custom and practice. Since the mid-1990s, there has been a substantial investment in
high-quality randomised controlled trials (RCTs) of different treatments for NSLBP. We now have good
evidence to show that several therapist-delivered treatment approaches are effective, and for some
of these there is also evidence that they are cost-effective.15,27 By ‘therapist-delivered interventions’ we
mean non-drug, non-surgical approaches to the treatment of LBP. Typically, these are delivered by
physiotherapists or health/clinical psychologists, but they may be delivered by doctors, health trainers,
statutorily regulated complementary practitioners (such as osteopaths or chiropractors), or independently
registered professionals providing treatments such as acupuncture or the Alexander technique. The types
of interventions offered include acupuncture, manual treatments, exercise regimens, cognitive behavioural
approaches or combinations of these.
A number of therapist-delivered interventions are superior to ‘treatment as usual’ (GP care) for participants
with chronic LBP. There are numerous treatment options for LBP and several guidelines recommending
treatment, including the National Institute for Health and Care Excellence (NICE), the European
Corporation in Science and Technology, and the American College of Physicians and American Pain Society
guidelines. Such guidance is typically framed as examining independent treatment modalities. Any
recommendation for a treatment modality is, inevitably, recommending a package of care including both
the non-specific effects of the therapist encounter and the specific effects of the treatment modality
in question.
In 2009, NICE guidance15 advised that all people with persistent LBP should be given advice and
encouraged to self-manage. As part of this advice, people are encouraged to remain physically active and
to engage in daily activity. Subsequently, those affected should be offered a course of acupuncture,
exercise or manual therapy.15 The decision on which treatment to select should be a collaborative decision,
taking into account the patient’s treatment preferences. If the selected treatment option is not effective
then the patient should be offered another option from the remaining recommended treatments. If the
patient is still troubled by back pain then he/she should be considered for an intense physical and
psychological intervention. NICE is currently revising its LBP guidelines.
OVERVIEW OF THE PROGRAMME
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Effectiveness and cost-effectiveness of treatments for low
back pain
Although the effectiveness of adding a range of therapist-delivered interventions to best usual care or to
no treatment has been well established, the typical mean effect sizes are, at best, modest. By way of
illustration, the minimally important (within-person) change in the Roland–Morris Disability Questionnaire
(RMDQ) score,28 the most commonly used outcome measure in back pain trials, has been established as
5 points.29,30 Typical between-group differences in high-quality RCTs are in the order of 1–2 points on the
RMDQ, although a few studies have found larger effect sizes (Table 1). These modest mean differences
probably translate into ‘numbers needed to treat’ in the order of 5–10.29,33 These are similar to the
numbers needed to treat that are found with antidepressant or antiepileptic drugs which are used to treat
chronic painful disorders.36
The cost per quality-adjusted life-year (QALY) for some of these treatments is well within cost-effectiveness
thresholds that are usually used by NICE. Despite this, evidence of access to such treatments within the
UK NHS remains patchy. The guideline-endorsed treatments of interdisciplinary rehabilitation, exercise,
acupuncture, spinal manipulation and cognitive–behavioural therapy for subacute or chronic LBP have
been shown to be cost-effective, but evidence for other endorsed treatments for NSLBP do not yield
conclusive or consistent evidence about their relative cost-effectiveness.37 The scarcity of economic
evaluations for some guideline-endorsed treatments means that well-conducted economic evaluations are
required to strengthen the evidence base of treatments for LBP.
Subgrouping
Identifying which participants are likely to gain the greatest benefit from different treatments for LBP is an
identified high research priority internationally and was one of the key recommendations for future
research in the 2009 NICE guidelines for the management of persistent LBP. Current research does not
provide any robust data on how to match back pain treatments to participants to maximise effects on
outcomes relevant to the participant and cost-effectiveness for the health service.
As different treatment options are argued to work in very different ways, it is a reasonable hypothesis that
matching people with LBP to those treatments that are more likely to be effective for their back pain will
be a more efficient use of health-care resources and will improve patient outcomes. One might expect that
TABLE 1 Between-group differences for the RMDQ outcome
Study Control Intervention
Mean difference in RMDQ score (95% CI); SMD
3 months 12 months
UK BEAM31 GP care Exercise 1.36 (0.63 to 2.10); 0.34 0.39 (–0.41 to 1.19); 0.10
Manipulation 1.57 (0.82 to 2.32); 0.39 1.01 (0.22 to 1.81); 0.25
Manipulation plus exercise 1.87 (1.15 to 2.60); 0.47 1.30 (0.54 to 2.07); 0.33
A-TEAM32 Usual care Massage 1.96 (0.74 to 3.18); 0.39 0.58 (0.77 to 1.94); 0.12
Alexander technique (six sessions) 1.71 (0.47 to 2.95); 0.34 1.40 (0.03 to 2.77); 0.28
Alexander technique (12 sessions) 2.91 (1.66 to 4.16); 0.58 3.40 (2.03 to 4.76); 0.68
BeST33,34 Advice only Cognitive–behavioural therapy 1.10 (0.38 to 1.71); 0.22 1.30 (0.56 to 2.06); 0.27
York Yoga35 Usual care Yoga 2.17 (1.03 to 3.31); 0.50 1.57 (0.42 to 2.71); 0.36
A-TEAM, Alexander technique lessons, exercise, and massage; BeST, Back Skills Training Trial; SMD, standardised mean
difference; UK BEAM, UK Back pain Exercise And Manipulation.
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3
people with high levels of psychological distress that is related to their back pain may gain greater benefit
from a psychologically orientated intervention, such as cognitive–behavioural therapy; those with marked
loss of physical fitness to benefit most from an exercise intervention; or those with poor back function to
benefit most from manual therapy interventions. Developing an evidence base to inform the development
of such a stratified care approach has great potential to improve outcomes for people with LBP.
We are aware of one trial of a stratified care approach, published after this programme of work started.
The STarT Back trial38 successfully demonstrated that a combination of using a stratification tool and
enhanced physiotherapy packages for selected participants improves outcomes and reduces costs when
compared with usual physiotherapy care. This study38 does not, however, allow the performance of the
stratification tool to identify subgroups to be assessed.
There is a myriad of RCTs that could be designed to address individual components of this problem.
High-quality trials in this area are very costly and time-consuming, and can address only one small part of
this complex problem. Alternative approaches, which make the best possible use of existing data, can
produce timely answers to a range of important research questions and provide substantial added value to
the money that is already invested in this area.
We present a programme of work – using systematic reviews, methodological development and secondary
analyses of existing data sets – to identify strategies to improve outcomes for people seeking treatment for
back pain, by improving how participants, clinicians and purchasers choose treatments. Our programme
of work ensures that the maximum information is gleaned from existing substantial trial data sets.
The analysis plan for these data and modelling of clinical effectiveness and cost-effectiveness are informed
by our literature reviews.
Aim and objectives
The overall aim was to improve the clinical effectiveness and cost-effectiveness of LBP treatment by
providing participants, their clinical advisors and health service purchasers with better information about
which participants are most likely to benefit from which treatment choices. To achieve this, our objectives
were to:
1. synthesise what is already known about the validity, reliability and predictive value of possible
treatment moderators
2. develop a repository of individual participant data from RCTs testing therapist-delivered interventions
for LBP
3. determine which participant characteristics, if any, predict clinical response to different treatments
for LBP
4. determine which participant characteristics, if any, predict the most cost-effective treatments for LBP.
We have defined a therapist as a person trained in administering any of the available recommended
treatments, excluding drug interventions and surgical interventions, for the management of LBP.
Structure of this report
This report has been structured as shown in Figure 1. In this report we use some specific terminology that
needs additional definition to aid understanding. We have defined these in the Glossary at the start of this
report and in more detail at relevant points in the report.
OVERVIEW OF THE PROGRAMME
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• Literature reviews: provides a background to the literature reviews
   conducted as part of this programme grant (objective 1)
Chapter 2
• Creating the repository database and data control: details
   how the clinical and economic data were coded and how the database
   was programmed to enable pooling of trials (objective 2)
• Collating data: outlines how trial data were obtained and 
   managed for analyses (objective 2)
• Recursive partitioning: methodological development and results
   (objectives 3 and 4)
• Preliminary statistical analyses and results (objective 3)
• Crosswalking between disability questionnaire scores: explores the 
   mapping of outcome measures to inform the pooling of data
• Individual participant data indirect network meta-analysis:
   methodological development and results (objectives 3 and 4)
• Discussion and conclusion
• Identification of cost-effective subgroups by directed peeling: 
   methodological development and results (objective 4)
• Adaptive refinement by directed peeling: methodological 
   development and results (objectives 3 and 4)
Chapter 4
Chapter 3
Chapter 7
Chapter 6
Chapter 5
Chapter 10
Chapter 11
Chapter 9
Chapter 8
FIGURE 1 The structure of the current report.
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Chapter 2 Literature reviews
As part of this programme of work, we carried out two systematic reviews. In this chapter, we havepresented the details and results of each review, followed by an overall summary.
Systematic review 1: identification of potential moderators
This review has been published in Physiotherapy under the terms of the Creative Commons Attribution –
NonCommercial – NoDerivs (CC BY-NC-ND 4.0) Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Here we present a summary of the paper.39
Abstract
Background: in RCTs, moderators are baseline characteristics that predict whether or not an intervention
will be more or less effective for an individual in the trial. For our final individual participant data
meta-analyses selected potential moderators grounded in existing data to inform our selection.
Aim: to identify potential moderators from existing studies of therapist-delivered interventions for LBP to
apply to our data set.
Methods: we developed a review protocol detailing the inclusion and exclusion criteria, search strategy,
data extraction process and quality assessment method. We conducted electronic searches in MEDLINE,
EMBASE, Web of Science (Science Citation Index and Social Science Citation Index) and Cochrane Central
Register of Controlled Trials (CENTRAL) databases for studies reporting moderator analyses. Two
researchers independently screened the titles and abstracts. Additionally, we searched the reference lists of
relevant articles for any further potential references. We included RCTs with ≥ 500 participants, and cohort
studies of ≥ 1000 participants. We classified potential moderators into those with strong evidence
(p< 0.05) or weaker evidence (p< 0.20, p≥ 0.05).
Results: we identified 914 potential citations. We selected 64 papers for detailed evaluation. Four papers,
all RCTs, were included. We identified potential moderators with strong evidence (p< 0.05) in one or more
studies as age, employment status and type, back pain status, narcotic medication use, treatment
expectations and education. Potential moderators with weaker evidence (0.05< p≤ 0.20) include gender,
psychological distress, pain/disability and quality of life.
Conclusion: the overall data obtained from this review were weak and lacked the in rigour to inform
clinical practice. However, this review has helped us to identify potential moderators of treatment effect
with some weak evidence to inform our further analyses.
Background
The ability to identify which patients are likely to gain the greatest benefit from a treatment would have
significant implications in clinical practice. To explore this it is crucial to identify moderators of treatment
response. These are factors measured prior to randomisation and subsequently influence the effect of the
treatment.40 To identify such moderators, large data sets are required to provide sufficient statistical power
to detect any interaction between the moderator and treatment.41
Aims
The purpose of this review was to identify potential moderators which we could test in our individual
participant data pooled repository.
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Method
Originally this review was conducted up until September 2011. Searches were updated in July 2014.
Electronic searches were conducted using the following databases:
l MEDLINE
l Ovid MEDLINE® In-Process & Other Non-Indexed Citations
l EMBASE
l Web of Science
l Citation Index and CENTRAL.
To ensure that we had not overlooked useful data identifying possible treatment moderators, we searched
for both RCTs and observational studies that had tested for effect modification.
Search strategy
We started our searches using the terms ‘low back pain’ combined with keywords including ‘subgroup’,
‘effect modifier’ and ‘moderator’. The results from this preliminary search allowed identification only of
publications that used the term ‘subgroup’ in the title and/or the abstract – it failed to pick up papers
that used the term in the main body of the text. We therefore re-ran searches using keywords (‘trial’) for
RCTs and (‘Observational’, ‘Cohort’, ‘Prospective studies’) for non-RCTs or observational studies separately
and then combining them with terms ‘low back pain’. Hand-searching and screening of included studies
were carried out for additional studies.
Minimum sample size for included studies
To allow us to identify meaningful interactions it was critical to select research based on an adequate
sample size. We made the following assumptions to determine the sample size criterion:
l the outcome of interest is continuous and normally distributed
l there are two treatment arms (intervention and control)
l the potential moderator is binary.
To determine the minimum sample needed to test for an interaction we used a model proposed by
Lachenbruch.42 To test for a long-term (12 months) moderate standardised effect size [between-group
difference/baseline standard deviation (SD)] of 0.5 for the interaction at a 0.05 level of significance and
80% power for the primary outcome, a minimum data set of 503 participants was needed. Recognising
the inherent risk of bias in observational studies we set a higher threshold of 1000 participants for any
observational studies included.
A priori we estimated that we needed to include RCTs with at least 500 participants to identify a moderate
standardised mean difference (SMD; between-group difference/baseline SD) of 0.5 for the interaction
at a 0.05 level of significance and 80% power. The SMDs in high-quality RCTs of therapist-delivered
interventions for LBP are typically in the range of 0.1–0.7 (see Table 1). Smaller trials would be able to
detect treatment moderation, at this level, only if the moderation effect was substantially larger than the
main treatment effect. Thus, even having set quite a large entry criterion by size we would run the risk of
failing to consider potential treatment effect moderators that did not reach the conventional level of
statistical significance. Therefore, any variables identified as moderators of treatment effect at p< 0.05
were classed as potential moderators with strong evidence and those at 0.05< p≤ 0.20 as potential
moderators with weak evidence. For our final analyses we considered potential moderators with both
strong and weak evidence to be worth exploring further.
Inclusion and exclusion criteria
Box 1 provides an outline of the inclusion and exclusion criteria for this review.
LITERATURE REVIEWS
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Screening and data extraction
At all stages two researchers (Dr Tara Gurung and DE) worked independently to screen titles and abstracts
based on the inclusion criteria. All agreed full papers were obtained for data extraction. Data were
extracted on to a standardised extraction form and any discrepancies were resolved using a third reviewer
(DM). As no relevant observational studies were identified we do not address further methodological
considerations related to observational studies.
Risk of bias and quality assessment
Both reviewers independently assessed risk of bias for the between-group comparison using the Cochrane
Collaboration risk-of-bias tool.43 From this tool the criteria used were:
l method of randomisation
l allocation concealment
l incomplete outcome data
l selective outcome reporting
l other sources of bias.
To assess quality we used the criteria developed by Pincus et al.,44 whereby the answers to the five
questions presented below allowed evidence to be classified as ‘confirmatory’ or ‘exploratory’:
1. Was the subgroup analysis specified a priori?
2. Was the selection of subgroup factors for analysis theory/evidence driven?
3. Were subgroup factors measured prior to randomisation?
4. Was measurement of subgroup factors, measured by adequate (reliable and valid) measurements,
appropriate for the target population?
5. Does the analysis contain an explicit test of the interaction between moderator and treatment?
To reduce conflicts of interest, members of the reviewing team who were authors on any included studies
did not participate in the quality assessment exercises.
BOX 1 Review 1: inclusion and exclusion criteria
Inclusion criteria
l Aged ≥ 18 years.
l NSLBP of any duration.
l Therapist-delivered interventions.
l RCTs with sample size of ≥ 500.
l Non-RCTs and observational studies with sample size of ≥ 1000.
l English language.
l Primary and secondary analysis seeking to identify predictors of response to treatment using ‘a priori’ and
‘post hoc’ subgroups and those looking for interaction between baseline variable and treatment.
Exclusion criteria
l Studies with no comparison between two treatment groups.
l Studies that did not report effect sizes for treatment by using moderator interactions.
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Results
Our initial electronic searches generated 7208 hits; 6294 were removed based on title, abstract and duplicates.
We obtained 64 papers for detailed review; of these, 60 papers were excluded (Figure 2). Four studies45–48
were included in this review (Table 2). All four trials45–48 were RCTs, constituting a total sample of n= 5514.
Once we had identified these papers we revisited our search results to include any studies with a sample
size of ≥ 300 in a two-group comparison because the trial by Cherkin et al.49 was a four-arm trial with a
sample of n= 638, whereas our sample size calculation of ≥ 500 was based on a two-arm trial. As this
paper48 generated some useful moderators for our exploratory work we decided to include it. We did not
identify any additional relevant studies with between 300 and 499 participants.
Although the Witt et al.47 paper provided insufficient data to judge the quality of its exploratory analysis,
it did include a specific test for interaction. The data presented did not allow for any pooling of moderator
analyses across studies testing similar interventions.
TABLE 2 Review 1: included studies
Study Country Sample Interventions
UK BEAM45 UK 1334 Group exercise, manual therapy and combination therapy
BeST46 UK 701 Group cognitive–behavioural approach
Witt47 Germany 2841 Acupuncture
Cherkin49 USA 638 Acupuncture
BeST, Back Skills Training Trial; UK BEAM, UK Back pain Exercise And Manipulation.
Total number of citations
identified from search strategy
(n = 7208)
Titles and abstracts of potentially
relevant studies identified and
retrieved for further assessment
(n = 914)
Full-text studies retrieved and
reviewed
(n = 64)
Final studies included in review
(n = 4)
Studies discarded on the basis of titles
and abstracts and duplicates
(n = 6294)
Reason for exclusion
(n = 60)
• Too-small sample size, n = 30
• Studies with no subgroup analysis, n = 13
• Age < 18 years, included both specific and
   non-specific LBP or neck pain, n = 5
• Studies with no comparator, n = 7
• Inappropriate subgroup analysis, n = 2
• Studies about predictors, n = 3
Not relevant studies
(n = 850)
FIGURE 2 Review 1: Quorum statement flow diagram.
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Risk of bias and methodological quality for subgroups
To assess risk of bias and quality of subgroups we used both the original main trial papers and the
associated secondary papers where appropriate (Tables 3 and 4).
Table 5 presents the potential moderators with strong and/or weak evidence from the four included
trials.45–48 The many interactions tested that were not statistically significant are not reported here.
TABLE 3 Review 1: results of the risk of bias assessment
Quality of the study based on main trial
paper(s) UK BEAM31 BeST33,34 Witt47 Cherkin48,49
Random sequence generation L L L L
Allocation concealment L L L L
Blinding of participants and personnel H H H H
Blinding of outcome assessment L L H L
Incomplete outcome data L L U L
Selective reporting L L U L
Generalisability L L L L
Sample size calculation L L U L
Conflict of interest L L H L
Source of funding MRC NIHR HTA Social Health
Fund Providers
National Institutes
of Health
BeST, Back Skills Training Trial; H, high risk of bias; L, low risk of bias; MRC, Medical Research Council; NIHR HTA, National
Institute for Health Research Health Technology Assessment; U, unclear; UK BEAM, UK Back pain Exercise
And Manipulation.
TABLE 4 Review 1: results of methodological quality assessments
Quality of the moderator analyses based on
subgroup paper(s) UK BEAM31 BeST33,34 Witt47 Cherkin48,49
Was the subgroup analysis specified a priori? N Y N N
Was the selection of subgroup factors for analysis
theory/evidence driven?
N Y N N
Were subgroup factors measured prior to
randomisation?
Y Y U Y
Was measurement of subgroup factors measured
by adequate (reliable and valid) measurements,
appropriate for the target population?
Y Y N Y
Does the analysis contain an explicit test of the
interaction between moderator and treatment?
Y Y U Y
Strength of evidence EE CE for two
potential
moderators
IE EE
BeST, Back Skills Training Trial; CE, confirmatory evidence – fulfils all five criteria for moderator studies; EE, exploratory
evidence – fulfils three, four or five criteria for moderator studies; IE, insufficient evidence to judge quality; N, no;
U, unclear; UK BEAM, UK Back pain Exercise And Manipulation; Y, yes.
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Moderator variables identified
Potential moderators with strong evidence (p< 0.05) in one or more studies include age (younger
participants may gain more benefit), employment status and type (those employed or in sedentary
occupations may gain greater benefit), back pain status (those who are worse may gain greater benefit),
narcotic medication use (users may benefit less), treatment expectations (those with a greater positive
expectation gained more benefit) and education (those with > 10 years of schooling gained a greater
benefit). Potential moderators with weaker evidence (0.05< p≤ 0.20) include gender (female participants
may gain greater benefit), psychological distress (those with anxiety and depressive symptoms may benefit
more), pain/disability (those with greater pain/disability at baseline may benefit more) and quality of life
(those with a better quality of life may benefit more). It should be noted that these findings might just be
a chance finding, particularly as these conclusions come from different studies.
Age: the BeST (Back Skills Training Trial), Cherkin and Witt trials46,49,50 found an interaction with age.
In the BeST trial,46 younger participants gained more benefit from cognitive behavioural therapy than older
participants on the RMDQ score. The treatment difference was –1.58 (p= 0.035; 95% CI –3.05 to –0.12).
As the p-value was < 0.05, the interactions provided strong evidence. Witt et al.50 found a statistically
significant additional benefit from acupuncture treatment in younger participants (p< 0.001).
Gender: the BeST trial46 found that gender had a moderating effect on treatment. In this trial, females had
comparatively greater improvement following group cognitive behavioural therapy than males. The
treatment difference between male and female was –1.27 (p= 0.102; 95% CI –2.79 to 0.25) for the
RMDQ score. As the p-value was 0.05< p≤ 0.20, the interaction provides weak evidence.
Employment status: employment was found to be one of the positive moderating factors. In the BeST
trial,46 the authors found that employed participants gained additional benefit from a cognitive behavioural
approach compared with those who were unemployed. The treatment difference between employed and
unemployed was 1.89 (p= 0.011; 95% CI 0.43 to 3.35) and 5.01 (p= 0.181; 95% CI –2.33 to 12.34) for
the RMDQ and Modified von Korff (MVK) pain scores, respectively. The interaction effect in the analysis of
the MVK pain score was weak.46 The Cherkin trial48,49 found some moderating effect according to types
of employment status. The participants in this trial48 received acupuncture therapy. Those participants
whose job involved heavy lifting showed positive moderating effect against back-related dysfunction score
at 8 weeks (p= 0.03 to 0.18) and 52 weeks (p= 0.01 to 0.04). Those participants doing medium/light
lifting at work showed positive moderating effect in terms of the bothersomeness score (p= 0.12)
at 8 and 52 weeks; however, the interaction was weak. Finally, those participants with sedentary work
showed positive moderating effect at 52 weeks (p= 0.12 to 0.19). The interaction was generally weak.
Education: the BeST trial46 found that participants who had left full-time education after the age of
16 years had better improvement from cognitive behavioural therapy than participants who left full-time
education aged ≤ 16 years. The treatment difference was 1.29 (p= 0.098; 95% CI –0.24 to 2.82)
for the RMDQ score. The interaction effect was > 0.05 and, therefore, this provides weak evidence.
Witt et al.50 found that those participants who have had > 10 years of schooling gained a greater benefit
from acupuncture (p= 0.01).
Back pain status: In the Cherkin and Witt trials48–50 participants with a worse initial back pain status
(baseline RMDQ score) gained an increased benefit from acupuncture compared with those with a
better back pain status at baseline (p-values ranged from< 0.001 to 0.16). The extent to which LBP
inconveniences participants – how troublesome or bothersome it is – was found to be a moderator in two
trials, with a greater benefit from treatment in those with a more troublesome/bothersome condition. The
interaction was weak, with the p-values being > 0.05. In the Cherkin trial,48,49 the p-value was 0.10,
whereas in the BeST trial46 the treatment difference for the RMDQ score was –1.01 (p= 0.190; 95% CI
–2.52 to 0.50) and –5.04 (p= 1.184; 95% CI –12.47 to 2.40) for MVK pain score.
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Pain/disability: similarly, those participants with greater pain/disability at baseline seemed to benefit more
at 3 months (p= 0.176) and 12 months (p= 0.143) for the RMDQ score with manipulation treatment
[UK Back pain Exercise And Manipulation (UK BEAM45)] (see Table 5). The p-values are > 0.05 and < 0.2,
therefore providing weak evidence.45
Narcotic: Cherkin et al.48,49 found that use of medication such as narcotics had a negative moderating
effect in those receiving acupuncture. The p-value for this interaction ranged from 0.01 to 0.19,
demonstrating a spectrum of strong to weak evidence.
Treatment expectations: having better expectations about the treatment was found to be a moderating
factor in two trials.45,48,49 The p-values ranged between 0.03 and 0.192, demonstrating a spectrum of strong
to weak evidence for the interactions.48,49 Cherkin et al.48,49 found that participants with higher expectation of
acupuncture treatment helpfulness gained more benefit in the back-related dysfunction score (p= 0.03–0.17)
and bothersomeness score (p= 0.05–0.10).48,49 In the UK BEAM trial,45 manipulation at 3 months (p= 0.113)
and 12 months (p= 0.083), or a combined treatment of manipulation and exercise (p= 0.03 to 0.192) at
both 3 and 12 months, showed positive moderating effect, as was demonstrated by the RMDQ score.
Overall, the interactions were found to range between a spectrum of strong to weak evidence.
Quality of life: good quality of life showed weak evidence for a moderating effect on treatment outcome for
both manipulation treatment (p= 0.118) and a combined manipulation and exercise treatment (p= 0.174).45
Psychosocial status: in the BeST trial,46 psychosocial status moderated treatment effect. The trial46
investigated whether psychological status moderated better outcome from a cognitive behavioural therapy.
Participants with higher levels of anxiety at baseline gained more benefit from treatment in terms of the
RMDQ score. The treatment difference was found to be –1.12 (p= 0.195; 95% CI –2.83 to 0.58),
demonstrating a weak interaction. Similarly, those participants who were depressed considerably gained
more benefit from the treatment than those who were less depressed as was found in the RMDQ and
MVK disability scores. The treatment difference was found to be –2.07 (p= 0.135; 95% CI –4.79 to 0.65)
and –14.58 (p= 0.051; 95% CI –29.19 to 0.03) for the RMDQ and MVK disability scores, respectively.
Discussion and conclusion
In this review we aimed to identify potential moderators of treatment effect to test in our repository of
data. Only four trials were included. We considered any variables that were identified as moderators
of treatment effect at p< 0.05 as potential moderators with strong evidence, and those at p< 0.20 and
p≥ 0.05 as potential moderators with weak evidence. Only for two comparisons, in one study,46 were
any confirmatory analyses performed. Any apparently positive findings need to be interpreted with
considerable caution. We have set the threshold for potential moderation with weak evidence at p= 0.02,
and the included studies included many comparisons, meaning that any positive results may well be no
more than chance findings. Nevertheless, we have identified some domains for which there is some weak
evidence of moderation that is worth exploring further.
Systematic review 2: quality of subgroup analyses in low back
pain trials
This review has been published in Spine.51 Here we present a summary of the paper.
Abstract
Background: trials of back pain interventions have generally shown small to moderate positive effects.
Therefore, identifying subgroups in this population is a research priority. This review evaluates the quality,
conduct and reporting of subgroup analyses performed in the NSLBP literature.
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Aim: to evaluate the quality, conduct and reporting of subgroup analyses performed in RCTs of
therapist-delivered interventions for NSLBP.
Method: electronic databases were searched for RCTs of therapist-delivered interventions for NSLBP.
We included papers reporting only subgroup analyses (confirmatory or exploratory). The quality of
subgroup analyses and quality of conduct and reporting were also evaluated.
Results: thirty-nine papers were included in the final review. Of these, only three (8%) tested hypotheses
about moderators (confirmatory findings); 18 (46%) generated hypotheses about moderators to inform
future research (exploratory findings) and 18 (46%) provided insufficient findings. The appropriate
statistical test for interaction was performed in 27 of the papers, of which 10 papers reported results from
interaction tests, four papers incorrectly reported results within individual subgroups and the remaining
papers either reported p-values or nothing at all.
Conclusions: subgroup analyses performed in NSLBP trials have been severely underpowered, are able to
provide only exploratory or insufficient findings and have rather poor quality of reporting. Using current
approaches, few definitive trials of subgrouping in back pain are very likely to be performed. There is a
need to develop new approaches to subgroup identification in back pain research.
Background
The identification of subgroups that gain the most benefit from interventions for the management of LBP
is an important research priority internationally.15,52–54 Although several trials claim to have performed
subgroup analyses, the quality, conduct and reporting of the analyses performed has not been critically
reviewed. There is some confusion in the papers between investigating ‘subgroup effects’ and investigating
‘differential subgroup effects’, where the former investigates a specific subset or subpopulation of the entire
sample for a main effect and the latter investigates treatment effect heterogeneity using an interaction test
between subgroups defined by factors measured prior to treatment.55
Aims
The objective of this literature review is to first identify RCTs of therapist-delivered interventions for NSLBP,
which have performed secondary analyses in the form of subgroup analyses. All identified literature was
assessed using a set of methodological criteria to evaluate the quality of subgroup analyses. Furthermore,
the conduct and reporting of subgroup analyses were also assessed.
Method
This literature review work was carried out as part of the PhD studentship funded in this programme
of work.
The same search strategy described above in our previous review was used in this review to identify
potential papers of RCTs looking at therapist-delivered interventions for LBP. Originally, the following
databases were searched until September 2011. Searches were updated in July 2014. Electronic searches
were conducted using the following databases:
l MEDLINE
l Ovid MEDLINE In-Process & Other Non-Indexed Citations
l EMBASE
l Web of Science
l Citation Index and CENTRAL.
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Search strategy
As described above we started our searches using the terms ‘low back pain’ combined with keywords
including ‘subgroup’, ‘effect modifier’ and ‘moderator’. This only yielded publications which used the term
‘subgroup’ in the title and/or the abstract, it failed to pick up papers that used the term in the main body
of the text. Therefore, we reran searches to identify all ‘low back pain’ and ‘RCTs’ which we filtered for
therapist-delivered interventions.
Inclusion and exclusion criteria
Box 2 outlines the inclusion and exclusion criteria for this review.
Screening and data extraction
We screened titles and abstracts based on the predetermined inclusion criteria. We selected all papers
potentially reporting subgroup analysis for further investigation. All agreed full papers were obtained for
data extraction. Data were extracted on to a standardised extraction form and any discrepancies were
resolved using a second reviewer.
Quality assessment of subgroup analysis
We used the same Pincus et al.44 criteria described in the previous review (see Risk of bias and quality
assessment, above) the review above to assess the quality of subgroups. Three independent reviewers
(DM, SP and SWH) assessed the quality of the identified papers. All discrepancies were addressed and
resolved through discussion.
To reduce conflicts of interest, members of the reviewing team who were authors on any included studies
did not participate in the quality assessment exercises.
BOX 2 Review 2: inclusion and exclusion criteria
Inclusion criteria
l Randomised controlled trials.
l Participants aged 18 years or more with history of NSLBP.
l Therapist delivered interventions for NSLBP (including psychological interventions and intensive
rehabilitation programmes).
l Primary or secondary analysis of RCTs reporting that a subgroup analysis had been conducted.
Exclusion criteria
l LBP with known likely cause (fracture, infection, malignancy specific cause, ankylosing spondylitis and other
inflammatory disorders).
l Studies investigating disorders additional to NSLBP, e.g. NSLBP and neck pain.
l Outcome not a valid clinical measure of NSLBP, e.g. number of days sick leave.
l Testing a clinical prediction rule.
l Treatment effect modification over time, i.e. treatment ×moderator × time.
l Pooled datasets of similar trials.
Reproduced from Mistry D, Patel S, Hee SW, Stallard N, Underwood M. Evaluating the quality of subgroup
analyses in randomized controlled trials of therapist-delivered interventions for nonspecific low back pain:
a systematic review. Spine 2014;39:618–29; with permission from Lippincott Williams & Wilkins.
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Analysis
To assess the conduct and reporting of subgroup analysis we referred to existing authoritative reviews.56,57
Papers were assessed for:
l design and methods – for all papers
l results g Only for those papers that used interaction tests forsubgroup analyses.l interpretation and discussion.
Each paper was examined to see if it conformed to four key recommendations in the area of subgroup
analyses (Box 3).
Results
Our initial search identified 5581 papers. All titles and abstracts were screened to identify potential papers
reporting results of RCTs of therapist-delivered interventions for LBP. We excluded 5521 papers during the
screening process. The full text for the remaining 60 papers was then thoroughly examined to look for
subgroup analyses, of which 21 were excluded as they either did not meet the inclusion criteria or they
met one or more of the exclusion criteria. We included 39 papers in the final review (Figure 3).
BOX 3 Key recommendations in the area of subgroup analyses
Key recommendations
l Exact subgroup definitions should be given beforehand for continuous and categorical variables, along with
some justification to avoid post-hoc data dependent definitions of subgroups.
l Subgroup analyses should be performed on the primary outcome in the study. This is simply because trials
are designed to detect differences in the primary outcome only; therefore, performing subgroup analyses
on any other outcome measure will substantially reduce the power.
l A differential subgroup effect should be formally evaluated using a statistical test for interaction and the
interaction effect reported. Performing tests within individual subgroups and then comparing the results is
an incorrect approach to subgroup analyses as it does not directly evaluate the subgroup effect.
l The number of subgroup analyses to be performed should be kept to a minimum. This is to avoid the issue
of false-positive discovery (type I error inflation) due to multiple testing; a well-known issue if there are
several subgroups of interest. Any concerns regarding multiplicity should be acknowledged and addressed
appropriately, e.g. applying a Bonferroni or Sidak correction.
Reproduced from Mistry D, Patel S, Hee SW, Stallard N, Underwood M. Evaluating the quality of subgroup
analyses in randomized controlled trials of therapist-delivered interventions for nonspecific low back pain:
a systematic review. Spine 2014;39:618–29; with permission from Lippincott Williams & Wilkins.
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A summary of the included studies is given in Table 6 and a summary of excluded studies can be found in
Appendix 1. A total of 63% of the included papers were from the Netherlands, the UK or the USA.
The median study size was 223, ranging from 100 to 3093.
Methodological quality of subgroup analyses
The methodological quality of the subgroup analyses performed in the identified papers was assessed to
determine the strength of evidence that they provide. Of the 39 papers:35,45,46,48–50,58–90
l Three (8%) papers46,53,54,58,59 met all five criteria and therefore provided confirmatory evidence. Two of
these papers58,59 were too small to anticipate finding any important interaction if it were present
(n= 148 and 259).
l Eighteen (46%) papers provided exploratory evidence, that is, they met criteria 3, 4 and 5
(see Table 6).
l Eighteen (46%) papers provided insufficient evidence (see Table 6).
Assessment of conduct and reporting of subgroups
We examined the conduct and reporting of subgroups in terms of design and methods and found that:
l One study50 had sufficient power to detect an interaction; however, subgroups of interest were not
prespecified a priori.
l Thirty-one (79%) studies35,45,48–50,60–63,66–74,76–78,80,81,83–90 did not prespecify subgroups of interest.
l Eight studies46,58,59,64,65,75,79,82 reported prespecified subgroups for confirmatory analyses; six of these
studies also carried out exploratory analyses without clear distinction between analysis types.
l Sometimes it was not clear from the methods that subgroup analyses were going to be performed;
they were just presented in the results.62,69,74,80
l All papers measured subgroups of interest prior to randomisation, with most using
adequate measurements.
l Prior to performing analyses, only one paper58 reported the expected size and direction of the
subgroup effect. A further three papers46,59,85 predicted the direction of the subgroup effect.
Total number of citations
identified from search strategy
(n = 5581)
Final papers included in review
(n = 39)
Full-text papers retrieved and
reviewed
(n = 60)
Excluded on the basis of titles and
abstract
(n = 5521)
Reason for exclusion 
(n = 21)
• Included participants aged < 18 years, n = 3
• Intervention not delivered by therapist, n = 3
• Looked at effect modification over time, n = 2
• Looked at an additional disorder, n = 2
• Outcome in subgroup analysis not a clinical outcome, n = 6
• Pooled data sets of similar trials, n = 1
• Testing a clinical prediction rule, n = 2
• HTA report: secondary subgroup analyses paper
   published elsewhere and used instead, n = 2
FIGURE 3 Review 2: Quorum statement flow diagram. Reproduced from Mistry D, Patel S, Hee SW, Stallard N,
Underwood M. Evaluating the quality of subgroup analyses in randomized controlled trials of therapist-delivered
interventions for nonspecific low back pain: a systematic review. Spine 2014;39:618–29; with permission from
Lippincott Williams & Wilkins.
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l One-third (13/39) of the papers45,46,48,58,59,72,77,79,83,85–87,90 provided some justification regarding the choice
of subgroups to be analysed.
l In two papers45,59 around 60 interaction tests were conducted, substantially increasing the chances of
detecting false-positive findings. Of the three papers46,58,59 that provided confirmatory findings, only one
of them46 adjusted for multiplicity. The authors applied a Bonferroni correction to their confirmatory
subgroup analyses.
l Twelve (31%) of the papers64,73,74,76,79–81,84,85,87,89,90 did not use a statistical test for interaction to assess
for treatment effect modification. Of these, two of the papers74,87 did not give any indication as to
what statistical method they used. Two papers73,84 looked at correlations between individual subgroups
and outcomes within each treatment arm separately. Two papers79,80 used t-tests between treatment
groups within individual subgroups. Five papers76,81,85,89,90 used either multiple linear regression or
multiple logistic regression for each individual subgroup. One paper64 compared the medians across
three trial arms within individual subgroups using Kruskal–Wallis tests.
We examined the conduct and reporting of subgroups in terms of reporting of results and found that:
l A statistical test for interaction was reported to have been used in 27 (69%) of
the papers.35,45,46,48–50,58–72,75,77,82,83,86,88
l Six studies45,48,61,72,75,77 reported both the interaction effect sizes with CIs and the corresponding
p-values.
l Four studies46,58,59,82 reported only the interaction effect sizes with CIs.
l Eight studies35,50,66,67,69,83,86,88 reported only the p-values.
l Nine papers49,60,62–65,68,70,71 did not report the interaction effect sizes, CIs or p-values.
l Four studies60,66,70,88 reported subgroup analyses within individual subgroups rather than
between-group interaction.
We examined the conduct and reporting of subgroups in terms of reporting of interpretation and
discussion and found that:
l Four60,66,70,88 out of 27 papers that performed interaction tests reported subgroup analyses within
individual subgroups and thus based the interpretations and discussion on this as well.
l Reference to other relevant studies (supporting or contradicting) were made in around one-third of
the papers.
l The limitations of subgroup analyses were reported in 12 papers.45,46,48,58–61,65,76,79,86,90
Discussion and conclusion
Subgroup analyses have been attempted in several papers; however, there is confusion between
investigating ‘subgroup effects’ and ‘differential subgroup effects’.55 The overall quality of the subgroups is
poor, with most papers providing only exploratory or insufficient findings. The overall reporting in papers
for subgroups is generally of poor standard. The sample sizes of the trials have been small and thus
underpowered to detect interactions. Only one trial50 was appropriately powered for the analysis; however,
the authors failed to specify the subgroups a priori. The recommended guidelines should be used when
performing subgroup analyses to ensure that they are reliable and of a good standard.56,91 The current
approaches are not suitable to address the research question. New methods to perform subgroup analyses
are required to address the methodological concerns highlighted.
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Summary of reviews
Both reviews conducted during this programme of work have been informative in developing our
understanding of subgrouping in LBP.
Review 1 looked at identifying potential moderators to be tested within the back pain repository. The
literature on moderators is weak and, subsequently, lacking in rigour to inform clinical practice. Despite
this, the review has helped us to identify some potential moderators of treatment effect, including age,
educational attainment, employment status, symptoms of anxiety or depression, longer history of back
pain and treatment expectations in at least one trial. We used these variables in our later analyses within
our repository of data.
Review 2 looked at the quality of subgroup analyses conducted in the LBP literature. This review concluded
that the overall quality was poor. A trial that is sufficiently powered to detect subgroups would need to be
approximately four times larger than a traditional trial powered to detect a main effect of the same
magnitude.92 This would be a timely and costly undertaking, for which care would also need to be taken
to select moderators that were clinically relevant and applicable.
In addition to these reviews we have previously published a systematic review93 that summarised findings
from RCTs testing the effects of a clinical prediction rule for NSLBP. Clinical prediction rules have been
developed and are being used in clinical practice to help clinicians to make decisions on treatment;
however, the overall effect of such tools is unclear. Multicomponent clinical prediction rules have the
potential to be much more powerful tools for targeting treatments than single-component measures.
We identified 1821 potential citations after all duplications had been removed. Two reviewers
independently screened the titles and abstracts, and consensus was reached on obtaining 35 papers for
full detailed evaluation. Of these, only three papers94–96 were included in the review. The results from the
available trials do not convincingly support the use of clinical prediction rules in the management of
NSLBP. We concluded that the existing RCTs looking to validate clinical prediction rules in LBP are limited.
Methodologies for the validation of these rules lack clarity and, subsequently, the evidence for, and
development of, the existing prediction rules in LBP is generally weak.
Current approaches have failed to provide the data needed to target treatments for LBP. There is therefore
a need to look at alternative methods to address this problem. We propose three recommendations:
1. To develop new and novel methods to identify multiple participant characteristics or clusters of
moderators that would identify who is most or least likely to benefit.97–99
2. To apply individual participant data meta-analysis to homogeneous pooled data sets, as this would
improve statistical power.
3. To develop subgroups, and suggested interventions, based on clinical reasoning, and test these within
trials to determine if the targeted intervention produces a larger average effect size than existing
non-specific interventions.
In this programme we address points 1 and 2, leaving point 3 for others within the back pain research
community to consider and address.
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Chapter 3 Collating data
In this chapter we detail the process of identifying and approaching chief investigators and/or datacustodians for trial data for inclusion in our repository of back pain trials.
Identification of potential trials
We used the search results generated from review 1 (Identification of potential moderators, described in
Chapter 2) as a starting point for identifying trials of interest. In the first instance we were interested in only:
l RCTs
l trials of therapist-delivered interventions
l trials with a sample size of > 179 participants.
Based on these criteria we filtered the original search output to identify 658 citations. These were
systematically screened by two members of the team independently (see Figure 2). Additionally, we also
obtained further data through snowballing; essentially, we were offered data (from researchers aware of
the project) from trials that were not on our original list. Although some of the trials obtained through the
snowballing process are smaller in sample size than our target studies, we decided to include these to add
power to our analysis.
Justification of sample size
We started with an original lower limit of 200 for the sample size. Allowing for some loss to follow-up,
a trial of 200 participants would have 90% statistical power to identify a SMD of 0.5 between two
treatment groups. Any individual trials smaller than this are likely to be seriously underpowered for their
primary outcome. Upon screening the trials there were many that obtained a final sample size of just
fewer than 200 participants; typically these were studies aiming for around 200 participants, which fell
short of the final target. We therefore revised our inclusion to more than 179 participants. From a practical
perspective of approaching trial investigators, this yielded a manageable number of trials to approach;
large trials (those with thousands of participants) and small trials (fewer than 100 participants) each create
a similar amount of work to collate.
Process for approaching investigators
We identified 42 trials33,49,50,62,63,65,70,76,82,84,94,100–130 that fitted our inclusion criteria. For these trials we
identified the chief investigator and the best e-mail contacts for them. Between 2011 and 2012 each
investigator was sent an e-mail to invite him/her to participate in the repository. Each e-mail included the
following attachments:
l formal invitation letter (see Appendix 2)
l information sheet (see Appendix 3)
l sample data sharing agreement (see Appendix 4).
If a response was not received within a 6- to 8-week period, a reminder e-mail was then sent. If a
response was received indicating an interest in sharing data then the data sharing agreement was
personalised and sent back to the investigator for review and signature. Once the signed document was
received by the university, the investigator was provided with details on how to securely send the data to
us. We used the University of Warwick secure file transfer service.
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Secure data transfer
We requested all data from a trial. Investigators were advised that any data sets being sent to us needed
to be anonymised and encrypted using an open-source compression software programme such as 7-Zip
9.20 © Igor Pavlov (www.7-zip.org/). Investigators were then provided with details on how to securely
transfer this data to the University of Warwick (see Appendix 5) using an upload system that was set up
for the project (available at https://files.warwick.ac.uk/repositorylbpdata/sendto).
Once these data were received it was the responsibility of the team’s statisticians and/or health economists
to transform the original data to the repository standard. To aid this process we requested all trial-specific
information, including the protocol and questionnaires if they were available.
Final data set obtained
We obtained 14 (33%) trial data sets31,33,50,65,70,76,101–107,131 from the original 42 trials33,49,50,62,63,65,70,76,82,84,94,100–130
we approached. A further five trials132–136 were obtained through snowballing, resulting in a total of 19 data
sets (Figure 4). We were unsuccessful in getting a response from 15 (36%) investigators and a further six
(14%) data sets were not available for data sharing. We still have seven (17%) data sets in negotiation, for
which we were unable to agree on the data sharing before starting our formal analysis; therefore, these
trials have not been included in this report.
Total number of citations identified
from search strategy 
(n = 658)
Titles and abstracts of potentially
relevant studies identified and 
retrieved for further assessment 
(n = 70)
Trials to approach 
(n = 42)
Trials obtained (n = 14) (from search)
plus (n = 5) from snowballing
Total trials obtained (n = 19)
Studies discarded on the basis of
titles and abstracts (n = 588)
• Multiple publications, n = 24
• Not in English, n = 1
• Not therapist delivered, n = 2
• Exercise vs. exercise, n = 1
• No response, n = 15
• In negotiation, n = 7
• Not available, n = 6
FIGURE 4 Quorum statement flow diagram for database identification.
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Through the process of snowballing, further smaller data sets were offered to be included in the
repository. The offer of these trials was carefully considered by the research team, and it was decided that
any additional data would be helpful in increasing power. Therefore, three (16%) of the 19 trials obtained
have a sample size of < 179 participants.
Table 7 shows the trials that were excluded and the reason for the exclusion. Details of papers excluded as
a result of multiple publications can be found in Appendix 6. A list of trials that were unavailable because
of a lack of response from the investigator, data sets not available and those still under negotiation are
documented in Appendix 7. A final table of included trials and associated papers is presented in Table 8.
TABLE 7 Trials excluded and reason for exclusion, n= 4
Author Number of participants Reason for exclusion
Jellema137 314 Not therapist delivered
Kainz B138 1274 Paper not in English
Long A139 312 Trial of exercise vs. exercise
Von Korff140 255 Not therapist delivered
TABLE 8 Trials included and associated publications, n= 19
Name of/given
name of trial
Corresponding
author/chief
investigator Relevant publications related to the trial of interest
Number of
participants
Witt Witt Witt CM, Jena S, Selim D, Brinkhaus B, Reinhold T, Wruck K,
et al. Pragmatic randomized trial evaluating the clinical and
economic effectiveness of acupuncture for chronic low back
pain. Am J Epidemiol 2006;164:487–9650
3093
UK BEAM Underwood UK BEAM Trial Team. United Kingdom back pain exercise and
manipulation (UK BEAM) randomised trial: effectiveness of
physical treatments for back pain in primary care. BMJ
2004;329:137731
Underwood MR, Morton V, Farrin A. Do baseline characteristics
predict response to treatment for low back pain? Secondary
analysis of the UK BEAM data set [ISRCTN32683578].
Rheumatology (Oxford) 2007;46:1297–30245
1334
Haake Haake Haake M, Müller HH, Schade-Brittinger C, Basler HD, Schäfer H,
Maier C, et al. Acupuncture Trials (GERAC) for chronic low back
pain: randomized, multicenter, blinded, parallel-group trial with
3 groups. Arch Intern Med 2007;167:1892–8132
1163
BeST Lamb Lamb SE, Hansen Z, Lall R, Castelnuovo E, Withers EJ, Nichols V,
et al. Group cognitive behavioural treatment for low-back
pain in primary care: a randomised controlled trial and
cost-effectiveness analysis. Lancet 2010;375:916–2333
Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V,
et al. A multicentred randomised controlled trial of a primary
care-based cognitive behavioural programme for low back pain.
The Back Skills Training (BeST) trial. Health Technol Assess
2010;14(41)34
701
continued
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TABLE 8 Trials included and associated publications, n= 19 (continued )
Name of/given
name of trial
Corresponding
author/chief
investigator Relevant publications related to the trial of interest
Number of
participants
Keele Hay Hay EM, Mullis R, Lewis M, Vohora K, Main CJ, Watson P,
et al. Comparison of physical treatments versus a brief
pain-management programme for back pain in primary care:
a randomised clinical trial in physiotherapy practice. Lancet
2005;365:2024–3065
Whitehurst DG, Lewis M, Yao GL, Bryan S, Raftery JP, Mullis R,
et al. A brief pain management program compared with
physical therapy for low back pain: results from an economic
analysis alongside a randomized clinical trial. Arthritis Rheum
2007;57:466–73141
402
Brinkhaus Brinkhaus Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Wagenpfeil S,
et al. Acupuncture in patients with chronic low back pain:
a randomized controlled trial. Arch Intern Med
2006;166:450–7101
298
Dufour Dufour Dufour N, Thamsborg G, Oefeldt A, Lundsgaard C, Stender S.
Treatment of chronic low back pain: a randomized, clinical trial
comparing group-based multidisciplinary biopsychosocial
rehabilitation and intensive individual therapist-assisted back
muscle strengthening exercises. Spine 2010;35:469–76102
286
Pengel Pengel Pengel LH, Refshauge KM, Maher CG, Nicholas MK, Herbert RD,
McNair P. Physiotherapist-directed exercise, advice, or both for
subacute low back pain: a randomized trial. Ann Intern Med
2007;146:787–96103
Smeets RJ, Maher CG, Nicholas MK, Refshauge KM, Herbert RD.
Do psychological characteristics predict response to exercise
and advice for subacute low back pain? Arthritis Rheum
2009;61:1202–959
260
YACBAC Thomas Thomas KJ, MacPherson H, Thorpe L, Brazier J, Fitter M,
Campbell MJ, et al. Randomised controlled trial of a short
course of traditional acupuncture compared with usual care for
persistent non-specific low back pain. BMJ 2006;333:62388
Ratcliffe J, Thomas KJ, MacPherson H, Brazier J. A randomised
controlled trial of acupuncture care for persistent low back pain:
cost effectiveness analysis. BMJ 2006;333:626142
Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J,
Campbell M, et al. Longer term clinical and economic benefits
of offering acupuncture care to patients with chronic low back
pain. Health Technol Assess 2005;9(32)107
241
Hancock Hancock Hancock MJ, Maher CG, Latimer J, Herbert RD, McAuley JH.
Independent evaluation of a clinical prediction rule for spinal
manipulative therapy: a randomised controlled trial. Eur Spine J
2008;17:936–4394
Hancock MJ, Maher CG, Latimer J, Herbert RD, McAuley JH.
Can rate of recovery be predicted in patients with acute low
back pain? Development of a clinical prediction rule. Eur J Pain
2009;13:51–5143
Hancock MJ, Maher CG, Latimer J, McLachlan AJ, Cooper CW,
Day RO, et al. Assessment of diclofenac or spinal manipulative
therapy, or both, in addition to recommended first-line
treatment for acute low back pain: a randomised controlled
trial. Lancet 2007;370:1638–43131
240
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TABLE 8 Trials included and associated publications, n= 19 (continued )
Name of/given
name of trial
Corresponding
author/chief
investigator Relevant publications related to the trial of interest
Number of
participants
VKBIA Von Korff Von Korff M, Balderson BH, Saunders K, Miglioretti DL, Lin EH,
Berry S, et al. A trial of an activating intervention for chronic
back pain in primary care and physical therapy settings. Pain
2005;113:323–30104
240
HullExPro Carr Carr JL, Klaber MJA, Howarth E, Richmond SJ, Torgerson DJ,
Jackson DA, et al. A randomized trial comparing a group
exercise programme for back pain patients with individual
physiotherapy in a severely deprived area. Disabil Rehabil
2005;27:929–3776
237
VKSC2 Moore Moore JE, von Korff M, Cherkin D, Saunders K, Lorig K.
A randomized trial of a cognitive-behavioural program for
enhancing back pain self care in a primary care setting.
Pain 2000;88:145–53105
226
Smeets Smeets Smeets RJ, Vlaeyen JW, Hidding A, Kester AD, van der Heijden GJ,
van Geel AC, et al. Active rehabilitation for chronic low back pain:
cognitive-behavioural, physical, or both? First direct post-treatment
results from a randomized controlled trial [ISRCTN22714229].
BMC Musculoskelet Disord 2006;7:570
223
Cecchi Cecchi Cecchi F, Molino-Lova R, Chiti M, Pasquini G, Paperini A,
Conti AA, et al. Spinal manipulation compared with back school
and with individually delivered physiotherapy for the treatment
of chronic low back pain: a randomized trial with one-year
follow-up. Clin Rehabil 2010;24:26–36106
210
York BP Torgerson Moffett JK, Torgerson D, Bell-Syer S, Jackson D,
Llewellyn-Phillips H, Farrin A, et al. Randomised controlled trial
of exercise for low back pain: clinical outcomes, costs, and
preferences. BMJ 1999;319:279–83133
187
Macedo Macedo Macedo LG, Latimer J, Maher CG, Hodges PW, McAuley JH,
Nicholas MK, et al. Effect of motor control exercises versus
graded activity in patients with chronic nonspecific low
back pain: a randomized controlled trial. Phys Ther
2012;92:363–77134
172
Carlsson Carlsson Carlsson CP, Sjölund BH. Acupuncture for chronic low back
pain: a randomized placebo-controlled study with long-term
follow-up. Clin J Pain 2001;17:296–305135
50
Kennedy Kennedy Kennedy S, Baxter GD, Kerr DP, Bradbury I, Park J,
McDonough SM. Acupuncture for acute non-specific low back
pain: a pilot randomised non-penetrating sham controlled trial.
Complement Ther Med 2008;16:139–46136
48
VKBIA, von Korff BIA; VKSC2, von Korff SC2; YACBAC, York Acupuncture Back Pain Trial.
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Summary of the included trials in the repository
The agreed and included trials in this repository are detailed in Table 9.
TABLE 9 Summary of the included trials in the repository
Name of/given
name of trial Witt, n= 309350
Country Germany
Interventions In the RCT part of study there were two arms
l Acupuncture
l Control – received acupuncture after 3 months
Recruitment Patients consulting a physician for LBP that were insured by one of the participating social health
insurance funds were recruited. Details of the study were provided to those patients requesting
acupuncture or when the physician considered acupuncture to be a suitable treatment option
Inclusion criteria Age ≥ 18 years, with the ability to provide informed consent. A diagnosis of CLBP with a duration of
more than 6 months
Exclusion criteria Disc prolapse/protrusion of with concurrent neurological symptoms, previous back surgery, infectious
spondylopathy, LBP caused by inflammatory, malignant or autoimmune disease, congenital
deformation fracture caused by osteoporosis, spinal stenosis, and spondylolysis or spondylolisthesis
Name of/given
name of trial UK BEAM including feasibility study, n= 133445,100
Country l UK
Interventions l Exercise programme: group exercise, including cognitive behavioural principles, delivered over up
to eight 60-minute sessions over 4–8 weeks. A refresher session was provided 12 weeks
after randomisation
l Spinal manipulation: a package of care was developed by chiropractors, osteopathic and
physiotherapy professions in the UK. Patients were randomised to private or NHS manipulation.
Up to eight 20-minute sessions were provided over 12 weeks
l Combined treatment: provision of eight sessions of manipulation over 6 weeks plus eight
sessions of exercise over the next 6 weeks plus a final refresher session at 12 weeks
l Best care in general practice: patients were advised to remain active and provided with a copy of
The Back Book144
Recruitment Recruited from GP practices after searching computerised records for potential eligible participants
Inclusion criteria Aged between 18 and 65 years, consulted with LBP, score of ≥ 4 on RMDQ at randomisation, pain
experienced every day for the 28 days before randomisation or 21 out of 28, agreement to avoid
other physical treatments during the treatment period
Exclusion criteria Aged ≥ 65 years, potential spinal disorder, including malignancy, osteoporosis, ankylosing
spondylitis, cauda equina compression, and infection, pain primarily below the knee, previous spinal
surgery, another musculoskeletal disorder reported to be more troublesome than the back pain, a
previous referral or attendance at a pain management clinic, a severe psychiatric or psychological
disorder, other medical condition that could interfere with therapy, moderate to severe hypertension,
intake of anticoagulants or long-term steroids, inability to walk 100m when free of back pain,
inability to get up off the floor unaided, receipt of physical therapy in the preceding 3 months,
RMDQ score of ≤ 3 on the day of randomisation, inability to read and write English fluently
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TABLE 9 Summary of the included trials in the repository (continued )
Name of/given
name of trial Haake, n= 1163132
Country Germany
Interventions All groups received 10 30-minute sessions (two per week). Five additional sessions were offered if
after the tenth session patients experienced a 10–50% reduction in pain intensity (von Korff CPG)
l Verum acupuncture: sterile disposable needles used to needle fixed points plus additional points
from a prespecified list; 14–20 needles used and manual stimulation to elicit ‘de qi’ (an
irradiating feeling)
l Sham acupuncture: number and type of needles were the same as verum acupuncture. Needling
of verum points or meridians was avoided and needles were inserted superficially and
without stimulation
l Conventional therapy: this was a multimodal treatment programme by which patients received
10 sessions with a physician or physiotherapist who administered physiotherapy and exercise
Recruitment Patients were recruited through advertising in newspapers, magazines, radio and television
Inclusion criteria Aged ≥ 18 years with a clinical diagnosis of CLBP of ≥ 6 months, no previous experience of
acupuncture for LBP
Mean von Korff CPG score of ≥ 1 and a FFbHR score of < 70%
Exclusion criteria Any previous spinal surgery or fractures, infectious or tumorous spondylopathy, and chronic pain
caused by other diseases
Name of/given
name of trial BeST, n= 70133,34
Country l UK
Interventions l Intervention arm: participants received an initial 15-minute advice session and were provided
with The Back Book. Subsequently they attended six 1.5-hour group sessions, which covered
cognitive behavioural topics
l Control arm: participants received a 15-minute advice session and were provided with
The Back Book
Recruitment Recruited from GP practices after being identified from patient records or from consultation with the
GP or practice nurse
Inclusion criteria Aged ≥ 18 years, with at least moderately troublesome subacute or chronic LBP, with a minimum of
6 weeks’ duration, consultation with the GP for LBP within the preceding 6 months
Exclusion criteria LBP related to a serious cause such as infection, fracture, malignancy, those with severe psychiatric or
psychological disorders, and individuals with previous experience of a cognitive–behavioural
intervention for LBP
Name of/given
name of trial Keele, n= 40265,141
Country UK
Interventions l Brief pain management programme: patients were encouraged to return to normal activity using
functional goal setting and strategies to overcome psychosocial barriers. A management plan
was developed covering psychological, physical and functional topics. Exercises were undertaken
both at the session and home
l Manual physiotherapy: this was aimed at spinal manual therapy techniques. The aim was to
diagnose and treat biomechanical dysfunction of the spine using manual therapy methods and
exercises. An individualised home exercise programme was also provided
Recruitment Recruited from GP practices
Inclusion criteria Adults aged 18–64 years consulting with NSLBP of < 12 weeks’ duration for the first or second time,
able to give informed consent
Exclusion criteria Those with signs of red flags, sick leave of > 12 weeks, diagnosed with osteoporosis or inflammatory
arthritis, taking systemic steroids for > 12 weeks, pregnant, previous fracture or hip/back surgery, any
abdominal surgery in the preceding 3 months, receipt of treatment by any other professional for the
current episode of back pain
continued
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TABLE 9 Summary of the included trials in the repository (continued )
Name of/given
name of trial Brinkhaus, n= 298101
Country Germany
Interventions The acupuncture and minimal acupuncture treatments consisted of 12 30-minute sessions delivered
over 8 weeks
l Acupuncture treatment: this was semistandardised. Single-use sterile disposable needles were
used. Physicians were instructed to achieve ‘de qi’ if possible. Manual stimulation of needles at
least once during each session
l Minimal acupuncture: therapist were advised to needle at least 6 of 10 predefined non-acupuncture
points using a superficial insertion with fine needles. None of the points was in the area of the lower
back; ‘de qi’ and manual stimulation of the needles were avoided
l WL group: patients received acupuncture 8 weeks after randomisation. At this point they
received 12 sessions as per the acupuncture treatment group
Recruitment Primary recruitment method was via advertisement in local newspapers and subsequent snowballing
Inclusion criteria Aged between 40 and 75 years, with a clinical diagnosis of chronic LBP present for > 6 months, a
VAS of ≥ 40 for average pain intensity over the previous 7 days and the use of only oral NSAIDs in
the four weeks preceding treatment
Exclusion criteria Disc prolapse/protrusion with concurrent neurological symptoms; radicular pain, previous back
surgery; infectious spondylopathy; LBP caused by inflammation, malignancy or autoimmune disease;
congenital spine problems excluding minor lordosis or scoliosis; compression fracture caused by
osteoporosis; spinal stenosis; spondylolysis or spondylolisthesis; those with diagnoses with Chinese
medicine warranting treatment with moxibustion and receipt of acupuncture treatment in the
preceding 12 months
Name of/given
name of trial Dufour, n= 286102
Country Denmark
Interventions l Multidisciplinary biopsychosocial rehabilitation: 12-week programme split into three periods of
4 weeks
¢ Period 1: exercise was performed three times per week in 2-hour sessions. Exercise
comprised warm-up, stretching, aerobic training, and training to strengthen the muscles.
Machines and circuit training were used. Biweekly session on anatomy, postural techniques
and pain management was provided by a physiotherapist, and back care and lifting
techniques by an occupational therapist
¢ Period 2: twice-weekly 2-hour exercise sessions at the study site and once per week at home
or a fitness centre
¢ Period 3: three times per week, 2-hour exercise sessions at home or in a fitness centre
l Individual strength training exercises encouraged by a specially trained therapist. Sessions ran for
1 hour, twice per week, for 12 weeks. The therapist initially supported the patient and then,
over time, reduced the amount of assistance
Recruitment Rheumatologists and GPs referred patients
Inclusion criteria Patients aged 18–60 years with LBP of > 12 weeks with or without pain radiating into the leg(s).
The lumbar spine was assessed through radiography, CT or MRI scans. Physical examinations were
also used
Exclusion criteria Those with symptoms of spinal pathology, including malignancy, osteoporosis, vertebral fracture and
spinal, stenosis, clinical symptoms of an acute herniated disc accompanied by nerve root entrapment,
unstable spondylolisthesis, spondylitis, other health conditions preventing engagement in exercise
and language problems
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TABLE 9 Summary of the included trials in the repository (continued )
Name of/given
name of trial Pengel, n= 26059,103
Country Australia
Interventions l Exercise: individualised exercise programme using principles of cognitive behavioural therapy
l Sham exercise: sham pulsed ultrasonography and sham pulsed short-wave diathermy (neither
provided output but acted as though it did)
l Advice: to address unhelpful beliefs and fear avoidance, and encourage return to
normal activities
l Sham advice: in this session the participant was free to talk about his/her back pain and any
other problems. The physiotherapist was emphatic but did not give advice
Recruitment Recruited by referral to trial from health-care professional, invitation to those on a WL for
physiotherapy and advert in newspaper
Inclusion criteria Those aged 18–80 years, NSLBP lasting for at least 6 weeks but no longer than 12 weeks
Exclusion criteria Those who have had spinal surgery in the past 12 months, any serious spinal abnormality,
pregnancy, nerve root compromise, limited understanding of English and a contraindication to
exercise
Name of/given
name of trial YACBAC, n= 24188,142
Country UK
Interventions l Traditional acupuncture: up to 10 sessions over 3 months
l Usual care: this group received treatment as usual determined by the GP
Recruitment Recruited from GP practices
Inclusion criteria 18–65 years with non-specific LBP of 4–52 weeks’ duration
Exclusion criteria Patients currently having acupuncture, those with possible spinal disease, motor weakness, prolapsed
central disc, past spinal surgery, bleeding disorders or pending litigation
Name of/given
name of trial Hancock, n= 24094,131,143
Country Australia
Interventions l Spinal manipulation: patients in this arm received two to three sessions of treatment per week,
limited to a maximum of 12 treatments over 4 weeks. Manipulation was provided as per
a protocol
l Placebo spinal manipulation: detuned pulsed ultrasound was used
l Both active and placebo manipulative therapy sessions were matched in time (30–40 minutes for
initial session, followed by 20-minute follow-up sessions)
Four arms in the trial
l SMT group (placebo drug and active SMT)
l SMT and NSAIDs group (diclofenac and active SMT)
l NSAIDs group (diclofenac and placebo spinal manipulation)
l control group (placebo drug and placebo SMT)
Recruitment Recruited from GP practices
Inclusion criteria Pain present in the region between the twelfth rib and buttock crease, causing moderate pain and
moderate disability
Exclusion criteria Present episode of pain not preceded by a pain-free period of at least 1 month, suspected or known
serious spinal pathology; nerve root compromise; presently taking NSAIDs or undergoing spinal
manipulation; any spinal surgery within the preceding 6 months; and contraindication to
paracetamol/diclofenac or SMT
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TABLE 9 Summary of the included trials in the repository (continued )
Name of/given
name of trial VKBIA, n= 240104
Country USA
Interventions l Brief individualised programme: aimed to reduce fear and increase activity levels. This was
delivered over four sessions, the first lasting 90 minutes with a psychologist, the second
60 minutes with a physiotherapists, the third lasting 30 minutes with a physiotherapist, and
the final visit lasting 30 minutes with a psychologist. Intervention patients also received up to
three bonus visits, a book on back pain self-management and video on back pain self-care
l Usual care: as provided to patients who were not participating in a trial. This care varied but
included the use of medication, primary care consultations and secondary care referrals
Recruitment Invitations were sent to patients who had consulted in primary care for their back pain and who
were enrolled in the Group Health Cooperative
Inclusion criteria Patients with back pain, aged 25–65 years, with a RMDQ score of ≥ 7 on a 23-item scale
Exclusion criteria Those waiting for back surgery, seeing a physical therapist or psychologist, patients planning to
unenrolled from the Group Health Cooperative
Name of/given
name of trial HullExPro, n= 23776
Country UK
Interventions l Back to fitness exercise programme: patients were invited to attend eight one hour sessions
aimed at increasing activity over a 4-week period. There was an underpinning cognitive
behavioural approach
l Individual physiotherapy: treatments were provided at the discretion of the therapist
Recruitment Physiotherapy departments at acute hospitals
Inclusion criteria Those with mechanical LBP lasting at least 6 weeks
Exclusion criteria Those with sciatica, recent significant surgery, the presence of a neurological or systemic condition,
psychiatric illness or pregnancy; individuals who have had spinal surgery, in receipt of physiotherapy
in the 6 weeks prior
Name of/given
name of trial VKSC2, n= 226105
Country USA
Interventions l Self-care arm: this was a group intervention of between 12 and 16 patients delivered over two,
2-hour sessions led by a psychologists covering a range of topics. Each patient had an individual
45-minute session with the psychologist to develop a personal self-care plan. Patients also
received one brief follow-up telephone call to encourage continued action on the self-care plan.
Patients were also provided with book on managing back pain, 40-minute videotape on back
pain self-care and a 25-minute videotape demonstrating exercises
l Usual care group: received usual care plus a book on back pain
Recruitment Patients were recruited from primary care by mail 6–8 weeks after a back pain visit to a Group
Health primary care physician
Inclusion criteria Patients with back pain, aged 25–70 years; patients who had been enrolled into Group Health for at
least 1 year
Exclusion criteria Those being considered for surgery
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TABLE 9 Summary of the included trials in the repository (continued )
Name of/given
name of trial Smeets, n= 22370
Country The Netherlands
Interventions l APT: this consisted of aerobic and strength training. This was delivered by two physiotherapists
in a maximum group of four. Sessions were delivered three times per week lasting 1 hour and
45 minutes
l CBT: this aimed to help patients reach their goals, manage beliefs and increase activity levels.
Therapists used graded activity and problem-solving training
l APT: aimed at increasing aerobic capacity and muscle conditioning
l CBT: aimed at helping individuals reach their goals to increase activity levels and manage beliefs.
Graded activity was used to encourage gradual increase or pacing of activities important to
them. The frequency of the sessions gradually decreased from three sessions to one session per
week. In total, 11 half hours of treatment
l CTrt: aim was to improve functioning by increasing fitness, behaviour change and management
of beliefs. CTrt consisted of APT together with problem-solving training
l WL: patients needed to wait 10 weeks before they were offered individual rehabilitation
treatment. While on the WL patients were unable to have diagnostic or therapeutic procedures
because of their CLBP
Recruitment Patients referred for the first time to a rehabilitation centre by their GP or other medical professional
were invited to the study
Inclusion criteria Aged 18–65 years with CLBP of ≥ 3 months with or without radiation to leg, a RMDQ score of > 3
and ability to walk at least 100m without interruption
Exclusion criteria Vertebral fracture, spinal inflammatory disease, spinal infections or malignancy, current nerve root
pathology, spondylolysis or spondylolisthesis, lumbar spondylodesis. A comorbidity preventing
exercise, ongoing treatment or investigation for CLBP at the time of referral or a clear treatment
preference. Use of other treatments for back pain except pain medication. Any psychopathology
affecting ability to take part. Not proficient in Dutch, being pregnant and having substance abuse
Name of/given
name of trial Cecchi, n= 210106
Country Italy
Interventions All patients were given an educational booklet on the back
l Back school: 15 1-hour sessions delivered over 15 days. The first five sessions focused on back
physiology and pathology. The remaining 10 sessions looked at relaxation techniques, group and
individual exercises. Groups were made up of eight patients and two therapists
l Individual physiotherapy: therapists were able to select from exercises in a protocol to suit the
patient. There were 15 sessions lasting 60 minutes delivered over 15 days
l Spinal manipulation: four to six weekly sessions of 20 minutes each over 4–6 weeks
Recruitment Rehabilitation outpatient department by psychiatrists
Inclusion criteria NSLBP over at least the last 6 months reported as present ‘often’ or ‘always’
Exclusion criteria Neurological signs or symptoms, spondylolisthesis, spinal stenosis, scoliosis of > 20°, rheumatoid
arthritis/spondylitis, previous vertebral fracture, psychiatric condition, cognitive impairment or
pain-related litigation
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TABLE 9 Summary of the included trials in the repository (continued )
Name of/given
name of trial York BP, n= 187133
Country UK
Interventions l Exercise programme: delivered as a group intervention of eight 1-hour sessions over a 4-week
period. The sessions comprised stretching, low-level aerobic exercises and strengthening.
The programme used cognitive behavioural principles and patients were encouraged increase
their activity levels
l Controls: patients received usual care from their GP
Recruitment Recruited from GP practices
Inclusion criteria Patients aged between 18 and 60 years with LBP that has lasted at least 4 weeks but < 6 months,
who had consulted their GP. Patients had to be deemed fit to be able to undertake exercise
Exclusion criteria Those with a potentially serious pathology, unable to attend or participate in the classes, and those
receiving ongoing physiotherapy
Name of/given
name of trial Macedo, n= 172134
Country Australia
Interventions In both arms patients received 12 1-hour sessions over an 8-week period. Home exercises were
encouraged in both groups. The home exercises and treatment sessions totalled 20 hours
l Graded activity: the aim of graded activity was to get patients to engage in activities that they
found difficult because of back pain. Patients were provided with an individualised progressively
increasing exercise programme to address functional problems. A cognitive–behavioural
approach was used by the physiotherapist
l Motor control exercise: the aim is to retain optimal control and coordination of the lumbar spine
and pelvis. Stage 1 involves regaining basic control strategies. In stage 2 participants progress
through to more complex static and dynamic tasks, and training of functional activities. At all
progressions the therapist evaluates and corrects trunk muscle recruitment strategies, posture,
movement patterns and breathing
Recruitment Recruitment via GPs, physiotherapists and public hospitals
Inclusion criteria Aged 18–80 years with NSLBP of at least 3 months and seeking care. English speaking, living in the
study region for the duration of the study, fit to engage in exercise, score of moderate or greater for
amount of bodily pain in the past week, and interference of pain with normal activities
Exclusion criteria Serious spinal pathology suspected or known, patients who have had spinal surgery or who are due
to have such surgery during the study period, nerve root compromise, any comorbidities preventing
participation in exercise
Name of/given
name of trial Carlsson, n= 50135
Country Sweden
Interventions l Manual acupuncture: needle acupuncture was used in predefined areas. There was a gradual
increase in the number of needles from 8 to 14–18 during the first three or four treatments.
The ‘de qi’ feeling was sought. Treatment sessions lasted 20 minutes and needles were
stimulated on three occasions during this time
l Electroacupuncture: the first two or three sessions were manual acupuncture followed by
treatments consisting of electrical stimulation of four needles in the low back. A similar number
of needles as in the manual acupuncture group were inserted and manually activated
l Placebo stimulation: this was a mock TENS given by a disconnected stimulator. The area targeted
was the most painful area in the low back. During the session patients were able to see a
flashing lamp
Recruitment Patients with CLBP, who were referred to an outpatient pain clinic during a 3-year period, were included
Inclusion criteria Patients with LBP without radiation below the knee for > 6 months, normal neurological examination
function of lumbosacral nerve
Exclusion criteria Those who have had previous acupuncture treatment, patients with major trauma or systemic
disease and pregnancy
COLLATING DATA
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Grouping of interventions
Initial examination of the data showed that no two trials studied identical interventions. Even the usual-care
arms of included studies are likely to differ according to jurisdiction, site of recruitment and age of the study.
Even with our initial large sample size it was clear that, to be able to make meaningful comparisons, we would
need to pool interventions into broad groups for our analyses. As a first stage we identified the control
interventions and classified these as either usual care or a sham control. There is, for example, evidence from
the acupuncture literature that the difference between sham acupuncture and usual care is greater than any
difference between sham and verum acupuncture.145 We therefore opted to separate the sham interventions
from the usual care control in our analyses comparing different treatments with control or with each other.
There may be qualitative differences between sham treatments. For example, sham acupuncture, through which
the participant has had the sensation of being needled, might have a different effect from a sham educational
intervention. In some analyses we have included sham interventions, typically sham acupuncture as a separate
category. For this reason we have, where appropriate, specified the nature of the sham intervention considered.
We used the following approach to develop our final grouping of interventions:
1. Careful reading of each trial intervention to decide on core groups [individual physiotherapy, exercise,
manipulation, advice/education, psychological therapy, graded activity, acupuncture, combination therapy,
mock transcutaneous electrical nerve stimulation (TENS), sham acupuncture and control]. We listed all of
the trials contributing to each of the core groups together with the number of participants. Subsequently,
links were made between core groups to indicate potential direct and indirect comparisons (Figure 5).
2. To explore further the potential direct and indirect comparisons, a second figure was constructed
(Figure 6). This shows the same groups presented in the first step with the additional information on
the number of trials and total number of participants contributing to each of the comparisons.
3. Finally, to allow for any meaningful comparisons, we split the groups mentioned in steps 1 and 2
into three broad categories, namely active physical (exercise and graded activity), passive physical
(individual physiotherapy, manipulation and acupuncture) and psychological (advice/education and
psychological therapy) (Table 10).
TABLE 9 Summary of the included trials in the repository (continued )
Name of/given
name of trial Kennedy, n= 48136
Country UK
Interventions l Verum acupuncture plus The Back Book – acupuncture was based on a ‘western’ approach.
Between 3 and 12 sessions were provided over a 4- to 6-week period. At each session
8–13 needles were inserted and manually stimulated until ‘de qi’ was achieved
l Sham acupuncture plus The Back Book – the Park Sham Device was used with
acupuncture needles
l Control intervention – the Park Sham Device was used with non-penetrating needles which
touched the skin but did not penetrate the skin
Recruitment Patients put on a WL for physiotherapy by their GP
Inclusion criteria Adults aged 18–70 years, who are able to give informed consent with NSLBP, with or without
referred pain, of up to 12 weeks’ duration
Exclusion criteria Those with red flags, pain that has lasted for > 12 weeks, those with a contraindications to
acupuncture or previous acupuncture treatment, any other conflicting or ongoing treatments
APT, active physical therapy; CBT, cognitive–behavioural treatment; CLBP, chronic low back pain; CPG, Chronic Pain Grade
Scale; CT, computerised tomography; CTrt, combined treatment; FFbHR, Hannover Functional Ability Questionnaire
for measuring back pain-related functional limitations (Funktionsbeeintrachtigung durch Ruckenschmerzen); MRI, magnetic
resonance imaging; NSAID, non-steroidal anti-inflammatory drug; SMT, spinal manipulative therapy; TENS, transcutaneous
electrical nerve stimulation; VAS, visual analogue scale; WL, waiting list; YACBAC, York Acupuncture Back Pain Trial.
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Individual physiotherapy  (n = 333)
All trials
Control (n = 3573)
Manipulation (n = 736)
• BEAM, n = 346
• Cecchi, n = 70
• Hancock, n = 119
• Keele, n = 201
Psychological (n = 901)
• BeST, n = 468
• Keele, n = 201
• VKBIA, n = 119
• VKSC2, n = 113
Graded activity (n = 144)
• Macedo, n = 86
• Smeets, n = 58
Acupuncture (n = 2201)
• Brinkhaus, n = 146
• Carlsson, n = 34
• Haake, n = 387
• Kennedy, n = 24
• Witt, n = 1451
• YACBAC, n = 159
Usual/GP care (n = 2885)
Sham (n = 688)
Brinkhaus (acupuncture), n = 73
Carlsson (mock TENS), n = 16
Haake (acupuncture), n = 387
Hancock (electrotherapy), n = 120
Kennedy (mock TENS), n = 24
Pengel (electrotherapy + 
education), n = 68
BEAM (exercise + manipulation), n = 327
Pengel (exercise + education), n = 63
Smeets (education + graded 
activity), n = 61
Combination (n = 451)
• Cecchi, n = 70
• Dufour, n = 144
• HullExPro, n = 119
Exercise (n = 770)
• BEAM, n = 303
• Dufour, n = 142
• HullExPro, n = 118
• aPengel, n = 65
• Smeets, n = 53
• York BP, n = 89 Advice/education (n = 219)
• Cecchi, n = 70
• Macedo, n = 86
• bPengel, n = 63
• BEAM, n = 332
• BeST, n = 233
• Brinkhaus, n = 79
• Haake, n = 388
• Smeets, n = 51
• VKBIA, n = 121
• VKSC2, n = 113
• Witt, n = 1390
• YACBAC, n = 80
• York BP, n = 98
FIGURE 5 Step 1: classification of trials into core groups. a, Plus sham advice/education; b, plus sham electrotherapy.
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m = 1;
n = 140
m = 2;
n = 523
m = 1;
n = 140
m = 1;
n = 128
m = 1;
n = 140
m = 1;
n = 649
m = 1;
n = 239
m = 1;
n = 678
m = 1;
n = 402
m = 3;
n = 1167
m = 2;
n = 771
m = 1;
n = 131 m = 4;
n = 4080 m = 4;
n = 1091
m = 2;
n = 927
m = 1;
n = 109
m = 1;
n = 172
m = 1;
n = 131
m = 1;
n = 133
m = 3;
n = 926
Individual
physiotherapy
ExerciseManipulation
Psychological
Combination
GP care
Acupuncture
Graded
activity
Sham
Advice
All trials
FIGURE 6 Step 2: classification of trials with indication of number of trials and participants for direct and indirect
comparisons. m, Number of trials; n, total number of participants.
TABLE 10 Step 3: final grouping of treatment arms for analyses
Parent group Subgroup Subtype
Intervention Active physical Exercise
Graded activity
Passive physical Acupuncture
Manual therapy
Individual physiotherapy
Psychological Advice/education
Psychological (cognitive behavioural approach)
Sham control Sham acupuncture
Sham electrotherapy
Mock TENS
Sham advice/education
Control (GP/usual care) GP
WL
WL, waiting list.
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In this programme of work we were not seeking to estimate the true effect size of any individual
intervention. Rather, we were seeking to identify predictors of treatment response. These analyses were
constrained by the availability of data on potential moderators that could be pooled across trials.
Considering the potential mechanisms through which the potential moderators might affect outcome, the
study team concluded that it was reasonable to pool interventions that might under other circumstances
appear rather heterogeneous. In particular, the decision to include several superficially different
interventions as passive physiotherapy might surprise some readers. Our view, however, is that these are
very distinctly different from active exercise-based interventions, or those working through a psychological
approach. Essentially, they all consist of an assessment, whatever reassurance and education is provided
as part of the treatment session, plus whatever modality is being offered, be it massage/mobilisation/
manipulation or needling. We consider these to be conceptually sufficiently close in their mode of action
that it is unlikely there will be distinctions in how the potential moderators included in our analyses might
affect outcomes. They are, however, distinctly different from their active physical or psychological
interventions in how treatment moderation might operate.
In organising the data we also identified combined interventions but there were too few data points for it
to be worthwhile pursuing these analyses. For this reason these were excluded from our final analyses.
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Chapter 4 Creating the repository database and
data control
Typographical conventions
This chapter presents the methods we used to create the repository database. To distinguish database
vocabulary and commands from regular texts, different typographical fonts are used. Database object-class
vocabulary is printed in sans-serif font [like this] and the command for mapping and transformation
procedures is printed in monospaced typewriter font [like this]. In addition, coloured command fonts
in the text are for ease of referencing between program commands shown in figures and text explanations.
Background
Clinical trial data sets can be stored in a tabular format, for example Microsoft Excel® or SPSS (Statistical
Package for the Social Sciences). A tabular format typically uses each row to represent data from a
participant and each column to represent an item from a case report form (CRF).
Tabular formats have the advantage of being intuitive, relatively simple to create and machine readable.
However, this format can be susceptible to excessive growth, especially when clinical and non-clinical items
are measured across multiple time points. Data collected for withdrawn participants or non-responders
would still require columns for all variables irrespective of whether or not they were used. Repeating
questions pose a similar problem, whereby storage space must be allocated across the whole domain to
accommodate all responses. For example, asking for a participant’s medical history of prescribed drugs
would require a new column to be added for every drug listed. If only one participant documented a long
list of drugs then many columns would have to be created for all participants.
Tabular formats are effective for only the smallest of trials and quickly become inefficient and difficult to
maintain when the range of data collected increases. For larger trials, a more robust solution is to use a
relational database. The relational database model allows individual tables to be created for each CRF and
for repeating sets of questions. Normalisation rules are often applied to define the columns for each table
and the logical relationships are used to create table joins.146
Figure 7 shows sample data in a tabular format and the normalised equivalent in a relational database.
The sample data consist of the subject identification, recruitment date, demographic data and the RMDQ
scores taken at baseline and at 3-month follow-up. The data are normalised into four tables, namely
SUBJECT, DEMOGRAPHICS, RMDQ (for the RMDQ measurement) and FU (follow-up); the last is used to
store the time points for each follow-up visit.
Each table has a primary key (PKey) column for storing a unique record identifier that is used as the basis
for creating relationships between tables (see Figure 7b). The relationship between SUBJECT and
DEMOGRAPHICS is one-to-zero-or-one, that is a subject can have zero or one demographic record. The PKey
from the SUBJECT table is copied to the DEMOGRAPHICS tables, thereby creating a join using a shared value.
The relationship between SUBJECT and RMDQ is one-to-zero-or-many, that is, a subject can have zero or
many RMDQ completed questionnaires. The FU table is joined to the RMDQ table using a one-to-zero-or-many
relationship. This join allows a RMDQ score to be associated with either a baseline or a 3-month follow-up
time point.
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To create the relationships to the RMDQ table, the PKeys from both the SUBJECT and FU tables are added
as foreign keys (FKeys). This has the result of allowing a subject to have either zero or many RMDQ scores
at all time points. A composite unique constraint is applied to the Subject FKey and FU FKey columns to
prevent a subject from having duplicate RMDQ scores for the same time point.
The repository differs from a typical clinical trial database in that it is not possible to predetermine
requirements by using annotated CRFs. The repository relies on data from multiple trials to be periodically
reviewed and classified, and must be frequently altered to accommodate new discoveries. The relational
database is not a suitable model for such a scenario because modifications to the schema can be
time-consuming and complex, often requiring the expertise of information technology specialists. Thus,
the database for this project needs to be flexible so that the end users, namely, statisticians and health
economists, can carry out modifications without having to change the database schema.
Our solution is to create a hybrid database that is a cross between an entity-attribute-value (EAV) open
schema model and a relational database. This hybrid database has the flexibility of storing sparse
heterogeneous data, which allows dynamic changes while enforcing data integrity.
The next section describes the architecture of the hybrid database. The rules used to map and transform
the original source data to the repository standard are described below in Mapping and transformation.
Using entity-attribute-value data shows how the repository database is manipulated, such that the data
can be viewed in an analysis-friendly format from any statistical program that supports Open Database
Connectivity (ODBC). Extract, transform and load describes how data from multiple RCTs were extracted,
transformed and harmonised to the repository standard and, finally, loaded to the repository database.
(a)
(b)
FIGURE 7 (a) A sample of original tabular format data; and (b) normalised relational interpretation of the original
tabular data.
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System architecture
Tables and columns in a relational database can be represented as classes and attributes in an EAV
model.147 In the subsequent text the terms ‘class’ and ‘attribute’ will be used to conform to the EAV
vocabulary. The term ‘entity’ is interchangeable with the term ‘object’ and can be thought of as providing
a similar role to a table row but with the significant difference of storing only a pointer to the data and not
the actual data itself. The entity–relationship diagram for the hybrid database is shown in Figure 8.
We anticipated that there would be some consistent data present in all of the RCTs for describing the trial
and for identifying the trial’s subjects. The two tables Primary Source and Subject were created with
fixed schemas to store this data (see Figure 8). The Primary Source table stores the name of the RCT
(prms_TrialName), a brief description of the trial (prms_Description) and the date on which the data were
imported into the repository (prms_ImportDate). The Subject table stores the original identifier assigned to
the trial participant (subj_OriginalID), the date the participant enrolled into the trial (subj_EDate), the date
the participant was randomised (subj_RDate) and a unique identifier generated by the system (subj_ID).
A foreign key relationship is created to link each subject to the Primary Source.
The EAV model uses a subschema consisting of tables for classes, attributes, objects and the EAV data.
The Class table is used to hold a list of all the identified domains, for example RMDQ and demographics.
These domains generally map to a CRF but can also be used to describe a subset of repeating questions,
for example repeated medical prescriptions.
The Attribute table is used to hold a list of all identified variables that typically map to a CRF question. The
Attribute table has columns for storing a short name, a verbose name, a reference to the containing class
and data type details. The short name is used to store a standardised version of the original CRF question.
The Object table stores a unique identifier for each instance of a class and a reference to the class itself.
A foreign key relationship is created to link each Object to a Subject. This relationship essentially makes
the EAV model subject centric, that is, all of the data stored in the Object and EAV tables must be directly
related to an imported subject. Relationship between objects is possible by using an ‘ancestor column’
to store the unique identifier of a related object. For example, an object used for repeated medical
prescriptions will store the unique identifier of the related follow-up object in the ‘ancestor column’.
The EAV data table has three columns and is used to store all of the repository’s RCT data. Two columns
hold references to the related objects and attributes, with the other column used for storing the actual
value of each object–attribute combination. The references to the objects and attributes take the form of
foreign keys to the object and attribute tables. The format of the value is coerced into a string regardless
of the intended data type. The intended data type – for example binary data, small integers or strings –
details are stored in the related attribute table.
A simplification of how tabular data are represented in an EAV table is shown in Figure 9. In this example,
the tabular data have one row for each subject (see Figure 9a). When the data are shown in the EAV table
there are four rows for subject #1000, three rows for subject #1001 and three rows for subject #1002.
For each populated cell in the tabular data a row is created in the EAV table. Subject #1000 has all cells
populated and, therefore, has a row for each entry. Only three rows are entered for the other subjects
because there was no RMDQ baseline score for #1001 and age was not recorded for #1002 (see Figure 9c).
In reality the EAV table will use the column Attribute ID to store the unique attribute identifier and
not the text value as shown in Figure 9c. In addition, the column Object ID stores a reference to the object
and not the subject ID. It is the related object that links back to the subject and to the class.
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Primary Source
Data Type
Class
Subject
Attribute
EAV
Object
prms_ID
prms_TrialName
dtyp_ID
dtyp_Name
cls_ID
cls_Name
cls_Description
subj_ID
subj_PrimarySourceID
subj_OriginalID
subj_RDate
subj_EDate
attr_ID
attr_ClassID
attr_ShortName
attr_LongName
attr_DataTypeID
attr_Length
attr_Precision
attr_Scale
eav_ObjectID
eav_Value
obj_ID
obj_ClassID
obj_AncestorID
eav_AttributeID
obj_SubjectID
prms_Description
PK
PK
PK
PK
PK
PK
PK
PK
FK
FK
FK
FK
FK
FK
FK
FK
prms_ImportDate
Repository fixed schema
Repository EAV subschema
FIGURE 8 The entity–relationship diagram for the hybrid repository database depicting the fixed schema with the
subschema EAV tables. Bold text represents required parameters.
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Mapping and transformation
Early evaluation of data sets from various RCTs in the project identified large variations between variable
naming and coding conventions. For example, the RMDQ was used to measure back pain disability and
the participant would tick all of the items that were applicable to him/her on that day. There are 24 items
in the questionnaire and the score is the sum of all of the ticked items. One trial might name each column
‘rm1’, ‘rm2’ and so on until ‘rm24’ for all 24 individual items and ‘rmscore’ as the RMDQ score measured
at baseline, ‘rm1_3mo’, ‘rm2_3mo’, . . ., ‘rm24_3mo’ and ‘rmscore_3mo’, for the 3-month follow-up data,
and so on. Another trial might name them ‘rdq1’, ‘rdq2’, . . ., ‘rdq24’ and ‘rdq’ for items measured at
baseline, ‘rdq11fu’, ‘rdq21fu’, . . ., ‘rdq241fu’ and ‘rdq1fu’ for items measured at the first follow-up, which
could have been 1 or 3 months post randomisation, depending on the protocol. In addition, some trials
might use the numerical value ‘1’ to represent a tick for that item and ‘0’ if it was not ticked. Other trials
might use ‘1’ as ticked and ‘2’ as not.
Pilot mapping and transformation
A system was required to efficiently extract, transform and load (ETL) the original trial data sets into the
repository. After evaluating a number of commercial and open-source ETL software packages, a prototype
was developed using Microsoft SQL Server Integration Services (SSIS; SQL Server 2005 Enterprise Edition)
and spreadsheets for documenting mapping and transformation instructions. The spreadsheet instructions
were passed from the statisticians and health economists to the programmer who in turn created the
SSIS program.
The pilot was deemed to be an inadequate solution. The versatility of SSIS as a data integration and
transformation tool become a hindrance when attempting to customise a solution specifically for the
repository. Setting up and configuring SSIS was found to be a laborious task, which was made even more
difficult by frequent change requests and the manual interpretation of the mapping and transformation
instructions. It became apparent that using SSIS was not viable and a decision was made to develop a
bespoke ETL application.
(a) (b)
(c)
FIGURE 9 (a) A sample of original tabular format clinical data; and (b) the XML mapping and transformation
instructions; and (c) the sample data represented as EAV. XML, extensible mark-up language.
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XML and XSD for mapping and transforming
The method used to store mapping and transformation instructions was vastly improved by using
extensible mark-up language (XML). XML is a free and open-source standard governed by the World Wide
Web Consortium (WC3) and can be used to define a set of rules for encoding documents in a format that
is both readable by human and machine.148 The mapping and transformation XML document is made up
of simple and intuitive keywords that both statisticians and health economists can easily interpret and
apply. Having non-programmers directly enter the mapping and transformation rules forgos the
requirement to pass these instructions on to a programmer, which, in turn, saves resources and decreases
misinterpretation errors.
To ensure that all mapping and transformation rules were specified in the correct format and the correct
order, an XML schema definition (XSD) was applied to validate the XML document. The XSD is a separate
document that defines the permitted structure of the XML document.
Mapping clinical data
Figure 9b shows an example of the XML mark-up to map the original data to the equivalent repository
attributes. The standard attributes age and sex from the DEMOGRAPHICS class are mapped to the
original variables age and gender. RMDQ scores for baseline and 3-month follow-up are mapped to the
RDQ attribute from the RMDQ class.
The XML element attributeName accepts values for the original variable name (originalName) and
the follow-up time point (fu) as XML attributes. The value of the attributeName XML element is set to
the name of the repository attribute. In the example for class RMDQ the attribute name is RDQ.
Unlike in the original tabular data, the repository does not store different attribute names for each time
point. Instead each time point will trigger a new object to be created. The XML fu attribute is used to
track to which time point an original variable belongs.
Transforming clinical data
The original demographics and RMDQ scores have to be transformed into the repository standard before
the data can be loaded into the repository database. Table 11 shows that the standard value for male is
represented numerically by 1 and female is 2 for attribute SEX. Based on the same example (see
Figure 9a), the values for male and female in the original data were entered as M and F, respectively.
Thus, the transformation for the SEX attribute uses two match rules to find values M and F. When the
value M is matched, the rule has been set to update the attribute’s value to 1. Likewise, when the value F
is matched, the attribute’s value is updated to 2. There is no transformation rule for AGE attribute, as the
repository accepts any valid integer value.
In the example for class RMDQ, the transformation uses a range rule to allow values of only between 0
and 24 to be imported. If any RDQ value falls outside this range then the system will transform the value to
Null (empty).
Mapping and transforming health-care resource-use data
Mapping health-care resource-use variables was more challenging because the different types of resources
used across all RCTs do not conform to any standard and are completely variable. However, each question
and answer in a typical health-care resource-use questionnaire can be broken down to the recall period,
the type of resource, the reason for using the resource, the location of the resource, the unit of
measurement, the quantity, the cost or expenses incurred and the payer.
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Figure 10 shows a simplified version of a typical health-care resource-use questionnaire. In this example,
participants were asked to record all of the health-care resources that they used at the 3-month follow-up
time point (see Figure 10a). The answers provided by the participants were stored in a tabular format,
which used 12 columns to capture all of the responses to the five questions (see Figure 10b). By using this
format, the number of required columns to accommodate the data would grow in line with the maximum
number of responses provided by any one individual. For example, if only one participant listed three items
he/she bought over the counter to treat his/her LBP, the number of columns required would have to be
increased from 12 to 13.
Figure 10c shows a view of the repository health-care resources data, generated from the EAV tables.
This view displays the eight standard repository health-care resource-use attributes (table columns) and an
additional attribute called ‘Text’, which is used to store all of the characters that are captured as comments
in the CRF.
The process for creating the transformed health-care resource-use data involves splitting the original
questions into a number of derived parts that will map to the standard attributes. For example, question 1
asked how many times the participant had consulted his/her doctor or any primary care doctor, for any
reason, in the last 3 months. Using the information contained in the question, the recall period is set to ‘3’,
the type of resource is ‘GP’, the reason for using the resource is ‘Any condition’, the location of the resource
TABLE 11 A sample of the repository standard attributes and values
Class Attribute short name Attribute long name Data type Value Label
DEMOGRAPHICS SEX Participant’s sex Integer 1 Male
2 Female
DEMOGRAPHICS AGE Participant’s age Integer > 0
RMDQ RDQ RMDQ score Integer Range 0–24
HE RP Recall period Integer > 0
HE TYPE Types of resource String 1a Primary care doctor
3a Physiotherapist
4M01 NSAIDs
6 Aids and adaptations
HE REASON Resource reason Integer 2 LBP
4 Any condition
HE LOCATION Resource location Integer 1 Primary care clinic
3 Private clinic
4 Community clinic
HE UNIT Resource units Integer 1 Visit
3 Prescription
4 Item
HE QUANTITY Integer > 0
HE COST Integer > 0
HE PAYER Resource payer Integer 1 Public health service
4 Individual
HE, health economics; NSAID, non-steroidal anti-inflammatory drug; RP, recall period.
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(a)
(b)
(c)
FIGURE 10 (a) A sample of questions in a CRF at 3-month follow-up; (b) a sample of original tabular format
health-care resource-use data; and (c) a sample of how the health-care resource-use data populate the repository
standard. CC, community clinic; GP, general practice; IND, individual; N/A, not applicable; PHS, public health service;
Pri, primary care; Physio, physiotherapist; Priv, private clinic; Px, prescription; RP, recall period.
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is ‘Primary Care Setting’, the unit of measurement is ‘Visit’ and the payer is ‘Public Health Service’. All of
these values are derived solely from the information contained in the original question as opposed to the
value of the variable. Only the attribute ‘Quantity’ is directly mapped to the original variable’s value.
The health-care resource-use data are stored in the EAV tables by creating relationships between objects.
For each time point, one or many resource-use objects can be created. The HE class is used to define the
time points for collecting only the health-care resource-use data. The actual resource-use data are defined
in the HE-DATA class and the time point value is used to link an HE-DATA object to an HE object.
The XML schema was modified to allow related classes to be described, which, in turn, gets interpreted by
the system to create the relationships in the Object table.
Figure 11 shows the HE-DATA class being used as a child class, that is, it has the HE class as its parent.
Creating child classes signifies to the system that a relationship exists between two classes. The linkedValue
attribute is used to specify a shared value between the parent and child classes. In a relational database, this
shared value would be created as a foreign key constraint. In the example shown in Figure 11, an HE class has
been defined for the 3-month follow-up time point using the attribute fu: <attributeName fu=“3”>
</attributeName>. A child HE-DATA class has been defined and linked to the parent HE class by
specifying the value “3” for the linkedValue: <childClass name=“HE-DATA” linkedValue=“3”>.
This corresponds with the 3-month follow-up time point specified in the HE class.
Child classes in the XML use groupName elements to signify the number of objects that need to be
created. In a relational database, this would result in adding a new groupName element for every table
row to be inserted. The value for the groupName element has no significance except that it must be
unique. In the example shown in Figure 11, six groups have been created for the 3-month resource-use
data, namely 3moResource1, 3moResource2, 3moResource3, 3moResource4, 3moResource5 and
3moResource6. These groups represent each question in the CRF shown in Figure 10a and the data
shown in Figure 10b.
The original tabular data required 13 columns across three rows to store all of the data for the three
participants. Instead of creating a new column for every resource, the repository creates a new object.
The seven groups are used to create objects for GP visit (Pri1), NHS physiotherapist visit (Pri2), private
physiotherapist visit (nPriv1), two instances of prescribed medicine (pmed1, pmed2) and two instances of
aids or medications bought over the counter (bmed1, bmed2). Although seven groups have been defined
in this example, the ETL system will create objects only where data exist. For example, subject #1000 will
create only four objects for GP visit (Pri1), NHS physiotherapist visit (Pri2), private physiotherapist visit
(nPriv1) and medicine prescribed by GP (pmed1).
Once all resources have been identified and a group has been defined, the mapping rules are used to
populate the repository’s standard resource-use attributes. Within the <mapping/> structure, the
groupName is used to allow the system to locate the correct object to process and the originalName is
used to store the name of the original variable. The attributeName element stores the name of the
mapped repository attribute.
The original variable Pri1 stores the quantity of doctor visits and hence Pri1 is mapped to the repository
attribute Quantity for the group 3moResource1. The other information required to make sense of
this value are hard coded to the repository standard within the <staticValue/> structure, which is
within the <transform/> structure. For example, the recall period (RP), the type (Type), the reason
(Reason), the location (Location), the unit (Unit) and the payer (Payer) of the resource allocated in
3moResource1 group is hard coded to 3, 1a, 4, 1, 1 and 1, respectively (see Table 11 for list of values
and corresponding labels). These values can be hard coded in the XML because they are known to be
based on the CRF and do not affect the original data. When the system processes this mapping
instruction, subject #1000 would have a health-care resource-use object that shows that there was one GP
visit made during the 3-month follow-up time point (see Figure 10b).
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FIGURE 11 The XML mapping and transformation instructions for the sample data in Figure 10.
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Other <transform/> rules can be applied to manipulate the original health-care resource-use data.
For example, the original medicines prescribed have to be transformed to the repository standard to the
standardised drug coding. Figure 11 shows a transformation for the Type attribute that uses a match rule to
check for the value Ibuprofen. If matched, the rule has been set to update the attribute’s value to 4M01.
The XML mapping and transformation instructions shown in Figure 11 were based on only one follow-up
time point. For mapping data from more than one follow-up time point, simply create more HE objects,
and map and transform health-care resource data within the child class HE-DATA that is linked to that
follow-up time point, for example:
<class name="HE"> 
<mapping> 
<attributeName fu="3"></attributeName> 
<attributeName fu="6"></attributeName> 
... 
<attributeName fu="n"></attributeName> 
</mapping> 
 
<childClass name="HE-DATA" linkedValue="3"> 
<grouping> 
<groupName>3moResource1</groupName> 
... 
<groupName>3moResourceN</groupName> 
</grouping> 
<mapping> 
<attributeName originalName="Pri1" groupName="3moResource1">Quantity</attributeName> 
... 
<attributeName originalName="cmed2" groupName="3moResource6">Cost</attributeName> 
</mapping> 
<transform> 
... 
</transform> 
</childClass> 
 
<childClass name="HE-DATA" linkedValue="6"> 
<grouping> 
<groupName>6moResource1</groupName> 
... 
<groupName>6moResourceN</groupName> 
</grouping> 
<mapping> 
<attributeName originalName="Pri1" groupName="6moResource1">Quantity</attributeName> 
... 
<attributeName originalName="cmedN" groupName="6moResourceN">Cost</attributeName> 
</mapping> 
<transform> 
... 
</transform> 
</childClass> 
… 
 
<childClass name="HE-DATA" linkedValue="n"> 
<grouping> 
<groupName>nmoResource1</groupName> 
... 
<groupName>nmoResourceN</groupName> 
</grouping> 
<mapping> 
<attributeName originalName="Pri1" groupName="nmoResource1">Quantity</attributeName> 
... 
<attributeName originalName="cmedN" groupName="nmoResourceN">Cost</attributeName> 
</mapping> 
<transform> 
... 
</transform> 
</childClass> 
 
</class> 
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Using entity-attribute-value data
Using the EAV with classes and relationships data in its raw state for any kind of analysis work would be
extremely difficult because of the fragmented nature of the EAV schema. For analysis purposes, it is
therefore necessary to piece together the data to form complete data sets that are comparable to the data
sets outputted from relational or tabular data sources. This task is achieved by processing the EAV table to
derive a table for each class, a column for each attribute and a row for every object. An excerpt of the SQL
statement to join the various data to extract the required data items for class RMDQ (whose identifier is 1
in this example) is shown below:
SELECT  
    eav_objectid, 
    prms_TrialName, 
    subj_ID, 
    subj_OriginalID,  
    attr_ShortName,  
    eav_Value  
FROM  
    attribute  
    inner join eavobject  
        on eav_AttributeID = attr_ID  
    inner join  
        object on obj_Id = eav_ObjectID  
    inner join  
        subject on obj_SubjectID = subj_ID  
    inner join  
        primarysource on prms_ID = subj_PrimarySourceID 
WHERE 
    obj_ClassID = 1 
The statement produces a table in a long format, which was subsequently pivoted to produce a row for
each object and a column for every attribute. The outcome of this query is a data set that resembles a
tabular structure that can easily be processed for further analysis.
Although this solution provides a means for generating a usable tabular format, the scalability is severely
limited. The server performance was found to decrease as the volume of data increases, and multiple pivot
operations were used for transforming object relationships. Querying the derived data sets directly was
also impractical because of the huge numbers of data that can be generated in the server’s temporary
database, causing the server to be unstable.
An initial solution used to overcome these issues was to disconnect from the actual query by using the
in-built functionality of the statistical analysis software to create a copy of the query results. A more
permanent solution, which is the current practice, is to periodically create a copy of the query results into
actual tables within the database.
Extract, transform and load
The bespoke ETL application was required to read the original source data, automatically apply mapping
and transformation rules from an XML document, and load the processed data into the repository. In
addition to these basic functions, the ETL application was also required to permit end users to set up new
RCTs for import, create new classes and attributes and make changes to existing ones, and to switch
between a testing and live environment.
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The bespoke ETL application was distributed as a Microsoft Windows® desktop application. It works by first
uploading the original data set and the XML mapping and transformation rules. The instructions defined in
the XML file are applied to the original data set and the transformed data are loaded into the repository
database. The ETL application allows the statistician and health economist to execute these steps from
their desktop computers. The ability to switch between a test and live environment gives the users the
flexibility and convenience of checking whether or not the instructions that they have delineated in the
XML file are correct before loading the data sets into the live database.
Data validation
Data integrity is vital throughout the repository ETL process. To check that the mapping and transformation
procedures were carried out correctly, the repository data were routinely checked against the original data
sets. To achieve this, at each time point (baseline and all follow-ups), a random sample of data was
extracted and manually cross-checked against the source data. Any inconsistencies were flagged and, if
required, the XML instructions were amended. This process was repeated until the data were deemed to
have been transformed correctly.
Storage
In condition of our data sharing agreements to hold the RCT data sets and to meet local governance and
standard operating procedures, the repository database server is held in a secure data centre, with robust
disaster recovery policies in place.
The appeal of having this hybrid system architecture is that the structure takes up very little space in the
server, and the time needed to query and retrieve data is very little, too. Naturally, the disk space needed
to store the data in this repository will grow in proportion in accordance to the number of data points.
Future data sharing
At the end of this programme of work we would like to make the pooled data available for future
analyses. We will go back to all of the principal investigators (PIs)/data custodians with a new data sharing
agreement to enable us to share their pooled data. Once these agreements have been signed, we will set
up a website with details of how to apply for the data. All requests will be:
1. forwarded to the study statistician who will carry out internal checks to ensure that the data being
requested can be provided; the response from the study statistician will be supplied with the original
request for the independent committee consideration
2. sent via e-mail to an independent committee, who will review the application and make a final decision
on data sharing; for the data requested, if a PI/data custodian has:
i. agreed to sharing the data but has asked to see a copy of the request, a copy will be sent to them
via e-mail for information purposes only
ii. not agreed to sharing their data, this data set will be removed from the pooled data before
providing the requested data to the applicant.
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Chapter 5 Crosswalking between disability
questionnaire scores
This chapter presents our methodological development, exploring how to most accurately map multipleparticipant-reported outcome measures (PROMs), which measure the same domain, to a common scale
(crosswalking). This work has now been published in Spine.149 We sought to develop a ‘crosswalk’ of
values from multiple measures of the same domain to a common single outcome score. This would allow
us to pool measures more accurately than normalising to a single scale (e.g. 0–100) or expressing values as
a proportion of their SD. The first step in this work is to ensure that changes in outcomes from two
measures in the same individuals are both correlated and similarly responsive to change. The results from
this work would inform us how, and if, we could pool various back pain-related disability outcomes into a
single outcome for the main analyses (see Chapter 6).
Background
There are six PROMs that have been used in one or more studies within the repository that aim to measure
back pain-related disability, namely the Chronic Pain Grade Scale (CPG) disability score (CPG-DS), which
is one of the two domains in the CPG that aims to grade chronic pain status,150 Hannover Functional
Ability Questionnaire for measuring back pain-related functional limitations (Funktionsbeeintrachtigung
durch Ruckenschmerzen) (FFbHR),151 Oswestry Disability Index (ODI),152 Pain Disability Index (PDI),153
Patient-Specific Functional Scale (PSFS)154 and RMDQ.28 Some trials also included generic health-related
quality-of-life instruments, such as the Short Form questionnaire-12 items (SF-12)155 or the Short Form
questionnaire-36 items (SF-36),156 for which the physical component score (PCS) measures the physical
functioning. As mentioned later in Chapter 6 (see Outcome variables), no common instrument was used
by the trials that were included in the repository. We sought to assess the agreement of these instruments
by determining their correlation and responsiveness at a trial level, in order to decide whether or not
data pooling was feasible. After we had completed this work, a National Institutes of Health task force
identified developing crosswalking values for ‘legacy’ measures of back pain outcome as a key priority for
back pain research.157
Data
We used data from 11 trials that had used at least two of the following measurements: CPG, FFbHR, PCS,
PSFS, PDI, ODI and RMDQ. For all of these analyses we used the short-term change score, as this is where
any treatment effects are likely to be greatest. For the purposes of this report we have defined a short-term
follow-up as a measurement taken at between 2 and 3 months post randomisation or entry to the trial. The
short-term change score is the difference between the baseline and the short-term follow-up (see Chapter 6,
Follow-up time point). In each case we have standardised the reporting so that a positive change score is
interpreted as an improvement. Where appropriate, we used the standardised response; change score
divided by the SD of the change. We used this in preference to the standardised effect size (change
score divided by the SD of the measure at baseline), so that all of the standardised scores had a SD of one.
This enables visual comparisons to be made between all of the scatterplots.
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Outcome conversion
All comparisons between instruments were carried out at an individual trial level. Each pair of outcome
measures was fitted with simple linear regression models. Denoting the change scores for the two
outcome measures by x and y, the simple linear model was:
y = α + βX + ε, (1)
where the intercept, α, and the coefficient, β, are parameters to be estimated and ϵ is the error term.
For the conversion to be meaningful, the standardised change scores have to be correlated and have
similar responsiveness; the latter is explained below.158
Correlation
Correlation was assessed by scatterplots and Pearson’s correlation coefficient, with a correlation coefficient
considered to be at least moderately high if it was > 0.5.
Responsiveness
Responsiveness is the ability to detect a change in condition; if a participant’s condition improves or
worsens over time then this should be reflected by a change in the participant’s score. If two outcome
measures do not have similar responsiveness then combining them in a meta-analysis may introduce
heterogeneity that could be falsely attributed to other sources, such as the treatment effect.
Similarity of responsiveness of two outcome measures was examined by categorising the change scores as
negative change (change score of < 0), no change (change score= 0) or positive change (change score
of > 0), and applying Cohen’s kappa (κ) to these categorisations.159 We considered κ> 0.4 to indicate
sufficiently similar responsiveness.160 These broad categories were chosen to demonstrate whether or not
the outcome measures had similar responsiveness in the most basic sense (improved, worsened or no
change). We also planned to examine narrower categorisations in the event that the agreements within
these three categories were good (κ> 0.4). However, as there was no standard on the levels of
categorisations, a few would be examined.
For it to be acceptable to pool two measures, they needed to meet two criteria; to be at least moderately
correlated (correlation > 0.5) and to have at least moderately similar responsiveness (κ> 0.4).
Results
Eleven trials31,33,50,76,101,103,104,107,131,132,134 (n= 6089) and seven instruments were included in these analyses
(Table 12). There was a total of 21 within-trial pairwise comparisons between two outcomes. Figures 12–16
show scatterplots of standardised change scores for each such pair of outcome measures. See Appendix 8 for
scatterplots between raw change. It is clear from these plots that the outcomes were positively correlated.
Note also that the standardised change scores were widely scattered around the reference line, suggesting
that there was a lack of agreement between the outcomes.
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FIGURE 12 Scatterplots of standardised change scores for (a) PCS vs. CPG (n= 2451); and (b) PCS vs. FFbHR
(n= 3620) outcome measures. PCS of SF-12/36.
TABLE 12 Instruments used and number of participants by trial
Trial n Outcome measures
BeST33 426 RMDQ CPG PCSa
Brinkhaus101 281 PCS FFbHR PDI
Haake132 1110 CPG FFbHR PCS
Hancock131 235 RMDQ PSFS
HullExPro76 203 RMDQ PCS
Macedo134 158 RMDQ PCS PSFS
Pengel103 232 RMDQ PSFS
UK BEAM31 885 RMDQ CPG PCS
VKBIA104 227 RMDQ CPG
Witt50 2229 PCS FFbHR
YACBAC107 206 PCS ODI
YACBAC, York Acupuncture Back Pain Trial.
a PCS of SF-12 or SF-36.
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FIGURE 14 Scatterplots of standardised change scores for (a) PCS vs. PSFS (n= 158); and (b) CPG vs. FFbHR (n= 1110)
outcome measures. PCS of SF-12/36.
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FIGURE 13 Scatterplots of standardised change scores for (a) PCS vs. RMDQ (n= 1694); and (b) PCS vs. ODI (n= 206)
outcome measures. PCS of SF-12/36.
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FIGURE 16 Scatterplots of standardised change scores for (a) PDI vs. PCS (n= 281), and (b) FFbHR vs. and PDI
(n= 284) outcome measures. PCS, physical component scale of SF-12/36.
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FIGURE 15 Scatterplots of standardised change scores for (a) CPG vs. RMDQ (n= 1661); and (b) PSFS vs. RMDQ
(n= 625) outcome measures.
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The correlations between outcomes ranged from 0.21 to 0.70; implying that the linear associations
between them range from weak to moderately strong (Table 13). Three trials50,101,132 had both SF-12/36 PCS
and FFbHR data, and their correlations were very similar, about 0.58. Another three trials33,101,132 had both
SF-12/36 PCS and CPG, and the correlations were reasonably similar, ranging from 0.41 to 0.56,
and four trials31,33,76,134 had both a SF-12/36 PCS and a RMDQ score with range 0.38–0.52, again similar.
However, correlations between other outcomes were quite wide ranging: between CPG and RMDQ scores
(m= 3 trials;31,33,104 range 0.21–0.47) and between PSFS and RMDQ scores (m= 3;103,131,134 range 0.40–0.70).
Cohen’s kappa was < 0.4 for all 21 comparisons. Some were similar between trials, namely for PCS and
FFbHR (range 0.27–0.30) and for PCS and CPG (range 0.27–0.31). However, the level of agreement was
never more than fair.160 As the Cohen’s kappa agreement was not > 0.4 narrower categorisations were
not investigated.
There were no pairs of outcomes that satisfied both criteria of at least moderately correlated (correlation
> 0.5) and at least moderately similar responsive (Cohen’s kappa > 0.4). Therefore, it was not meaningful
to convert any outcome to another one.
TABLE 13 Pearson’s correlation coefficient and Cohen’s kappa agreement for responsiveness of each pairwise
comparison of outcome measures by trial
Outcome measure
Trial Pearson’s correlation coefficient Cohen’s kappa1 2
CPG RMDQ BeST33 0.44 0.22
UK BEAM31 0.47 0.27
VKBIA104 0.21 0.12
CPG FFbHR Haake132 0.48 0.25
PCSa RMDQ BeST33 0.38 0.17
HullExPro76 0.45 0.29
Macedo134 0.52 0.27
UK BEAM31 0.51 0.33
PCS CPG BeST33 0.41 0.27
Haake132 0.49 0.27
UK BEAM31 0.56 0.31
PCS FFbHR Brinkhaus101 0.59 0.30
Haake132 0.58 0.29
Witt50 0.59 0.27
PCS PSFS Macedo134 0.36 0.17
PCS ODI YACBAC107 0.60 0.28
RMDQ PSFS Hancock131 0.70 0.38
Macedo134 0.40 0.26
Pengel103 0.53 0.18
PDI FFbHR Brinkhaus101 0.55 0.32
PDI PCS Brinkhaus101 0.54 0.31
YACBAC, York Acupuncture Back Pain Trial.
a PCS of SF-12 or SF-36.
CROSSWALKING BETWEEN DISABILITY QUESTIONNAIRE SCORES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Conclusion
In view of the lack of correlation and responsiveness, it is not recommended to map any physical disability
outcome measures to another considered in this investigation.
For each of our subsequent analyses we have pooled data only where the same participant-reported
outcomes are available from multiple trials. The one exception is that the SF-12 and SF-36 are explicitly
designed to have similar measurement properties when converted into their physical and mental
component scores. We have therefore pooled the mental component score (MCS) and PCS from studies
using SF-12 or SF-36.
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Chapter 6 Preliminary statistical analyses
and results
Background
In this chapter we present the results of preliminary statistical analyses performed on the individual
participant data, specifically the analysis of covariance (ANCOVA) comparing all treatments with all controls
(usual care plus sham) to identify individual potential moderators to take forward into our main analyses.
The methodological development work to identify multiple covariates’ baseline characteristics that
moderate treatment effect is presented in later chapters (see Chapters 7–10). We do not, in this preliminary
analysis, seek to define subgroups using multiple parameters.
Statistical analysis plan
In accordance with the standard operating procedure in the Warwick Clinical Trials Unit, a detailed
statistical analysis plan was written by the study’s statistician (SWH) and health economist (JJ). The plan
was subsequently reviewed and approved by the study team and members of the repository oversight
committee (see Appendix 9), whereas the overview of the plan is described in the following sections.
Definitions
Treatment arms
Treatments are broadly classified into intervention, sham control and control. The intervention grouping
may be further classified into three broad categories, namely active physical, passive physical and
psychological. Exercise and graded activity are considered as active physical; acupuncture, manual therapy
and individual physiotherapy are considered as passive physical; and advice or education, and a
cognitive–behavioural approach or cognitive–behavioural therapy, are considered as psychological
interventions. Sham control may be sham acupuncture, sham electrotherapy, mock TENS or sham advice or
education. The control arm is the non-active usual care, namely GP treatment or a waiting list control. Sham
acupuncture may be a special case of a sham intervention. If it is the sensation of needling that is the active
ingredient of acupuncture then the location of any needling, whether or not skin penetration takes place,
or depth of any needling might have little effect on outcomes seen. Thus, sham acupuncture might be
considered to be a ‘true’ intervention and is included in our analyses of passive physical treatments.
Follow-up time point
The follow-up times are classified into short term, mid term and long term. A short-term follow-up is a
measurement taken between 2 and 3 months post randomisation or entry to the trial. A mid-term follow-up
is a measurement taken at 6 months post randomisation or entry to the trial. A long-term follow-up is a
measurement taken at 12 months post randomisation or entry to the trial. Data collected at immediate
follow-up (< 2 months post randomisation or entry to the trial) and beyond the long-term follow-up
(> 12 months post randomisation or entry to the trial) were also entered into the repository but were not
considered for analysis.
Selection of follow-up time points
Some RCTs collected weekly data. For the short-term follow-up, data from the 3-month follow-up were
considered for analysis. If data were missing (non-response), data from the nearest week to the 3-month
follow-up were used as long as the time point was within the 2- and 3-month follow-up time point.
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Outcome variables
Clinical outcomes
The response for each of the outcome variables of interest is presented as change score and standardised
change score. The change score is the change from baseline to the follow-up time point. A positive
change score is interpreted as an improvement.
Health-economic outcomes
For the initial economic analysis presented here, the outcome of QALYs was used. Estimated QALY gains
from treatment were compared with the mean estimated costs of treatment to assess cost-effectiveness.
Individual participant data on resource use or costs were available for some trials but, after allowing for
availability of the European Quality of Life-5 Dimensions (EQ-5D) or SF-12/36 scores (required to calculate
QALYs) and of a common set of moderator variables, no two studies provided both individual-level cost and
QALY data for a common comparison. We were, therefore, unable to generate pooled cost/QALY data.
The heterogeneous nature of the trials posed some challenges for the economic analysis. To pool the data
across trials, a consistent health outcome measure over time was required. The QALY is a standardised
measure of health outcomes used for economic analysis, which summarises patients’ profiles of health-related
quality of life (‘utility’) over time. The QALY score for each patient was estimated using the EQ-5D, which is a
generic measure of quality of life, suitable for calculation of QALYs. The EQ-5D index score, calculated using
the UK Tariff, measures an individual’s health state at a single time point.161 EQ-5D index scores can be
integrated over time to estimate QALYs. QALYs were calculated for trial participants over 1 year of follow-up,
using the area under the curve (AUC) method. For each participant the AUC was calculated from the EQ-5D
index scores that were captured at each follow-up point for that participant, from baseline to 52 weeks
(with linear interpolation between observations). Trials with more follow-up points arguably have greater
resolution and therefore the QALY estimated will be more precise. However, in all regression analyses the
differences between trials were controlled for, so this potential issue was mitigated.
For one trial,132 EQ-5D data were not available, but full data on patient responses to the SF-12 instrument
were recorded. The SF-12 is a generic measure of health, similar to the EQ-5D, and a number of methods
to estimate a utility index score from the SF-12 instrument have been published. To ensure that the index
scores provided by the SF-12 are comparable to those obtained for the other trials using the EQ-5D, a
mapping approach was applied. This mapped the SF-12 item responses on to the EQ-5D index scores.
The specific mapping approach applied was based on the work of Gray et al.;162 in this study, a
multinominal logit model was used to estimate the probability that a particular EQ-5D level would be
chosen, based on the participants’ SF-12 responses. The authors have made available an algorithm
applying this method as an add-on programme in Stata 12 (StataCorp LP, College Station, TX, USA).
This mapping approach was compared with other published methods by Rowen et al.163 They found similar
levels of performance across the alternative approaches. In our analysis, the mapped SF-12 index scores
were integrated over time in the same manner as the EQ-5D scores to estimate an individual-level QALY.
Use of SF-6D (Short Form questionnaire-6 Dimensions) to EQ-5D mapping might have introduced
additional errors or bias, although the method was well developed and has been subject to validation.
The potential for bias should also have been mitigated by the method of analysis, with a mixed model
accounting for differences between trials. Furthermore, the outcomes of interest were the treatment
subgroup coefficients rather than the magnitude of main effects per se.
One trial132 had data only up to 26 weeks. For this trial,132 it was assumed that the quality-of-life score
measured at 26 weeks persisted up to 52 weeks, which allowed QALYs over 1 year to be estimated in the
same way as for the other trials. This assumption might be seen as a limitation but, again, the potential for
bias from this source should have been reduced through the inclusion of the trial as a random effect and
the focus on treatment–subgroup interactions.
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It is important to adjust for any baseline differences in EQ-5D scores when comparing QALY estimates
between treatment groups. There are two ways of making this adjustment: by calculating a ‘change from
baseline’ QALY at the individual level or adding the baseline EQ-5D score as a covariate in regression
analysis. The latter approach has been used in the analyses presented here, as it is recommended as
more efficient.164
Selection of instrument
Clinical outcomes are classified broadly into physical disability, pain, psychological distress and non-utility
quality of life. Nine instruments in the repository have been identified as measurements for physical
disability and four instruments for pain (see Appendix 9). No single instrument was used by all RCTs to
measure physical disability and hence we explored how to map some of these instruments to one single
outcome. The mapping methodology is described in Chapter 5. We concluded that it was not possible to
map to one single outcome. Therefore, analyses were undertaken on common outcomes only.
Most of the RCTs in the repository had asked the participant to rate or mark on a numerical rating scale or
a visual analogue scale (VAS) that described either their average or worst pain at the present time or over
defined weeks or months. This item was presented either as a single stand-alone instrument or as an item
that was part of a collective pain measurement; for example, in the McGill Pain Questionnaire a VAS was
presented as a line that anchors with ‘no pain’ at one end and ‘worst possible pain’ at the other end.165
For the analyses of average pain, one of the following instruments from each trial, where available, was
chosen (in descending order):
1. individual VAS on average pain today
2. average pain over the past 1 week
3. average pain over the past 2 weeks, average pain over the past 1 month
4. average pain over the past 3 months
5. the individual item of the CPG pain intensity score (CPG-PS) that is equivalent to the VAS if it
is available150
6. the summary score of the CPG-PS otherwise or
7. the bodily pain domain of SF-12/36.155,156
Where a numerical rating scale (range 0–10) was used, it was scaled to an analogue scale so that it gives a
range from 0 to 100.
There are two dimensions of psychological distress that are of interest: depression and anxiety. Six and
four instruments have been identified to measure depression and anxiety, respectively (see Appendix 9).
Within each instrument there is usually a classification system that is widely used to classify participants
into ordinal categories, for example with a minimal, a moderate or a severe level of depression. Thus, all
instruments were mapped into a single ordinal categorical variable. Instruments with no threshold
guideline to discriminate level of risk or severity were categorised into tertiles to discriminate the low- and
high-risk or low- and high-severity groups from the moderate-risk or moderate-severity group. Other
psychosocial measures – catastrophising, coping and fear avoidance – were handled in the same manner.
In each case, the reference standard for comparison was the tertile with the least favourable score.
Data sets
Individual participant data without treatment assignment were excluded from the repository. This exclusion
criterion applies to individual participants whose data were included in the data set but the treatment
allocation was not available in the data set. We were not able to allocate these participants to a treatment
group and they were thus excluded.
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Clinical analysis
The main analysis, which is to confirm proof of concept, was based on complete case analysis. Missing
data due to non-responders or withdrawals were not imputed. Missing items were imputed and the
method for imputation is as described in the statistical analysis plan (see Appendix 9). When available,
individual items were used to obtain the composite score for each measurement, otherwise the composite
score provided to the repository was used for all analyses.
For the overall exploration of moderation by single variables, the sham control was grouped with non-active
usual care. All direct analyses were based on pairwise comparisons, that is, only two treatment arms were
compared each time. For the overall analysis, intervention was compared against control/placebo arm,
where intervention was any therapist-delivered intervention given either singly or in combination
with another intervention, and the control/placebo arm was either the non-active usual care control or
sham treatment. Other pairwise comparisons considered were active physical against non-active usual care
control, passive physical against non-active usual care control, psychological against non-active usual
care control, and sham against non-active usual care control. In all cases for the pairwise comparisons we
separated sham and usual care controls, as this reflects more accurately the clinical choice than adding of
an intervention on to a sham control intervention.
Direct analyses were performed if the individual participant data were from at least two trials, that is,
no direct analysis was performed if the individual participant data were from one single trial.
Health-economic analysis
The health-economic analysis focused on the QALY score as the outcome measure. QALYs were calculated
for individuals, using the estimated EQ-5D index scores or a mapped SF-12 outcome at multiple follow-up
points. This means that missing data can be more of a problem than for outcomes measured at a single
time point. If data are missing at any follow-up point, the QALY cannot be estimated and the entire
observation is lost. An observation was also lost if data on the moderator at baseline were missing. All
analyses were based on complete cases only; therefore, caution must be taken in interpretation of the
results, as the missing data may be a source of bias.
In order to simplify the analysis it was split into four overarching comparisons; all interventions collectively
against non-active usual care, active physical interventions against non-active usual care, passive physical
interventions against non-active usual care and active physical against passive physical. For each analysis,
the treatment arms for the included trials were pooled appropriately by the type of treatment and used
collectively as the intervention group for each of the respective analyses. Seven trials in total were included
in the analysis. The first three analyses described limited the sample to a maximum of six trials, which
included a non-active usual care as the control arm and reporting EQ-5D outcomes or a mapped SF-12
outcome. The comparison between active physical and passive physical allowed the inclusion of one
additional trial. Data for comparisons against a sham treatment arm were excluded from this analysis,
as these are not plausible choices for a health-economic analysis.
Methods
Descriptive summary
The baseline data were summarised by treatment arm (non-active usual care, active physical, passive
physical, psychological, combination or sham control). The continuous data were summarised as mean and
SD, and the categorical data were summarised as the number of participants and percentage.
One-step meta-analysis
In a one-step meta-analysis, individual participant data from all studies were modelled simultaneously in
a single model adjusting for the study effect.166 It can be viewed analogously as an analysis of a
multicentre study, for which, instead of multicentres in a study, we have multitrials in a study.
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The one-step meta-analysis was performed to explore the efficacy between treatment arms.
A mixed-effects model was used as analysis, for which the intercept and the interaction between
treatment arm and trial were modelled as random effects, and treatment arm as the fixed effect.
Moderator identification
Systematic review
We identified potential moderators from the literature via a systematic review. Details of this review and
the outcomes are presented in Chapter 2.
Analysis of covariance
Analysis of covariance was performed to identify any covariate that moderates outcomes. Similarly, the
one-step meta-analysis approach was used, that is, all of the available individual participant data were
pooled into a single mixed-effects model for which the intercept and the interaction between treatment
and trial were modelled as random effects. The treatment arm (intervention against control), covariate and
the interaction between treatment and covariate were modelled as fixed effects. For analysis with QALYs
as the outcome measure, the baseline EQ-5D score was also included as a fixed effects model in the
mixed-effects model described above.
As stated in the statistical analysis plan, covariates were declared weakly statistically significant at the
two-sided 20% level and statistically significant at the two-sided 5% level. This ensured that covariates that
approach the conventional statistical significance at 5% level would not be missed for the final clinical and
health-economic prediction rule analyses. All moderators identified from the systematic review and ANCOVA
were considered for the clinical and health-economic prediction rule analyses. The prediction rule analyses
were to determine which participant characteristics at baseline were optimal to different treatments and
associated with the end points of interest, namely disability or pain, or cost-effective treatments for LBP.
The methodology of identifying a combination of characteristics is presented in detail in Chapters 7–10.
As seen in the results from the one-step meta-analysis, the estimated efficacy between intervention and
control/placebo arm for most of the outcomes at mid-term and long term were not statistically significant.
Therefore, the ANCOVA was not performed for the mid- and long-term outcomes. In addition, the short-term
outcomes were those in which the maximum clinical effects were observed between intervention and
control/placebo. This is where the largest differential subgroup effects are likely to be seen. In the absence of
substantial short-term effect moderation there is little point in exploring mid- and long-term effect moderation.
The list of moderators assessed for each of the short-term clinical outcomes and QALYs were presented.
As not all trials have the same moderators, the sample size varied depending on which moderator was
being assessed and for which outcome.
Results
Descriptive
Table 14 shows the response rates for each of the outcomes of interest per treatment groups in different
time points. Most trials collected data 3 months post randomisation or entry to the trial, and this is
recorded as 13 weeks, whereas one RCT had specifically mentioned in its protocol to collect data at
12 weeks and thus this was recorded as per protocol.
Most of the RCTs collected short- and mid-term outcomes and some collected more immediate outcomes
(typically measured within 6 weeks post randomisation or entry to the trial) (see Table 14). Two RCTs collected
longer-term effects (outcomes measured at or after 12 months post randomisation or entry to the trial). Each of
the RCTs was designed with a unique protocol and this was apparent from the choice of different instruments
used to measure the physical disability, pain and psychological distress outcomes, and at different time points.
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TABLE 14 Number of trials (m) and participants (n) for each outcome by follow-up time points and treatment arms
Outcomes
Follow-up
(weeks)
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All
(m= 19;
n= 9326)
Physical disability
CPG-DSa 0 m= 1;
n= 284
m= 2;
n= 721
m= 2;
n= 572
m= 1;
n= 312
m= 1;
n= 387
m= 4;
n= 1052
m= 5;
n= 3328
4 m= 1;
n= 228
m= 1;
n= 315
– m= 1;
n= 280
– m= 1;
n= 262
m= 4;
n= 1085
8 – – m= 1;
n= 109
– – m= 1;
n= 120
m= 2;
n= 229
13 m= 1;
n= 214
m= 2;
n= 653
m= 1;
n= 345
m= 1;
n= 252
m= 1;
n= 376
m= 3;
n= 797
m= 5;
n= 2637
26 – m= 1;
n= 377
m= 2;
n= 491
– m= 1;
n= 376
m= 3;
n= 656
m= 2;
n= 1900
52 m= 1;
n= 212
m= 1;
n= 267
m= 2;
n= 473
m= 1;
n= 254
– m= 3;
n= 530
m= 5;
n= 1736
104 – – m= 1;
n= 94
– – m= 1;
n= 92
m= 2;
n= 186
FFbHR 0 – m= 3;
n= 1927
– – m= 2;
n= 460
m= 3;
n= 1789
m= 3;
n= 4176
6 – m= 1;
n= 370
– – m= 1;
n= 375
m= 1;
n= 362
m= 1;
n= 1107
8 – m= 1;
n= 140
– – m= 1;
n= 70
m= 1;
n= 74
m= 1;
n= 284
13 – m= 2;
n= 1723
– – m= 1;
n= 376
m= 2;
n= 1605
m= 2;
n= 3704
26 – m= 3;
n= 1825
– – m= 2;
n= 446
m= 3;
n= 1620
m= 3;
n= 3891
52 – m= 1;
n= 137
– – m= 1;
n= 68
m= 1;
n= 70
m= 1;
n= 275
ODI 0 – m= 1;
n= 159
– – – m= 1;
n= 80
m= 1;
n= 239
13 – m= 1;
n= 146
– – – m= 1;
n= 71
m= 1;
n= 217
52 – m= 1;
n= 136
– – – m= 1;
n= 57
m= 1;
n= 193
104 – m= 1;
n= 114
– – – m= 1;
n= 50
m= 1;
n= 164
PDI 0 – m= 1;
n= 146
– – m= 1;
n= 73
m= 1;
n= 79
m= 1;
n= 298
8 – m= 1;
n= 140
– – m= 1;
n= 70
m= 1;
n= 74
m= 1;
n= 284
26 – m= 1;
n= 138
– – m= 1;
n= 70
m= 1;
n= 73
m= 1;
n= 281
52 – m= 1;
n= 137
– – m= 1;
n= 66
m= 1;
n= 69
m= 1;
n= 272
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TABLE 14 Number of trials (m) and participants (n) for each outcome by follow-up time points and
treatment arms (continued )
Outcomes
Follow-up
(weeks)
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All
(m= 19;
n= 9326)
PSFS 0 m= 2;
n= 150
m= 1;
n= 119
m= 2;
n= 148
m= 1;
n= 62
m= 2;
n= 188
– m= 3;
n= 667
1 – m= 1;
n= 119
– – m= 1;
n= 118
– m= 2;
n= 237
2 – m= 1;
n= 119
– – m= 1;
n= 119
– m= 1;
n= 238
4 – m= 1;
n= 118
– – m= 1;
n= 117
– m= 1;
n= 235
6 m= 1;
n= 58
– m= 1;
n= 54
m= 1;
n= 57
m= 1;
n= 59
– m= 1;
n= 228
8 m= 1;
n= 82
– m= 1; n= 76 – – – m= 1;
n= 158
12 m= 1;
n= 57
– m= 1;
n= 56
m= 1;
n= 58
m= 1;
n= 61
– m= 1;
n= 232
13 – m= 1;
n= 118
– – m= 1;
n= 117
– m= 1;
n= 235
26 m= 1;
n= 81
– m= 1;
n= 74
– – – m= 1;
n= 155
52 m= 2;
n= 136
– m= 2;
n= 132
m= 1;
n= 56
m= 1;
n= 56
– m= 2;
n= 380
RMDQ 0 m= 7;
n= 907
m= 7;
n= 1087
m= 7;
n= 1120
m= 3;
n= 446
m= 3;
n= 212
m= 6;
n= 938
m= 14;
n= 4710
1 – m= 1;
n= 119
– – m= 1;
n= 118
– m= 1;
n= 237
2 – m= 2;
n= 119
– – m= 1;
n= 118
– m= 1;
n= 237
4 m= 1;
n= 234
m= 2;
n= 436
– m= 1;
n= 283
m= 1;
n= 117
m= 1;
n= 264
m= 2;
n= 1334
6 m= 2;
n= 144
m= 1;
n= 23
m= 1;
n= 55
m= 1;
n= 58
m= 2;
n= 81
m= 1;
n= 94
m= 3;
n= 455
8 m= 1;
n= 82
– m= 2;
n= 186
– – m= 1;
n= 120
m= 2;
n= 388
10 m= 1;
n= 107
– – m= 1;
n= 55
– m= 1;
n= 50
m= 1;
n= 212
12 m= 1;
n= 58
– m= 1;
n= 58
m= 1;
n= 59
m= 1;
n= 61
– m= 1;
n= 236
13 m= 3;
n= 433
m= 7;
n= 963
m= 4;
n= 670
m= 1;
n= 255
m= 2;
n= 135
m= 3;
n= 537
m= 9;
n= 2993
26 m= 4;
n= 371
m= 2;
n= 262
m= 5;
n= 706
m= 1;
n= 53
– m= 5;
n= 474
m= 8;
n= 1866
52 m= 7;
n= 722
m= 5;
n= 771
m= 7;
n= 903
m= 3;
n= 365
m= 1;
n= 56
m= 6;
n= 690
m= 12;
n= 3507
104 m= 1;
n= 83
m= 1;
n= 95
m= 1;
n= 94
– – m= 1;
n= 92
m= 2;
n= 364
continued
DOI: 10.3310/pgfar04100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Patel et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
73
TABLE 14 Number of trials (m) and participants (n) for each outcome by follow-up time points and
treatment arms (continued )
Outcomes
Follow-up
(weeks)
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All
(m= 19;
n= 9326)
Troublesomeness 0 m= 2;
n= 344
m= 3;
n= 556
m= 1;
n= 426
m= 1;
n= 312
– m= 3;
n= 604
m= 4;
n= 2242
4 m= 1;
n= 225
m= 1;
n= 313
– m= 1;
n= 279
– m= 1;
n= 262
m= 1;
n= 1079
13 m= 2;
n= 280
m= 3;
n= 494
– m= 1;
n= 253
– m= 2;
n= 318
m= 3;
n= 1345
52 m= 2;
n= 302
m= 3;
n= 493
– m= 1;
n= 252
– m= 2;
n= 297
m= 8;
n= 1344
104 – m= 1;
n= 113
– – – m= 1;
n= 50
m= 3;
n= 162
Pain
CPG-PSb 0 m= 1;
n= 283
m= 2;
n= 721
m= 2;
n= 582
m= 1;
n= 312
m= 1;
n= 387
m= 4;
n= 1054
m= 4;
n= 3339
4 m= 1;
n= 228
m= 1;
n= 316
– m= 1;
n= 281
– m= 1;
n= 261
m= 1;
n= 1086
6 – m= 1;
n= 370
– – m= 1;
n= 375
m= 1;
n= 362
m= 1;
n= 1107
8 – – m= 1;
n= 110
– – m= 1;
n= 120
m= 1;
n= 230
13 m= 1;
n= 214
m= 2;
n= 653
m= 1;
n= 354
m= 1;
n= 252
m= 1;
n= 376
m= 3;
n= 799
m= 3;
n= 2648
26 – m= 1;
n= 377
m= 2;
n= 497
– m= 1;
n= 376
m= 3;
n= 661
m= 3;
n= 1911
52 m= 1;
n= 211
m= 1;
n= 269
m= 2;
n= 491
m= 1;
n= 253
– m= 4;
n= 536
m= 3;
n= 1760
104 – – m= 1;
n= 94
– – m= 1;
n= 92
m= 1;
n= 186
VAS
Average pain
today
0 m= 2;
n= 253
m= 3;
n= 461
m= 1;
n= 196
m= 1;
n= 61
m= 1;
n= 120
m= 1;
n= 51
m= 3;
n= 1142
1 – m= 1;
n= 119
– – m= 1;
n= 119
– m= 1;
n= 238
2 – m= 1;
n= 119
– – m= 1;
n= 119
– m= 1;
n= 238
3 – m= 1;
n= 118
– – m= 1;
n= 118
– m= 1;
n= 236
4 m= 1;
n= 83
m= 1;
n= 118
m= 1;
n= 80
– m= 1;
n= 118
– m= 2;
n= 399
6 – m= 1;
n= 36
– – m= 1;
n= 38
– m= 1;
n= 74
8 m= 1;
n= 81
m= 1;
n= 24
m= 1;
n= 79
– m= 1;
n= 23
– m= 2;
n= 207
10 m= 1;
n= 107
m= 1;
n= 16
– m= 1;
n= 55
m= 1;
n= 18
m= 1;
n= 49
m= 2;
n= 245
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TABLE 14 Number of trials (m) and participants (n) for each outcome by follow-up time points and
treatment arms (continued )
Outcomes
Follow-up
(weeks)
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All
(m= 19;
n= 9326)
11 – m= 1;
n= 15
– – m= 1;
n= 17
– m= 1;
n= 32
12 – m= 1;
n= 15
– – m= 1;
n= 17
– m= 1;
n= 32
13 m= 1;
n= 81
m= 1;
n= 153
m= 2;
n= 231
– – – m= 1;
n= 465
17 m= 1;
n= 79
– m= 1;
n= 75
– – – m= 1;
n= 154
21 m= 1;
n= 81
– m= 1;
n= 76
– – – m= 1;
n= 157
26 m= 2;
n= 186
– m= 1;
n= 75
m= 1;
n= 53
– – m= 2;
n= 314
30 m= 1;
n= 79
– m= 1;
n= 72
– – – m= 1;
n= 151
34 m= 1;
n= 81
– m= 1;
n= 73
– – – m= 1;
n= 154
39 m= 1;
n= 80
– m= 1;
n= 74
– – – m= 1;
n= 154
43 m= 1;
n= 78
– m= 1;
n= 74
– – – m= 1;
n= 152
47 m= 1;
n= 76
– m= 1;
n= 71
– – – m= 1;
n= 147
52 m= 2;
n= 183
m= 1;
n= 164
m= 2;
n= 238
m= 1;
n= 53
– – m= 6;
n= 638
Average pain over
past 1 week
0 m= 2;
n= 150
m= 2;
n= 235
m= 3;
n= 349
m= 1;
n= 63
m= 2;
n= 84
– m= 4;
n= 881
1 – m= 1;
n= 235
– – m= 1;
n= 119
– m= 1;
n= 238
2 – m= 1;
n= 235
– – m= 1;
n= 119
– m= 1;
n= 238
3 – m= 1;
n= 235
– – m= 1;
n= 118
– m= 1;
n= 237
4 m= 1;
n= 82
m= 2;
n= 152
m= 1;
n= 80
– m= 2;
n= 134
– m= 3;
n= 448
6 m= 1;
n= 59
m= 1;
n= 49
m= 1;
n= 55
m= 1;
n= 58
m= 2;
n= 97
– m= 2;
n= 306
8 m= 1;
n= 81
m= 1;
n= 24
m= 1;
n= 79
– m= 1;
n= 24
– m= 2;
n= 208
10 – m= 1;
n= 16
– – m= 1;
n= 19
– m= 1;
n= 35
11 – m= 1;
n= 11
– – m= 1;
n= 17
– m= 1;
n= 33
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TABLE 14 Number of trials (m) and participants (n) for each outcome by follow-up time points and
treatment arms (continued )
Outcomes
Follow-up
(weeks)
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All
(m= 19;
n= 9326)
12 m= 1;
n= 58
m= 1;
n= 15
m= 1;
n= 58
m= 1;
n= 59
m= 2;
n= 78
– m= 2;
n= 268
13 m= 1;
n= 81
m= 2;
n= 180
m= 2;
n= 231
– m= 1;
n= 9
– m= 3;
n= 501
17 m= 1;
n= 79
– m= 1;
n= 75
– – – m= 1;
n= 154
21 m= 1;
n= 81
– m= 1;
n= 76
– – – m= 1;
n= 157
26 m= 1;
n= 81
m= 1;
n= 21
m= 1;
n= 75
– m= 1;
n= 6
– m= 2;
n= 183
30 m= 1;
n= 79
– m= 1;
n= 72
– – – m= 1;
n= 151
34 m= 1;
n= 81
– m= 1;
n= 73
– – – m= 1;
n= 154
39 m= 1;
n= 80
– m= 1;
n= 74
– – – m= 1;
n= 154
43 m= 1;
n= 78
– m= 1;
n= 74
– – – m= 1;
n= 152
47 m= 1;
n= 77
– m= 1;
n= 71
– – – m= 1;
n= 148
52 m= 2;
n= 140
m= 1;
n= 163
m= 3;
n= 297
m= 1;
n= 57
m= 1;
n= 56
– m= 3;
n= 713
Average pain over
past 1 month
0 – m= 1;
n= 24
– – m= 1;
n= 24
– m= 1;
n= 48
6 – m= 1;
n= 23
– – m= 1;
n= 22
– m= 1;
n= 45
13 – m= 1;
n= 22
– – m= 1;
n= 18
– m= 1;
n= 40
Worst pain today 0 m= 1;
n= 111
– – m= 1;
n= 61
– m= 1;
n= 51
m= 1;
n= 223
10 m= 1;
n= 107
– – m= 1;
n= 53
– m= 1;
n= 49
m= 1;
n= 209
26 m= 1;
n= 103
– – m= 1;
n= 53
– – m= 1;
n= 156
52 m= 1;
n= 103
– – m= 1;
n= 52
– – m= 1;
n= 155
Worst pain over
past 1 month
0 – m= 2;
n= 24
– – m= 1;
n= 24
– m= 2;
n= 48
6 – m= 1;
n= 23
– – m= 1;
n= 22
– m= 2;
n= 45
13 – m= 1;
n= 22
– – m= 1;
n= 18
– m= 2;
n= 40
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TABLE 14 Number of trials (m) and participants (n) for each outcome by follow-up time points and
treatment arms (continued )
Outcomes
Follow-up
(weeks)
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All
(m= 19;
n= 9326)
Quality of life
SF-12/SF-36 PCSa 0 m= 4;
n= 617
m= 7;
n= 2544
m= 2;
n= 507
m= 1;
n= 305
m= 2;
n= 460
m= 6;
n= 2262
m= 9;
n= 6695
4 m= 1;
n= 214
m= 1;
n= 300
– m= 1;
n= 264
– m= 1;
n= 249
m= 1;
n= 1027
8 m= 1;
n= 82
m= 1;
n= 139
m= 1;
n= 76
– m= 1;
n= 69
m= 1;
n= 73
m= 2;
n= 439
13 m= 3;
n= 415
m= 6;
n= 2276
m= 1;
n= 332
m= 1;
n= 243
m= 1;
n= 376
m= 5;
n= 2006
m= 7;
n= 5648
26 m= 2;
n= 185
m= 4;
n= 1850
m= 2;
n= 436
– m= 2;
n= 444
m= 4;
n= 1711
m= 6;
n= 4626
52 m= 4;
n= 469
m= 5;
n= 719
m= 2;
n= 449
m= 1;
n= 235
m= 1;
n= 68
m= 4;
n= 545
m= 7;
n= 2485
104 m= 1;
n= 83
m= 2;
n= 206
– – – m= 1;
n= 49
m= 2;
n= 338
SF-12/SF-36 MCSb 0 m= 4;
n= 617
m= 7;
n= 2544
m= 2;
n= 507
m= 1;
n= 305
m= 2;
n= 460
m= 6;
n= 2262
m= 9;
n= 6695
4 m= 1;
n= 214
m= 1;
n= 300
– m= 1;
n= 264
– m= 1;
n= 249
m= 1;
n= 1027
8 m= 1;
n= 82
m= 1;
n= 139
m= 1;
n= 76
– m= 1;
n= 69
m= 1;
n= 73
m= 2;
n= 439
13 m= 3;
n= 415
m= 6;
n= 2276
m= 1;
n= 332
m= 1;
n= 243
m= 1;
n= 376
m= 5;
n= 2006
m= 7;
n= 5648
26 m= 2;
n= 185
m= 4;
n= 1850
m= 2;
n= 436
– m= 2;
n= 444
m= 4;
n= 1711
m= 6;
n= 4626
52 m= 4;
n= 469
m= 5;
n= 719
m= 2;
n= 449
m= 1;
n= 235
m= 1;
n= 68
m= 4;
n= 545
m= 7;
n= 2485
104 m= 1;
n= 83
m= 2;
n= 206
– – – m= 1;
n= 49
m= 2;
n= 338
Health utility
EQ-5D-3L 0 m= 1;
n= 85
– – – – m= 1;
n= 94
m= 1;
n= 179
6 m= 1;
n= 85
– – – – m= 1;
n= 94
m= 1;
n= 179
26 m= 1;
n= 77
– – – – m= 1;
n= 86
m= 1;
n= 163
52 m= 1;
n= 82
– – – – m= 1;
n= 88
m= 1;
n= 170
EQ-5D-3L, EQ-5D three-level version.
a PCS of SF–12/SF–36.
b MCS of SF–12/SF–36.
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There were 9328 participants in the trials included in the repository. Table 15 shows the demographics and
clinical characteristics at baseline by treatment arms. All of the trials were able to provide information on
sex and age. Of the 9326 participants (missing data from two participants), 5316 (57%) were females. The
proportion of males and females was similar across all treatment arms. The average age of the participants
in the repository was 49 years (SD 14 years). The average age of participants from trials that had active
physical therapies (APTs) was slightly lower [44 years (n= 914; SD 12 years)] compared with the average
age from trials that had passive and psychological treatments [49 years (n= 3270; SD 14 years) and
50 years (n= 1118; SD 14 years)], respectively. This difference is mainly due to the inclusion criteria of
the trials.
TABLE 15 Demographics and clinical characteristics at baseline by treatment arms
Characteristics
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All (m= 19;
n= 9328)
Demographics
Age, years
Number of trials, m 7 12 7 3 6 10 19
n 914 3270 1118 451 688 2885 9326
Mean 43.67 49.39 50.08 43.77 48.54 50.51 48.92
SD 11.74 14.13 14.22 12.51 15.22 13.37 13.88
Sex
Number of trials, m 7 12 7 3 6 10 19
Female (%) 497 (54.4) 1907 (58.3) 655 (58.5) 237 (52.6) 412 (59.9) 1641 (56.9) 5349 (57.4)
Male (%) 417 (45.6) 1363 (41.7) 464 (41.5) 214 (47.5) 276 (40.1) 1243 (43.1) 3977 (42.6)
Ethnicity
Number of trials, m 1 1 4 – – 4 5
White (%) 65 (75.6) 159 (100.0) 667 (87.8) – – 478 (89.4) 1369 (88.9)
Mixed (%) – – 4 (0.5) – – 3 (0.6) 7 (0.5)
Black (%) – – 26 (3.4) – – 21 (3.9) 47 (3.1)
Asian (Indian,
Pakistani,
Bangladeshi,
others) (%)
7 (8.1) – 37 (4.9) – – 17 (3.2) 61 (4.0)
Chinese (%) 1 (1.2) – 1 (0.1) – – 1 (0.2) 3 (0.2)
Others (%) 13 (15.1) – 25 (3.3) – – 15 (2.8) 53 (3.4)
Smoking status
Number of trials, m 5 3 3 1 1 1 6
No (%) 333 (66.7) 211 (52.4) 167 (76.3) 52 (82.5) 54 (79.4) 69 (70.4) 886 (65.6)
Yes (%) 167 (33.3) 192 (47.6) 52 (23.7) 11 (17.5) 14 (20.6) 29 (29.6) 465 (34.4)
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TABLE 15 Demographics and clinical characteristics at baseline by treatment arms (continued )
Characteristics
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All (m= 19;
n= 9328)
Employment status
Number of trials, m 5 6 5 1 1 6 11
Full-time
employment (%)
307 (51.3) 424 (51.7) 360 (42.2) 165 (64.7) 4 (25.0) 485 (54.3) 1745 (50.8)
Part-time
employment (%)
120 (20.0) 130 (15.9) 132 (15.5) 60 (23.5) – 190 (21.3) 632 (18.4)
No employment (%) 172 (28.7) 266 (32.4) 362 (42.4) 30 (11.8) 12 (75.0) 218 (24.4) 1060 (30.8)
BMI
Number of trials, m 2 4 2 – 2 2 5
n 222 811 156 – 453 462 2,104
Mean 27.03 26.60 26.52 – 26.45 26.42 26.57
SD 5.31 4.60 5.22 – 4.73 4.48 4.73
Physical disability
CPG-DS (0–100; 100=worst)a
Number of trials, m 1 2 2 1 1 5 4
n 284 721 572 312 387 1052 3328
Mean 47.44 51.82 49.38 44.76 55.36 49.87 50.16
SD 22.66 20.9 23.77 21.86 18.92 22.14 21.99
FFbHR (0–100; 100= best)
Number of trials, m – 3 – – 2 3 3
n – 1927 – – 460 1789 4176
Mean – 58.33 – – 48.01 59.38 57.64
SD – 20.63 – – 16.14 20.69 20.5
ODI (0–100; 100=worst)
Number of trials, m – 1 – – – 1 1
n – 159 – – – 80 239
Mean – 33.72 – – – 31.36 32.93
SD – 15.40 – – – 14.24 15.03
PDI (0–70; 70=worst)
Number of trials, m – 1 – – 1 1 1
n – 146 – – 73 79 298
Mean – 28.92 – – 31.53 30.95 30.10
SD – 11.12 – – 11.14 13.27 11.75
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TABLE 15 Demographics and clinical characteristics at baseline by treatment arms (continued )
Characteristics
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All (m= 19;
n= 9328)
PSFS (0–10; 10= best)
Number of trials, m 2 1 2 1 2 – 3
n 150 119 148 62 188 – 667
Mean 3.57 3.78 3.76 3.83 3.97 – 3.79
SD 1.79 1.60 1.67 1.94 1.84 – 1.76
RMDQ (0–24; 24=worst)
Number of trials, m 7 7 7 3 3 6 14
n 907 1087 1,120 446 212 938 4710
Mean 10.07 10.89 9.85 9.59 11.09 8.57 9.91
SD 5.08 5.03 5.33 4.33 5.95 4.69 5.09
Troublesomeness
Number of trials, m 2 3 1 1 – 3 4
Not at all
troublesome (%)
3 4 – – – 4 11
Slightly
troublesome (%)
41 62 26 29 – 51 209
Moderately
troublesome (%)
146 213 211 154 – 284 1008
Very troublesome (%) 115 205 151 107 – 211 789
Extremely
troublesome (%)
39 72 38 22 – 54 225
Pain
CPG-PS (0–100; 100=worst)a
Number of trials, m 1 2 3 1 1 5 5
n 283 721 582 312 387 1054 3,339
Mean 60.82 64.93 58.93 59.91 67.60 62.65 62.66
SD 17.62 16.79 18.53 17.91 13.16 17.41 17.31
Average pain (0–100; 100=worst)b
Number of trials, m 4 6 6 3 5 6 12
n 472 922 969 380 493 1118 4354
Mean 52.42 59.79 48.20 50.63 65.54 52.53 54.40
SD 22.49 20.96 24.74 21.50 15.20 24.64 23.18
Quality of life
SF-12/SF-36 PCSa (0–100; 100= best)
Number of trials, m 4 7 2 1 2 6 9
n 617 2544 507 305 460 2262 6695
Mean 37.14 36.03 37.15 38.14 32.87 36.30 36.19
SD 7.42 8.05 9.06 7.46 7.09 8.74 8.29
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TABLE 15 Demographics and clinical characteristics at baseline by treatment arms (continued )
Characteristics
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All (m= 19;
n= 9328)
SF-12/SF-36 MCSb (0–100; 100= best)
Number of trials, m 4 7 2 1 2 6 9
n 617 2544 507 305 460 2262 6695
Mean 43.94 44.89 44.38 44.84 46.61 45.89 45.22
SD 11.66 12.23 11.28 10.84 11.42 11.90 11.90
Health utility
EQ-5D-3L (–0.11 to 1;1= best)
Number of trials, m 4 4 2 2 – 5 7
n 593 740 652 371 – 724 3080
Mean 0.57 0.61 0.6 0.58 – 0.59 0.59
SD 0.27 0.27 0.29 0.25 – 0.26 0.27
Depression (DE)
DASS–DE (0–42; 42=worst)
Number of trials, m 1 – 1 1 1 – 1
n 65 – 62 63 68 – 258
Mean 7.11 – 7.55 7.08 7.06 – 7.19
SD 7.84 – 7.67 8.79 7.61 – 7.94
DRAM
Number of trials, m 2 1 – 1 – 2 2
Type N (%) 135
(36.49)
122 (36.75) – 116 (37.54) – 184 (44.88) 557 (39.20)
Type R (%) 147
(39.73)
147 (44.28) – 120 (38.83) – 158 (38.54) 572 (40.25)
Type DD (%) 55 (14.86) 41 (12.35) – 46 (14.89) – 49 (11.95) 191 (13.44)
Type DS (%) 33 (8.92) 22 (6.63) – 27 (8.74) – 19 (4.63) 101 (7.11)
HADS–DE (0–21; 21=worst)
Number of trials, m – – 1 – – 1 1
n – – 464 – – 231 695
Mean – – 6.04 – – 5.54 5.87
SD – – 3.81 – – 3.6 3.75
MZDI (0–69; 69=worst)
Number of trials, m 2 2 1 1 – 2 3
n 411 485 148 309 – 411 1724
Mean 19.77 21.44 22.41 21.24 – 19.77 21.06
SD 10.75 10.55 9.37 10.93 – 10.75 10.70
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TABLE 15 Demographics and clinical characteristics at baseline by treatment arms (continued )
Characteristics
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All (m= 19;
n= 9328)
Anxiety (AN)
DASS–AN (0–42; 42=worst)
Number of trials, m 1 – 1 1 1 – 1
n 65 – 62 63 68 – 258
Mean 6.22 – 5.23 4.76 5.35 – 5.40
SD 7.57 – 7.44 6.68 6.92 – 7.14
HADS–AN (0–21; 21=worst)
Number of trials, m – – 1 – – 1 1
n – – 458 – – 230 688
Mean – – 8.22 – – 7.49 7.98
SD – – 4.3 – – 4.43 4.35
Fear avoidance
ALBPSQ–FA (0–30; 30=worst)
Number of trials, m 2 – 2 1 1 – 2
n 121 – 117 36 33 – 307
Mean 18.14 – 18.58 17.14 18.42 – 18.22
SD 6.91 – 6.16 5.97 5.90 – 6.40
FABQ–PC (0–24; 24=worst)
Number of trials, m 2 3 1 1 2 4 5
n 366 840 443 311 506 1016 3482
Mean 14.70 16.65 13.59 14.96 17.79 15.85 15.84
SD 5.27 5.24 6.34 5.30 4.87 5.65 5.61
TSK (16–68; 68=worst)
Number of trials, m 2 1 4 2 1 3 5
n 176 177 472 124 68 285 1302
Mean 39.08 44.05 41.64 39.33 38.07 39.71 40.79
SD 7.44 7.09 8.14 7.51 8.16 8.58 8.12
Catastrophising (CAT)
CSQ–CAT (0–36; 36=worst)
Number of trials, m 1 1 2 – – – 2
n 86 193 282 – – – 561
Mean 10.84 7.83 9.62 – – – 9.19
SD 7.61 6.65 7.22 – – – 7.16
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TABLE 15 Demographics and clinical characteristics at baseline by treatment arms (continued )
Characteristics
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All (m= 19;
n= 9328)
PRSS–CAT (0–45; 45=worst)
Number of trials, m 1 1 1 1 2 – 2
n 65 119 62 63 188 – 497
Mean 17.92 16.43 17.9 17.29 17.23 – 17.22
SD 8.61 8.12 10.55 9.05 8.53 – 8.77
Coping (CSS)
CSQ–CSS (0–36; 36= best)
Number of trials, m – 1 1 – – – 1
n – 198 196 – – – 394
Mean – 25.13 25.33 – – – 25.23
SD – 6.23 6.64 – – – 6.43
PRSS–CSS (0–45; 45 =best)
Number of trials, m 1 2 1 1 2 – 2
n 65 119 62 63 188 – 497
Mean 30.18 31.26 30.06 30.37 31.97 – 31.13
SD 7.34 6.95 8.36 6.81 6.85 – 7.15
PSEQ (0–60; 60= best)
Number of trials, m 3 1 3 1 1 1 4
n 268 117 601 63 67 223 1,339
Mean 40.49 36.85 40.12 44.38 43.70 41.15 40.46
SD 12.93 10.94 13.17 12.77 13.38 12.54 12.90
Somatic perception
MSPQ (0–39; 39=worst)
Number of trials, m 2 2 1 1 – 2 3
n 372 526 195 310 – 411 1814
Mean 6.78 6.43 5.58 7.07 – 6.14 6.45
SD 5.52 5.38 4.29 5.43 – 5.34 5.32
Sensory index (SE)
McGill–SE (0–33; 33=worst)
Number of trials, m – 1 1 – – – 1
n – 185 170 – – – 355
Mean – 14.21 14.26 – – – 14.24
SD – 6.10 6.36 – – – 6.22
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Most of the participants with data in the repository had similar physical disability or functional limitation at
baseline. One trial88 (n= 239) used the ODI as its outcome measure and the average baseline score was
33 (SD 15), which was somewhere between no disability and moderate disability. Three trials50,101,132
(n= 4176) used the FFbHR and the average baseline score was 58 (SD 21), which was slightly above moderate
functional limitation. Fourteen trials31,33,65,70,76,102–106,131,133,134,136 (n= 4710) used the RMDQ as their outcome
measure and the average baseline score was 10 (SD 5), which was slightly below moderate disability.
Nine trials31,33,50,76,101,102,107,132,134 (n= 6695) collected quality-of-life information with either the SF-12 or
SF-36 instrument. The mean PCS at baseline was 36 (SD 8) and the mean MCS at baseline was 45 (SD 12).
The mean values were similar across treatment arms.
Only a minority of the RCTs provided information on psychological distress at baseline and were
insufficient to provide any qualitative comparison across treatment arms.
TABLE 15 Demographics and clinical characteristics at baseline by treatment arms (continued )
Characteristics
Active
physical
(m= 7;
n= 914)
Passive
physical
(m= 12;
n= 3270)
Psychological
(m= 7;
n= 1120)
Combination
(m= 3;
n= 451)
Sham
(m= 6;
n= 688)
Control
(m= 10;
n= 2885)
All (m= 19;
n= 9328)
SES–SE (10–40; 40=worst)
Number of trials, m – 1 – – 1 1 1
n – 146 – – 73 79 298
Mean – 49.7 – – 49.11 49.77 49.57
SD – 9.05 – – 8.39 11.06 9.45
Affective index (AF)
McGill–AF (0–12; 12=worst)
Number of trials, m – 1 1 – – – 1
n – 192 187 – – – 379
Mean – 4.21 4.25 – – – 4.23
SD – 3.31 3.36 – – – 3.33
SES–AF (14–56; 56=worst)
Number of trials, m – 1 – – 1 1 1
n – 146 – – 73 79 298
Mean – 50.19 – – 50.88 50.01 50.31
SD – 8.38 – – 8.17 9.34 8.57
AF, Affective Index; ALBPSQ, Acute Low Back Pain Screening Questionnaire; BMI, body mass index; CAT, Catastrophising;
CSQ, Coping Strategy Questionnaire; CSS, Coping; DASS, Depression Anxiety Stress Scales; DD, distressed–depressive;
DRAM, Distress and Risk Assessment Method; DS, distressed–somatic; FABQ, Fear-Avoidance Beliefs Questionnaire;
HADS, Hospital Anxiety and Depression Scale; McGill, McGill Pain Questionnaire; MSPQ, Modified Somatic Perception
Questionnaire; MZDI, Modified Zung Depression Index; N, normal; PSEQ, Pain Self-Efficacy Questionnaire;
PRSS, Pain-Related Self-Statement; R, at risk; SES, Pain Experience Scale (Schmerzempfindungsskala); TSK, Tampa Scale
for Kinesiophobia.
a PCS of SF–12/SF–36.
b MCS of SF–12/SF–36.
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One-step meta-analysis
Box plots of change of outcome measures from baseline to short-, mid- and long-term follow-up by
treatment arms show that participants in all groups are behaving as expected, with all groups improving
over time (data not shown). This observation was examined further in the one-step meta-analysis
(adjusting for study effects) and the results are shown in Figures 17–19 and Table 16. There was a
statistically significant difference between control and intervention for all outcomes at the short-term
follow-up.
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FIGURE 17 The estimated efficacy between control (non-active usual care and sham) and intervention treatments
from one-step meta-analysis for (a) FFbHR; and (b) RMDQ score. AT, number of participants in the intervention
arm; Est (95% CI), estimated treatment efficacy and 95% CI; m, number of trials; UC, number of participants in the
control arm.
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FIGURE 18 The estimated efficacy between control (non-active usual care and sham) and intervention treatments
from one-step meta-analysis for (a) average pain (based on VAS); and (b) PCS of SF-12/36. AT, number of
participants in the intervention arm; Est (95% CI), estimated treatment efficacy and 95% CI; m, number of trials;
UC, number of participants in the control arm.
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FIGURE 19 The estimated efficacy between control (non-active usual care and sham) and intervention treatments
from one-step meta-analysis for (a) MCS of SF-12/36; and (b) EQ-5D. AT, number of participants in the intervention
arm; Est (95% CI), estimated treatment efficacy and 95% CI; m, number of trials; UC, number of participants in the
control arm.
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Analyses of covariance
Table 17 shows the list of moderators for each of the outcomes of interest at short-term follow-up, namely
FFbHR, RMDQ, average pain, PCS and MCS. There were three trials50,101,132 with FFbHR short-term outcomes
and the explanatory variables that may potentially be treatment moderators provided by these trials were
age, sex, SF-12/36 PCS and SF-12/36 MCS. For the change of FFbHR from baseline to short-term follow-up,
the treatment effect for younger participants was weakly statistically significant (p= 0.2018). Participants
with lower value of FFbHR at baseline (more physical disability) had a larger treatment effect and this was
statistically significant (p< 0.0001). Similarly, participants with lower value of PCS at baseline (substantial
physical limitations) had larger treatment effect (p< 0.0001). Therefore, age, and the baseline values of
FFbHR and PCS were considered for inclusion in further analyses.
TABLE 16 One-step meta-analysis: estimated mean change from baseline to short-term follow-up by treatment
arms and the estimated difference between treatment arms (95% CI)a
Outcomes Number of trials, m Intervention Controlb Differencec p-value
FFbHR 3 n= 1841 n= 2118 0.0165
13.88 5.80 8.08
1.24 to 26.51 –6.93 to 18.53 3.46 to 12.69
RMDQ 8 n= 1778 n= 897 < 0.0001
4.43 2.97 1.46
1.56 to 7.29 0.10 to 5.84 1.10 to 1.81
Average paind 10 n= 2061 n= 1546 < 0.0001
18.03 11.57 6.46
8.65 to 27.41 2.18 to 20.97 4.86 to 8.06
PCSe 6 n= 2793 n= 2415 0.0006
6.86 3.72 3.15
4.90 to 8.83 1.75 to 5.68 1.99 to 4.30
MCSf 6 n= 2793 n= 2415 0.0044
2.69 0.62 2.07
1.54 to 3.84 –0.55 to 1.79 0.93 to 3.20
EQ-5D 4 n= 1271 n= 503 < 0.0001
0.1065 0.03422 0.072
0.008 to 0.205 –0.059 to 0.127 0.04538 to 0.099
a Adjusted by random intercept, trial and interaction between treatment and trial effects.
b Control, usual care/GP and sham control.
c Difference, intervention−control (thus, positive= favours intervention arm).
d Obtained from either VAS or CPG-PS (see Selection of instrument, above).
e PCS of SF-12/36.
f MCS of SF-12/36.
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TABLE 17 Analysis of covariance: analysis for short-term outcomes (change from baseline to short-term
follow-up)a
Outcome Covariates
Number of
trials, m
Number of
participants,
AT : UC
Estimate
(interaction
term) LCI UCI p-value
FFbHR Age 3 1841 : 2118 –0.051 –0.131 0.028 0.2018
Sex (male vs. female)b 3 1841 : 2118 –0.684 –2.851 1.483 0.5361
FFbHR 3 1841 : 2118 –0.177 –0.229 –0.125 < 0.0001
PCS (< 50 vs. ≥ 50)c 3 1718 : 2000 2.521 –2.361 7.403 0.3114
PCS (continuous) 3 1718 : 2000 –0.318 –0.451 –0.186 < 0.0001
MCS (< 50 vs. ≥ 50) 3 1718 : 2000 0.612 –1.618 2.842 0.5903
MCS (continuous) 3 1718 : 2000 –0.039 –0.130 0.051 0.3949
RMDR Age 8 1778 : 897 –0.009 –0.036 0.018 0.514
Sex (male vs. female) 8 1778 : 896 0.136 –0.591 0.863 0.7133
RMDQ 8 1778 : 897 –0.017 –0.085 0.050 0.6176
Average pain 8 1649 : 790 –0.003 –0.018 0.011 0.6548
PCS (continuous) 2 1009 : 401 –0.016 –0.076 0.044 0.594
PCS (< 50 vs. ≥ 50) 2 1009 : 401 0.546 –1.463 2.556 0.5939
MCS (continuous) 2 1009 : 401 –0.002 –0.046 0.042 0.9177
MCS (< 50 vs. ≥ 50) 2 1009 : 401 –0.423 –1.435 0.589 0.4123
EQ-5D 3 1201 : 460 –0.366 –2.162 1.429 0.6892
Anxiety 4 1388 : 523 0.3332
Low riskd –0.295 –1.713 1.123 0.6832
Moderate riske 0.452 –1.089 1.994 0.5649
Depression 4 1387 : 525 0.5684
Low risk 0.078 –1.337 1.492 0.9143
Moderate risk 0.559 –0.933 2.051 0.4622
Catastrophising 2 293 : 178 0.2360
Positivef 0.387 –2.271 3.046 0.7747
Moderateg 2.030 –0.461 4.521 0.1099
Coping 3 620 : 348 0.6797
Positiveh 0.428 –1.127 1.982 0.5895
Moderatei 0.729 –0.904 2.362 0.3813
Fear avoidance 7 1706 : 858 0.1933
Positive
j
0.786 –0.125 1.697 0.0907
Moderatek 0.714 –0.225 1.653 0.1361
Average painl Age 10 2061 : 1546 –0.047 –0.162 0.068 0.4216
Sex (male vs. female) 10 2061 : 1545 0.784 –2.381 3.950 0.6272
RMDQ 8 1657 : 794 0.156 –0.293 0.604 0.497
Average pain 10 2061 : 1546 0.047 –0.017 0.111 0.1451
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TABLE 17 Analysis of covariance: analysis for short-term outcomes (change from baseline to short-term
follow-up)a (continued )
Outcome Covariates
Number of
trials, m
Number of
participants,
AT : UC
Estimate
(interaction
term) LCI UCI p-value
PCS (continuous) 3 1390 : 1144 –0.167 –0.400 0.066 0.1587
PCS (< 50 vs. ≥ 50) 3 1390 : 1144 1.569 –8.473 11.610 0.7594
MCS (continuous) 3 1390 : 1144 0.111 –0.047 0.268 0.1677
MCS (< 50 vs. ≥ 50) 3 1390 : 1144 –1.270 –4.942 2.403 0.498
EQ-5D 3 1208 : 464 –3.192 –13.603 7.219 0.5477
Anxiety 4 1394 : 528 0.2488
Low risk –6.939 –15.111 1.233 0.096
Moderate risk –5.509 –14.423 3.405 0.2256
Depression 4 1394 : 530 0.9355
Low risk –1.519 –9.809 6.772 0.7195
Moderate risk –1.076 –9.843 7.692 0.8099
Catastrophising 2 198 : 85 0.9797
Positive –0.400 –19.050 18.250 0.9664
Moderate –1.573 –17.280 14.133 0.8438
Coping 3 544 : 264 0.4009
Positive –6.107 –14.999 2.786 0.178
Moderate –2.864 –11.995 6.266 0.5382
Fear avoidance 8 1991 : 1505 0.3577
Positive 1.396 –2.525 5.317 0.4851
Moderate 2.808 –1.031 6.646 0.1516
SF-12/36
PCSm
Age 6 2793 : 2415 –0.034 –0.068 0.001 0.0538
Sex (male vs. female) 6 2793 : 2414 –0.176 –1.106 0.755 0.7111
FFbHR 3 1675 : 1955 –0.016 –0.045 0.013 0.2766
RMDQ 2 966 : 383 0.012 –0.210 0.234 0.9187
Average pain 3 1346 : 1125 –0.011 –0.044 0.023 0.5313
PCS (continuous) 6 2793 : 2415 –0.057 –0.109 –0.005 0.0313
PCS (< 50 vs. ≥ 50) 6 2793 : 2415 1.995 0.018 3.973 0.048
MCS (continuous) 6 2793 : 2415 0.023 –0.015 0.060 0.2395
MCS (< 50 vs. ≥ 50) 6 2793 : 2415 –0.913 –1.827 0.002 0.0504
EQ-5D 3 1046 : 425 1.216 –2.364 4.795 0.5054
Anxiety 3 1051 : 428 0.6537
Low risk 1.315 –1.638 4.267 0.3826
Moderate risk 1.398 –1.750 4.545 0.3839
Depression 3 1053 : 430 0.6277
Low risk 1.261 –1.640 4.163 0.3939
Moderate risk 1.462 –1.559 4.483 0.3427
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TABLE 17 Analysis of covariance: analysis for short-term outcomes (change from baseline to short-term
follow-up)a (continued )
Outcome Covariates
Number of
trials, m
Number of
participants,
AT : UC
Estimate
(interaction
term) LCI UCI p-value
Fear avoidance 3 1332 : 1114 0.8438
Positive –0.311 –2.029 1.408 0.7229
Moderate 0.211 –1.435 1.857 0.8019
Somatic symptoms 2 805 : 365 0.9147
Positiven 0.542 –1.989 3.072 0.6746
Moderateo 0.249 –1.907 2.405 0.8206
SF-12/36
MCS
p
Age 6 2793 : 2415 0.008 –0.035 0.050 0.7273
Sex (male vs. female) 6 2793 : 2414 –0.324 –1.470 0.822 0.579
FFbHR 3 1675 : 1955 –0.046 –0.081 –0.011 0.0093
RMDQ 2 966 : 383 –0.011 –0.298 0.276 0.9395
Average pain 3 1346 : 1125 –0.007 –0.048 0.034 0.7423
PCS (continuous) 6 2793 : 2415 –0.035 –0.102 0.033 0.3133
PCS (< 50 vs. ≥ 50) 6 2793 : 2415 0.649 –1.821 3.118 0.6067
MCS (continuous) 6 2793 : 2415 –0.052 –0.093 –0.011 0.0128
MCS (< 50 vs. ≥ 50) 6 2793 : 2415 1.490 0.442 2.539 0.0054
EQ-5D 3 1046 : 425 –0.059 –4.576 4.458 0.9795
Anxiety 3 1051 : 428 0.4267
Low risk –1.201 –4.918 2.517 0.5265
Moderate risk 0.406 –3.558 4.369 0.8409
Depression 3 1053 : 430 0.863
Low risk –0.334 –3.983 3.314 0.8573
Moderate risk 0.343 –3.456 4.142 0.8594
Fear avoidance 3 1332 : 1114 0.7926
Positive 0.732 –1.378 2.843 0.4964
Moderate 0.278 –1.744 2.299 0.7877
Somatic symptoms 2 805 : 365 0.575
Least –0.978 –4.351 2.395 0.5695
Moderate 0.789 –2.087 3.665 0.5906
EQ-5D Age 4 1271 : 503 0.001 –0.001 0.003 0.503
Sex (male vs. female) 4 1271 : 502 –0.040 –0.094 0.015 0.1543
RMDQ 3 1177 : 455 0.007 0.001 0.013 0.0219
Average pain 3 1183 : 459 0.002 0.000 0.003 0.0094
PCS (continuous) 3 1068 : 439 –0.004 –0.008 –0.001 0.0128
PCS (< 50 vs. ≥ 50) 3 1068 : 439 0.045 –0.072 0.162 0.4494
MCS (continuous) 3 1068 : 439 –0.002 –0.004 0.001 0.1834
continued
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TABLE 17 Analysis of covariance: analysis for short-term outcomes (change from baseline to short-term
follow-up)a (continued )
Outcome Covariates
Number of
trials, m
Number of
participants,
AT : UC
Estimate
(interaction
term) LCI UCI p-value
MCS (< 50 vs. ≥ 50) 3 1068 : 439 0.024 –0.034 0.082 0.4102
EQ-5D 4 1271 : 503 –0.054 –0.144 0.035 0.2358
Anxiety 4 1269 : 500 0.0032
Low risk –0.143 –0.232 –0.055 0.0015
Moderate risk –0.086 –0.180 0.009 0.0753
Depression 4 1265 : 500 0.5331
Low risk –0.033 –0.120 0.054 0.4573
Moderate risk –0.003 –0.094 0.088 0.9511
Fear avoidance 3 1163 : 450 0.0533
Positive –0.001 –0.072 0.071 0.9856
Moderate 0.073 –0.002 0.147 0.0565
QALY Age 6 1539 : 814 0.001 –0.0003 0.002 0.1850
RMDQ 4 1092 : 422 0.003 –0.001 0.008 0.1270
PCS (continuous) 4 1273 : 715 –0.001 –0.003 0.0004 0.1160
MCS (continuous) 4 1273 : 715 –0.0001 –0.002 0.001 0.8340
EQ-5D 4 1273 : 715 –0.018 –0.082 0.045 0.5730
AT, number of patients in the intervention arm (active physical, passive physical, psychological or combination; LCI, lower
limit of the 95% CI; UC, number of patients in the control arm (usual care/GP or sham); UCI upper limit of the 95% CI.
a Mixed-effects models with intercept, trials and interaction between treatments and trials as random effects, and
covariate and interaction between covariates.
b Estimate of the treatment effect for male was less than for female.
c Estimate of the treatment effect for participants with SF-12/36 PCS lower than general norm (< 50) was greater than for
those with a score at or above the general norm (≥ 50).
d Estimate of the treatment effect for participants with low risk of anxiety was less than for those with high risk of anxiety.
e Estimate of the treatment effect for participants with moderate risk of anxiety was greater than for those with high risk
of anxiety.
f Estimate of the treatment effect for participants with positive attitude of catastrophising (low catastrophising score) was
greater than for those with negative attitude (high catastrophising score).
g Estimate of the treatment effect for participants with moderate attitude of catastrophising was greater than for those
with negative attitude.
h Estimate of the treatment effect for participants with positive attitude of coping strategy (high coping score) was greater
than for those with negative attitude (low coping score).
i Estimate of the treatment effect for participants with moderate attitude of coping strategy was greater than for those
with negative attitude.
j Estimate of the treatment effect for participants with positive belief (low fear avoidance) of fear avoidance belief was
greater than for those with negative attitude.
k Estimate of the treatment effect for participants with moderate belief of fear avoidance was greater than for those with
negative attitude.
l Obtained from either VAS or CPG-PS (see Selection of instrument, above).
m PCS of SF-12/36.
n Estimate of the treatment effect for participants with least general somatic symptoms was greater than for those with
more general somatic symptoms.
o Estimate of the treatment effect for participants with moderate general somatic symptoms was greater than for those
with more general somatic symptoms.
p MCS of SF-12/36.
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Roland–Morris Disability Questionnaire
There were eight trials31,33,70,103–105,131,136 with RMDQ score as a short-term outcome, and the explanatory
covariates provided by them were age, sex, RMDQ score, average pain, PCS, MCS, EQ-5D, anxiety level,
depression level, catastrophising, coping strategy and fear avoidance at baseline. Seven trials31,33,70,103–105,131
provided information on fear avoidance at baseline and the original values were mapped to a single ordinal
categorical variable. The covariate was weakly statistically significant, at our lower threshold for inclusion in
further analyses (p< 0.20), in moderating the change of RMDQ score over the short term, for which those
with either positive or moderate attitude (lower fear avoidance score) had greater treatment effect than
those with negative attitude (higher fear avoidance score). Although the covariate catastrophising was
not statistically significant (p= 0.236) in predicting the change of RMDQ score in the short term, there
was a weakly statistically significant difference between the moderate and negative statement (mean
difference= 2.03; p= 0.1099), that is, those with a moderate attitude towards catastrophising had greater
treatment effect than those with a negative attitude. Therefore, both fear avoidance and catastrophising
were considered for the prediction rule analyses.
Pain
Ten trials31,33,70,103–105,131,132,135,136 provided an average pain short-term outcome. The list of covariates that
were considered in the ANCOVA were age, sex, RMDQ score, average pain, PCS, MCS, EQ-5D, anxiety
level, depression level, catastrophising, coping strategy and fear avoidance at baseline. Similar to the
results seen for the change of RMDQ score in the short term, anxiety level, coping strategy and fear
avoidance were not statistically significant but there was weakly significant difference between the low
and high risk of anxiety level (p= 0.0960), between the positive and negative statement of coping strategy
(p= 0.1780), and between the moderate and negative statement of fear avoidance (p= 0.1516). Similar to
the results seen above, those with moderate fear avoidance belief had greater treatment effect than those
with a negative attitude. However, those with low risk of anxiety had less treatment effect than those with
high risk of anxiety. Similarly, those with a positive attitude towards coping had less treatment effect than
those with a negative attitude. As the average pain increased, the estimated treatment effect was greater,
that is, as participants had worse average pain, they gained greater treatment effect and this was
weakly significant (p= 0.1451). The estimated treatment effect decreased as PCS increased, that is, as a
participant’s physical functioning score got worse, he/she had greater treatment effect (p= 0.1587). The
interaction term between treatment and MCS was also weakly statistically significant (p= 0.1677), for
which participants with higher (better) MCS had larger treatment effect. Therefore, average pain, PCS,
MCS, anxiety level, coping strategy and fear avoidance at baseline were considered for the prediction
rule analyses.
Mental component score and physical component score
There were six trials31,33,50,88,101,132 with PCS and MCS short-term outcomes and the covariates considered
were age, sex, FFbHR, RMDQ, average pain, PCS, MCS, EQ-5D, anxiety level, depression level, fear
avoidance and somatic symptoms. Psychological distress at baseline measured by the MCS instrument
was not significant in predicting the change of PCS at short term but when the score was dichotomised
to < 50 against ≥ 50, that is, ‘below the norm’ against ‘at or above the general population norm’,
participants with more psychological distress (score of < 50) had worse treatment effect and this was
possibly statistically significant (p= 0.0504). In addition, age and PCS at baseline were significant when
those who were younger and those with substantial physical limitations had a larger treatment effect.
Therefore, age, PCSs and MCSs at baseline were included for the prediction rule analyses for the change
of SF-12/36 PCS at short term.
For the short-term MCS outcome, only FFbHR and MCS at baseline were found to be statistically
significant in predicting the change of SF-12/36 MCS. Those with higher physical disability and more
psychological distress had a greater treatment effect. Therefore, both FFbHR score and MCS at baseline
were included for the prediction rule analyses for the change of SF-12/36 MCS in the short term.
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European Quality of Life-5 Dimensions (EQ-5D)
Four trials31,33,70,105 provided health utility measured by EQ-5D over the short term. The covariates examined
in the ANCOVA were age, sex, RMDQ score, average pain, PCS, MCS, EQ-5D, anxiety level, depression
level and fear avoidance. Seven of these were statistically or weakly significant in predicting the change of
EQ-5D at short term and these were sex, RMDQ score, average pain, PCS, MCS, anxiety level and fear
avoidance at baseline. Females had greater treatment effect (p= 0.1543) and so had those with worse
physical disability (RMDQ score, p= 0.0219; average pain, p= 0.0094; PCS, p= 0.0128). Participants with
more psychological distress at baseline, high risk of anxiety, high risk of depression, negative beliefs about
physical activity affecting their LBP (fear avoidance) or frequent psychological distress (MCS) had a larger
treatment effect. Therefore, these were considered for the prediction rule analyses.
Quality-adjusted life-years
There were six trials,31,33,70,105,132,133 with QALY data, age and baseline RMDQ score and PCS, which were
possibly statistically significant in moderating QALYs. The age-by-treatment interaction was possibly
significant, with a coefficient of 0.001 and a p-value of 0.19. The coefficient was positive, suggesting that
older participants within this sample achieved a higher treatment effect. The RMDQ score by treatment
interaction was significant (p= 0.13) at our prespecified level of 0.2. The coefficient of 0.003 was positive.
The scale on the RMDQ score is such that lower scores denote better health states; therefore, participants
with better (lower) RMDQ scores should be peeled off first for the health-economic prediction rule analyses
(see Chapter 9). The coefficient of PCS-by-treatment interaction was –0.001 (p= 0.12). The negative
coefficient indicates that participants with a worse physical functioning score at baseline achieved a greater
treatment effect than those with better physical functioning scores at baseline. The baseline scores of
EQ-5D and MCS were not significant. The EQ-5D-by-treatment interaction was not significant, with a
coefficient of –0.018 (p= 0.57). The coefficient was negative, suggesting that participants with worse
baseline EQ-5D scores achieved better treatment outcomes. However, this result should not be considered
reliable, given the low level of significance. The coefficient of MCS by treatment interaction was
–0.0001 (p= 0.83).
Summary
This analysis has provided the largest analysis of possible treatment moderation in LBP. Overall, these
analyses do not provide strong evidence for substantial effect moderation. Using conventional criteria for
statistical significance we can conclude, overall, only that back pain disability moderates effect size on back
pain disability outcomes (FFbHR moderates FFbHR); physical state and back pain moderate effect size
on physical outcomes (PCS and FFbHR moderate PCS); psychological state moderates effect size on
psychological outcomes (MCS moderates MCS); overall psychological state and anxiety moderate effect
size on quality of life (PCS and anxiety moderate EQ-5D); and back pain severity moderates effect size on
psychological outcomes (FFbHR moderates MCS).
Age, gender, back pain disability, pain severity, MCS, PCS, anxiety, catastrophising and coping were all at
least weakly statistically significant (p< 0.2) in one, or more, ANCOVA and were considered further for our
main analyses.
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Chapter 7 Methodology and statistical
developments 1: subgroup identification with
recursive partitioning
In Chapter 2 we concluded that current approaches using tests for interactions on single potentialmoderators may not be the best approach to identifying subgroups; specifically in the case of LBP but
this may be generalisable to other disorders. We argued that new statistical methods may be needed to
improve subgroup identification. In the succeeding chapters we describe our exploration of the different
methods that we have applied to addressing this problem. In particular, we were interested in how
subgroups might be defined using multiple parameters. We first describe two recursive partitioning
approaches then an adaptive peeling approach and, finally, an indirect meta-analytical approach.
This chapter presents the two methodological developments, using recursive partitioning, to identify
subgroup characteristics that moderate response to treatment. Both methods were the works of a PhD
project that was part of this programme grant.167 The other methods are described in later chapters
(see Chapters 8–10).
Background
Two methods were considered as suitable and appropriate to perform subgroup analyses using a recursive
partitioning approach. They are the interaction tree (IT) and subgroup identification based on a differential
effect search (SIDES).97,99 These methods were initially developed and implemented in a single-trial setting.
Therefore, they have to be extended so that they can be applied in an individual patient data (IPD)
meta-analysis framework. The extended IT and SIDES methods are known as IPD-IT and IPD-SIDES,
respectively. Details of each of these methods are given below.
Both IT and SIDES are tree-based methods that rely on technique referred to as recursive partitioning.
This technique recursively forms binary splits of the covariate space in order to grow a tree-like structure.
An example of a tree structure is displayed in Figure 20. In this example, we start off with the root node of
the tree, which consists of the entire data set. The method then searches all possible binary splits for every
covariate to find the best split that maximises some splitting criterion. Suppose that ‘sex’ is identified as the
first best split. The method, therefore, splits the root node using the sex covariate to form two child nodes;
Root node
Female Male
Age > 50 yearsAge < 50 years
FIGURE 20 Example of a tree structure.
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females (left child node) and males (right child node). The newly formed child nodes are also referred to as
internal nodes. The same search process is then conducted on all of the internal nodes of the tree, that is,
the two child nodes, to try and identify the next best split. No additional splits are identified for the left
child node and hence the node is not split any further. This node is thus referred to as a terminal node, as
it cannot be split any further and is represented by a square box in Figure 20. For the right child node, the
method identifies age of ≤ 50 years as the next best split and thus forms two new child nodes accordingly.
In the same manner, this search process is repeated until a full tree is grown.
The objective of both the IPD-IT and IPD-SIDES methods are somewhat different. The aim of the IPD-IT
method is to identify moderators of treatment effect whereas the aim of the IPD-SIDES method is to
identify candidate subgroups with enhanced treatment effect. In other words, the IPD-IT method is driven
by identifying the split that results in the largest interaction effect whereas the IPD-SIDES method is driven
by identifying the spilt that maximises the overall treatment benefit in one of the subgroups formed from
the split.
Individual patient data interaction tree
The IPD-IT method primarily consists of three steps:
1. growing an initial tree
2. pruning the initial tree
3. selecting the best tree.
The third and final step in the process will result in either tree structure with just the root node (i.e. no
moderators identified) or a larger tree structure that stems from the root node (i.e. some moderators
identified). In the latter case, the subgroups identified by the final selected tree are interpreted using its
terminal nodes.
Growing an initial tree
The first iteration of the procedure starts at the root node and evaluates a splitting criterion that assesses
the interaction effect for every possible binary split of each covariate in order to identify an optimal split.
For a continuous or discrete ordered covariate, the total number of binary split points is just one fewer
than the total number of distinct values. For example, a discrete ordered covariate with 10 distinct values
will have 10 – 1= 9 possible split points. For a categorical covariate with k different categories, there are
2k–1 – 1 different split points. For example, a categorical covariate such as ethnicity with four different
categories (white, Asian/Asian British, black/African/Caribbean/black British, and other) will have seven
possible ways of forming two groups using a binary split.
The splitting criterion is used to evaluate the interaction effect for any particular split. The original IT
method used a splitting criterion that was equivalent to the square of the t-test statistic of the interaction
term in a linear regression model consisting of a treatment indicator variable T, a covariate indicator
representing a particular split X and the interaction between T and X. As we are now applying this method
to IPD from different trials, we extended the original method so that the splitting criterion adjusts for
the between-trial variability when evaluating the interaction. This was done by fitting the same linear
regression model but also including dummy variables for each trial, that is, fitting a fixed-effects model.167
A split with a larger splitting criterion value indicates a larger interaction effect. Therefore, an optimal split
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is defined as the split that maximises the splitting criterion having searched every possible split point of
each covariate. Having defined the splitting criterion, the algorithm for growing a full tree can be applied
as follows:
l Start at the root node consisting of the entire data set.
l Iteration:
¢ Step 1 Evaluate the splitting criterion for all possible splits for every single covariate.
¢ Step 2 Select the optimal split from step 1 and form a split to create two new child nodes.
¢ Step 3 Repeat steps 1 and 2 for each of the newly formed child nodes.
¢ Step 4 Repeat steps 1–3 until either a full tree is grown or some stopping criterion is satisfied,
for example minimum number of observations in a node is 30.
Pruning the initial tree
The fully grown tree is well fitted to the available data; however, it would be quite poorly fitted and
unstable if applied to new data. For this reason, a pruning procedure is applied to the full tree to
sequentially remove any branches of the tree that least contribute to the overall predictive accuracy of the
tree. The procedure continues until we are just left with the root node and thus have a sequence of
subtrees from which the optimal final subtree will be chosen. A more detailed description of the pruning
procedure can be found elsewhere.97,167,168
Selecting the best tree
Once the sequence of subtrees has been determined, an interaction complexity measure is used to
evaluate the quality of each tree. The interaction complexity is basically the total amount of interaction of
the internal nodes for a tree. Although the interaction–complexity measure is computed for each of the
subtrees, these estimates are known to be over-optimistic and thus need to be validated to obtain more
reliable estimates. To validate the tree selection, the method applies a bootstrapping procedure, used by
LeBlanc and Crowley,169 for validating the trees. As a guideline, LeBlanc and Crowley169 suggested that
around 25–100 bootstrap samples is sufficient. The subtree with the largest interaction–complexity
measure estimated from the bootstrapping procedure is chosen as the best tree. Conclusions can then be
drawn from the best tree by simply computing the treatment effect in each of the terminal nodes of
the tree.
Individual patient data subgroup identification based on a
differential effect search
The IPD-SIDES method consists of two key steps:
1. growing an initial tree
2. selecting the final candidate subgroups.
The tree growing procedure for the IPD-SIDES method (step 1) relies on two different criteria; a splitting
criterion to help search the covariate space for the best splits and a continuation criterion to control the
complexity of the tree. Details are given below. Unlike the IPD-IT procedure, the IPD-SIDES method does
not require a pruning step, as the tree complexity is controlled using the continuation criterion. Ultimately,
after step 2, the method outputs a list of candidate subgroups that have enhanced treatment effect.
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Growing an initial tree
We first describe the algorithm for the IPD-SIDES procedure followed by a more detailed description of the
splitting criterion and the continuation criterion. The algorithm for growing the tree is as follows:
l Start at the root node consisting of the entire data set.
l Iteration:
¢ Step 1 Evaluate the splitting criterion for all splits of every covariate, excluding any covariates that
have already been used to define the parent node, retaining only the best split for each covariate.
Order the covariates from smallest adjusted p-value to largest adjusted p-value, where the adjusted
p-values are computed using the Sidak-based multiplicity adjustment.
¢ Step 2 Select the best M covariates from the ordered best splits. The value of M is specified by the
user where the recommended value is 5. For each of the M splits, form the split creating two child
nodes and retain the child node with the larger positive treatment effect, providing that it satisfies
the continuation criterion. The retained nodes now become parent nodes for the next iteration.
¢ Step 3 Repeat steps 1 and 2 for the newly formed parent nodes.
¢ Step 4 Repeat steps 1–3 until either a prespecified maximum number of levels is reached or no
more splits can be formed, that is, the continuation criterion is not satisfied. In both cases, the
previously formed parent nodes become terminal nodes.
The IPD-SIDES procedure starts at the root node consisting of the entire data set. The method then
evaluates the splitting criterion for all splits for every covariate, retaining only the single best split for each
covariate. The original SIDES method used a splitting criterion in a single-trial setting, which tested the
difference in the treatment effect precision between two child nodes with the aim of identifying the
subgroup or child node with the most significant treatment effect. This objective is different from what we
require the method to do; we require the method to test the differential treatment effect between the two
groups in an IPD meta-analysis setting. For this reason, a new splitting criterion was proposed, which uses
the same fixed-effects model described earlier for the IPD-IT method but instead uses the p-value of the
interaction effect, for which a smaller p-value is indicative of a larger interaction effect. If a covariate has
more than two distinct cut-off points, the p-value computed using the splitting criterion is adjusted to
overcome variable selection bias – a well-known issue with recursive partitioning-based methods when
covariates with a larger number of splits have a greater probability of being chosen as the splitting
variable.170,171 The method adjusts the p-value by applying a Sidak-based multiplicity adjustment, as
described in the original SIDES method paper.99
Continuation criterion
In step 2 of the IPD-SIDES iteration algorithm, a child node with a large positive treatment effect is retained
only if it satisfies the continuation criterion. The continuation criterion is given by Equation 2:
pc≤ γ ⋅pp, (2)
where pc is the treatment effect p-value of the child node, pp is the treatment effect p-value of the parent
node and γ is the relative improvement parameter that controls the complexity of the tree. Prior to running
the method, the user must specify the maximum number of covariates, L, that defines a subgroup, for
which the recommended value is ’3’. This means that any identified subgroups will at most be defined by
L covariates and hence the tree will have at most L levels. Each level of the tree has a relative improvement
parameter value that ranges from 0 to 1, for which a smaller value makes the procedure more selective.
The values for each level can be either user specified or optimally selected using a cross-validation
procedure as described by the authors.99 Hence once the relative improvement parameter values are in
place, a child node is retained only if its treatment effect p-value is less than or equal to the right-hand
side of the continuation criterion.
METHODOLOGY AND STATISTICAL DEVELOPMENTS 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
Selecting the final candidate subgroups
The first step of the IPD-SIDES procedure grows the tree and produces a list of candidate subgroups.
Many of these subgroups may be spurious findings and thus need to be removed. To control for this, the
authors of the original SIDES method proposed a resampling-based procedure that computes an adjusted
treatment effect p-value for each of the identified candidate subgroups to control the overall type I error in
the weak sense.99 Comparing the unadjusted p-value to the adjusted p-value gives a good indication of
whether or not the identified subgroups are spurious.
Analyses
Two sets of analyses were performed using the repository data. In the first analyses (analysis 1), we
grouped all of the interventions together as being one arm, and grouped the non-active usual care and
sham control together as being the comparator arm. We then sought to identify subgroups within these
data by applying the IPD-IT and IPD-SIDES methods. These analyses were performed for all of the following
absolute change from baseline to short-term follow-up outcome variables: average pain, EQ-5D, FFbHR,
MCS of SF-12/36, PCS of SF-12/36 and RMDQ.
In addition to the above outcome measures, we also looked at the QALYs health-economics outcome.
This analysis provides proof of principle that the analytical techniques are robust when used with real data
rather than simply in the simulated data sets in which we originally developed our techniques.167
In the second set of analyses (analysis 2), the following interventions against the non-active usual care
comparisons were investigated for subgroups:
1. active physical against non-active usual care
2. passive physical against non-active usual care
3. psychological against non-active usual care
4. sham against non-active usual care.
Both the IPD-IT and IPD-SIDES methods were applied to the above for each of the short-term outcomes
common to all trials. For example, active physical against non-active usual care may consist of three trials
with RMDQ, MCS and PCS as common short-term outcome measures. Thus the analyses would be applied
to only these three outcome measures.
Prior to performing each of the analyses, any observations with missing data were removed from the data
set. A mixed-effects model was then applied to adjust for the clustering inherent within the data and thus
obtain an estimate of the overall treatment effect. In both sets of analyses, the potential moderator variables
identified from the univariate analyses as well as those moderators identified in systematic review 1
(see Chapter 2) were considered. From this set of moderator variables, only the variables that were most
common across all trials were entered into each of the analyses in order to retain as much data as possible.
The IPD-IT and IPD-SIDES methods both require certain parameters to be prespecified to aid or control the
methods when applied to the data. For both methods, the minimum number of participants in any given
node of a tree was set to r= 1/20 of the population being analysed. The maximum number of splits for
the fully grown IPD-IT tree was set as 15. For the IPD-SIDES methods, the maximum number of levels,
that is, the maximum number of covariates defining any particular subgroup, was set as being the number
of potential moderators being considered. Moreover, the maximum number of best splits to consider for
each node during the IPD-SIDES procedure was set to ‘3’, with a restriction of p≤ 0.20 placed on the
splitting criterion. This is the same constraint that we set in the identification of a promising moderator.
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Before applying the IPD-SIDES method, we performed a grid search to obtain an optimal sequence of
complexity control parameters for the first three levels of the tree. The grid search considered all
permutations from 0.2 to 1, in steps of 0.2 at the first level and then from 0 to 1 in steps of 0.2 at levels
two and three. When validating or selecting the final subgroups, we used 500 bootstraps for the IPD-IT
procedure and used 1000 repetitions of the resampling procedure for the IPD-SIDES procedure. Any
identified subgroups from the analyses were then summarised using the treatment effect and 95% CI. All
analyses were performed using R version 3.0.3 (The R Foundation for Statistical Computing, Vienna, Austria).
Results
Analysis 1
The intervention (active physical, passive physical or psychological given either singly or as combined
regimen with the other interventions) against control/placebo data were searched for subgroups for the
first set of analyses. Table 18 provides a summary of the trials included and the variables used to search for
subgroups for each short-term outcome measure. Number included from each trial is dependent on the
number of complete cases available for each analysis.
Subgroups identified by the individual patient data interaction tree method
The IPD-IT method did not identify any subgroups that moderate treatment effect when comparing any
intervention compared with usual care control/sham.
TABLE 18 Summary of the included trials and variables used for each short-term outcome measure in analysis 1
Outcomea Trials Variables
Average pain m= 2; n= 1377
bUK BEAM31 (n= 910)
cBeST33 (n= 467)
Age, sex, anxiety, fear avoidance, MCS, PCS,
average pain and RMDQ score at baseline
EQ-5D m= 2; n= 1339
UK BEAM31 (n= 883)
BeST33 (n= 456)
Age, sex, anxiety, fear avoidance, MCS, PCS,
RMDQ and average pain at baseline
FFbHR m= 3; n= 3718
dBrinkhaus101 (n= 284)
eHaake132 (n= 1110)
fWitt50 (n= 2324)
Age, sex, PCS, FFbHR and MCS at baseline
MCSg m= 3; n= 3630
Brinkhaus101 (n= 281)
Haake132 (n= 1110)
Witt50 (n= 2239)
Age, sex, FFbHR, MCS and PCS at baseline
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TABLE 18 Summary of the included trials and variables used for each short-term outcome measure in
analysis 1 (continued )
Outcomea Trials Variables
PCSh m= 6; n= 5208
UK BEAM31 (n= 893)
BeST33 (n= 470)
Brinkhaus101 (n= 281)
Haake132 (n= 1110)
Witt50 (n= 2248)
iYACBAC107 (n= 206)
Age, sex, MCS and PCS at baseline
RMDQ m= 7; n= 2564
UK BEAM31 (n= 951)
BeST33 (n= 488)
jHancock131 (n= 235)
kPengel103 (n= 236)
lSmeets70 (n= 212)
mVKBIA104 (n= 229)
nVKSC2105 (n= 213)
Age, sex, fear avoidance and RMDQ score at
baseline
QALYo m= 4; n= 1514
UK BEAM31 (n= 728)
BeST33 (n= 468)
Smeets70 (n= 151)
p
York BP133 (n= 167)
Age and RMDQ score at baseline
YACBAC, York Acupuncture Back Pain Trial.
a Change from baseline to short-term follow-up (between 2 and 3 months post randomisation or entry to the trial).
b UK BEAM (Exercise, spinal manipulation, combined, best care).
c BeST (cognitive behavioural approach, control).
d Brinkhaus (acupuncture, minimal acupuncture, waiting list).
e Haake (verum acupuncture, sham acupuncture, conventional therapy).
f Witt (acupuncture, control).
g MCS of SF-12/36.
h PCS of SF-12/36.
i YACBAC (traditional acupuncture, usual care).
j Hancock (spinal manipulation, placebo spinal manipulation, advice).
k Pengel (exercise, sham exercise, advice, sham advice).
l Smeets (APT, cognitive–behavioural treatment, combined treatment, waiting list).
m Von Korff BIA (Brief Individualised Programme, usual care).
n Von Korff SC2 (Self-Care, usual care).
o The QALY that was measured over 1 year of follow-up using the AUC method.
p York BP (exercise, control).
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Subgroups identified by the individual patient data subgroup identification
based on a differential effect search method
The application of the IPD-SIDES method for the first set of analyses found candidate subgroups for three
of the short-term outcome measures when comparing intervention with control/placebo (Table 19); namely
short-term FFbHR (Figure 21), SF-12/36 MCS (Figure 22) and SF-12/36 PCS (Figure 23). No candidate
subgroups were identified for the average pain, EQ-5D and RMDQ short-term outcomes, as well as the
QALY health outcome measure.
Short-term Hannover Functional Ability Questionnaire for measuring back pain-related
functional limitations outcome
For the short-term FFbHR outcome, five variables were included in the IPD-SIDES analyses. The overall
treatment effect for the FFbHR outcome was 8.93 (95% CI 7.81 to 10.05). Three candidate subgroups
with enhanced treatment effect were identified by the IPD-SIDES procedure. Those with baseline FFbHR
score of ≤ 54.2 had a treatment effect of 11.31 (95% CI 9.38 to 13.23), those with baseline FFbHR score
of ≤ 54.2 and age ≤ 60 years had a treatment effect of 13.17 (95% CI 10.56 to 15.77) and those with
FFbHR score of ≤ 54.2 and age ≤ 66 years had a treatment effect of 12.26 (95% CI 10.06 to 14.46).
l Those with more disability at baseline and who are younger are likely to gain a greater benefit
on disability.
Short-term mental component scale of SF-12/36 outcome
For the short-term MCS outcome, five variables were included in the IPD-SIDES analyses. The overall
treatment effect for the MCS outcome was 2.61 (95% CI 1.92 to 3.29). Only one candidate subgroup was
identified for MCS outcome. Those with baseline MCS of ≤ 54.4 had a treatment effect of 3.46 (95% CI
2.62 to 4.30).
l Those with more psychological distress at baseline will get better outcomes on psychological distress.
Short-term physical component scale of SF-12/36 outcome
For the short-term PCS outcome, four variables were included in the analyses and four candidate
subgroups were identified. The overall treatment effect for the PCS outcome was 3.48 (95% CI 3.01 to
3.96). Those with baseline MCS of > 50.9 had a treatment effect of 4.09 (95% CI 3.32 to 4.87), those
with baseline MCS of > 50.9 and female had a treatment effect of 4.72 (95% CI 3.67 to 5.78), those with
baseline MCS of > 50.9 and baseline PCS of ≤ 43.2 had a treatment effect of 4.62 (95% CI 3.75 to 5.49)
and, finally, those with baseline MCS of > 50.9 and baseline PCS of ≤ 40.0 had a treatment effect of
4.89 (95% CI 3.96 to 5.82).
l Those with less psychological distress and worse physical status will get better outcomes on
physical status.
l Women with low levels of psychological distress will get better outcomes on physical status.
These analyses do not consider any differences between different treatment approaches.
Analysis 2: pairwise comparisons
Each of the subgrouped interventions (active physical, passive physical or psychological) against non-active
usual care data were searched for subgroups for the second set of analyses. Table 20 provides a summary
of the trials included and the variables used to search for subgroups for each short-term outcome measure
analysed for the different comparisons.
Subgroups identified by the ‘individual patient data interaction tree’ method
The IPD-IT method did not identify any subgroups that moderate treatment effect when comparing any of
the subgrouped interventions against non-active usual care.
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TABLE 19 Candidate subgroups identified by the IPD-SIDES method for the intervention vs. control/
placebo comparisona
Subgroups n Treatment effect (95% CI) Interaction effect Unadjusted p-value
Outcome: short-term FFbHRb
Overall treatment effect (95% CI): 8.93 (7.81 to 10.05)
Candidate 1
FFbHR ≤ 54.2 1709 11.31 (9.38 to 13.23) 4.69 < 0.001
FFbHR> 54.2 2009 6.62 (5.46 to 7.78)
Candidate 2
FFbHR ≤ 54.2 and Age ≤ 60 1043 13.17 (10.56 to 15.77) 5.03 0.019
FFbHR ≤ 54.2 and Age > 60 666 8.14 (5.47 to 10.80)
Candidate 3
FFbHR ≤ 54.2 and Age ≤ 66 1367 12.26 (10.06 to 14.46) 5.14 0.043
FFbHR ≤ 54.2 and Age > 66 342 7.12 (3.42 to 10.82)
Outcome: short-term MCSc
Overall treatment effect (95% CI): 2.61 (1.92 to 3.29)
Candidate 1
MCS ≤ 54.4 2541 3.46 (2.62 to 4.30) 2.62 0.002
MCS> 54.4 1089 0.84 (0.01 to 1.67)
Outcome: short-term PCSd
Overall treatment effect (95% CI): 3.48 (3.01 to 3.96)
Candidate 1
MCS> 50.9 2082 4.09 (3.32 to 4.87) 0.97 0.033
MCS ≤ 50.9 3126 3.12 (2.54 to 3.71)
Candidate 2
MCS> 50.9 and Sex= Female 1125 4.72 (3.67 to 5.78) 1.38 0.097
MCS> 50.9 and Sex=Male 957 3.34 (2.20 to 4.48)
Candidate 3
MCS> 50.9 and PCS ≤ 43.2 1666 4.62 (3.75 to 5.49) 2.61 0.020
MCS> 50.9 and PCS> 43.2 416 2.01 (0.69 to 3.33)
Candidate 4
MCS> 50.9 and PCS ≤ 40.0 1457 4.89 (3.96 to 5.82) 2.61 0.007
MCS> 50.9 and PCS> 40.0 625 2.28 (1.12 to 3.44)
a The first row of each candidate subgroup is the selected subgroup with enhanced treatment effect.
b FFbHR, ranging from 0 to 100 where a lower score represents greater disability.
c MCS of SF-12/36 ranging from 0 to 100 where a lower score represents worse mental functioning.
d PCS of SF-12/36 ranging from 0 to100 where a lower score represents worse physical functioning.
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(n = 3718)
8.93
(7.81 to 10.05)
(n = 2009)
6.62 (5.46 to 7.78)
(n = 1709)
11.31
(9.38 to 13.23)
FFbHR < 54.2 FFbHR > 54.2
Age > 66 yearsAge < 66 years
(n = 1367)
12.26 (10.06 to 14.46)
(n = 342)
7.12 (3.42 to 10.82)
Age > 60 yearsAge < 60 years
(n = 1043)
13.17 (10.56 to 15.77)
(n = 666)
8.14 (5.47 to 10.80)
FIGURE 21 Candidate subgroups identified (shaded green) by the IPD-SIDES method when applied to change from
baseline to short-term FFbHR (range 0–100; lower score implies greater disability) outcome for the intervention
against control/placebo comparison. Results presented as treatment effect (95% CI) in each node.
n = 3630
2.61 (1.92 to 3.29)
n = 1089
0.84 (0.002 to 1.67)n = 2541
3.46 (2.62 to 4.30)
MCS < 54.4 MCS > 54.4
FIGURE 22 Candidate subgroup identified (shaded green) by the IPD-SIDES method when applied to change from
baseline to short-term SF-12/36 MCS outcome (range 0–100; lower score implies worse mental functioning) for the
intervention against control/placebo comparison. Results presented as treatment effect (95% CI) in each node.
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Subgroups identified by the ‘individual patient data subgroup identification
based on a differential effect search’ method
The application of the IPD-SIDES method for the second set of analyses found candidate subgroups for one
or more short-term outcome measures for the passive physical against non-active usual care (Table 21),
psychological against non-active usual care (Table 22) and sham against non-active usual care (Table 23).
No candidate subgroups were identified for the active physical against non-active usual care comparison.
TABLE 21 Candidate subgroups identified by the IPD-SIDES method for the passive physical vs. non-active usual
care comparisona,b
Subgroups n
Treatment effect
(95% CI)
Interaction
effect
Unadjusted
p-value
Outcome: short-term FFbHR
Overall treatment effect (95% CI): 9.95 (8.80 to 11.11)
Candidate 1
FFbHR score of ≤ 54.2 1424 12.86 (10.81 to 14.91) 5.45 < 0.001
FFbHR score of > 54.2 1848 7.41 (6.23 to 8.59)
Candidate 2
FFbHR score of ≤ 54.2 and age ≤ 57 years 731 15.86 (12.80 to 18.92) 6.63 0.002
FFbHR score of ≤ 54.2 and age > 57 years 693 9.23 (6.64 to 11.82)
Candidate 3
FFbHR score of ≤ 54.2 and age ≤ 53 years 571 16.67 (13.16 to 20.18) 6.85 0.001
FFbHR score of ≤ 54.2 and age > 53 years 853 9.83 (7.43 to 12.22)
Candidate 4
FFbHR score of ≤ 41.7 792 15.03 (12.06 to 18.01) 6.71 < 0.001
FFbHR score of > 41.7 2480 8.32 (7.19 to 9.45)
Outcome: short-term MCS
Overall treatment effect (95% CI): 2.96 (2.31 to 3.61)
Candidate 1
MCS of ≤ 54.3 2714 3.76 (2.97 to 4.55) 2.82 < 0.001
MCS of > 54.3 1165 0.93 (0.10 to 1.76)
Candidate 2
MCS of ≤ 54.3 and PCS ≤ 43.9 2171 4.27 (3.39 to 5.15) 2.43 0.019
MCS of ≤ 54.3 and PCS > 43.9 543 1.85 (0.11 to 3.59)
Candidate 3
MCS of ≤ 51.3 2327 3.83 (2.96 to 4.70) 2.57 < 0.001
MCS of > 51.3 1552 1.26 (0.52 to 1.99)
continued
DOI: 10.3310/pgfar04100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Patel et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
107
TABLE 21 Candidate subgroups identified by the IPD-SIDES method for the passive physical vs. non-active usual
care comparisona,b (continued )
Subgroups n
Treatment effect
(95% CI)
Interaction
effect
Unadjusted
p-value
Outcome: short-term PCS
Overall treatment effect (95% CI): 4.10 (3.56 to 4.63)
Candidate 1
PCS of ≤ 43.6 3103 4.39 (3.78 to 4.99) 1.61 0.013
PCS of > 43.6 776 2.77 (1.87 to 3.67)
Candidate 2
PCS of ≤ 43.6 and age ≤ 44 years 942 5.35 (4.21 to 6.49) 1.45 0.040
PCS of ≤ 43.6 and age > 44 years 2161 3.90 (3.20 to 4.60)
Candidate 3
PCS of ≤ 37.8 2326 4.61 (3.90 to 5.32) 1.23 0.025
PCS of > 37.8 1553 3.37 (2.66 to 4.09)
Candidate 4
PCS of ≤ 37.8 and age ≤ 62 years 1682 5.08 (4.21 to 5.94) 1.97 0.016
PCS of ≤ 37.8 and age > 62 years 644 3.11 (1.94 to 4.28)
Candidate 5
PCS of ≤ 37.8 and MCS > 44.0 1396 5.48 (4.55 to 6.41) 1.80 0.011
PCS of ≤ 37.8 and MCS ≤ 44.0 930 3.68 (2.64 to 4.71)
Candidate 6
PCS of ≤ 37.8 and MCS> 51.8 932 5.77 (4.63 to 6.91) 1.78 0.012
PCS of ≤ 37.8 and MCS ≤ 51.8 1394 3.99 (3.11 to 4.87)
Candidate 7
PCS of ≤ 37.8 and MCS> 51.8 and sex= female 520 6.64 (5.12 to 8.16) 1.73 0.167
PCS of ≤ 37.8 and MCS> 51.8 and sex=male 412 4.91 (3.17 to 6.65)
Candidate 8
PCS of ≤ 40.3 2715 4.51 (3.85 to 5.16) 1.61 0.006
PCS of > 40.3 1164 2.90 (2.11 to 3.68)
Candidate 9
PCS of ≤ 40.3 and MCS > 51.5 1086 5.43 (4.37 to 6.48) 1.38 0.042
PCS of ≤ 40.3 and MCS ≤ 51.5 1629 4.05 (3.24 to 4.85)
a The baseline FFbHR score ranges from 0 to 100, for which a lower score represents greater disability. The baseline MCSs
and PCSs range from 0 to 100, for which a lower score represents worse mental and physical functioning.
b The first row of each candidate subgroup is the selected subgroup with enhanced treatment effect.
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Passive physical results compared with non-active usual care results
Short-term Hannover Functional Ability Questionnaire for measuring back pain-related
functional limitations outcome
The overall treatment effect for the FFbHR short-term outcome was 9.95 (95% CI 8.80 to 11.11). Four
candidate subgroups were identified for the FFbHR short-term outcome. Those with a baseline FFbHR score
of ≤ 54.2 had a treatment effect of 12.86 (95% CI 10.81 to 14.91), those with a baseline FFbHR score of
≤ 54.2 and age ≤ 57 years had a treatment effect of 15.86 (95% CI 12.80 to 18.92), those with a FFbHR
score of ≤ 54.2 and age ≤ 53 years had a treatment effect of 16.67 (95% CI 13.16 to 20.18) and those
with a baseline FFbHR score of ≤ 41.7 had a treatment effect of 15.03 (95% CI 12.06 to 18.01).
l Overall, those with more disability and who are younger are likely to gain a greater benefit on disability
from passive physical treatments.
TABLE 22 Candidate subgroups identified by the IPD-SIDES method for the psychological vs. non-active usual care
comparisona,b
Subgroups n Treatment effect (95% CI) Interaction effect Unadjusted p-value
Outcome: short-term RMDQ
Overall treatment effect (95% CI): 1.40 (0.89 to 1.91)
Candidate 1
RMDQ score of > 4 697 1.72 (1.12 to 2.31) 1.07 0.038
RMDQ score of ≤ 4 231 0.65 (–0.11 to 1.40)
a The baseline RMDQ score ranges from 0 to 24, for which a higher score represents greater disability.
b The first row of each candidate subgroup is the selected subgroup with enhanced treatment effect.
TABLE 23 Candidate subgroups identified by the IPD-SIDES method for the sham vs. non-active usual care
comparisona,b
Subgroups n Treatment effect (95% CI) Interaction effect Unadjusted p-value
Outcome: short-term MCS
Overall treatment effect (95% CI): 2.59 (1.13 to 4.04)
Candidate 1
Age ≤ 65 years 705 3.42 (1.80 to 5.04) 4.32 0.019
Age > 65 years 174 –0.90 (–4.16 to 2.35)
Candidate 2
PCS of ≤ 42.0 791 3.10 (1.55 to 4.65) 4.99 0.043
PCS of > 42.0 88 –1.89 (–6.07 to 2.28)
a The baseline PCS ranges from 0 to 100, for which a lower score represents worse physical functioning.
b The first row of each candidate subgroup is the selected subgroup with enhanced treatment effect.
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Short-term mental component score of SF-12/36 outcome
The overall treatment effect for the SF-12/36 MCS short-term outcome was 2.96 (95% CI 2.31 to 3.61).
Three candidate subgroups were identified for the MCS short-term outcome. Those with a baseline MCS
of ≤ 54.3 had a treatment effect of 3.76 (95% CI 2.97 to 4.55), those with a MCS of ≤ 54.3 and PCS of
≤ 43.9 had a treatment effect of 4.27 (95% CI 3.39 to 5.15) and those with a MCS of ≤ 51.3 had a
treatment effect of 3.83 (95% CI 2.96 to 4.70).
l These results suggest that those with more psychological distress and worse physical status at baseline
will get better outcomes on psychological distress from passive physical treatments.
Short-term physical component score of SF-12/36 outcome
The overall treatment effect for the SF-12/36 PCS short-term outcome was 4.10 (95% CI 3.56 to 4.63).
Nine candidate subgroups were identified for the PCS short-term outcome. Those with a baseline PCS of
≤ 43.6 had a treatment effect of 4.39 (95% CI 3.78 to 4.99), those with a baseline PCS of ≤ 43.6 and age
≤ 44 years had a treatment effect of 5.35 (95% CI 4.21 to 6.49), those with a baseline PCS of ≤ 37.8 had
a treatment effect of 4.61 (95% CI 3.90 to 5.32), those with a PCS of ≤ 37.8 and age ≤ 62 years had a
treatment effect of 5.08 (95% CI 4.21 to 5.94), those with a baseline PCS of ≤ 37.8 and a MCS of > 44.0
had a treatment effect of 5.48 (95% CI 4.55 to 6.41), those with a PCS of ≤ 37.8 and a MCS of > 51.8
had a treatment effect of 5.77 (95% CI 4.63 to 6.91), those with a PCS of ≤ 37.8, a MCS of > 51.8 and
female had a treatment effect of 6.64 (95% CI 5.12 to 8.16), those with PCS ≤ 40.3 had a treatment
effect of 4.51 (95% CI 3.85 to 5.16) and, finally, those with a PCS of ≤ 40.3 and a MCS of > 51.5 had a
treatment effect of 5.43 (95% CI 4.37 to 6.48). Broadly speaking, these results suggest that:
l Younger patients with worse physical status at baseline will get better outcomes on physical status
from passive physical treatments.
l Those with worse physical status but less psychological distress at baseline will get better outcomes on
physical status from passive physical treatments.
l Females with worse physical status and less psychological distress at baseline will get better outcomes
on physical status from passive physical treatments.
Psychological results compared with non-active usual care results
Short-term Roland–Morris Disability Questionnaire outcome
The overall treatment effect for the RMDQ short-term outcome was 1.40 (95% CI 0.89 to 1.91). One
candidate subgroup was identified for the RMDQ short-term outcome. Those with a baseline RMDQ score
of > 4 had a treatment effect of 1.72 (95% CI 1.12 to 2.31).
l This suggests that those with worse disability at baseline gain more benefit from psychological
treatment on disability than usual care control.
Sham results compared with non-active usual care results
Short-term mental component score of SF-12/36 outcome
Two trials were included in the analyses and the sham treatment in both was sham acupuncture. The
overall treatment effect for the MCS short-term outcome was 2.59 (95% CI 1.13 to 4.04). Two candidate
subgroups were identified for the MCS short-term outcome. Those with age ≤ 65 years at baseline had a
treatment effect of 3.42 (95% CI 1.80 to 5.04) and those with a baseline PCS of ≤ 42.0 had a treatment
effect of 3.10 (95% CI 1.55 to 4.65). No candidate subgroups were identified for the FFbHR and PCS
short-term outcomes.
l This suggests that younger people and those with worse physical status at baseline have a greater
benefit from sham treatment on psychological distress than usual care control.
METHODOLOGY AND STATISTICAL DEVELOPMENTS 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
Chapter 8 Methodology and statistical
developments 2: subgroup identification using an
adaptive refinement by directed peeling algorithm
Background
The adaptive risk group refinement introduced by LeBlanc et al.172 aims to identify subgroups of
participants with poor prognosis, whereby the subgroups are defined by cut-offs for the covariates
resulting in box-shaped subgroups that are easy to interpret. The approach is based on a so-called
‘adaptive refinement by directed peeling’ (ARDP) algorithm. Starting with the whole data set, the
algorithms peel off fractions of the data in a series of locally optimal steps optimising a prognostic
indicator (e.g. median survival in the paper by LeBlanc et al.172). We aim to identify subgroups of
participants who benefit in particular from a specific treatment in that they respond particularly well to the
treatment. The approach to subgroup identification presented in this chapter builds on the work by
LeBlanc et al.172 and extends it in two ways: (1) the criterion for optimisation is now based on the
interaction effects between treatment and subgroup, and (2) data from multiple trials can now be
analysed, allowing between-trial heterogeneity in the treatment-by-subgroup interactions thereby
generalising the ARDP algorithm from a single-study setting to individual participant data meta-analysis
setting. With regard to the latter, this is similar to the IT and SIDES methods (see Chapter 7). In the
following sections we describe the modified ARDP algorithm for individual participant data meta-analysis.
Adaptive refinement by directed peeling in individual patient
data meta-analysis
The ARDP in individual patient data meta-analysis (ARDP-MA) algorithm to construct a region that predicts
the best or worst response to treatment consists of the following steps:
1. To determine the covariates to be included and their direction of peeling, run regression analyses on
the entire data set to investigate interactions of covariates with treatment. For the identified
moderators, the sign of the interaction effect determines the direction of peeling. If larger values of a
covariate lead to larger treatment effects then peel off the cases with a smaller value of this covariate.
Correspondingly, if smaller values of the covariate lead to larger treatment effects then peel off the
larger values of the covariate.
2. Start with a ‘subgroup’ B0 that includes all observations, n.
3. The proportion of data to be removed in one step is denoted by α and the minimum number of
observations to be peeled off is denoted by nmin. For each variable, we move the threshold so that max
(αn,nmin observations are removed; the resulting subgroups for the L covariates we denote by B
m
j , j = 1,
…, L. For each subgroup Bmj calculate the treatment-by-subgroup interaction effect and select the B
m
j ,
which gives the largest improvement on the interaction effect in comparison with the previous iteration
standardised by change in subgroup size. In the setting of data from multiple trials, the interaction
effects estimated from the individual trials are combined in a random-effects meta-analysis (two-stage
procedure); alternatively an equivalent hierarchical model can be fitted (one-step procedure).
4. The selected subgroup is then called Bm+1.
5. Estimate the treatment effects for the outcome of interest for subgroup Bm+1.
6. Repeat steps 3–5 until the size of the remaining region is not smaller than r.
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Figure 24 illustrates the ARDP algorithm for the identification of subgroups of treatment responders.
Expecting a large number of covariates to be included in the analyses, we developed this algorithm earlier
on in the project. However, it turned out that situations with a small number of covariates were most
relevant for the data sets to be analysed. By restricting the number of covariates to four, we could do far
more extensive searches by considering all of the possible combinations of boxes described in the ARDP
algorithm above. This allowed us to interrogate the data sets more thoroughly.
Note that this algorithm can be applied to various kinds of end points, as we assume that only appropriate
regression models can be fitted to model the outcome. For instance, Gaussian linear models could be
applied to continuous outcomes, logistic regression to binomial outcomes, and Cox’s proportional hazard
models to time-to-event data. No distributional assumption regarding the covariates is required, but they
should be ordinal and have a sufficient number of possible outcomes so that the peeling in several steps
makes sense. If a covariate is not ordinal then an order could be imposed on it by ordering the outcomes
by the regression coefficients estimated in step 1 of the algorithm.172
Analyses
The minimum sample size of the subpopulation was defined as r= 0.10 of the population analysed.
The appeal of the ARDP-MA method is the ability to remove a small proportion of participants at each
iteration. Categorical covariates that delineate participants into three or fewer categories would cause the
ARDP-MA method to remove a large proportion of participants, an unappealing feature. As all the
categorical covariates identified in the analyses of covariance have three or fewer categories, none of them
was considered in the ARDP-MA analyses.
Similar to analyses seen in Chapter 7 (see Analyses), two sets of analyses were performed. The first one
was to confirm proof of concept, when all interventions (active physical, passive physical and psychological,
delivered singly or in combination with the others) were grouped together as being one arm and the
non-active usual care grouped with the sham as a control/placebo arm. Analyses were performed for these
measurements: average pain, EQ-5D, FFbHR, MCS of SF-12/36, PCS of SF-12/36 and RMDQ score.
The outcome was the absolute change from baseline to short-term follow-up. In the second set of
analyses, similarly, two treatments are compared and the pairwise comparisons investigated were active
physical against non-active usual care, passive physical against non-active usual care, psychological against
non-active usual care, and sham against non-active usual care.
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FIGURE 24 Schematic diagram of the ARDP algorithm to identify subgroups of treatment responders. Here the
subgroups are defined by thresholds for the two covariates A and B. (a) Shows how two covariates might affect
response to treatment. In the upper right hand corner is the group, defined by those two covariates, who have the
largest response to treatment; and (b) shows how size of the treatment effect might increase as the size of the
subgroup decreases as the peeling processes from bottom left to top right.
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Results
We programmed the ARDP-MA method to do a full search, but this limits the number of covariates. As the
number of covariates increased, the computational time and resources needed to store the data increased
exponentially, causing a massive strain on the system server. Therefore, up to four covariates when
necessary were included in the analyses.
Analysis 1: overall comparison treatment compared with control
Table 24 shows the summary of the trials and continuous variables used in the ARDP-MA algorithm to
construct a region that predicts the best or worst response for each of the short-term outcome measures.
Short-term average pain outcome
Figure 25 shows the trajectory plot for the treatment effect for the short-term outcome of average pain.
The treatment effect increased as more and more participants were excluded from the subgroup.
However, Table 25 shows that age and average pain might not be important covariates in improving the
treatment effect as their thresholds fluctuate. Of note was that substantial physical limitation (low PCS)
seemed to gain benefit in short-term average pain.
TABLE 24 Summary of included trials and variables considered to construct a region that predicts the best or worst
response to treatmenta
Outcomeb Trials Variables
Average pain m= 3; n= 2534
UK BEAM31 (n= 926), BeST33 (n= 498), Haake (n= 1110)
Age, average pain, PCS and
MCS at baseline
EQ-5D m= 2; n= 1365
UK BEAM31 (n= 890), BeST33 (n= 475)
RMDQ, average pain, PCS and
MCS at baseline
FFbHR m= 3; n= 3718
Brinkhaus101 (n= 284), Haake132 (n= 1110), Witt50 (n= 2324)
Age, FFbHR, PCS and MCS at
baseline
MCSc m= 3; n= 3,630
Brinkhaus101 (n= 281), Haake132 (n= 1110), Witt50 (n= 2239)
Age, FFbHR, PCS and MCS at
baseline
PCSd m= 6; n= 5208
UK BEAM31 (n= 893), BeST33 (n= 470), Brinkhaus101 (n= 281),
Haake132 (n= 1110), Witt50 (n= 2248), YACBAC107 (n= 206)
Age, PCS and MCS at baseline
RMDQ m= 8; n= 2675
UK BEAM31 (n= 995), BeST33 (n= 514), Hancock131 (n= 235),
Kennedy136 (n= 40), Pengel103 (n= 236), Smeets70 (n= 212),
VKBIA104 (n= 230), VKSC2105 (n= 213)
Age and RMDQ score at baseline
YACBAC, York Acupuncture Back Pain Trial.
a Any active intervention (active physical, passive physical or psychological delivered either singly or in combination with
other intervention) against control/placebo, which is either GP usual care or sham.
b Change from baseline to short-term follow-up (between 2 and 3 months post randomisation or entry to the trial).
c MCS of SF-12/36.
d PCS of SF-12/36.
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FIGURE 25 Trajectory plot for the treatment effect against the size of the constructed region for the average pain
short-term outcome.
TABLE 25 Thresholds for selected size of subgroup for the short-term average pain as seen in Figure 25
Subgroup size Age, years (<) Pain (>) PCSa (<) MCSb (>) Treatment effect
0.106c 50 50 33.62 38.21 14.04
0.206 67 50 31.34 28.93 13.18
0.217 67 40 31.34 28.93 12.10
0.227 67 0 31.34 28.93 13.48
0.238 62 50 33.62 28.93 11.49
0.247 91 50 31.34 28.93 13.22
0.255 91 0 31.34 34.18 11.86
0.262 91 40 31.34 28.93 12.38
0.275 91 0 31.34 28.93 13.08
0.285 91 40 31.34 9.46 10.81
0.300 91 0 31.34 9.46 12.23
0.307 67 30 33.62 28.93 10.11
0.402 91 50 35.66 28.93 11.20
0.414 67 50 47.59 38.21 9.39
0.426 91 20 40.45 42.95 9.77
0.434 67 20 43.62 42.95 10.07
0.442 67 0 43.62 42.95 10.34
0.459 91 30 35.66 28.93 9.30
0.501 91 0 43.62 42.95 9.58
0.600 91 0 40.45 34.18 8.76
0.710 67 40 47.59 9.46 7.72
0.804 91 30 47.59 28.93 8.23
a PCS of SF-12/36.
b MCS of SF-12/36.
c For about 10.6% of the population with age < 50 years, average pain score of > 50, SF-12/36 PCS of < 33.62 and
SF-12/36 MCS of > 38.21, the treatment effect was 14.04.
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Short-term European Quality of Life-5 Dimensions outcome
Figure 26 shows the trajectory plot for the short-term outcome of health utility measured by the EQ-5D.
As seen in Table 26, approximately 90% of the initial 1365 participants (corresponding to PCS of < 68 and
MCS of < 60, regardless of the average pain and RMDQ score at baseline) had an average treatment effect
of 0.073. The treatment effect increased sharply to 0.100 after approximately 30% of the participants
were excluded in the model. From then on the treatment effect was quite ‘stable’ despite a further 40%
of participants being excluded from the analysis. There was a marked increase in treatment effect for
about 20% of the population (corresponding to PCS of < 31, MCS of < 72, average pain> 0 and RMDQ
score of > 6), for whom the average treatment effect was about 0.160.
Short-term Hannover Functional Ability Questionnaire outcome
Figure 27 shows the trajectory plot for the treatment effect against the size of the constructed region for
the change of FFbHR score between baseline and short-term follow-up. In the first iteration, approximately
10% of the initial 3718 participants were excluded from the subgroup box and these participants had a
high value of PCS at baseline, that is, the remaining 90% in the subgroup correspond to any age, FFbHR
score of < 100, PCS of < 48 and MCS of < 72. The average treatment effect was 8.5 (Table 27).
The average treatment effect increased as more participants were excluded from the subgroup box.
The average treatment effect for the last 10% of the participants (corresponding to any age, FFbHR score
of < 29, PCS of < 68 and MCS of < 57) was 16.8. Although an increase of 8 units of the FFbHR score
may be of clinical importance, the proportion of participants who would benefit from such improvement is
very small. Nevertheless, those with more functional limitation (greater disability) and more psychological
distress would benefit more on the FFbHR disability outcome at short term. If we were interested in
an improvement from an average of 8.5 to at least 12 then approximately 30% of the participants
(age < 67 years, FFbHR score of < 54, PCS of < 40 and MCS of < 72) would benefit more on the disability
outcome at short term, a similar result to that observed in the IPD-SIDES Analysis 1, for which participants
with FFbHR score of ≤ 54.2 and age ≤ 66 years had an enhanced treatment effect (see Chapter 7,
Subgroups identified by the individual patient data subgroup identification based on a differential effect
search method). It is of note that results from both methods suggest that MCS may not be an essential
covariate in improving treatment effect.
l Those with more functional limitation at baseline and who were younger would gain greater
improvement in short-term functional ability as measured by the FFbHR.
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FIGURE 26 Trajectory plot for the treatment effect against the size of the constructed region for the EQ-5D
short-term outcome.
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TABLE 26 Thresholds for selected size of subgroup for the short-term EQ-5D as seen in Figure 26
Subgroup size PCSa (<) MCSb (<) Pain (>) RMDQ (>) Treatment effect
0.101c 35.66 60.35 0.00 14 0.208
0.119 38.01 60.35 0.00 14 0.196
0.127 38.01 72.11 0.00 14 0.185
0.136 47.59 60.35 0.00 14 0.185
0.144 47.59 72.11 0.00 14 0.174
0.151 31.34 56.82 0.00 0 0.170
0.166 31.34 60.35 0.00 6 0.158
0.171 31.34 60.35 0.00 0 0.153
0.188 31.34 72.11 20.00 6 0.157
0.190 31.34 72.11 0.00 6 0.160
0.210 33.62 56.82 0.00 6 0.134
0.219 40.45 47.17 20.00 10 0.125
0.221 40.45 47.17 0.00 10 0.127
0.233 33.62 60.35 0.00 6 0.126
0.244 38.01 47.17 0.00 6 0.124
0.259 33.62 72.11 30.00 6 0.122
0.267 33.62 72.11 0.00 6 0.124
0.303 40.45 47.17 0.00 6 0.123
0.407 67.75 72.11 57.00 0 0.106
0.415 43.62 50.61 20.00 6 0.095
0.429 40.45 56.82 30.00 6 0.099
0.437 38.01 72.11 20.00 6 0.099
0.446 40.45 56.82 0.00 6 0.106
0.451 47.59 50.61 30.00 6 0.094
0.464 47.59 72.11 50.00 6 0.102
0.477 40.45 60.35 20.00 6 0.102
0.482 40.45 60.35 0.00 6 0.103
0.498 43.62 56.82 30.00 6 0.093
0.505 40.45 72.11 30.00 6 0.098
0.512 47.59 56.82 20.00 7 0.099
0.530 40.45 72.11 0.00 6 0.100
0.540 47.59 53.87 0.00 6 0.095
0.541 67.75 60.35 40.00 6 0.095
0.552 47.59 56.82 30.00 6 0.099
0.570 43.62 60.35 0.00 6 0.100
0.574 67.75 56.82 30.00 6 0.097
0.581 47.59 56.82 20.00 6 0.102
0.593 47.59 56.82 0.00 6 0.103
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TABLE 26 Thresholds for selected size of subgroup for the short-term EQ-5D as seen in Figure 26 (continued )
Subgroup size PCSa (<) MCSb (<) Pain (>) RMDQ (>) Treatment effect
0.610 67.75 56.82 20.00 6 0.099
0.704 47.59 60.35 20.00 5 0.085
0.803 47.59 60.35 0.00 0 0.080
0.909 67.75 60.35 0.00 0 0.073
a PCS of SF-12/36.
b MCS of SF-12/36.
c For about 10.1% of the population with SF-12/36 PCS of < 35.66, SF-12/36 MCS of < 60.35, average pain> 0 and
RMDQ score of > 14, the treatment effect was 0.208.
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FIGURE 27 Trajectory plot for the treatment effect against the size of the constructed region for the FFbHR
short-term outcome.
TABLE 27 Thresholds for selected size of subgroup for the short-term FFbHR outcome as seen in Figure 27
Subgroup size Age, years (<) FFbHR (<) PCSa (<) MCSb (<) Treatment effect
0.102c 91 29.17 67.75 56.82 16.79
0.118 54 58.33 40.45 47.17 16.35
0.121 54 45.83 67.75 60.35 16.07
0.132 54 45.83 67.75 72.11 15.97
0.150 54 62.50 33.62 72.11 14.92
0.155 54 54.17 40.45 56.82 14.43
0.163 58 45.83 40.45 72.11 14.49
0.171 54 54.17 40.45 60.35 14.06
0.190 54 54.17 40.45 72.11 14.35
0.200 54 54.17 43.62 72.11 13.74
0.206 54 54.17 67.75 72.11 14.18
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TABLE 27 Thresholds for selected size of subgroup for the short-term FFbHR outcome as seen in
Figure 27 (continued )
Subgroup size Age, years (<) FFbHR (<) PCSa (<) MCSb (<) Treatment effect
0.308 62 54.17 67.75 72.11 12.72
0.314 67 54.17 40.45 60.35 11.90
0.327 62 58.33 40.45 72.11 12.05
0.340 67 54.17 67.75 60.35 11.70
0.345 58 62.50 67.75 72.11 11.82
0.352 67 54.17 40.45 72.11 12.03
0.361 62 58.33 67.75 72.11 11.76
0.378 67 54.17 67.75 72.11 11.82
0.385 91 54.17 40.45 60.35 11.33
0.400 62 70.83 40.45 60.35 11.32
0.402 67 58.33 40.45 72.11 11.20
0.509 67 62.50 67.75 72.11 10.36
0.513 62 100.00 40.45 72.11 10.30
0.528 91 75.00 40.45 56.82 9.99
0.535 91 58.33 67.75 72.11 10.16
0.548 91 62.50 40.45 72.11 10.37
0.553 91 83.33 40.45 56.82 9.82
0.570 67 75.00 40.45 72.11 9.95
0.573 91 70.83 40.45 60.35 10.22
0.582 91 62.50 43.62 72.11 9.96
0.599 67 75.00 47.59 60.35 9.37
0.602 91 75.00 40.45 60.35 9.96
0.702 91 75.00 47.59 60.35 9.14
0.808 91 100.00 47.59 60.35 8.59
0.906 91 100.00 47.59 72.11 8.47
a PCS of SF-12/36.
b MCS of SF-12/36.
c For about 10.2% of the population with age < 91 years, FFbHR score of < 29.17, SF-12/36 PCS of < 67.75 and SF-12/36
MCS of < 56.82, the treatment effect was 16.79.
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Short-term Short Form questionnaire-12 items/-36 items mental component
score outcome
Figure 28 is the trajectory plot for the treatment effect for the short-term outcome of MCS. Table 28
shows a selection of constructed regions and the corresponding thresholds for covariates age, FFbHR
score, PCS and MCS. The average treatment effect of approximately 90% of the initial 3630 participants
(corresponding with age > 16 years, FFbHR score of < 100, PCS of < 48 and MCS of < 72) was 2.23, and
this increased to 5.98 for approximately 10% of the participants (corresponding to age > 16 years, FFbHR
score of < 100, PCS of < 29 and MCS of < 51). Approximately 55% of the participants (corresponding to
age > 31 years, FFbHR score of < 63, PCS of < 44 and MCS of < 72) had an average treatment effect of
3 units. A smaller region consisting of 30% of the participants (corresponding to age > 54 years, FFbHR
score of < 75, PCS of < 44 and MCS of < 57) would gain greater improvement in psychological outcome,
that is, an average treatment effect of 4 units. Of interest is the conflicting cut-off suggested by FFbHR
and PCS at baseline in constructing these regions, for which the former seemed not to play a critical
role and the latter suggested that those with poor physical status would gain greater improvement.
l Those with more psychological distress and who were younger would gain greater improvement in the
short-term psychological outcome as measured by the SF-12/36 MCS.
Short-term Short Form questionnaire-12 items/-36 items physical component
score outcome
Figure 29 shows the trajectory plot for the treatment effect for the short-term outcome of PCS. Although it
shows a general trend of higher treatment effect as subgroups were removed from the initial pool of 5208
participants, the treatment effect increased but was not monotonic and the improvement did not increase
very much to warrant a clinical importance. Table 29 shows a selection of constructed regions and the
corresponding thresholds for covariates age, PCS and MCS. We thus conclude that there was also no
subgroup who would gain benefit in short-term SF-12/36 PCS.
0.20.40.60.8
Subgroup size
Tr
ea
tm
en
t 
ef
fe
ct
5
4
3
2
FIGURE 28 Trajectory plot for the treatment effect against the size of the constructed region for the SF-12/36 MCS
short-term outcome.
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TABLE 28 Thresholds for selected size of subgroup for the short-term SF-12/36 MCS as seen in Figure 28
Subgroup size Age, years (>) FFbHR (<) PCSa (<) MCSb (<) Treatment effect
0.108c 16 100.00 28.84 50.61 5.98
0.159 58 75.00 35.66 53.87 5.23
0.163 58 83.33 35.66 53.87 5.11
0.176 58 70.83 38.01 53.87 4.90
0.181 58 75.00 38.01 53.87 5.16
0.194 31 75.00 31.34 53.87 4.76
0.207 31 45.83 43.62 50.61 4.72
0.301 54 75.00 43.62 56.82 4.05
0.317 31 54.17 47.59 53.87 4.08
0.328 31 54.17 40.45 56.82 3.93
0.334 45 62.50 38.01 60.35 3.84
0.341 31 54.17 43.62 56.82 3.93
0.351 31 54.17 67.75 56.82 3.86
0.365 45 62.50 40.45 60.35 3.81
0.373 31 70.83 38.01 53.87 3.64
0.384 45 62.50 43.62 60.35 3.86
0.401 45 62.50 67.75 60.35 3.64
0.505 31 75.00 38.01 60.35 3.37
0.515 45 75.00 67.75 60.35 3.27
0.526 31 83.33 38.01 60.35 3.28
0.535 31 100.00 38.01 60.35 3.29
0.541 31 100.00 67.75 50.61 3.25
0.551 31 62.50 43.62 72.11 3.03
0.568 37 75.00 43.62 60.35 3.10
0.577 31 100.00 47.59 53.87 3.05
0.582 31 70.83 43.62 60.35 3.17
0.597 31 100.00 43.62 56.82 2.96
0.604 45 100.00 67.75 60.35 2.94
0.701 16 75.00 47.59 60.35 2.75
0.807 16 100.00 47.59 60.35 2.55
0.907 16 100.00 47.59 72.11 2.23
a PCS of SF-12/36.
b MCS of SF-12/36.
c For about 10.8% of the population with age > 16 years, FFbHR score of < 100, SF-12/36 PCS of < 28.84 and SF-12/36
MCS of < 50.61, the treatment effect was 5.98.
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FIGURE 29 Trajectory plot for the treatment effect against the size of the constructed region for the SF-12/36 PCS
short-term outcome.
TABLE 29 Thresholds for selected size of subgroup for the short-term SF-12/36 PCS as seen in Figure 29
Subgroup size Age, years (<) PCSa (<) MCSb (>) Treatment effect
0.110c 54 40.45 56.82 5.30
0.153 54 35.66 47.17 5.14
0.169 67 31.34 47.17 5.29
0.176 91 31.34 50.61 4.95
0.189 67 40.45 56.82 5.15
0.193 67 33.62 50.61 4.89
0.202 91 31.34 47.17 5.03
0.211 58 35.66 42.95 4.76
0.224 62 35.66 47.17 4.98
0.233 67 35.66 50.61 4.87
0.245 62 43.62 53.87 4.47
0.253 67 40.45 53.87 4.82
0.263 58 40.45 47.17 4.79
0.270 67 35.66 47.17 4.98
0.289 67 43.62 53.87 4.42
0.292 91 40.45 53.87 4.38
0.307 62 43.62 50.61 4.67
0.316 67 40.45 50.61 4.78
0.326 67 47.59 53.87 4.15
0.334 54 40.45 34.18 4.14
0.348 62 47.59 50.61 4.23
0.360 58 43.62 42.95 4.39
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TABLE 29 Thresholds for selected size of subgroup for the short-term SF-12/36 PCS as seen in Figure 29 (continued )
Subgroup size Age, years (<) PCSa (<) MCSb (>) Treatment effect
0.366 62 40.45 42.95 4.58
0.372 67 40.45 47.17 4.77
0.385 67 35.66 34.18 3.85
0.391 62 67.75 50.61 4.14
0.409 91 43.62 50.61 4.29
0.413 62 47.59 47.17 4.21
0.427 91 40.45 47.17 4.50
0.430 67 40.45 42.95 4.47
0.443 58 40.45 28.93 3.86
0.459 91 47.59 50.61 4.05
0.467 62 67.75 47.17 3.93
0.471 58 67.75 42.95 3.75
0.486 91 43.62 47.17 4.17
0.496 91 40.45 42.95 4.22
0.508 91 67.75 47.17 3.85
0.609 67 40.45 28.93 3.73
0.703 91 40.45 28.93 3.59
0.802 91 43.62 28.93 3.37
0.903 91 47.59 28.93 3.26
a PCS of SF-12/36.
b MCS of SF-12/36.
c For about 11.0% of the population with age < 54 years, SF-12/36 PCS of < 40.45 and SF-12/36 MCS of > 56.82, the
treatment effect was 5.30.
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Short-term Roland–Morris Disability Questionnaire outcome
As seen in Figure 30, the non-monotonic trajectory plot for the short-term outcome of RMDQ score
suggested that there was no subgroup that would gain greater improvement in short-term disability
outcome as measured by the RMDQ.
Table 30 shows the selection of a subgroup of participants with thresholds for covariate age and RMDQ
score at baseline and their treatment effects.
Analysis 2: pairwise comparisons
Similar to the analyses seen in Chapter 7 (see Analysis 2: Pairwise comparisons), a further examination of
the treatment effect between active physical and non-active usual care (usual care/GP or waiting list only),
between passive physical and non-active usual care, between psychological and non-active usual care, and
between sham and non-active usual care arms, was performed for selected short-term outcomes. Table 31
summarises the trials and variables considered in the construction of a region that predicts the best or
worst response for each pairwise comparison for selected short-term outcome measures.
Active physical versus non-active usual care
Short-term Roland–Morris Disability Questionnaire outcome
Figure 31 shows the trajectory plot for the treatment effect between active physical and non-active usual
care for the short-term RMDQ outcome. The figure shows a similar result to the one seen above
(see Analysis 1: overall comparison treatment compared with control/Short-term Roland–Morris Disability
Questionnaire outcome), that is, there was no subgroup that would have a substantial improvement in
treatment effect. Table 32 shows the average treatment effect for selected constructed regions with the
corresponding thresholds.
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FIGURE 30 Trajectory plot for the treatment effect against the size of the constructed region for the RMDQ
short-term outcome.
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TABLE 30 Thresholds for selected size of subgroup for the short-term RMDQ outcome as seen in Figure 30
Subgroup size Age, years (<) RMDQ (<) Treatment effect
0.110a 45 5 1.13
0.111 41 6 1.29
0.123 31 24 0.88
0.138 37 9 1.15
0.144 45 6 1.27
0.152 37 10 1.10
0.169 54 5 1.18
0.178 45 7 1.30
0.184 50 6 1.36
0.199 37 14 1.56
0.216 37 16 1.35
0.225 50 7 1.35
0.242 37 24 1.56
0.250 58 6 1.26
0.310 50 9 1.37
0.318 91 6 1.13
0.322 45 12 1.34
0.335 41 24 1.46
0.341 62 7 1.56
0.405 50 12 1.37
0.416 54 10 1.29
0.426 58 9 1.33
0.443 45 24 1.55
0.460 50 14 1.48
0.506 50 16 1.48
0.523 62 10 1.39
0.539 91 9 1.30
0.626 54 16 1.51
0.645 58 14 1.46
0.707 58 16 1.47
0.903 91 16 1.46
a For about 11.0% of the population with age < 45 years and RMDQ score of < 5, the treatment effect was 1.13.
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TABLE 32 Thresholds for selected size of subgroup for the short-term RMDQ outcome as seen in Figure 31
Subgroup size Age (>) RMDQ (>) Treatment effect
0.109 45 14 3.54
0.190 33 14 2.66
0.211 52 6 2.63
0.291 43 10 2.09
0.314 33 12 2.26
0.405 43 7 2.22
0.495 43 5 2.14
0.527 43 4 2.14
0.592 40 5 1.90
0.605 33 7 1.87
0.807 19 6 1.76
0.908 19a 5 1.73
a Minimum age= 19 years.
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FIGURE 31 Trajectory plot for the treatment effect between active physical and non-active usual care against the
size of the constructed region for the RMDQ short-term outcome.
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Passive physical care compared with non-active usual care
Short-term Hannover Functional Ability Questionnaire outcome
Figure 32 shows the trajectory plot for the treatment effect between passive physical and non-active usual
care against the size of the constructed region for short-term outcome of FFbHR. Table 33 shows that the
average treatment effect for approximately 90% of the population (corresponding to a FFbHR score of
< 86, regardless of age, PCS and MCS values at baseline) was 10.41, which was slightly higher than the
average treatment effect between any therapist-delivered intervention (active, passive, psychological or
any combination treatment) and control/placebo (usual care/GP and sham treatment), which was 8.5.
Approximately 20% of the population (corresponding to age < 59 years, FFbHR score of < 50, PCS of
< 68 and MCS of < 72) gained at least an average treatment effect of 16 units. Younger participants with
substantial physical disability (low FFbHR score) gained the most benefit. The PCS and MCS at baseline did
not play an influential role in improving treatment effect.
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FIGURE 32 Trajectory plot for the treatment effect between passive physical and non-active usual care against the
size of the constructed region for the FFbHR short-term outcome.
TABLE 33 Thresholds for selected size of subgroup for the short-term FFbHR outcome as seen in Figure 32
Subgroup size Age, years (<) FFbHR (<) PCSa (<) MCSb (<) Treatment effect
0.101 55 41.67 67.75 72.11 18.42
0.196 68 41.67 67.75 72.11 16.18
0.207 59 50.00 67.75 72.11 16.14
0.306 68 50.00 67.75 72.11 14.57
0.407 91 54.17 40.41 72.11 12.97
0.503 63 86.36 40.41 72.11 12.08
0.602 91 79.17 40.41 60.38 11.62
0.702 68 79.17 47.80 72.11 11.10
0.807 91 100.00 43.73 72.11 10.64
0.904 91 86.36 67.75 72.11 10.41
a PCS of SF-12/36.
b MCS of SF-12/36.
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Short-term Short Form questionnaire-12 items/-36 items mental component
score outcome
Figure 33 shows the trajectory plot for the treatment effect between passive physical and non-active usual
care, which is quite similar to the one seen above (see Analysis 1: Overall comparison treatment compared
with control/Short-term Short Form questionnaire-12 items/-36 items mental component score outcome)
where approximately 90% of the initial 3879 participants (corresponding to age < 68 years, PCS of < 68
and MCS of < 71) had an average treatment effect of 3.06 (Table 34). The treatment effect increased as
more participants were excluded from the region to a clinical important difference of 6.3, but this was
TABLE 34 Thresholds for selected size of subgroup for the short-term SF-12/36 MCS as seen in Figure 33
Subgroup size Age, years (<) PCSa (<) MCSb (<) Treatment effect
0.105 51 43.50 37.86 6.33
0.193 68 35.54 47.60 4.38
0.208 63 47.65 37.86 5.26
0.296 91c 67.75 37.86 4.45
0.307 63 43.50 47.60 4.05
0.392 91 43.50 47.60 4.21
0.403 91 37.84 54.15 3.99
0.496 91 67.75 47.60 3.77
0.500 63 47.65 54.15 3.27
0.594 91 67.75 51.02 3.67
0.603 55 67.75 71.32 2.88
0.706 91 43.50 60.37 3.57
0.802 91 47.65 60.37 3.22
0.904 68 67.75 71.32 3.06
a PCS of SF-12/36.
b MCS of SF-12/36.
c Maximum age= 91 years.
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FIGURE 33 Trajectory plot for the treatment effect between passive physical and non-active usual care against the
size of the constructed region for the SF-12/36 MCS short-term outcome.
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applicable to only a small proportion of participants – approximately 10% of them (corresponding to age
< 51 years, PCS of < 44 and MCS of < 38), that is, only younger participants with substantial physical
limitations and psychological distress would benefit from greater improvement in passive physical
treatment against control.
Short-term Short Form questionnaire-12 items/-36 items physical component
score outcome
The trajectory plot for the treatment effect between passive physical and non-active usual care is shown in
Figure 34. The trajectory indicates an increase of improvement as regions narrowed but the fluctuation of
the treatment effect suggests that there might be no definite subgroup that would gain substantial
treatment effect. Table 35 summarises the average treatment for selected constructed regions with the
corresponding thresholds for the comparison seen in Figure 34.
Psychological versus non-active usual care
Short-term Roland–Morris Disability Questionnaire outcome
Figure 35 shows the trajectory plot for the treatment effect between psychological and non-active usual
care for the short-term RMDQ outcome, and Table 36 shows the average treatment effect for selected
constructed regions with the corresponding thresholds. The results are very similar to those seen above
(see Analysis 1: Short-term Roland–Morris Disability Questionnaire outcome), that is, there was no
subgroup that would gain a substantial improvement in treatment effect.
Sham care compared with non-active usual care
Short-term Hannover Functional Ability Questionnaire outcome
Three trials50,101,132 were included in the comparison between passive physical and non-active usual care.
All three trials50,101,132 had acupuncture as the therapist-delivered intervention; of these, two trials101,132
also had sham acupuncture. Figure 36 shows the trajectory plot for the treatment effect between sham
acupuncture and non-active usual care. The average treatment effect was slightly lower between passive
physical (acupuncture) and non-active usual care. However, the treatment effect increased as more and
more participants were excluded from the ARDP-MA algorithm. Table 37 shows the average treatment
effect between sham acupuncture and non-active usual care for selected constructed regions with the
corresponding thresholds.
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FIGURE 34 Trajectory plot for the treatment effect between passive physical and non-active usual care against the
size of the constructed region for the SF-12/36 PCS short-term outcome.
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TABLE 35 Thresholds for selected size of subgroup for the short-term SF-12/36 PCS as seen in Figure 34
Subgroup size Age, years (<) PCSa (<) MCSb (>) Treatment effect
0.107 63 31.19 51.02 6.17
0.192 68 35.54 51.02 5.84
0.205 91c 31.19 43.02 5.99
0.292 68 43.50 51.02 5.30
0.310 55 40.28 33.48 5.09
0.394 68 35.54 28.47 4.56
0.406 91 43.50 47.60 4.93
0.495 91 40.28 37.86 5.02
0.503 68 43.50 37.86 4.95
0.599 91 37.84 9.46 4.45
0.604 91 67.75 43.02 4.33
0.709 68 43.50 9.46 4.47
0.802 91 67.75 33.48 4.14
0.904 68 67.75 9.46 3.88
a PCS of SF-12/36.
b MCS of SF-12/36.
c Maximum age= 91 years.
0.20.40.60.8
Subgroup size
Tr
ea
tm
en
t 
ef
fe
ct
2.5
2.0
1.5
FIGURE 35 The size of the constructed region for the RMDQ short-term outcome.
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TABLE 36 Thresholds for selected size of subgroup for the short-term RMDQ outcome as seen in Figure 35
Subgroup size Age, years (<) RMDQ (>) Treatment effect
0.107 41 7 2.84
0.197 49 8 2.58
0.214 69 13 1.46
0.295 45 0 1.81
0.305 49 5 2.52
0.400 52 4 2.19
0.493 56 4 2.02
0.528 85a 8 1.39
0.591 60 4 1.90
0.606 63 5 1.79
0.809 63 0 1.48
0.909 69 0 1.39
a Maximum age= 85 years.
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FIGURE 36 The size of the constructed region for the FFbHR short-term outcome.
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Short-term SF-12/36 MCS outcome
Figure 37 shows the trajectory plot for the treatment effect between sham and non-active usual care.
The two trials included in this pairwise analysis had sham acupuncture. The figure shows that the average
treatment effect did not improve much in the exclusion of the first 70% participants (Table 38).
Nevertheless, there was a markedly higher treatment effect which was 6.22 for approximately 20% of the
participants (corresponding to PCS of < 36 and MCS of < 39, regardless of age).
Short-term physical component score outcome
The trajectory plot for the treatment effect between sham and non-active usual care is shown in Figure 38
and Table 39 summarises the average treatment for selected constructed regions with the corresponding
thresholds. There was an increase of improvement as regions narrowed, but the fluctuation of the treatment
effect suggests that there might be no definite subpopulation that would gain substantial treatment effect.
TABLE 37 Thresholds for selected size of subgroup for the short-term FFbHR outcome as seen in Figure 36
Subgroup size Age, years (<) FFbHR (<) PCSa (<) MCSb (<) Treatment effect
0.103 52 41.67 44.78 51.61 12.64
0.199 52 54.17 60.47 51.61 12.58
0.208 62 45.83 44.78 51.61 12.26
0.301 62 45.83 60.47 72.11 9.85
0.402 52 95.83 60.47 57.68 7.53
0.510 68 58.33 41.50 61.38 6.49
0.605 87c 62.50 41.50 57.68 6.84
0.700 68 66.67 44.78 61.38 6.00
0.806 68 95.83 44.78 72.11 5.95
a PCS of SF-12/36.
b MCS of SF-12/36.
c Maximum age= 87 years.
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FIGURE 37 Trajectory plot for the treatment effect between sham and non-active usual care against the size of the
constructed region for the SF-12/36 MCS short-term outcome.
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TABLE 38 Thresholds for selected size of subgroup for the short-term SF-12/36 MCS as seen in Figure 37
Subgroup size Age, years (<) PCSa (<) MCSb (<) Treatment effect
0.104 43 36.48 51.97 7.86
0.199 43 39.17 61.54 6.43
0.201 87 36.48 39.07 6.22
0.296 87 57.59 39.07 5.06
0.300 65 42.29 44.25 4.01
0.396 87c 39.17 48.42 4.40
0.410 52 42.29 61.54 4.57
0.501 61 57.59 55.18 3.09
0.709 70 39.17 70.46 3.59
0.809 70 42.29 70.46 3.67
0.902 70 57.59 70.46 3.09
a PCS of SF-12/36.
b MCS of SF-12/36.
c Maximum age= 87.
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FIGURE 38 Trajectory plot for the treatment effect between sham and non-active usual care against the size of the
constructed region for the SF-12/36 PCS short-term outcome.
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TABLE 39 Thresholds for selected size of subgroup for the short-term SF-12/36 PCS as seen in Figure 38
Subgroup size Age, years (<) PCSa (>) MCSb (<) Treatment effect
0.100 70 39.17 48.42 6.26
0.195 52 32.56 51.97 6.04
0.206 70 36.48 55.18 5.37
0.296 52 30.95 58.10 5.59
0.303 70 30.95 48.42 5.43
0.398 87c 34.31 70.46 4.46
0.403 65 32.56 61.54 4.86
0.495 87 26.96 51.97 4.55
0.503 87 30.95 58.10 4.66
0.598 87 30.95 70.46 4.06
0.602 70 29.16 61.54 3.71
0.801 65 14.41 70.46 3.46
0.902 70 14.41 70.46 3.56
a PCS of SF-12/36.
b MCS of SF-12/36.
c Maximum age= 87 years.
METHODOLOGY AND STATISTICAL DEVELOPMENTS 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
Chapter 9 Methodology and statistical
developments 3: identification of cost-effective
subgroups by directed peeling
Introduction
The economic analyses sought to identify the most cost-effective treatments for subgroups of patients with
LBP. A search algorithm, similar to that used in the previous chapter, was used to identify subgroups to
maximise the expected QALY gain from treatment. Although some of the trials in the database provided
individual-level data on use of health-care resources, these data were not used in the analyses presented in
this chapter. Instead, a threshold approach was used to assess the cost-effectiveness of treatment for
defined groups of patients. This was done by comparing estimates of treatment cost from the literature
with the maximum cost required to stay below the cost-effectiveness threshold (£20,000–30,000 per
QALY, as recommended by NICE), given the estimated QALY gain from treatment.173
The use of the QALY outcome reduced the available data for analysis more than for the short-term clinical
outcomes in the previous chapter. We therefore used a search algorithm that is suited to data with a lower
signal–noise ratio: the directed peeling approach of LeBlanc et al.,172 which works by ‘peeling’ a fraction of
patients (with the least favourable effect) from the subgroup in a series of steps. This differs from the full
search algorithm described in the previous chapter, as each successively smaller subgroup is constrained to
be a subset of the previous one. Both approaches use a ‘directed’ peeling approach, designed to provide
simpler descriptions of groups for variables with a monotonic relationship with the outcome of interest.
The LeBlanc et al.172 algorithm was developed for analysis of data from a single trial, and so it was adapted
here for IPD meta-analysis by incorporating random trial effects into the model.
The analysis was split into four overarching comparisons: all interventions collectively compared with best
care; active physical interventions compared with best care; passive physical interventions compared with
best care; and active physical interventions compared with passive physical interventions. Psychological
interventions were not included in the comparison, as only one trial had the EQ-5D data that was
necessary to calculate a QALY and a control arm. Data for comparisons against a ‘sham’ treatment arm
were also excluded from this analysis.
Methods
Quality-adjusted life-years
The outcome used for the analysis was the QALY. We calculated QALYs for individuals based on EQ-5D
utility scores at baseline and short-, medium- and long-term follow-up (up to 1 year). For trials with
SF-36/SF-12 outcomes but no EQ-5D, we used a mapping algorithm162 to estimate EQ-5D scores.
QALYs were estimated using an AUC approach, adjusting for baseline EQ-5D scores (see Chapter 6,
Health-economic outcomes).
Moderator identification
The specification of the search algorithm required an initial analysis to identify moderating variables, and to
determine the direction of peeling. A mixed-effects model was used to identify moderators with a
significant interaction with treatment effect on the QALY outcome. The model was specified with
moderator, treatment and treatment-by-moderator interaction as fixed effects, and trial and
treatment-by-trial interaction as random effects (see Chapter 6, Outcome variables). The sign on the
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moderator by treatment interaction coefficient dictated whether or not the algorithm should peel from the
top or the bottom of the moderator range. A positive relationship with treatment effect suggested that
peeling away individuals with lower values of the moderator would yield higher average treatment benefits.
A negative relationship suggests that peeling individuals with higher values of the moderator would be best.
Peeling algorithm
The peeling algorithm started by setting the subgroup indicator (B) to ‘1’ for all individuals. Incremental QALY
gain from treatment for the whole patient sample was estimated using a mixed-effects model with baseline
EQ-5D score and treatment as fixed effects, and trial and treatment-by-trial interaction as random effects.
The algorithm then looped through the following steps until the stopping criteria were met:
l For each moderator, a small proportion of the data was peeled off, taking out the individuals with the
highest (lowest) value of the moderator (depending on the direction of the moderator treatment
interaction effect). The subgroup indicator (B) was set to ‘1’ for the remaining individuals (the ‘in’
group) and ‘0’ for the peeled individuals (the ‘out’ group).
l The difference in incremental QALY gain was estimated for those inside the subgroup compared with
those outside using a mixed-effects model: with baseline EQ-5D, treatment effect, subgroup identifier
and treatment-by-subgroup interaction as fixed effects, and trial and treatment-by-trial interaction as
random effects.
l The magnitude of the treatment by subgroup interaction effect was compared for each moderator.
The peel decision was then based on the moderator with the greatest effect.
l Summary statistics were calculated, including the incremental QALY gain within the subgroup, the
incremental QALY gain outside the subgroup and the weighted mean incremental QALY across the
whole sample.
l If the subgroup contained fewer individuals than a preset minimum number (nmin) then the algorithm
stopped. Otherwise, the above steps were repeated.
Cost-effectiveness
Individual patient data on health-care resource use was available for some trials in the repository. An initial
analysis was conducted using the data from the UK BEAM trial31 using individual-level estimates of costs
(C) and QALYs (Q) over the 12-month follow-up period. From these data, the net monetary benefit (NMB)
was calculated for each individual: NMB= λ ×Q – C, where λ is a set cost-effectiveness threshold (£20,000
per QALY). This NMB variable was then used as an outcome in the above search algorithm. However, we
found that the addition of the cost data increased variation without increasing predictive power. The
results of this analysis are not presented here, as one condition of use of the repository data is that all
results must include at least two trials to avoid re-analysis of the original trial data. Given that the addition
of the individual-level costs was not advantageous in the UK BEAM31 analysis, and also the heterogeneity
in the resource-use items recorded across those studies with data, we decided to focus on QALYs as the
outcome for the economic analysis, and to use a threshold approach to assess cost-effectiveness.
The threshold analysis presents the maximum incremental cost of intervention in order for a treatment
subgroup to be deemed cost-effective based on the lower and upper limits of the NICE-recommended
threshold (£20,000–30,000 per QALY). For example, if a treatment yields an average incremental QALY
gain for a treatment population of 0.05, one would pay up to £1000 (0.05 × £20,000) for the treatment,
using the lower threshold or £1500 (0.05 × £30,000) at the upper threshold.
Published literature was used to provide indicative costs of treatment for comparison with the estimated
thresholds. The incremental cost of passive treatment over 1 year was estimated at £541(SD £768) from
the UK BEAM31 economic analysis: £147 for the intervention and £394 relating to other health-care costs.
Estimates for other treatments varied, ranging from £422 (£187 for the intervention, £235 for other
health-care costs) for a psychological intervention (BeST33) to £486 (SD £907) comprised £41 for the
intervention and £445 relating to other health-care costs for active therapies (UK BEAM31).
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Results
Six analyses were run (Table 40), dictated by the moderators with significant treatment interaction terms in the
QALY ANCOVA. These included the following comparisons: all interventions compared with control; active
physical interventions compared with control; passive physical interventions compared with control; and active
physical interventions compared with passive physical interventions. As noted above, analyses of psychological
intervention and sham were omitted, as in each case only one study provided data for QALY calculation.
As shown in Table 40, not all trials had data for all three potential moderators. We therefore conducted
three analyses for the intervention against control comparison: the first to include as many trials as possible
with QALY data (age and PCS as moderators).
All interventions versus control: moderators – age and physical
component score
The algorithm trace is shown in Figure 39. The y-axis shows the estimated treatment effect for the
subgroup, that is, the ‘incremental QALYs’ gained from treatment compared with the control arm.
The x-axis is the proportion of the starting population peeled away from the treatment group. Figure 40
shows the mean incremental QALYs for the whole sample, both inside and outside the treatment group.
It can be seen that for the full sample, the incremental QALY is declining as a function of the treatment
subgroup size. This suggests that those being peeled from the subgroup had a net QALY gain from
treatment. However, there is no strong signal in these data. The peeling trace in Figure 39 shows no
notable increase in QALY gain from treatment when up to 80% of the sample are removed from the
treatment group. Full details of the peeling trace are available in Table 41. Both age and PCS were used
for peeling, although over the trace the algorithm favoured peeling that was based on PCS. There is a
small rise in QALY gain at the point where 90% of the sample had been removed; the subgroup
comprising 10% of the sample included participants aged between 54 and 84 years with a PCS of
between 7 and 28. The estimated QALY gain from treating only this subgroup was 0.0852, whereas the
estimated mean QALY gain from treating the whole population was lower, at 0.0624.
TABLE 40 Adaptive refinement by directed peeling in IPD meta-analysis: analyses conducted on
economic outcomes
Analysis
Outcome
variable
Moderators
included Trials included
Sample size:
intervention, control
All interventions vs. control
9.3.1 QALY Age, PCSa UK BEAM,31 BeST,33 YACBAC,107
Haake132
1273, 715
9.3.2 QALY Age, RMDQ UK BEAM,31 BeST,33 York BP,133
Smeets70
1092, 422
9.3.3 QALY Age, PCS, RMDQ UK BEAM,31 BeST33 827, 323
Active physical interventions vs. control
9.3.4 QALY Age, RMDQ UK BEAM,31 York BP133 232, 264
Passive physical interventions vs. control
9.3.5 QALY Age, PCS UK BEAM,31 YACBAC,107 Haake132 643, 566
Active physical vs. passive physical interventions
9.3.6 QALY Age, RMDQ UK BEAM,31 HullExPro76 232, 288
BEAM, Back pain Exercise And Manipulation; YACBAC, York Acupuncture Back Pain Trial.
a PCS of SF-12/36.
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FIGURE 39 Mean treatment effect in subgroup. All interventions vs. control: moderators – age and PCS.
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FIGURE 40 Weighted mean treatment effect across treatment subgroup and non-treatment subgroup.
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Depending on the cost of intervention, and NHS ‘willingness-to-pay’ per QALY, it might be cost-effective
for all patients to be offered treatment or for treatment to be limited to a selected subgroup. For example,
at a cost-effectiveness threshold of £20,000 per QALY, the maximum that the NHS would pay for the
‘intervention’ reflected here would be £1248 (per patient over the course of a year) if all patients were to
be offered treatment or £1704 if only patients in the 10% subgroup were to be offered treatment. If the
threshold of £30,000 was applied then this will be £1872 and £2556, respectively. However, these results
do not incorporate any measure of uncertainty and should be considered as only illustrative of the method.
l Older patients with relatively worse physical functioning as measured using the PCS at baseline appear
to have moderately better response to treatment.
All interventions versus control: moderators – age and Roland–Morris
Disability Questionnaire
Figures 41 and 42 illustrate the peeling trace with moderator’s age and RMDQ. The inclusion of the RMDQ
limited the sample to four trials (see Table 40). As shown by Figure 41, the peeling algorithm did achieve
small but consistent gains in treatment effect within the subgroup, as participants with better (lower)
baseline RMDQ scores and who were younger were removed from the treatment group. The algorithm
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FIGURE 41 Mean treatment effect in subgroup. All interventions vs. control: moderators – age and RMDQ.
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FIGURE 42 Weighted mean treatment effect across treatment subgroup and non-treatment subgroup.
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favoured peeling that was based on RMDQ score during the earlier iterations. The apparent monotonicity
of RMDQ with respect to treatment effect (as measured in QALYs) is consistent with the regression analysis
used for moderator identification (see Table 17), as the RMDQ had a more significant relationship with
treatment effect compared with age. Owing to some correlation with RMDQ score and age, some older
patients were removed from the treatment subgroup as the algorithm peeled based on RMDQ score.
The peeling trace for Analysis 2 is shown in Table 42. The subgroup at 20% of the initial sample
comprised participants aged > 34 years with a RMDQ score of ≥ 13. A modest improvement in QALYs
gained from treatment can be seen for this subgroup: from 0.043 if the whole population were to be
offered treatment to 0.076 for the subgroup. As described previously, the maximum willingness to pay for
an intervention yielding these QALY gains would be £860 and £1520, respectively, for the whole
population and for the subgroup, where a threshold of £20,000 is applied, or £1290 and £2280,
respectively, at a threshold of £30,000 per QALY. As there is no estimation of uncertainty, this result
should be seen as illustrative.
l Older patients with worse baseline physical functioning as measured by the RMDQ score at baseline
appear to achieve a moderately better response to treatment.
All interventions versus control: moderators – age, physical component
score and Roland–Morris Disability Questionnaire
Figures 43 and 44 illustrate the peeling results for the analysis with age, PCS and RMDQ score. As some
trials did not have available PCSs and others did not have RMDQ scores, the sample was restricted to two
trials.31,33 The results of the peeling trace are very similar to those of analysis 2, shown in Table 42). The
algorithm chose to peel almost exclusively on RMDQ score and age. PCS was used for the first iteration
only. As the algorithm reduced the size of the treatment subgroup, the results showed that generally,
older patients with worse (higher) RMDQ scores achieved better QALY gains from treatment. Although
PCS was not much used for peeling, as the sample size was reduced participants with higher (better) PCSs
were removed from the treatment subgroup; this is unsurprising as RMDQ score and PCS are correlated.
As shown in Table 43 at the point where 19% of the starting sample was left in the treatment subgroup,
the subgroup comprised participants aged 44 to 82 years with a RMDQ score over 12 and a PCS of
between 7 and 49. At this point the treatment subgroup achieved a QALY gain of 0.0981 from treatment.
When the whole population was treated, the mean QALY gain was lower at 0.0504. At a £20,000 per
QALY cost-effectiveness threshold, the maximum willingness to pay for an intervention yielding these
QALY gains would be £1008 and £1962 for the whole population and the refined subgroup, respectively.
At £30,000 per QALY, these figures are £1512 and £2943, respectively. However, as there is no measure
of uncertainty reflected in these results, they should only be seen as illustrative.
l Older patients with worse physical functioning as measured using the RMDQ score at baseline appear
to have a moderately better response to treatment.
Active physical intervention versus control: moderators – age and
Roland–Morris Disability Questionnaire
Analysis so far has pooled all treatment modalities and compared these collectively with control. For analysis
9.3.4 (see Table 40) the intervention considered is made up of only active physical interventions, in this case
‘exercise’. The comparator arm is still control. This approach limited the data set to two trials.31,133 Figure 45
shows the peeling trace, with RMDQ score and age included as moderators within the algorithm.
The algorithm peeled almost exclusively based on the RMDQ score. As the algorithm reduced the sample
size, patients with lower (better) RMDQ scores were removed, suggesting that patients with worse baseline
RMDQ scores achieve better treatment outcomes. At iteration 10, age was peeled on, removing patients
who were younger.
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FIGURE 44 Weighted mean treatment effect across treatment subgroup and non-treatment subgroup.
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FIGURE 43 Mean treatment effect in subgroup. All interventions vs. control: moderators – age, PCS and RMDQ.
METHODOLOGY AND STATISTICAL DEVELOPMENTS 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
TA
B
LE
43
A
lg
o
ri
th
m
o
u
tp
u
t
fo
r
an
al
ys
is
9.
3.
3
(s
ee
Ta
b
le
40
)
It
er
at
io
n
M
o
d
er
at
o
r
D
ir
ec
ti
o
n
p
ee
le
d
Pr
o
p
o
rt
io
n
in
su
b
g
ro
u
p
≈
n
In
cr
em
en
ta
l
Q
A
LY
s
A
g
e
PC
Sa
R
M
D
Q
sc
o
re
Su
b
g
ro
u
p
A
ll
M
in
im
u
m
M
ax
im
u
m
M
in
im
u
m
M
ax
im
u
m
M
in
im
u
m
M
ax
im
u
m
0
–
–
1.
00
11
50
0.
05
04
18
85
7
61
0
24
1
PC
S
To
p
0.
95
10
93
0.
05
34
–
0.
00
86
18
85
7
51
0
24
2
RM
D
Q
Bo
tt
om
0.
90
10
34
0.
05
33
0.
00
37
18
85
7
51
4
24
3
RM
D
Q
Bo
tt
om
0.
82
94
1
0.
05
74
–
0.
01
33
19
84
7
51
5
24
4
A
ge
Bo
tt
om
0.
78
89
4
0.
06
24
0.
01
87
29
84
7
51
5
24
5
A
ge
Bo
tt
om
0.
74
85
0
0.
06
69
0.
00
87
32
84
7
51
5
24
6
RM
D
Q
Bo
tt
om
0.
65
74
8
0.
06
69
0.
00
87
32
84
7
51
6
24
7
RM
D
Q
Bo
tt
om
0.
56
64
8
0.
07
33
0.
01
00
32
84
7
51
7
24
8
RM
D
Q
Bo
tt
om
0.
48
55
4
0.
06
29
0.
03
54
32
84
7
51
8
24
9
RM
D
Q
Bo
tt
om
0.
41
47
2
0.
06
53
0.
04
10
32
84
7
51
9
24
10
RM
D
Q
Bo
tt
om
0.
35
39
7
0.
06
84
0.
04
38
32
84
7
49
10
24
11
A
ge
Bo
tt
om
0.
33
37
8
0.
07
51
0.
04
29
35
84
7
49
10
24
12
RM
D
Q
Bo
tt
om
0.
28
32
1
0.
07
51
0.
04
29
35
82
7
49
11
24
13
A
ge
Bo
tt
om
0.
27
30
5
0.
07
62
0.
03
94
38
82
7
49
11
24
14
A
ge
Bo
tt
om
0.
25
29
0
0.
08
55
0.
03
67
40
82
7
49
11
24
15
A
ge
Bo
tt
om
0.
24
27
6
0.
08
99
0.
03
63
42
82
7
49
11
24
16
A
ge
Bo
tt
om
0.
23
26
3
0.
09
81
0.
03
43
44
82
7
49
11
24
17
RM
D
Q
Bo
tt
om
0.
19
21
3
0.
09
81
0.
03
43
44
82
7
49
12
24
a
PC
S
of
SF
-1
2/
36
.
DOI: 10.3310/pgfar04100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Patel et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
145
As can be seen in Figure 45, improvements in the mean incremental treatment effect for the subgroup
were very small as no relevant subgroup could be identified from APT in these analyses.
Passive physical intervention versus control: moderators – age and physical
component score
Analysis 9.3.5 (see Table 40) follows the same approach as analysis 9.3.4 (see Table 40); however, in this
instance the treatment arm comprised only passive interventions, including manipulation and acupuncture
treatments; the comparator remained as a control. These conditions limited the data set to three
trials.31,105,132 The peeling algorithm was set to peel based on age and PCS. RMDQ score was not available
for all of the trials included in this analysis.
As can be seen on Figure 46, there was very little change in the incremental treatment effect as the
algorithm refined the treatment subgroup. No relevant subgroup could be identified correlating age and/or
PCS with above average treatment effect from passive physical treatment in these analyses.
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FIGURE 45 Mean treatment effect in subgroup. Active physical intervention vs. control: moderators – age
and RMDQ.
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FIGURE 46 Mean treatment effect in subgroup. Passive physical intervention vs. control: moderators – age and PCS.
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Adaptive refinement by directed peeling in individual patient data
meta-analysis directed peel
Active physical interventions compared with passive physical interventions:
moderators – age and Roland–Morris Disability Questionnaire
Analysis 9.3.6 (see Table 40) was a comparison of active physical interventions and passive physical
interventions. The analysis includes data from two trials. The active treatment was made up of exercise and
the passive treatment was made up of manual therapy. For the analysis, passive treatment was considered
the reference case for all of the incremental estimates. The peel algorithm was set to refine the subgroup
based on the age and RMDQ moderators. The algorithm elected to peel predominantly on the RMDQ
score, removing patients with lower (better) RMDQ scores from the treatment group. As can be seen in
Figure 47, the incremental effect of changing between these two treatment modalities was near zero.
The result of the analysis suggests there is no difference in these two treatment modalities across the
whole sample, or for any subgroup explored within the analysis of these data.
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FIGURE 47 Mean treatment effect in subgroup. Active physical interventions compared with passive physical
interventions: moderators – age and RMDQ.
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Discussion
The application of the peeling algorithm was successful in identifying potentially interesting subgroups for
the interventions against control comparison. These subgroups comprised patients who were older, with
relatively worse physical functioning at baseline. The gain in treatment effect for the subgroup was small;
therefore, given the relatively low cost of the intervention treatment, it is likely to be cost-effective to
offer treatment to the whole patient group. The algorithm, however, was not successful in finding any
convincing subgroup in the pairwise comparison of active and passive physical treatment. This may be
caused by lack of power or simply because there is no subgroup to be found.
The QALY has some key advantages over the other available clinical outcomes. It is a holistic measure of
health-related quality of life designed to encompass both physical and mental aspects of a patient’s health
state. Constructed using EQ-5D responses over time, the QALY also takes account of a patient’s recovery
profile, integrating short- and long-term treatment response into a single measure. The EQ-5D is scored
using the UK social tariff, which is validated and standardised allowing direct comparison of the treatment
response for different interventions and diseases. The QALY estimated using the EQ-5D tariff is the
accepted measure used by NICE for assessing the cost-effectiveness of new treatments for approval in
the NHS. The QALY did, however, raise some particular challenges for the analysis. The use of repeated
measures to estimate the QALY restricted the size of the sample, as more observations were lost to missing
data when compared with the point estimates used in the clinical analysis. This reduced the power of
statistical analyses.
The same approach was taken for moderator identification for the economic component of the analysis as
for the clinical analyses. Three potential moderators (age, PCS, RMDQ) of treatment response were
identified for the economic analysis. However, the relationship of the QALY with the moderators differed
in some cases to that of the clinical outcome measures. For the short-term clinical outcome of PCS, the
age-by-treatment interaction was found to be negative and significant (p< 0.2), suggesting that younger
patients had a better treatment effect. For the outcome of FFbHR, the age-by-treatment interaction
was also negative but was just outside the significance threshold of p< 0.2. For the other included
clinical outcomes, age was not significant. When the QALY was used as the outcome measure, the
age-by-treatment interaction was significant at p< 0.2 but the relationship was positive, indicating that
older patients had a better treatment effect. The EQ-5D at short-term follow-up also exhibited a positive
relationship with age, although this relationship was not significant. It may not be surprising that the
relationship of the moderators with the different outcomes differed, as they measure different aspects of
patient health. Furthermore, the QALY differs by construction from the other outcome measures, as it is
calculated as the AUC for a sequence of follow-up points. However, it is also possible that the results are
susceptible to missing data bias. Patients with missing EQ-5D data at one or more follow-up points were
on average 4 years younger than patients with complete EQ-5D data (p< 0.05). One could speculate that
younger patients with better expected outcomes might have been excluded from our complete case
analysis, as they failed to return follow-up questionnaires. This could bias the treatment response down for
younger patients. Four trials had short-term EQ-5D data, comprising 1774 patients (1271 intervention,
503 control) for which there were complete data. Of the 1774 patients, 1467 (1093 intervention,
374 control) had complete data at all of the EQ-5D follow-up points that were necessary to calculate a
QALY estimate. This equates to an additional 17% missing data for QALYs compared with short-term
outcomes. This might possibly explain the difference in direction of relationship between age and
treatment response by outcome measure, as the short-term measures were less prone to missing data
than the QALY.
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Chapter 10 Methodology and statistical
developments 4: subgroup identification with
individual participant data indirect network
meta-analysis
Background
The recursive partitioning and adaptive peeling approaches described in our analysis plan, although
technically of a high standard, failed to identify clinically useful subgroups for whom treatment choices
might be prioritised. We therefore also did an exploratory network meta-analysis (NWMA) to identify
groups that may gain the greatest benefit from different treatment choices from a Bayesian, rather than a
frequentist, perspective.
Methods
We carried out NWMAs of the repository trials to explore how the optimal choice of treatment for LBP
might vary across subgroups. NWMA is an extension of standard pairwise meta-analysis, applicable in
situations in which we have multiple treatments and an evidence base of trials that individually provide
evidence on different subsets of all possible pairwise treatment combinations.174 NWMA involves analysing
this network as a whole, by assuming consistency across treatment effects, so that a given pairwise
comparison B against C can be derived from trials against a common comparator (A vs. B and A vs. C
trials), even if no B versus C trials exist.175 NWMA has become increasing popular in decision-making
contexts because choosing among more than two treatments requires all pairwise treatment effects to be
consistent in this way (the true treatment effects in the decision problem will always be consistent176,177).
Given their widespread use in Health Technology Assessment, NWMA commonly uses aggregate data,
although there are examples illustrating the value of this approach when IPD are available, particularly in
understanding participant-level effect modification.178,179
The standard model for pairwise meta-analysis involving a continuous normally distributed outcome with
linear effect modification can be written as equations:
yit ∼ Normal(µit + Δit, σt ) (3)
Δit = Iit(dt + βt(Xit−X )), (4)
in which yit is the outcome for participant i in trial t, µit is the expected outcome for participant i if he/she
had been given the control treatment for that trial, Δit is the expected impact of the treatment participant i
received, Iit takes value ‘0’ if participant i is in the control arm of trial t and ‘1 if they are in the intervention
arm, dt is the impact of the intervention for a reference participant, Xit is a vector of covariate values for
participant i, X is a vector of covariate values for the reference participant, and βt is a vector of coefficients
determining how the effect of the intervention evaluated in trial t varies as a function of the covariates of
interest. It is possible to further allow for µit to vary by participants, as shown by Equation 5:
µit = µt + b (Xit−X ), (5)
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where µt is the expected outcome in the control arm of trial t for the reference participant, and b is a
vector of coefficients determining how the control outcome varies as a function of the covariates
of interest.
Network meta-analysis extends this analysis by introducing the consistency assumption as shown by
Equation 6:
dt = d1,active(t)−d1,control(t), (6)
in which d1,j is defined as the treatment effect of any treatment j in the network compared with a
reference treatment (such as standard care), and active(t) and control(t) are the active and control
treatments in trial t, respectively. The consistency assumption can further be applied to the βt parameters
as shown by Equation 7:
βt = β1,active(t)−B1,control(t). (7)
We carried out three separate NWMAs for the outcomes of interest – short-term change in RMDQ score,
short-term change in PCS of SF-12/36 and short-term change in MCS of SF-12/36. All models explore age,
sex and baseline PCS/MCS as covariates for both control outcome variation and effect modification. RMDQ
models also include baseline RMDQ score for both adjustments. Model estimation involved Bayesian
Markov Chain Monte Carlo simulation carried out using WinBUGS 1.4.3 (MRC Biostatistics Unit,
Cambridge, UK), using NWMA models that were adapted for IPD analysis from aggregate-data NWMA
models that were developed for NICE.180
Results
Short-term Roland–Morris Disability Questionnaire outcome
Thirteen trials31,33,65,70,76,102–106,131,134,136 (n= 3447) in the repository reported this outcome.
The resulting network of evidence is illustrated in Figure 48.
Table 44 gives the predicted treatment effects from the NWMA of these trials for any pairwise comparison
of the five treatment classes in the network, assuming a participant profile representing a typical (male)
participant. This shows that, for the paradigmatic case of a male aged 50 years, with baseline values of
RMDQ= 10, PCS= 40 and MCS= 40, all treatment choices are superior to usual care control treatment.
For sham treatment, however, the point estimate for the 95% credible interval for RMDQ does include
zero. In addition, the differences between any two treatment approaches can be estimated. For example,
in this paradigmatic case there does not seem to be a meaningful difference between sham treatment and
psychological treatment.
Table 45 presents coefficient values reflecting the degree of effect modification for the participant
characteristics of interest. The evidence for effect modification appears strongest for RMDQ; it is the only
characteristic whose coefficient credible intervals for all three treatment serum interventions exclude zero;
for sham treatment it does include zero. This analysis suggests that for each 1-point increase in baseline
RMDQ score, an additional 0.17- to 0.26-point benefit from active treatments and a 0.43-point benefit
from sham treatment will be achieved. However, the 95% credible intervals suggest that the evidence for
effect modification related to other covariates is less strong. To quantify the strength of evidence for effect
modification, we calculated ‘Bayesian Probabilities of effect modification’ (BP), defined as the greater of
two probabilities: that an increase in the characteristic predicts an increase in treatment effect or that it
predicts a decrease. A BP of 0.8, for example, suggests that we are 80% sure that a change in the
characteristic will increase the effect of treatment. For RMDQ score, the BPs are all > 0.99 (except for
sham, with a BP of 0.92) – overwhelming evidence that the effect of treatment depends on
baseline scores.
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FIGURE 48 Network of evidence for the short-term RMDQ outcome. Each line denotes the existence of head-of-
trials of the two treatments being connected, and the accompanying information denotes the number and names
of trials making the comparison.
TABLE 44 Treatment effect with modification (absolute reduction in the short-term RMDQ outcome, mean and
95% credible interval). Coefficients given for individual aged 50 years, male, RMDQ score= 10, PCS= 40 and
MCS= 40 at baselinea
Intervention
Comparator
Control Active physical Passive physical Psychological
Active physical 1.94 (1.17 to 2.72)
Passive physical 2.17 (1.39 to 1.95) 0.23 (–0.61 to 1.07)
Psychological 1.45 (0.74 to 2.15) –0.49 (–1.31 to 0.32) –0.72 (–1.52 to 0.08)
Sham 1.60 (–1.07 to 4.11) –0.34 (–2.95 to 2.1) –0.57 (–3.2 to 1.9) 0.15 (–2.47 to 2.63)
a Predicted change in condition without treatment adjusted for age, sex and baseline values of RMDQ score, SF-12/36 PCS
and SF-12/36 MCS.
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The BPs indicate some, possibly important, differences in benefit by other baseline variables. For example,
it is at least 70% likely that men respond more strongly than women to sham treatments and physical
treatment but it is equally likely that men respond more or less strongly than women following psychological
treatments. On the other hand, baseline MCS has a BP of 85% of positively influencing response to
psychological treatments (i.e. those with low levels of psychological distress respond more strongly to
psychological treatments than those with high levels of psychological distress), but is almost equally likely to
be positively or negatively related to outcomes following physical treatments or sham treatment.
All treatment effects increase, but at different rates, so that the optimal treatment changes as RMDQ score
varies. Passive physical therapy is the optimal therapy for the participant as described in Table 45, whose
RMDQ score is 10. However, sham therapy becomes the optimal treatment if the RMDQ score increases
beyond 14 points, whereas APT becomes optimal if the RMDQ score decreases below 7 points.
These thresholds depend on values for other effect modifiers, although their influence is less certain.
The only other characteristics with a BP of > 0.90 are age (psychological therapy) and sex (sham therapy).
There is evidence, albeit inconclusive, that, as age decreases, active physical and psychological therapies are
relatively more effective. Figures 49 and 50 show how this relationship can be used to define age–RMDQ
zones in which each treatment is optimal. Broadly speaking, passive physical therapy is optimal for older
participants with a mild to moderate RMDQ score at baseline, APT is optimal for participants with a low
RMDQ score at baseline, and sham therapy is optimal for participants with a high RMDQ score at baseline.
If we disregard sham treatments as an inappropriate choice for clinical guidelines, passive physical therapies
would be optimal for all but the youngest participants with high RMDQ baseline scores (the division would
be determined by extending the active–passive equal line into the right-hand side of the graphs). There are
no participant profiles for which no intervention is the optimal treatment.
To quantify the strength of evidence for these optimal zones, we calculated the probability that each
treatment is optimal for a representative participant profile in each zone. The results (Table 46) show that
there is considerable uncertainty around the optimal treatment: participant profile 1, for example, is in the
passive physical optimal zone, but there is a 54% chance that this is not the optimal treatment for this
profile. However, suboptimal treatments can be identified with a greater degree of certainty: psychological
therapies, for example, are highly unlikely to be optimal for older participants, or those with a high RMDQ
score at baseline (i.e. participant profiles 1, 3, 4 and 6).
TABLE 45 Means, 95% credible intervals and BPs (%) for impact of participant characteristics on effect of
treatments (vs. control)
Participant
characteristics Active physical Passive physical Psychological Sham
Agea –0.02 (–0.05 to 0.02) 0.00 (–0.03 to 0.03) –0.02 (–0.05 to 0.01) –0.01 (–0.08 to 0.07)
BP= 0.83 BP= 0.60 BP= 0.91 BP= 0.56
Sexb –0.22 (–1 to 0.56) –0.38 (–1.16 to 0.4) –0.01 (–0.78 to 0.77) –1.12 (–2.74 to 0.49)
BP= 0.71 BP= 0.83 BP= 0.51 BP= 0.91
RMDQa 0.18 (0.06 to 0.31) 0.26 (0.14 to 0.39) 0.17 (0.05 to 0.29) 0.43 (–0.11 to 0.93)
BP> 0.99 BP> 0.99 BP> 0.99 BP= 0.92
MCSa –0.01 (–0.06 to 0.05) 0 (–0.05 to 0.05) 0.03 (–0.03 to 0.08) –0.06 (–0.35 to 0.24)
BP= 0.59 BP= 0.51 BP= 0.85 BP= 0.59
PCSa 0.05 (–0.03 to 0.13) 0.04 (–0.04 to 0.12) 0.03 (–0.04 to 0.11) –0.04 (–0.53 to 0.41)
BP= 0.89 BP= 0.84 BP= 0.81 BP= 0.52
a Positive value indicates greater reduction in RMDQ from treatment (vs. control) as covariate increases.
b Positive value indicates greater reduction in RMDQ from treatment (vs. control) for females vs. males.
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FIGURE 50 Roland–Morris Disability Questionnaire outcome: optimal treatment as a function of RMDQ score at
baseline and age for women with MCS= PCS= 40, with proportion of female trial participants whose baseline
RMDQ score and age fit into each zone (n= 1054).
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FIGURE 49 Roland–Morris Disability Questionnaire outcome: optimal treatment as a function of RMDQ score at
baseline and age for men with MCS= PCS= 40, with proportion of male trial participants whose baseline RMDQ
score and age fit into each zone (n= 721).
TABLE 46 Probability that any given treatment is optimal for a range of participant profiles
Participant profile
Probability (%) that treatment is optimal for this participant profile
Active physical Passive physical Psychological Sham
1. Male, RMDQ score of 10, age 50 years 18 46 < 1 35
2. Male, RMDQ score of 6, age 30 years 57 11 19% 13
3. Male, RMDQ score of 16, age 40 years 8 34 < 1 57
4. Female, RMDQ score of 14, age 50 years 11 46 2 41
5. Female, RMDQ score of 10, age 30 years 53 14 27 6
6. Female, RMDQ score of 20, age 40 years 8 35 2 54
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Short-term Short Form questionnaire-12 items/-36 items physical component
summary outcome
Nine trials31,33,50,76,101,102,107,132,134 (n= 5574) in the repository reported this outcome. The resulting network of
evidence is illustrated in Figure 51.
Table 47 gives the predicted treatment effects from the NWMA of these trials for any pairwise comparison
of the five treatment classes in the network, assuming a participant profile representing a typical (male)
participant. Table 48 presents coefficient values reflecting the degree of effect modification for the
participant characteristics of interest. All characteristics, except for age, have at least one effect
modification coefficient with a BP of > 0.95.
1: 
BE
AM
1: BeST
3: BEAM, Witt,
YACBAC
2: 
Br
ink
ha
us
, H
aa
ke
3: BEAM, Dufour,
HullExPro
1: M
acedo
3: Passive
physical
2: Active
physical
4: Psychological
5: Sham
1: Control
Network of evidence: PCS/MCS
FIGURE 51 Network of evidence for short-term PCS. Each line denotes the existence of head-of-trials of the two
treatments being connected, and the accompanying information denotes the number and names of trials making
the comparison.
TABLE 47 Treatment effect with modification (absolute increase in short term PCS, mean and 95% credible
interval). Coefficients given for individual aged 50 years, male, PCS and MCS= 40, Predicted change in condition
without treatment adjusted for age, sex, MCS
Intervention
Comparator
Control Active physical Passive physical Psychological
Active physical 3.93 (2.55 to 5.32)
Passive physical 3.16 (2.4 to 3.92) –0.77 (–2.13 to 0.58)
Psychological 2.58 (0.85 to 4.29) –1.36 (–3.36 to 0.63) –0.58 (–2.33 to 1.18)
Sham 1.64 (–0.03 to 3.32) –2.29 (–4.33 to –0.25) –1.52 (–3.18 to 0.15) –0.93 (–3.23 to 1.38)
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Figures 52 and 53 show how effect modification can be used to define PCS/MCS zones in which each
treatment is optimal with short-term PCS as the outcome of interest. Broadly speaking, passive physical
therapy is optimal for participants with low PCSs and high MCSs, whereas APT is optimal for participants
with high PCSs and low MCSs. Sham appears optimal for participants with low PCSs and MCSs at
baseline. If we disregard sham as a valid optimal treatment, the optimal non-sham treatment zones can be
identified by extending the active–passive equal line, as with the RMDQ-based zones. Again, there are no
participant profiles for which no intervention is optimal.
To quantify the strength of evidence for these optimal zones, we calculated the probability that each
treatment is optimal for a representative participant profile in each zone.
TABLE 48 Means, 95% credible intervals and BPs (%) for impact of participant characteristics on effect of
treatments (vs. control)
Participant
characteristics Active physical Passive physical Psychological Sham
Agea 0.02 (–0.05 to 0.08) –0.01 (–0.04 to 0.03) –0.04 (–0.1 to 0.03) 0.00 (–0.06 to 0.06)
BP= 0.68 BP= 0.71 BP= 0.87 BP= 0.52
Sexb 0.25 (–1.25 to 1.75) 0.95 (0.04 to 1.87) 0.29 (–1.43 to 2.01) 1.55 (–0.15 to 3.23)
BP= 0.63 BP= 0.98 BP= 0.63 BP= 0.96
MCS 0a –0.01 (–0.07 to 0.06) 0.01 (–0.02 to 0.05) 0.03 (–0.04 to 0.11) –0.07 (–0.14 to 0.00)
BP= 0.59 BP= 0.76 BP= 0.80 BP= 0.97
PCS 0a –0.05 (–0.15 to 0.05) –0.07 (–0.13 to –0.02) –0.03 (–0.13 to 0.06) –0.10 (–0.22 to 0.02)
BP= 0.85 BP > 0.99 BP= 0.76 BP= 0.95
a Positive value indicates greater increase in PCS from treatment (vs. control) as covariate increases. MCS 0 and PCS 0 are
baseline scores for MCS and PCS, respectively.
b Positive value indicates greater increase in PCS from treatment (vs. control) for females vs. males.
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FIGURE 52 Physical component score outcome: optimal treatment as a function of MCS and PCS at baseline for
men aged 50 years, with proportion of male participants whose MCSs and PCSs at baseline fit into each
zone (n= 2296).
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The results (Table 49) show that, as with the RMDQ score, there is greater certainty around which
treatments are suboptimal than around which treatments are optimal. For the paradigmatic cases in
Figures 52 and 53, it is unlikely that psychological treatments would be the best choice for either gender,
but there is a clear indication that there might be differences in proportions who might benefit from active
or passive physical treatments if PCS/MCS and sex were the only parameters used for decision-making.
Short-term Short Form questionnaire-12 items/-36 items mental component
score outcome
The network of evidence for this outcome is the same as for the SF-12/36 PCS. Table 50 gives the
predicted treatment effects from the NWMA of these trials for any pairwise comparison of the five
treatment classes in the network, assuming a participant profile representing a typical (male) participant.
Table 51 presents coefficient values reflecting the degree of effect modification for the participant
characteristics of interest. All characteristics, except for sex, have at least one effect modification coefficient
with a BP of > 0.95. It is, perhaps, worth noting here that, for short-term MCS as an outcome, passive
physical therapy has the largest effect size for our paradigmatic case. At least for the comparison with
active physical, the 95% credibility interval does not cross zero.
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FIGURE 53 Physical component score outcome: optimal treatment as a function of MCS and PCS at baseline for
women aged 50 years, with proportion of female participants whose MCSs and PCSs at baseline fit into each
zone (n= 3278).
TABLE 49 Probability that any given treatment is optimal for a range of participant profiles with PCS as outcome
of interest
Participant profile
Probability (%) that treatment is optimal for this participant profile
Active physical Passive physical Psychological Sham
1. Male, MCS 40 and PCS 40 81 11 7 < 1
2. Male, MCS 70 and PCS 20 42 43 15 < 1
3. Female, MCS 30 and PCS 50 55 18 6 21
4. Female, MCS 60 and PCS 30 23 68 9 < 1
5. Female, MCS 20 and PCS 20 20 11 1 68
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Figures 54 and 55 show how effect modification can be used to define PCS/MCS zones in which each
treatment is optimal. Broadly speaking, psychological therapy is optimal for participants with high PCSs
(low levels of disability) and moderate to high MCSs (low levels of psychological distress). Passive physical
therapy is optimal for participants with low PCSs and high MCSs, and sham therapy is optimal for
participants with low PCSs and MCSs (high disability and high levels of psychological distress). If we
disregard sham as a feasible recommendation, passive physical therapy becomes optimal for these
participants (there are no participant profiles for which no intervention is optimal). To quantify the strength
of evidence for these optimal zones, we calculated the probability that each treatment is optimal for a
representative participant profile in each zone. The results (Table 52) show that, as with the RMDQ score,
there is greater certainty around which treatments are suboptimal than around which treatments are
optimal. However, the evidence for effect modification appears strongest on this outcome. It is perhaps of
note that for some participant groups (those with high disability and high levels of psychological distress) it
appears that sham treatment is highly likely to be the most effective option.
TABLE 50 Treatment effect with modification (absolute change in short-term MCS, mean and 95% credible
interval). Coefficients given for individual aged 50 years, male, PCS and MCS= 40. Predicted change in condition
without treatment adjusted for age, sex, baseline values of SF-12/36 PCS and MCS
Intervention
Comparator
Control Active physical Passive physical Psychological
Active physical 1.53 (0.04 to 3.02)
Passive physical 3.04 (2.23 to 3.85) 1.50 (0.05 to 2.96)
Psychological 2.59 (0.80 to 4.39) 1.06 (–1.04 to 3.17) –0.44 (–2.26 to 1.39)
Sham 2.13 (0.44 to 3.82) 0.60 (–1.53 to 2.73) –0.90 (–2.59 to 0.79) –0.46 (–2.83 to 1.90)
TABLE 51 Mean, 95% credible intervals and BPs (%) for impact of participant characteristics on effect of
treatments in the network
Participant
characteristics Active physical Passive physical Psychological Sham
Agea –0.02 (–0.09 to 0.05) –0.03 (–0.07 to 0.01) 0.00 (–0.06 to 0.07) –0.09 (–0.15 to –0.03)
BP= 74 BP= 93 BP= 53 BP> 99
Sexb 0.36 (–1.23 to 1.96) –0.20 (–1.18 to 0.78) –0.47 (–2.26 to 1.34) 0.73 (–0.99 to 2.44)
BP= 67 BP= 66 BP= 70 BP= 63
MCSa –0.06 (–0.13 to 0.01) –0.10 (–0.14 to –0.06) –0.05 (–0.13 to 0.03) –0.17 (–0.24 to –0.09)
BP= 97 BP> 99 BP> 90 BP> 99
PCSa –0.03 (–0.13 to 0.08) –0.08 (–0.14 to –0.02) 0.05 (–0.04 to 0.15) –0.15 (–0.27 to –0.03)
BP= 68 BP> 99 BP> 86 BP> 99
a Positive value indicates greater increase in MCS from treatment (vs. control) as covariate increases.
b Positive value indicates greater increase in MCS from treatment (vs. control) for females vs. males.
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FIGURE 54 Mental component score outcome: optimal treatment as a function of MCS and PCS at baseline for
men aged 50 years, with proportion of male participants whose MCSs and PCSs at baseline fit into each
zone (n= 2296).
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FIGURE 55 Mental component score outcome: optimal treatment as a function of MCS and PCS at baseline for
women aged 50 years, with proportion of female participants whose MCSs and PCSs at baseline fit into each
zone (n= 3278).
TABLE 52 Probability that any given treatment is optimal for a range of participant profiles
Participant profile
Probability (%) that treatment is optimal for this participant profile
Active physical Passive physical Psychological Sham
1. Male, MCS 60 and PCS 60 6 < 1 91 < 1
2. Male, MCS 70 and PCS 20 11 65 13 10
3. Male, MCS 30 and PCS 30 < 1 31 < 1 68
4. Female, MCS 60 and PCS 60 12 < 1 82 < 1
5. Female, MCS 80 and PCS 20 26 32 15 11
6. Female, MCS 80 and PCS 20 < 1 13 < 1 87
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Chapter 11 Discussion
Introduction
This work is grounded in the pressing need to improve the outcomes for people living with LBP.
The targeting of treatments of proven but modest average effectiveness at those who are likely to
gain the greatest benefit holds promise. The driver for this research is the considerable uncertainty over
which patients are most likely to benefit from which treatment strategy. Improved matching of patients to
individual treatments has the potential to improve the overall health gain from, and cost-effectiveness of,
treatments for LBP. In particular, how individual patient factors, including duration and severity of the back
pain, and physical, social and psychological factors, might affect both adherence and treatment response.
There is much published work on predictors of poor outcome for people with LBP, for example the
psychosocial ‘yellow flags’181 or the STarT Back tool.182 None, of this work has, however, addressed how
these risk factors affect response to treatment. Without explicitly addressing if a particular patient
characteristic moderates treatment outcome, targeting treatments at those who are perceived to be at
high risk may not be an appropriate choice. During this programme of work we have explored in
considerable detail – in two systematic reviews – what is already known about identifying subgroups of
people with LBP. This work has demonstrated that the existing work to identify subgroups of patients with
LBP within RCTs is generally of a poor methodological quality, and even the high-quality studies do not
present evidence to support treatment choices at an individual patient level. Importantly, in this work we
have moved beyond using data from single trials and use of single parameters to define subgroups.
A large focus of this work has been very technical, on how best to address the challenge of pooling very
complex data sets and how best to define subgroups using multiple parameters. To do this we made
a series of methodological developments, including three novel methods for subgroup identification:
two algorithmic approaches (recursive partitioning, and adaptive risk group refinement) and individual
participant data indirect NWMA.
Within the limits of the data that were suitable for pooled analysis, we have identified exploratory
subgroups of people who might gain a greater benefit from different treatment approaches in a
consistent manner. Interestingly, the groups that we identified as possibly gaining greater benefit from
therapist-delivered interventions rather than usual care were typically the converse of expectations. So far
as the evidence goes, it seems that younger people with less psychological distress are likely to gain the
greatest benefit from these treatments. Although the findings are not strong enough to support these as
parameters to prioritise treatment, they do challenge conventional wisdom that people with psychological
distress should be targeted for treatment.
Summary of key findings
Systematic reviews (see Chapter 2)
Notwithstanding the perceived importance of performing research to identify subgroups of people living
with chronic LBP, there is a paucity of high-quality research in this area. We have identified that nearly
all papers reporting analyses of subgroup effects provide no more than exploratory evidence, and that
only one study reporting treatment moderation was adequately powered for this analysis. Although
it is the identification of differential subgroup effects that is of interest, we failed to identify any robust
research that considered subgroups defined by multiple parameters. Rather, we found studies that tested
the effect of single potential effect moderators. We have previously found that the available data do not
support the use of clinical prediction rules in the management of LBP.93
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Age, employment status, education level, back pain status, narcotic use, treatment expectations,
moderated treatment effect with p< 0.05 in one or more study. The exploratory nature of nearly all of
the comparisons, the inconsistent findings across the four included studies and the large number of
comparisons made mean that these findings cannot, in themselves, be used to inform management.
Notwithstanding the limitations of the existing research we were able to identify some potential
moderators to include in our final analyses. The overall weakness of the underpinning data meant that we
included potential moderators in our analyses that did not meet conventional criteria for statistical
significance. By including moderators found to be significant at the 20% level, our pool of potential
moderators became age, gender, employment status, education, back pain status, pain-related disability,
narcotic use, treatment expectations, quality of life and psychosocial status.
Analyses of covariance (see Chapter 6)
Our ANCOVAs replicate the conventional approach to moderator identification in a pooled data set.
The main purpose of these analyses was to inform selection of potential moderators for our main analysis
based on identifying variables significant at the 20% level. In our analyses, we were restricted by the pool of
trials using a common set of baseline covariates and outcomes. In this analysis, comparing all intervention
groups with all control groups (‘non-active usual care plus sham for clinical outcomes’ or ‘usual care for
health-economic outcomes’), we identified some moderators that reached conventional statistical
significance for some outcomes. Summarising these findings, these data suggest that those who are worse
on a measure of physical function (FFbHR/SF-12/36 PCS) have the most to gain from treatment on physical
outcomes and those who are worse on the SF-12/36 MCS at baseline gain the most on this outcome
measure. For the outcome of EQ-5D, its baseline value did not moderate treatment response, but pain,
physical function (SF-12/36 PCS) and anxiety, which are arguably components of the EQ-5D, did moderate
response. The exception to the observation that it is severity at baseline that predicts response to treatment
on that measure is that a less favourable baseline FFbHR score moderates outcome on the SF-12/36 MCS.
Anxiety – but not catastrophising, coping strategies and depression – moderated treatment response, at
p< 0.05 in the analyses for the outcome of EQ-5D in which those with lower risk of anxiety had less
treatment effect than those with higher risk of anxiety. This is the first meta-analysis to assess effect
moderation in the treatment of LBP and hence gives a far more robust assessment than any previous work
in this area. The numbers in our analyses mean that if there were true moderation effects in this comparison
of all treatments against control then they should have been identified.
Although these observations are of some interest, the main purpose of these analyses was to select
potential moderators that were significant at the 20% level to take forward for our main analyses. We
were able to take forward FFbHR, RMDQ, SF-12/36 PCS and MCS, age, gender, pain, fear avoidance and
coping as variable with a possible signal in one or more analysis.
Recursive partitioning (see Chapter 7)
We successfully adapted two recursive partitioning approaches to identify subgroups in an individual
participant data meta-analysis. There are important distinctions in the way they work. The IPD-IT method is
seeking to maximise the size of the interaction term when making splits, whereas the IPD-SIDES method
is seeking to detect groups with the largest treatment effects.167 The choice of approach in any future
analyses using a recursive partitioning approach will depend on the primary outcome of interest. For our
current purpose we prefer the IPD-SIDES approach, as we think it is more likely to identify clinically useful
subgroups with large effect sizes. The IPD-IT approach may be more suitable for more exploratory analyses
for which maximising any moderation is the outcome of interest. We have presented both analyses here
to explore how they perform on a real data set. The IPD-SIDES approach appears to be more sensitive,
as it has successfully identified some subgroups within our data, whereas the IPD-IT method did not
(Tables 53–57 and see Chapter 7). Our overall analysis of all interventions compared with control (usual
care or sham control) provides evidence that the IPD-SIDES method functions well; we found candidate
subgroups in a real data set, as well as the simulation in which it was originally tested. For the choice of
treatment compared with control (sham plus usual care) using the full data set, there are some clusters of
characteristics with different treatment outcomes. For example, for the outcome FFbHR (range of the score
DISCUSSION
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is from 0= great limitation to 100= no limitation) the overall treatment effect of 8.93 (95% CI 7.81 to
10.05) increases to 13.17 (95% CI 10.56 to 15.77) in those with a FFbHR score of ≤ 54.2 and aged
≤ 60 years or for the SF-12/36 PCS (range 0–100 best) the overall treatment effect increases from 3.48
(95% CI 3.01 to 3.96) to 4.89 (95% CI 3.96 to 5.82) in those with a SF-12/36 PCS of ≤ 40.0 and a
SF-12/36 MCS of > 54.2. It is, however, the pairwise comparisons, with usual care control, which might
be useable to inform clinical practice.
Passive physical therapy
For passive physical therapy we identified subgroups for the outcomes of FFbHR, plus SF-12/36 MCS/PCS.
The results for FFbHR, which represent just acupuncture trials, find a maximal effect of 16.67 (95% CI
13.16 to 20.18) compared with an overall treatment effect of 9.95 (95% CI 8.80 to 11.11) in those aged
≤ 53 years and with a FFbHR score of ≤ 54.2. Thus acupuncture is likely to be more effective in those with
a worse baseline score and who are younger. This finding is probably of little clinical importance, as none
of the splits identified a group in which the treatment was ineffective and only 17% of participants
(571/3272) were in this group with the largest effect. For the SF-12/36 MCS the maximal effect is seen in
those with a low score on both PCS and MCS. In the group with a MCS of ≤ 54.3 and PCS of ≤ 43.9, the
treatment effect increases from 2.96 (95% CI 2.31 to 3.61) to 4.27 (95% CI 3.39 to 5.15). On this
occasion, 56% of participants (2171/3898) fall into this group. Again, none of the splits identified a group
in which the treatment was not effective, suggesting that it would not be helpful in clinical practice. This
could, in any event, be plausibly clinically important only if the outcome of interest was mental health.
For the SF-12/36 PCS, IPD-SIDES found nine candidate models, including one with three splits: baseline
PCS, MCS and gender. The final split on gender did not, however, achieve conventional statistical PCS as
the first split with either age or MCS as the second split. Treatment was most effective in those with more
severe problems and who were younger or had better mental health. There was little to choose from
between the added effect from each of the different models with two splits, and no split was found for
which the intervention was ineffective. This makes it difficult to suggest a ‘best’ choice. It is, however, of
note that increasing psychological distress appears to make it less likely that passive physical interventions
will be effective. This does not support the notion that such treatments should be targeted at those with
increased psychological distress.
Active physical therapy
We did not find any subgroups with an enhanced response to active physical therapy.
Psychological therapy
There were fewer participants included in this analysis (n= 928) than for passive physical treatments
(n= up to 3898), reducing potential for finding subgroups. Nevertheless, the IPD-SIDES method did identify
one split for the RMDQ outcome, based on baseline severity as measured using the RMDQ (range 0–24,
0= best). This split might be of clinical relevance: the 75% (231/928) of participants with a RMDQ score of
> 4 gained an additional 1.07 points benefit, taking the average treatment effect from 1.40 (95% CI 0.89
to 1.91) to 1.72 (95% CI 1.12 to 2.31). Furthermore, for the group with a RMDQ score of ≤ 4 the 95% CI
for the mean effect included zero (0.65, 95% CI –0.11 to 1.40). This indicates that psychological
treatments should be reserved for those with higher RMDQ scores. For the RMDQ score, unlike the other
outcome measures reported here, there is an established minimally important change for an individual:
5.0 points.30 The size of the interaction can be interpreted as a small difference, that is, 0.21 of the
minimally important change.183 It is nevertheless comparable with the overall effect size at 3 months
identified in the BeST Trial (1.1 points on the RMDQ, 95% CI 0.38 to 1.71 points), which did not have a
lower limit of RMDQ score for study entry.33 These data can reasonably be used to indicate that
psychological treatments should be reserved for those with a RMDQ score of > 4. Interpretation of the
importance of this observation needs to include the important caveat that all of the analyses reported here
are exploratory rather than confirmatory. It also fits with the general pattern that treatments tend to have
greater effects in those with worse baseline scores on the outcome of interest.
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Sham treatment
Interpreting the findings for sham treatments, on this occasion sham acupuncture from two trials132,136 on
the SF-12/36 MCS is quite challenging. The results of the IPD-SIDES analysis appear to show that for those
aged > 65 years, and for those with a SF-12/36 PCS of > 42.0, sham acupuncture is substantially less
effective, and that in rest of the population the effect size is enhanced. Although the point estimates
indicate harm, the 95% CIs include zero and, at least for SF-12/36, the interaction effect is of borderline
statistical significance (p= 0.043). It may well be that, for age, we are observing the same phenomena
seen for other interventions whereby older people, and those with fewer symptoms, are less likely to
benefit. The option of a sham treatment is unlikely to be explicitly offered by the NHS. It could be argued
that we do not need to consider this further. On the other hand, any sham intervention includes the
potentially very important therapist–patient interaction that is part of all of the interventions we have
examined. The differential effects observed might be clinically important in that we have identified
subgroups (those aged > 65 years and those with a better PCS> 42.0) who might be harmed by the sham
intervention. If this were a true observation it might lead one to question the benefit of offering some
therapist-delivered interventions to an older age group or to those with less disability as a consequence of
potential adverse effects on their mental health.
Adaptive refinement by directed peeling in individual patient data
meta-analysis (see Chapter 8)
We have successfully extended an adaptive risk group refinement method for use in identifying subgroups
of patients who may respond better to different treatments. In contrast with the recursive partitioning
approaches, adaptive risk group refinement produces multiple solutions representing different-sized
proportions of the population, allowing the user to decide at which point on any trajectory plot the
additional benefit of selecting subgroups would be clinically worthwhile. This is achieved by repeatedly
searching within the data set to identify successively smaller subgroups with larger effects. This approach
does not produce the monotonic changes in subgroup specification seen when a peeling approach (see
Chapter 9) is used, but may give a better representation of effect for a prespecified size of subgroup.
We were limited, by lack of computational power, to just exploring the effect of four covariates; there is,
however, no statistical reason for restricting the covariates used to just four. In this restriction we were able
to do a more extensive search by considering all possible combinations of subgroups, thus interrogating
the data more thoroughly. It can be seen how this approach can define subgroups in the example of the
FFbHR outcome (three acupuncture trials) for all interventions compared with control (usual care and sham)
(see Figure 21 and Table 27). Here a clear trajectory, with average effect size increasing from 8.47 to
16.79, is seen. This is largely driven by baseline FFbHR score. In contrast, no such pattern is seen for the
RMDQ outcomes (see Figure 25), suggesting that there is not potential for subgroup identification for this
group of studies. For the SF-12/36 MCS and PCS outcomes the high variability as subgroup size decreases
suggests that it is not possible to define subgroups reliably for these outcomes. Thus for our interpretation
of all interventions compared with control (non-active usual care/placebo) is that for the FFbHR outcome
younger people with a worse FFbHR score and worse PCS may gain more from treatment and that, for the
SF-12/36 MCS outcome, those who are younger and with a worse MCS are likely to gain the greatest
benefit. Results from pairwise comparisons between different types of treatment and non-active usual care
controls are considered in the following subsections.
Passive physical therapy
We found a similar pattern to the overall comparison for the FFbHR result when passive physical
(acupuncture) was compared with non-active usual care, that is, it was more effective for those who were
younger with a worse baseline score.
We also found that, for the outcome of SF-12/36 MCS, those who were younger with worse PCS and
MCS gained a greater benefit.
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Active physical therapy
We did not find any subgroups with an enhanced response to APT. In particular, we did not find that
baseline RMDQ score consistently identified subgroups with a better treatment effect.
Psychological therapy
We did not find any subgroups with an enhanced response to psychological therapy.
Sham
We were again able to identify a group that might do better with sham treatment. Its definition was,
again, driven by age and baseline severity. Curiously, a worse baseline MCS appears to predict who
responds better to sham acupuncture, but not who responds to true acupuncture.
Identification of cost-effective subgroups by direct peeling (see Chapter 9)
The application of the peeling algorithm was successful in identifying potentially interesting subgroups for
the interventions against control comparison. These subgroups comprised patients who were older, with
relatively worse physical functioning at baseline. The gain in treatment effect for the subgroup was small.
Therefore, given the relatively low cost of the intervention, treatment is likely to be cost-effective for the
whole patient group. The algorithm, however, was not successful in finding any convincing subgroup in
the pairwise comparison of active and passive physical treatment. This may be due to lack of power, or
simply that there is no subgroup to be found.
The QALY has some key advantages over the other available clinical outcomes. It is a holistic measure of
health-related quality of life, designed to encompass both physical and mental aspects of a patient’s health
state. Constructed using EQ-5D responses over time, the QALY also takes account of a patient’s recovery
profile, integrating short- and long-term treatment response into a single measure. The EQ-5D is scored
using the UK social tariff; this is validated and standardised, allowing direct comparison of the treatment
response for different interventions and diseases. The QALY estimated using the EQ-5D tariff is the accepted
measure used by NICE for assessing the cost-effectiveness of new treatments for approval in the NHS. The
QALY did, however, raise some particular challenges for the analysis. The use of repeated measures to
estimate the QALY restricted the size of the sample, as more observations were lost to missing data when
compared with the point estimates used in the clinical analysis. This reduced the power of statistical analyses.
For the QALY analyses, the group that had sham treatment were excluded. Although of some interest to
explore the effects of sham treatments for clinical outcomes, these are not relevant to an economic analysis.
The same approach was taken for moderator identification for the economic component of the analysis
as for the clinical analyses. Three potential moderators (age, PCS, RMDQ score) of treatment response
were identified for the economic analysis. However, the relationship of the QALY with the moderators
differed in some cases to that of the clinical outcome measures. It was only for the overall comparison of
treatment with control that any potential subgroups were identified.
For the short-term clinical outcome of PCS, the age-by-treatment interaction was found to be negative and
significant (p< 0.2), suggesting that younger patients had a better treatment effect. For the outcome of
FFbHR score, the age-by-treatment interaction was also negative but was just outside the significance
threshold of p< 0.2. For the other included clinical outcomes, age was not significant. When the QALY
was used as the outcome measure, the age-by-treatment interaction was significant at p< 0.2 but the
relationship was positive, indicating that older patients had a better treatment effect. The EQ-5D at
short-term follow-up also exhibited a positive relationship with age, although this relationship was not
significant. It may not be surprising that the relationship of the moderators with the different outcomes
differed, as they measure different aspects of patient health. Furthermore, the QALY differs, by
construction from the other outcome measures, as it is calculated as the AUC for a sequence of follow-up
points. However, it is also possible that the results are susceptible to missing data bias. Patients with
missing EQ-5D data at one or more follow-up points were, on average, 4 years younger than patients with
complete EQ-5D data (p< 0.05). One could speculate that younger patients with better expected
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outcomes might have been excluded from our complete-case analysis, as they failed to return follow-up
questionnaires. This could bias the treatment response down for younger patients. Four trials had
short-term EQ-5D data, comprising 1774 patients (1271 intervention, 503 control) for which there were
complete data. Of the 1774 patients, 1467 (1093 intervention, 374 control) had complete data at all
EQ-5D follow-up points necessary to calculate a QALY estimate. This equates to an additional 17% missing
data for QALYs compared with short-term outcomes. This might possibly explain the difference in direction
of relationship between age and treatment response by outcome measure, as the short-term measures
were less prone to missing data than the QALY.
Overall, our interpretation is that those who are older, with worse RMDQ and SF-12/36 PCS are likely to
gain a greater benefit on QALY outcomes from treatment. Doing this will not, however, improve overall
QALY gain for the whole population, as those outside this subgroup are likely, on average, to benefit from
treatment. Treating only this subgroup is very unlikely to be seen as cost-effective, given the relatively low
cost of treatment and the NICE threshold of £20,000–30,000 per QALY.
Network meta-analysis (see Chapter 10)
In a further methodological development, we successfully adapted a NWMA approach to identify effect
moderators and produce a probability that a particular treatment choice is optimal for individuals with
particular profiles. This approach presents the data in a format that is very different from our other
approaches to subgroup identification. Analysing the trials as a single network of evidence allows us to
detect subgroup effects with greater precision, and the use of Bayesian methods allows quantification of
the strength of evidence for alternative modalities. This has allowed us to estimate effect sizes for groups
with similar characteristics. See, for example, Table 44, which shows that for a paradigmatic case (male,
age 50 years, baseline RMDQ score= 10, baseline PCS and MCS both equal 40) active physical, passive
physical and psychological treatments are all likely to be effective in reducing RMDQ score compared with
control; the credible intervals exclude zero. For sham treatment, the point estimate is consistent with it
being effective but the 95% credible interval includes zero. Consistent with the preplanned analyses,
baseline severity strongly predicts response to treatment across all interventions (slightly weaker for sham
treatment). The effect of age, gender, plus the baseline SF-12/36 PCS and MCS are weaker and are not
consistent across modalities. It is this variability that allows tables of probability for a particular treatment
choice to be the optimum choice. For our paradigmatic case the probability that passive physical is optimal
is 45% and that psychological is optimum is < 1%. These sorts of outputs have the potential to inform
clinical decision-making. It should, however, be noted that this approach generates a ranking and that the
differences in effect sizes from moderation of the primary outcome by baseline characteristics remains
modest. For our paradigmatic case, all treatment options (except sham) have evidence of effectiveness;
the 95% credible interval excludes zero. The additional benefit for passive physical treatment over
psychological treatment, however, is only 0.72 (95% credible interval –0.08 to 1.52) points on the RMDQ
and the 95% credibility interval includes zero. Nevertheless, this approach does have the potential to
provide some information, tailored to the individual, which can be used to inform clinical decision-making.
Interpretation
Clinical relevance
In our overall analyses (all interventions compared with control) it appears that women with more severe
disability and lower levels of psychological distress are likely to gain the greatest benefit on back pain
disability and the PCS of the SF-12/36. For psychological outcomes, as measured by the SF-12/36 MCS,
those with poorer baseline psychological health gained the greatest benefit. That those with a less
favourable baseline score gain the greatest treatment benefit, on the same measure, may not be surprising,
as these are the individuals with the greatest potential for improvement. We have in all of our analyses
presented here, and as outlined in our analysis plan, used absolute differences in outcome rather than
percentage changes from baseline. In a post hoc analysis we re-ran our initial ANCOVAs, with percentage
change from baseline as the dependent variable (data not shown). The apparent significance of any
moderator effects was substantially reduced, for example the significance of any moderation of effect of
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baseline FFbHR score as the outcome, p-value changed from< 0.0001 to 0.0703. This suggests that our
finding that baseline severity predicts outcome on the same measure might depend on the scale of
measurement used for the change.
Our prespecified approaches, recursive partitioning and ARDP did produce identifiable subgroups, the
parameter definitions of which were grounded in the data. The differences in effect sizes were generally
small, however, and unlikely to be clinically meaningful. The effect sizes in the groups who did less well
would still justify the use of these interventions. This overall picture is potentially misleading, however,
as the choice is not typically between treatment and no treatment; rather, it is how to select particular
treatments for individuals.
Our prespecified analyses give some insights here. For passive physical treatments (acupuncture, manual
therapy), those who are younger, with less psychological distress and worse disability were likely to gain
the greatest benefit on disability. For psychological treatments, those with more baseline disability were
likely to gain a greater benefit on disability. In both of these cases the difference in effect sizes are unlikely
to be clinically important. Defining what is clinically important is a challenge for LBP researchers exploring
treatment moderation. The authors of the published protocol for an IPD meta-analysis of studies of
exercise treatment for LBP have set a minimally clinically important difference for moderation, where the
p-value is < 0.05, to be 20 points on a 100-point scale for pain, and 10 points on a 100-point scale for
disability or ‘another magnitude deemed clinically important by experts’.184 Others have argued that,
for exercise interventions for LBP, worthwhile between-group differences in pain may be as much as
10 points.185 None of the subgroups identified by the IPD-SIDES or ARDP-MA method met these criteria.
All of the subgroups identified in this work had quantitative effects when the direction of the treatment
effect was in favour of the intervention arm in both subgroups. It is open to debate whether or not a
differential subgroup effect that is smaller than a main treatment effect is worthwhile. When the choice is
between treatment or no treatment, one might expect that to be clinically meaningful, any moderator
effect should be larger than the main effect. Otherwise, as our data show, the overall net benefit from
treatment may decrease as it is offered selectively. If the choice is between different treatments with
similar main effect sizes, acquisition and opportunity costs, and risk profiles, then quite small moderation
effects might increase over treatment effectiveness.
Our health-economic analysis suggests that it is possible to identify groups with better-than-average QALY
gain from treatment. Nevertheless, even in the groups with a smaller QALY gain, the incremental cost per
QALY gained is sufficiently low that it falls far below the NICE threshold of £20,000. Our analyses show
that selecting subgroups of individuals for treatment reduces the overall QALY gain. This means there is
not a cost-effectiveness argument for excluding some groups from access to treatments.
On the basis of these analyses we can be confident that the only potentially worthwhile screening tool to
select treatments is baseline severity of the measure of interest, although even here those who are less
severe will still gain a benefit and we have failed to find evidence that it would be worthwhile offering
treatment to selected patients based on baseline severity. We have found that those with higher levels of
psychological distress are less likely to benefit from some interventions. Nevertheless, the size of the
interaction effect means it is unlikely to serve as a discriminator for selecting treatment approaches as
those with higher levels of distress may still benefit from treatment.
The importance of these findings is that there is no justification for using higher levels of psychological
distress to target treatments. This runs contrary to received wisdom that psychosocial yellow flags could be
used to select those who would benefit from treatment.
A RCT of stratified care based on patient prognosis using the STarT Back tool found it to be a very
effective and cost-effective approach to managing with LBP.38 The study design, however, did not allow
the effect of the stratification tool to be separated out from the effects of therapist selection and the
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additional benefits of the customised treatment packages provided after stratification. Thus, although a
promising overall approach to targeting back pain treatments, this does not help us to identify differential
subgroup effects in this population.
Currently, treatment choices between the types of interventions we have examined here is largely decided
by the treating therapist in consultation with the patient. A shared informed decision-making model in
which patients are given more information on the evidence for different treatment options and
physiotherapists are trained to implement shared informed decision-making does not improve outcomes;
indeed it may have an overall harmful effect.186 An alternative approach of using the output from NWMA
to help physiotherapists and their patients choose treatment options could be tested empirically.
Psychological distress as a treatment moderator
That increased psychological distress, as measured by the SF-12/36 MCS, does not appear to increase
treatment effect from either passive physical or psychological interventions is an important finding. There is
a substantial body of literature suggesting that those with psychological distress should be prioritised for
treatment of their LBP because their prognosis is worse.187–192 Our data suggest that, for the interventions
assessed here, those with higher levels of psychological distress are less likely to benefit. These observations
are, of course, limited by the measures we were able to use as potential moderators and that other
moderator variables, for example back beliefs or self-efficacy, might have produced different findings. There
is some limited evidence (p< 0.2) in our overall ANCOVA that catastrophising and fear avoidance might
moderate treatment response for the RMDQ outcome when people with a more positive attitude (low
scores on catastrophising or low scores on fear avoidance) had greater treatment effect than those with a
more negative attitude. In our data set, psychological distress as measured by the MCS is positively
correlated with other measures such as fear avoidance (Spearman correlation, r= 0.064), depression
(r= 0.137), and anxiety (r= 0.151) (data not presented). This means that it is extremely unlikely that
increased values in these scores would have an opposite effect to those we observed for the SF-12/36 MCS.
Thus, taking all of these findings together, a policy of treatment with conventional therapist-delivered
interventions focusing on those with higher levels of psychological distress is not sustainable. What these
data cannot tell us is whether or not there is a differential effect from a much more intensive treatment
programme based on levels of psychological distress at baseline. In the absence of any such evidence, or
any reasonable prospect that direct RCT data will become available, one might be able to infer from our
findings for less intense interventions that such more intense interventions might be best targeted at those
with more severe disability (however defined). This would concur with that which is current practice (where
such services are available) and 2009 NICE guidance.
Methodological development
A substantial part of the programme grant was around the development of new approaches to identifying
subgroups. From our review of the literature on subgroups, we concluded that the existing methods have
a number of problems, including being severely underpowered, able to provide only exploratory or
insufficient findings and having rather poor quality of reporting (see Chapter 2). Therefore, there is a need
to develop new approaches to subgroup identification in back pain research.
We have developed three approaches to subgroup identification:
1. recursive partitioning (IPD-IT and IPD-SIDES method) (see Chapter 7)
2. adaptive risk group refinement (see Chapters 8 and 9)
3. individual participant data indirect NWMA (see Chapter 10).
These new methods challenge the current paradigm for subgroup identification in which single moderator
variables are sought. Although such an approach provides a useful first step to exploring subgroups,
the outputs have not produced clinically useful data to inform treatment choices for LBP. The more
comprehensive methods developed as part of this programme of work use a multiparametric approach to
subgroup identification, which gives far greater flexibility and clinical application.
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The recursive partitioning and adaptive methods we developed for this work did not allow us to identify
clinically relevant subgroups within this data set. We think that this reflects both the limitations of the data
set and the likelihood that there are no distinct subgroups that might be identified in this manner.
Nevertheless, the techniques performed well on the available data and the different techniques have
typically generated consistent outputs. These are important methodological innovations, which we
anticipate to have potential across a wide range of clinical areas. Importantly, they both use an approach
that examines both the effect of variables and provides cut-off points grounded in the data. In particular,
the adaptive methods allow the end-user to judge for themselves the size of any differential subgroup
effect (clinical effectiveness or cost-effectiveness) that would be worthwhile and identify the parameters
that would define such a group. For our adaptive approaches we have here presented just point estimates,
without also ascribing statistical inference to them. This is for the sake of clarity of presentation. We have
explored how to add statistical inference to these analyses. This is possible but uses an extremely large
amount of computer time and generates little additional information. They are an additional approach that
could be used in future analyses.
The development of NWMA to provide individualised advice on which treatment has the highest
probability of being optimal for a particular patient profile is extremely exciting. Although no more than
exploratory here, as it was not prespecified in our analysis plan, there is potential for this approach to
inform clinical decision-making in this and other fields. Analysing the trials as a single network of evidence,
and also adopting a Bayesian approach to probability, has provided us with what appears to be useful data
to inform clinical decision-making in a field that has previously been devoid of useful information. When
evidence is suggestive but not conclusive, Bayesian methods allow this to be quantified in a way that can
be incorporated into decision-making by individual clinicians and patients.
We have developed a large and complex data set. This has presented substantial challenges (not fully
appreciated at the start of the project) in terms of data management and coding. In contrast with some
other areas for which IPD meta-analysis is more common, for example cardiovascular disorders, there is no
consistency in how baseline variables or outcomes are measured, and there is the need for a core outcome
set in this area. This has meant that we have had to do further methodological development in order to
develop a new EAV approach to managing such data sets, which is far more flexible and simple for
non-specialist IT staff to adapt as needed. We think that this approach is more robust and flexible than
the approach of utilising an Access database used by others doing IPD meta-analysis of back pain trials.184
This is an important methodological development, which we consider to have utility beyond the scope of
this project.
Although not exactly a methodological development, we have examined carefully how one might map
between different back pain outcome measures. The finding here that they are neither sufficiently
correlated nor sufficiently similar in their responsiveness for data from trials using different outcomes to be
pooled is important. This may not be entirely surprising if one examines the time frames over which
different measures are considering outcome and the exact content of the measures. We are aware that
the National Institutes of Health task force on back pain research identified producing crosswalk values for
these ‘legacy measures’ as priority.157 Our findings demonstrate that this exercise is not worth pursuing
further. These findings also mean that existing meta-analyses of back interventions, for which results from
different trials that have used different outcome measures have been pooled, may not be robust. There are
multiple examples in the literature of meta-analyses that have either used SMDs or scaled measure to a
0–100 scale. We suggest that all of these reviews need to be interpreted with caution until such time as
this issue has been addressed in their analyses. We have also succeeded in developing an approach to
judging if different PROMs measuring the same domain can be pooled for meta-analysis that has
applicability outside the field of back pain.
It may well be that the lasting legacy and impact of the programme of work reside in the methodological
developments needed to do the analyses rather than the outputs of the analyses.
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Strengths
This pooled data set of RCTs of therapist-delivered interventions for LBP is a valuable resource for
academics and researchers in the field for the future. Such a large data set provides the statistical power
needed for subgroup analyses, something that was lacking in many previous studies. This means that
negative findings can be taken as absence of effect rather than absence of evidence of effect. In our
original proposal we estimated that we needed data on around 3000 participants to do our analyses.
Having a pooled data set of 9328 means that we have substantially more statistical power than
anticipated. This means that although for many analyses we were able to use only relatively small subsets
of the data for which the same outcomes had been used, we were still able to perform robust analyses.
Although not being able to pool data from all trials reduces numbers in each analysis, we are confident
that in each analysis the same thing is being measured in each trial. This contributes substantially to the
strength of our conclusions.
The whole of this programme of work hinges on the strength of the programming and coding of trials,
which have enabled the data to be pooled. The data we obtained came from varied and complex data sets
using different coding structures. A large amount of work went into standardising the coding. The final
database we have developed is probably over-engineered for the analyses that we have conducted. In
particular we have included, wherever possible, individual item data rather than scores for any outcome
measures. In the end we were not able to use this fine resolution data for our subgroup analyses.
Nevertheless, we have created an excellent resource for future researchers to use to explore other research
questions. Nearly all of the contributing triallists have indicated that they may be prepared to make the
data available for future analyses; we would therefore be keen to encourage back pain researchers to
formally bid to access the data. Furthermore, we would like to continue to add data to the repository
to increase its future utility and, therefore, we would encourage academics in the field to approach us with
data sets that they would like us to include. It is likely that we would need to charge researchers to upload
the data to cover the research and programming time. We would therefore encourage researchers to
include costs of uploading their final data into this data set in any future grant applications.
The results obtained come from the application of two different frequentist approaches to subgroup
identification: recursive partitioning and adaptive risk group refinement. Both approaches yield similar
conclusions: that although it is possible to use multiple parameters to describe subgroups, these are
unlikely to be clinically important. Additionally, the NWMA has identified the same parameters as being
important and with the same directionality (although noting here that for the QALY analysis it is older
people who gain a greater benefit). Therefore, as a strength we can be confident that our analyses are
robust, yielding the same overall outcome.
Limitations
Our exploratory work on mapping between outcome measures which measure the same domain, to a
common scale, led us to conclude that this is not possible and therefore we would be unable to pool
outcomes measuring the same domain (see Chapter 5). For this reason, despite having a large data set,
for some comparisons we had rather fewer data. As the programme was originally produced, we had
anticipated using individual item data to help define subgroups. However, as we developed our methodology
it became clear that we would not be able to use such a large number of items and obtain meaningful
outcomes in a reasonable time frame; such analyses would be beyond capacity of our computing systems.
Furthermore, as the work developed, we selected moderators for our analyses grounded in existing data.
There is a hazard that we would falsely identify moderators, as data from three of the four studies that
informed our choice of potential moderators were included in our analyses here. As we have not identified
any large subgroup effects this need not be of great concern. We were able to explore only some of the
domains that were identified in our literature review because in many cases only one study had measured
that particular variable, and there would be no added value to be gained from running an analysis in the
pooled data set.
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The interventions used in the trials were trial specific. To enable grouping of interventions, trials were
broadly grouped into active physical, passive physical, psychological, sham and control.
Initially, we grouped the sham and control together as a single control group. This was later separated out,
based on some exploratory analyses indicating a treatment effect for sham. The sham group is largely
made up of participants who received sham acupuncture. Some may argue that our approach to grouping
these interventions is not conventional, as every intervention is different, and therefore how can they be
grouped and treated as being the same. From a practical perspective of managing the data and using it to
do any meaningful analyses it was essential that the data were grouped in some manner. The approach
we have taken was carefully considered by the research team, including our lay members, before the final
groupings were decided.
Therapist and group effects can also affect the analysis of trials of the types of interventions that we are
evaluating here. We did not have enough detail to include these in our pooled analyses. From our
experience of the BeST33 and BEAM31 trials, for which we know therapist effects were measured, we have
found these to be negligible and therefore are unlikely to be a source of bias.
All of these findings need to be interpreted with some caution. We have undertaken many analyses,
meaning that some positive findings might have been observed by chance. In addition, several of the data
sets that we included in our analyses were also data sets that were used in other studies to identify our
possible moderators, and were the same data sets that we used for our ANCOVAs. This, again, increases
the possibility that we might have found a spurious positive result. From our pairwise comparisons, and
with these caveats, we failed to identify any clear and consistent differential subgroup effects beyond
‘those who have more problems at baseline have more to gain and those, with increased psychological
distress, as measured by the SF-12/SF-36 MCS, may gain less benefit’; consequently, this becomes a very
strong finding.
Our exploratory analytical approach to identifying subgroups that may do best with different treatment
approaches using a Bayesian NWMA has provided some promising results. In this analysis we have not
identified subgroups in a conventional manner. Rather, we have used all of the available data to assess the
probability that, for a group of patients with a similar profile, a particular treatment choice is the most
likely to be effective. For some of our paradigmatic cases there are clear messages as to which treatment
types may be more effective. In some cases, sham treatment (typically sham acupuncture) appears to be
the preferred choice. As the NHS is unlikely to offer sham treatment as a patient choice, some thought is
needed on how to interpret these findings. Perhaps one would choose to offer verum acupuncture, which
some argue is no more than a therapeutic placebo.193 Even if it is truly a sham treatment, it is one that
many have belief in, which could be offered, rather than something that no-one has belief in, such as
de-tuned ultrasound. Although of some academic interest to explore how sham treatment could appear to
be the optimal treatment, even ahead of the active treatment for which it is the control, this is not of clinical
relevance. If this approach to treatment selection was implemented clinically then the option of sham
treatment could be removed and the second-choice approach advised.
Meaning of the results and clinical implications
The important clinical implication of the results is that there is very little clinical effectiveness or
cost-effectiveness justification for using the baseline characteristics we studied to define groups who
might benefit from different back pain treatment. Based on these data, the hypothesis that low-intensity
therapist-delivered interventions should be targeted at those with higher levels of psychological distress
(as measured by SF-12/36 MCS) is not supported. It is possible that the results of the Bayesian analysis
might allow us to give more information which might help improve treatment selection; this will need
empirical testing before it can be recommended. Most importantly, we have developed statistical methods
for subgroup analysis that move beyond simply looking for interaction effects with single moderator
variables. These approaches may have quite wide applicability.
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Recommendations for future research
We have made a number of suggestions for further research; however, these are not necessarily in order
of priority.
1. Making the data set available to other researchers. We are in the process of updating data sharing
agreements to allow us to make our data available to other researchers.
2. Adding additional trial data sets to the repository. We are aware of two other groups that are working
on intervention-specific IPD meta-analyses. We are working with them to develop a shared codebook
for these trials. A next step would be to develop a user-friendly interface that would allow the original
researchers to upload their data into the repository. We are aware of moves to make trial data more
freely available for secondary research. Further development of this data set will provide such a resource
for the back pain research community.
3. Application of these methods for the identification of subgroups in other clinical areas. We will make
our methods freely available to other researchers.
4. Re-analysis of existing meta-analyses of back pain treatments that have pooled different outcome
measures. As current Cochrane reviews are updated, it would be possible to group any meta-analyses
according to the outcome measure being reported. In the absence of heterogeneity in outcome
according to outcome measure used, it may be possible to pool data to give an overall estimate with
some caveats as to whether pooling in this manner is robust.
5. Further development of methods and application to the data we already have.
6. Explore the need for a core outcomes set for LBP in the light of existing developments in the area.
Conclusions
The lasting legacy of this work is likely to be the methodological developments needed to do our analyses.
We have developed improved systems for storing large, complex data sets; developed methods for
assessing comparability of outcome measures, which have demonstrated that different back pain outcome
measures cannot be safely pooled for meta-analyses; and we have developed three different approaches
to the identification of differential subgroup effects, which provide considerable added values compared
with conventional analyses that simply test for interactions.
Using frequentist approaches (recursive partitioning or adaptive approaches) has not allowed the
identification of subgroups that might have worthwhile additional benefits from different treatment
approaches beyond the potential benefits of being greater in those with more disability at baseline.
Importantly, increased psychological distress, as measured using the SF-12/36 MCS, may identify those less
likely to benefit from treatment – the opposite of conventional wisdom, which is that this group should be
targeted for intervention.
An approach based on Bayesian NWMA offers a potential approach to deciding on optimal therapies. We
would suggest that these methods are applied in other clinical areas in which subgroup identification and
targeting of treatment may be advantageous.
Our findings do challenge conventional wisdom on who should be prioritised for back pain treatments,
that is, those with greater psychological distress. We would not support such an approach until there is
evidence to challenge our findings.
Finally, we have developed an important resource for back pain researchers wishing to do further analyses
on data from multiple trials.
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Appendix 2 Invitation letter
 
Professor Martin Underwood 
 Warwick Medical School Clinical Trials Unit 
    University of Warwick 
  Coventry 
  CV4 7AL 
[INSERT ADDRESS] 
 
[INSERT DATE] 
 
Study Title: Improving outcomes from the treatment of back pain 
 
Dear [INSERT NAME] 
 
We have successfully obtained funding from the National Institute for Health Research for a 
programme grant on the management of low back pain.  One aspect of this is programme is to 
develop a pooled database of the original data from randomised controlled trials of therapist 
delivered interventions for low back pain.   
 
The overall aim of our programme grant is to improve the clinical and cost-effectiveness of 
low back pain treatment by providing patients, their clinical advisors, and health service 
purchasers with better information about which patients are most likely to benefit from which 
treatment choices.  
 
By developing this repository of original patient data we hope to conduct pooled secondary 
analyses. This will help us to determine which patient characteristics, if any, predict clinical 
response to different treatments for low back pain and/or predict the most cost-effective 
treatments for low back pain. 
 
We would be very grateful if you would consider sharing the data from your [INSERT 
STUDY] trial for this important study. If you have any questions or you are interested in 
sharing this data with us please could you email repository@warwick.ac.uk in the first 
instance.  
 
We look forward to hearing from you.  
 
Yours sincerely 
 
 
Martin Underwood 
Professor of Primary Care Research  
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Appendix 3 Information sheet
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Appendix 4 Sample data sharing agreement
Data sharing agreement
Standard template
Research project title: Improving outcomes from the treatment of back pain
Reference: RP-PG-0608–10076
1.0 Organisations
This Data Sharing Agreement is drawn up between:
Professor Martin Underwood
Warwick Clinical Trials Unit
University of Warwick
Gibbet Hill
Coventry
CV4 7AL
and:
[INSERT DETAILS]
2.0 Period of agreement
This agreement commences on [INSERT DATE] and will terminate on [INSERT DATE] unless extended by
mutual agreement of both parties in writing, at which point an Amendment will be issued by University of
Warwick to replace this document.
3.0 Data required
[INSERT INSTITUTION NAME] will supply all anonymous trial data from [INSERT TRIAL NAME].
Data required:
Individual patient data with descriptions of variable coding
AND/OR
Scored variable databases with descriptions of variable coding
We will require confirmation from the Chief Investigator that patients in the original trial have given
informed consent.
4.0 Permissions
The data will come from completed randomised controlled trials. All data will be anonymous and no
patient identifiable information will be shared.
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Approval to obtain data will be obtained from the University of Warwick’s Biological Research Ethics
Committee and the Oxford ‘C’ NHS REC.
5.0 Purpose for which the data are to be used
The data will be used to develop a repository of IPD on potential moderators, health outcomes, and
health-care resource use and costs, from RCTs testing therapist-delivered interventions for low back pain.
We will conduct statistical and health-economic analyses on this pooled data set.
We will not reanalyse any trial data already published.
Data access is restricted to those named in Table A of this agreement. Any changes will be notified to
[INSERT INSTITUTION NAME].
6.0 User obligations
The University of Warwick formally wishes to acknowledge its explicit commitment to maintaining the
confidentiality, safety, security and integrity of all data to which the organisation is privy and which may be
held under its guardianship.
The University of Warwick continues to legitimately enter into formal agreement and/or implicit
undertaking with all its clients, staff, visitors, suppliers and others, in recognition of the fact that the data
are held under the guardianship of the University of Warwick which is pertinent to the individual client,
staff member, visitor, supplier and/or other, will only be used for the explicit agreed purpose or purposes
for which it has been provided, and that there will be no unlawful disclosure or loss of the same.
TABLE A Individuals who will have access to and use of the repository
Permitted users Job title – organisation they work for – where they will access data
Martin Underwood Chief investigator based at Warwick CTU – Medical School, data will be accessed within the
university only
Shilpa Patel Study Manager based at Warwick CTU – Medical School, data will be accessed within the
university only
Sallie Lamb Co-investigator based at Warwick CTU – Medical School, data will be accessed within the
university only
Nigel Stallard Statistical lead based at Warwick CTU – Medical School, data will be accessed within the
university only
Tim Friede Statistical advisor based at Göttingen University, data will be accessed within their institution
Statistician
(Research Fellow)
Statistics Research based at Warwick CTU – Medical School, data will be accessed within the
university only
Joanne Lord Health Economist lead based at Brunel University, data will be accessed within their institution
Health Economist
(Research Fellow)
Health Economist Research Fellow based at Brunel University, data will be accessed within
their institution
Dipesh Mistry PhD student based at Warwick CTU – Medical School, data will be accessed within the
university only
Programming Team Programming team based at Warwick CTU – Medical School, data will be accessed within the
university only
Claire Daffern Quality Assurance Manager at Warwick CTU – Medical School, data will be accessed within
the university only
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Users of the data supplied are obliged to fully comply with The Data Protection Act 1998, together with all
other related and relevant legislation and Department of Health directives covering issues of data sharing
and including:
l British (International) Standard ISO 27001
l The Caldicott Report 1997
l The Freedom of Information Act 2000
l Section 251 of the Health and Social Care Act 2006
l Confidentiality: NHS Code of Practice 2003
l NHS Records Management Code of Practice (Part 1, 2006 & Part 2, 2009)
l The NHS Information Security Management Code of Practice 2007
l The Computer Misuse Act 1990
l The Electronic Communications Act 2000
l The Regulation of Investigatory Powers Act 2000
l The Copyright, Designs and Patents Act 1988
l The Re-Use of Public Sector Information Regulations 2005
l The Human Rights Act 1998.
7.0 Transfer of data from [INSERT INSTITUTION NAME] and the University
of Warwick
Anonymous data will be obtained from [INSERT INSTITUTION NAME]. Data will be encrypted and sent to
the University of Warwick by [INSERT INSTITUTION NAME] via the University’s file transfer application.
Once the data have been received, the original source will be moved to an encrypted drive. A processed
copy of the data will be imported into a secure database.
Together with the encrypted data [INSERT INSTITUTION NAME] will provide a detailed description of
the variables.
8.0 Storage of data
The original data source will be temporarily stored on a file server directory that is only accessible to the
chief investigator and study manager until it is moved to an AES 256 encrypted volume. Data will be
processed and imported from the encrypted volume into a Microsoft 2005 SQL Server database hosted in
the University of Warwick’s data centre. The data will be regularly replicated on to a failover server and
routinely backed up to a Storage Area Network.
9.0 Data retention
The intention is to keep the repository once it has been developed and make it available to other
researchers. An independent steering committee will be convened to assess applications for the repository.
If the repository is deemed to be no longer required, all data will be deleted from the servers. Deletion of
data is irreversible and involves the database being disconnected and all data and transaction files being
destroyed using a secure deletion application.
The WCTU may invoke the right to implement the research exemption clause of the Data Protection Act in
order to retain the data for future research activities.
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10.0 Agreement signatures
For and on behalf of: For and on behalf of:
Warwick Clinical Trials Unit [INSERT INSTITUTION NAME]
Signed: Signed:
Print name: Professor Martin Underwood Print name:
Post/title: Head of Division of Health Sciences, Warwick Medical School Post/title:
Date: Date:
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Appendix 5 Instruction on secure data transfer
Repository programme
Instructions for transferring data sets to the University of Warwick
l Please ensure your data sets are anonymised.
l Compress/encrypt your data set using an open-source compression software programme (e.g. 7Zip)
l Follow this link: https://files.warwick.ac.uk/repositorylbpdata/sendto
¢ Please fill in the boxes as required:
¢ Your name
¢ Your e-mail; and
¢ Any message (e.g. name of the trial, contact telephone number)
¢ Click on the ‘Browse’ button
¢ Choose the file to upload
¢ Click on the ‘Upload and send file’ button.
A member of the Repository team will send an e-mail confirming that the data set has been uploaded
successfully. We will also call you to obtain the password required to decrypt the file.
Thank you.
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Appendix 6 Excluded studies
Paper Trial
Number of
participants
Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Irnich D, et al. Interventions and
physician characteristics in a randomized multicenter trial of acupuncture in patients with
low-back pain. J Altern Complement Med 2006;12:649–57
Brinkhaus 301
Hancock MJ, Maher CG, Latimer J, McLachlan AJ, Cooper CW, Day RO, et al. Assessment
of diclofenac or spinal manipulative therapy, or both, in addition to recommended
first-line treatment for acute low back pain: a randomised controlled trial. Lancet
2007;370:1638–43
Hancock 240
Hancock MJ, Maher CG, Latimer J, Herbert RD, McAuley JH. Can rate of recovery be
predicted in patients with acute low back pain? Development of a clinical prediction rule.
Eur J Pain 2009;13:51–5
Hancock 240
Härkäpää K, Järvikoski A, Mellin G, Hurri H. A controlled study on the outcome of
inpatient and outpatient treatment of low back pain. Part I. Pain, disability, compliance,
and reported treatment benefits three months after treatment. Scand J Rehabil Med
1989;21:81–9
Härkäpää 459
Härkäpää K, Mellin G, Järvikoski A, Hurri H. A controlled study on the outcome of
inpatient and outpatient treatment of low back pain. Part III. Long-term follow-up of
pain, disability, and compliance. Scand J Rehabil Med 1990;22:181–8
Härkäpää 476
Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F, et al. A randomized
trial of medical care with and without physical therapy and chiropractic care with and
without physical modalities for patients with low back pain: 6-month follow-up outcomes
from the UCLA low back pain study. Spine 2002;27:2193–204
Hurwitz 681
Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F, et al. The
effectiveness of physical modalities among patients with low back pain randomized to
chiropractic care: findings from the UCLA low back pain study. J Manipulative Physiol
Ther 2002;25:10–20
Hurwitz 681
Hurwitz EL, Morgenstern H, Chiao C. Effects of recreational physical activity and back
exercises on low back pain and psychological distress: findings from the UCLA Low Back
Pain Study. Am J Public Health 2005;95:817–1824
Hurwitz 681
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Appendix 8 Scatterplots of raw change scores of
outcome measures
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Appendix 9 Statistical analysis plan
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List of Abbreviations 
ALBPSQ Acute Low Back Pain Screening Questionnaire 
ANCOVA Analysis of covariance 
AUC Area under the curve 
BBQ Back Beliefs Questionnaire 
BDI Beck Depression Inventory 
BMI Body mass index 
CES-D Center for Epidemiologic Studies Depression 
CPG Chronic Pain Grade Scale 
CSQ Coping Strategy Questionnaire 
DASS Depression Anxiety and Stress Scale 
DRAM Distress and Risk Assessment Method 
FABQ Fear-Avoidance Beliefs Questionnaire 
FFbHR Hannover Functional Ability Questionnaire for Measuring Back Pain-
Related Functional Limitations (Funktionsbeeintrachtigung durch 
Ruckenschmerzen) 
GP General practitioner 
HADS Hospital Anxiety and Depression Scale 
INMB Incremental net monetary benefit 
IPD Individual patient data 
LBP Low back pain 
MAR Missing at random 
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NICE National Institute for Health and Clinical Excellence 
NMB Net monetary benefit 
ODI Oswestry low back pain Disability Questionnaire 
PCS Physical Component Scale 
PDI Pain Disability Index 
PI Principal investigator 
PRSS Pain-Related Self Statement 
PSEQ Pain Self-Efficacy Questionnaire 
PSFS Patient Specific Functional Scale 
QALY Quality-Adjusted Life Year 
QoL Quality of Life 
RCT Randomized controlled trials 
RMDQ Roland-Morris Disability Questionnaire 
SES Pain Experience Scale (Schmerzempfindungsskala) 
TENS Transcutaneous electrical nerve stimulation 
TSK Tampa Scale for Kinesiophobia 
VAS Visual analogue scale 
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Statistical Analysis Plan for the Low Back Pain Repository 
 
1. Background 
1.1 Summary 
The aim of the Low Back Pain Repository is to develop a repository of individual patient data 
(IPD) from randomized controlled trials (RCT) testing therapist-delivered interventions for 
low back pain (LBP). Principal investigators (PI) whose trials satisfy the inclusion criteria 
(Table 1.1) are approached to share their anonymized data with us. Datasets from them are 
then queried and validated before they are uploaded to the standardized repository database.  
 
The primary objective of this study is to determine which patient characteristics at baseline 
predict clinical response to different treatments and the most cost-effective treatments for low 
back pain. 
 
1.2 Design of the programme 
Development of the data repository 
The flow diagram of the development of the data repository is shown in Figure 1.1. 
 
Identification of treatment moderators 
A systematic review was performed to search for RCT of therapist delivered interventions for 
LBP that identified patient characteristics at baseline that might predict the response to 
treatments. Variables that were identified from this review are entered into the pool of 
potential moderators to inform the final analysis. 
 
1.3 Timing of analysis and reporting 
The timeline for the data collection, analysis and reporting is shown in Table 1.2. All the 
investigators who have consented to share their data uploaded their data to the secure shared 
space before 28 February 2013.  
Table 1.1 Inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
Randomized controlled trials for non-specific low back 
pain 
Therapist delivered interventions trials (including 
psychological interventions and intensive 
rehabilitation programmes) 
Participants aged ≥ 18 
Non-randomized controlled trials (for example, 
observational, cohort, retrospective study) 
Pharmacotherapy trials 
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Abbreviations: RCT, randomized controlled trials; LBP, low back pain. 
Figure 1.1 Flow diagram of the development of the data repository 
2. Aims of the analysis 
The primary aim of the analysis is to identify a combination of patient characteristics at 
baseline to recommend a particular therapist delivered intervention to a subpopulation where 
it would be optimal to and are associated with the endpoints of interest, namely, disability 
(Section 4.1), pain (Section 4.2), psychological distress (Section 4.3), non-utility quality of 
life (Section 4.4), health utility (Section 4.5) and cost-effectiveness (Section 4.6).  
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Table 1.2 Timing of analysis and reporting 
 2013 2014 
 Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun 
1. Freeze collection of data                 
2. Query, validate and 
upload all data obtained 
to the Repository 
database 
                
3. Map the network 
diagram 
                
4. Develop statistical 
models for clinical 
analysis 
                
5. Develop the models for 
economic analysis 
                
6. Analyse the data with 
models developed in (4) 
and (5) 
                
7. Refine the predictor 
model 
                
8. Test and validate the 
refined predictor model 
                
9. Result report                 
10. Final report                 
11. Dissemination and 
publication 
                
 
3. Quality control 
3.1 Data query 
Data query is performed on all data uploaded to the secure shared space. Any inconsistency, for 
example, out-of-range values, inconsistent dates, is resolved before being uploaded to the 
standardized repository database.  
3.2 Extract, transform and load 
A technical guideline (Appendix A) gives a detailed procedure to transfer, query, map, report and load 
the shared trial data to the repository database. 
3.3 Verification of uploaded data to the repository database 
Once the original data have been uploaded to the repository database, the data are verified manually to 
ensure that the process of uploading did not compromise the data integrity. 
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4. Outcome variables 
This section describes the derivations of the scoring and scales for the measurements of the outcomes 
of interest. Clinical outcomes are classified broadly into physical disability (Section 4.1), pain 
(Section 4.2), psychological distress (Section 4.3) and non-utility quality of life (Section 4.4). The 
health utility and cost-effectiveness outcomes are presented in Sections 4.5 and 4.6. 
As there is no single instrument that was used by all trials, the methodology in either selecting an 
instrument or scaling each instruments to one standard measurement will be discussed within each 
subsection; section 4.1.2 for physical disability, section 4.2.2 for pain and section 4.3.2 for 
psychological distress. 
4.1 Physical disability  
According to the definition from the World Report on Disability by World Health Organization 
(2011), disability refers to difficulties arising from any or all three of these conditions; impairments, 
activity limitations and participation restrictions. It is not merely a health problem but arises from the 
interaction between the health condition(s) and environmental and personal factors. 
4.1.1 Instruments 
Benefits of treatments 
Some RCTs might have a single standalone instrument that asked the participant to rate the benefit of 
the treatment they have received. It is usually presented as a numerical rating scale with “substantial 
benefit” on one end, “substantial harm” on the other end, and a “no benefit” in between. 
Chronic Pain Grade Scale 
The Chronic Pain Grade Scale (CPG) is an instrument to grade chronic pain status (Von Korff et al., 
1992). It has two dimensions, namely, disability and pain intensity scores. It used with different 
durations recall, and may refer to all pain or specifically to low back pain. The disability score is 
made up of three items: 
• In the past XX months/weeks, how much has (back) pain interfered with your daily activities 
rated on a 0-10 scale where 0 is 'no interference' and 10 is 'unable to carry on any activities'? 
• In the past XX months/weeks, how much has (back) pain changed your ability to take part in 
recreational, social and family activities where 0 is 'no change' and 10 is 'extreme change'? 
• In the past XX months/weeks, how much has (back) pain changed your ability to work 
(including housework) where 0 is 'no change' and 10 is 'extreme change'? 
 
The disability score is derived as followed,  
Disability score = mean(of the three items) × 10. 
The range of the score is from 0 to 100 where the higher score means more severe disability.  
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Hannover Functional Ability Questionnaire for Measuring Back Pain-Related Functional 
Limitations (Funktionsbeeintrachtigung durch Ruckenschmerzen) 
The Hannover Functional Ability Questionnaire for measuring back pain-related functional 
limitations (FFbHR) is a self-administered questionnaire developed to assess the functional limitations 
in daily living activities (Kohlmann and Raspe, 1996). There are 12 items and participants are 
instructed to tick if they could perform the activity (Yes, final score 2), could perform but with 
difficulty (Yes but with difficulty, final score 1) or not (No or with external help, final score 0). 
FFbHR score = (sum of all items)/24 × 100. 
The range of the score is from 0 (great limitation) to 100 (no limitation). 
 
Oswestry Disability Index 
The Oswestry low back pain Disability Questionnaire (ODI) is made up of 10 sections that are found 
to be most relevant to people suffering from low back pain (Fairbank et al., 1980). It aims to assess 
the limitations of various activities of daily living. The activities are pain intensity, person care, 
lifting, walking, sitting, standing, sleeping, sex life, social life and travelling. Each section is scored 
between 0 and 5 (greatest disability) and the final score is 
ODI score = Total score from all sections/Total possible score × 100. 
For example, if all 10 sections were completed and the total score was 16, then ODI score was 
16/50×100=32. However, if one section was missing or not applicable and the total score was also 16 
then ODI score was 16/45×100=35.5. The range of the score is from 0 (no disability) to 100 (greatest 
disability). 
 
Pain Disability Index 
The Pain Disability Index (PDI) is a measurement of the degree to which pain interferes with 
functioning in family/home responsibilities, recreation, social activity, occupation, sexual behaviour, 
self-care, and life-support activities (Tait et al., 1990). Each item score ranges from 0 (no disability) 
to 10 (worst disability).  
PDI score = sum of all seven items. 
The range of the score is from 0 (no disability) to 70 (worst disability). 
Patient Specific Functional Scale 
The Patient Specific Functional Scale (PSFS) is an instrument that requires participants to identify up 
to 5 important activities that they are unable to perform or have difficulty with because of their low 
back pain (Stratford et al., 1995). Participants are also asked to rate the level of difficulty, from 0 
(unable to perform activity) to 10 (able to perform activity at preinjury level) associated with each 
activity. Participants are reminded of these activities at subsequent follow-ups and rate the level of 
difficulty. 
 
DOI: 10.3310/pgfar04100 PROGRAMME GRANTS FOR APPLIED RESEARCH 2016 VOL. 4 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Patel et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
227
   
Statistical Analysis Plan for the Low Back Pain Repository 
 
Effective: 9 December 2013 Version 1.0 
  
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
228
   
Statistical Analysis Plan for the Low Back Pain Repository 
 
Effective: 9 December 2013 Version 1.0 
Roland-Morris Disability Questionnaire 
The Roland-Morris Disability Questionnaire (RMDQ) is a measurement for low back pain function in  
primary care trials (Roland and Morris, 1983). Participants are instructed to tick the statement that 
describes them on the day of completing the questionnaire. Item that is ticked is represented 
numerically by 1 and by 0, otherwise.  
RMDQ score = sum of all items that are ticked. 
The range of the score is from 0 (no disability) to 24 (severe disability). 
 
SF-12/SF-36 
The standard (4-week recall) and acute (1-week recall) of SF-12 (versions 1 and 2) and SF-36 
(version 1 and 2) are 12- and 36-item generic measurements of quality of life, respectively (Ware et 
al., 2002; and Ware et al., 2000). The 12 items in the SF-12 measure eight scales, namely, physical 
functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and 
mental health. The 36 items in the SF-36 measure the same eight scales and an additional scale, health 
transition. Each of the scale is transformed and standardized to compute physical (PCS) and mental 
(MCS) summary measures. The steps for scoring and standardized transformation are available in the 
manuals. The standardized and norm-based scales are necessary for direct interpretation. 
 
The PCS component is of interest as a measurement disability measurement. The range of the score is 
from 0 (substantial limitations) to 100 (no physical limitations). 
 
Troublesomeness 
This is a 6-point Likert item to ascertain the troublesomeness of LBP symptom. It is rated as “no pain 
experienced” (score of 1) to “extremely troublesome” (score of 6) (Parsons et al., 2006). 
 
4.1.2 Selection of instrument 
All the trials had used either FFbHR, RMDQ or Von Korff as their disability outcome. An exploratory 
research will be performed to map FFbHR, RMDQ and Von Korff into quality-adjusted life years 
(QALY) or health utility outcome. The analysis is then based on the QALY/utility outcome. 
In the event that it is not possible to map any of the instruments’ scores to one common outcome, 
trials will be grouped by common outcome and analyses for these trials will be based on that common 
outcome. 
4.2 Pain 
4.2.1 Instruments 
Chronic Pain Grade Scale 
The Chronic Pain Grade Scale (CPG) is an instrument to grade chronic pain status (Von Korff et al., 
1992). It has two dimensions, namely, disability and pain intensity scores. It used with different 
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durations recall, and may refer to all pain or specifically to low back pain. The pain intensity score is 
made up of three items: 
• How would you rate your (back) pain on a 0-10 scale at the present time, that is, right now, 
where 0 is 'no pain' and 10 is 'pain as bad as could be'? 
• In the past XX months/weeks, how intense/bad was your worst pain rated on a 0-10 scale 
where 0 is 'no pain' and 10 is 'pain as bad as could be'? 
• In the past XX months/weeks, on the average, how intense/bad was your pain rated on a 0-10 
scale where 0 is 'no pain' and 10 is 'pain as bad as could be'? 
The pain intensity score is derived as followed,  
Pain score = mean(of the three items) × 10. 
The range of the score is from 0 to 100 where the higher score means more severe pain. Underwood et 
al. (1999) modified the CPG pain intensity scale to be more specific for low back pain. However, the 
scoring for pain intensity remains the same. 
 
McGill Pain Questionnaire (VAS) 
The long (Melzack, 1975) and short (Melzack, 1987) forms of the McGill Pain Questionnaire aim to 
quantify the sensory, affective and evaluative dimensions of pain experience and are commonly used 
in diagnosis. The short form also has a visual analogue scale (VAS) that anchors with “no pain” at the 
left pole and “worst possible pain” at the right pole. 
 
SF-12/SF-36 
As described in Section 4.1.1, the SF-12/36 is made up of eight scales, namely, physical functioning, 
role physical, bodily pain, general health, vitality, social functioning, role emotional and mental 
health. One of them, bodily pain, is of interest as a measurement for pain. The range of the score is 
from 0 (very severe and extremely limiting pain) to 100 (no pain or limitations due to pain). 
Visual Analogue Scale 
Most RCTs might have a single standalone instrument that asked the participant to either rate or mark  
in an analogue scale that describes their average/worst pain at the present time or over the past XX 
months/weeks. The VAS is usually presented as a line that anchors with “no pain” at one end and 
“worst possible pain” at the other end. The line could be either horizontal or vertical.  
 
4.2.2 Selection of instrument 
There exist slight differences between average pain and worst pain. The recall period asked in each 
instrument and between trials may also differ slightly and this may have an impact in the analyses. 
Thus, analyses will be performed for the following pain outcomes: 
• Average pain today 
• Average pain over the past 1 week 
• Average pain over the past 1 month 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
230
   
Statistical Analysis Plan for the Low Back Pain Repository 
 
Effective: 9 December 2013 Version 1.0 
• Average pain over the past 3 months 
• Worst pain today   
• Worst pain over the past 1 week 
• Worst pain over the past 1 month 
• Worst pain over the past 3 months 
For all analyses, individual VAS will be the primary pain outcome. Where a numerical rating scale 
(range, 0 to 10) is used it will be scaled to an analogue scale that gives a range from 0 to 100. 
 
If VAS was not available from a trial, the following instruments will be used (in descending order): 
• The CPG pain intensity score is an average of the three possible questions that are usually 
asked in VAS. Thus, if scoring from individual items were available then the scoring of the 
individual item that is equivalent to the VAS item will be used and scaled to an analogue 
scale to give a range from 0 to 100. However, if only the CPG pain intensity score is available 
then the summary score will be used. 
• The bodily pain domain of SF-12/36. 
4.3 Psychological distress 
4.3.1 Instruments 
Beck Depression Inventory 
The Beck Depression Inventory (BDI) is an instrument used to assess the intensity of depression in 
psychiatrically diagnosed patients and also to detect depression in normal population (Beck et al., 
1961 and 1979). It is made up of 21 items (symptoms) and the intensity is rated from 0 (neutral) to 3 
(maximum severity). 
BDI score = sum of all 21 items. 
The range of the score is from 0 to 63 where the higher score means severe depression. The 
classification (for those diagnosed with affective disorder) (Beck et al., 1988): 
None or minimal depression < 10 
Mild to moderate depression 10 - 18 
Moderate to severe depression 19 - 29 
Severe depression 30 - 63 
Center for Epidemiological Studies Depression Scale 
The Center for Epidemiologic Studies Depression Scale (CES-D Scale) is an instrument to measure 
current level of depressive symptomatology in normal population (Radloff, 1977). There are 20 items 
in the list that the participant might have felt or behaved during the past week. There are four possible 
frequency of occurrence for each symptom (item), namely, less than 1 day, 1 to 2 days, 3 to 4 days 
and 5 to 7 days. The response is subsequently scored from 0 to 3 where a score of 0 represents less 
than 1 day and a score of 3 represents the highest frequency. 
CES-D score = sum of all 20 items. 
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The range of the score is from 0 to 60 where the higher score indicates more symptoms. A score of 16 
or higher is an indicator of high depressive symptoms (Radloff, 1977). 
Depression Anxiety Stress Scales 
The Depression Anxiety and Stress Scale (DASS) is an instrument that measure depression, anxiety 
and stress in diverse settings (Lovibond and Lovibond, 1995). The full version of DASS consists of 
42 items whereas the short-form version, DASS-21, consists of 21 items taken from the full version 
(Henry and Crawford, 2005).  Each item asks the participant how much the statement applies to them 
over the past week and is scored from 0 (did not apply at all) to 3 (very much or most of the time). 
DASS-42depression/anxiety/stress = sum of all the corresponding items. 
DASS-21depression/anxiety/stress = sum of all the corresponding items × 2. 
 
The range for each subscale is from 0 to 42 with higher score indicates severity. The classification: 
 Depression Anxiety Stress 
Normal 0 - 9 0 - 7 0 - 14 
Mild 10 - 13 8 - 9 15 - 18 
Moderate 14 - 20 10 - 14 19 - 25 
Severe 21 - 27 15 - 19 26 - 33 
Extremely severe ≥ 28 ≥ 20 ≥ 34 
 
 
Distress and Risk Assessment Method 
The Distress and Risk Assessment Method (DRAM) is constructed from Modified Somatic 
Perception Questionnaire (MSPQ) and Modified Zung Depression Index (MZDI) (Main et al., 1992). 
It identifies four types of patients, namely, normal (N), at risk (R), distressed-depressive (DD) and 
distressed-somatic (DS). The cut-offs for classification: 
Type N MZDI < 17 
Type R 17 – 33 MZDI and MSPQ < 12 
Type DD MZDI > 33 
Type DS: 17 – 33 MZDI and MSPQ ≥ 12. 
EuroQol (Anxiety/Depression) 
The descriptive system of EQ-5D-3L consists of five dimensions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) (EuroQol Group, 1990). Only the anxiety/depression 
dimension is of interest here. The dimension has three severity levels indicating no problem (level 1), 
moderate (level 2) and extreme (level 3) problems. 
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Hospital Anxiety and Depression Scale 
The hospital anxiety and depression scale (HADS) is an instrument to detect anxiety and depression 
(Snaith, 2003). Each dimension consists of seven items and each item is rated from 0 to 3. 
• Anxiety = sum(of items 1, 3, 5, 7, 9, 11, 13). 
• Depression = sum(of items 2, 4, 6, 8 ,10, 12, 14). 
Therefore, the possible score for anxiety is from 0 to 21, and similarly, for depression, 0 to 21. The 
classification: 
Normal 0 - 7 
Possible presence of respective state 8 - 10 
Presence of respective state ≥ 11 
Table 4.1 Dimensions of psychological distress and the instruments used to measure them. 
Dimensions Instruments 
Depression DASS-42/21depression, DRAM, EuroQol (Anxiety/Depression), HADSdepression, MZDI, MCS of 
SF-12/36 
Anxiety DASS-42/21anxiety, EuroQol (Anxiety/Depression), HADSanxiety, MCS of SF-12/36 
 
 
Modified Zung Depression Index 
The Modified Zung Depression Index (MZDI) is an instrument that could recognise depressive 
features and has been highly associated with participant’s level of disability (Main et al., 1992). It 
consists of 23 items and participant is to rate how frequent they experience each of the statement 
recently. The scoring for each item ranges from 0 (less than 1 day per week) to 3 (5 to 7 days per 
week). The scoring for items 2, 6, 7, 12, 14, 16, 18, 20, 21 and 23 is reversed. 
MZDI score = sum of all items. 
The range of the score is from 0 to 69 where higher score indicates more depressed. 
 
SF-12/SF-36 
As described in Section 4.1.1. The MCS component is of interest as a psychological distress 
measurement. The range of the score is from 0 (substantial social and role disability due to emotional 
problems) to 100 (absence of psychological distress). 
 
4.3.2 Selection of instrument 
There are two dimensions of psychological distress that are of particular interest, namely, depression 
and anxiety. Table 4.1 shows the instruments that are used to measure these dimensions. Within each 
instrument there is usually a classification system that is widely used to classify patients into ordinal 
category, for example, with minimal, moderate, or severe level of anxiety/depression. Therefore, all 
the instruments will be mapped into a single ordinal categorical variable. The scores will be 
categorized by the 33.33rd and 66.67th percentile or by the instrument’s cut-off that discriminate the 
low and high risk from the moderate risk group. 
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4.4 Quality of life 
SF-12/SF-36 
As described in Section 4.1.1. Both the PCS and MCS components are considered in the quality of 
life measurement. The range of the score is from 0 (substantial limitations/frequent psychological 
distress) to 100 (no physical limitations/absence of psychological distress). 
4.5 Health utility 
4.5.1 Utility measures hierarchy (EQ-5D – SF-12/36) 
One of the challenges with the economic analysis is differing Quality of Life (QoL) instruments being 
used to estimate patient utility across the different trials. As the primary measure to estimate utility we 
will use the EQ-5D.  If the data from the EQ-5D were not collected, the SF-12/36 will be used and a 
mapping process applied to convert the SF-12/36 results to EQ-5D dimension scores and utility 
estimates. 
 EuroQol 
The EQ-5D-3L is a standardized measurement of health status for clinical and economic appraisal 
(Brooks, 1996; Dolan, 1997). It incorporates the description and valuation of health status into a 
single package with two components. One component is a standardized multi-dimensional descriptive 
system of general health. The second is a ready-to-use preference-based value set obtained from the 
general population. The descriptive system of EQ-5D-3L consists of five dimensions (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression), and each dimension has three severity 
levels indicating no problem (level 1), moderate (level 2) and extreme (level 3) problems. The 
patient’s health status can be described and defined by filling in the descriptive system. Once the 
health status has been identified, an attached preference-based value can be calculated from the value 
set, which will serve as the quality adjustment weight for calculating quality-adjusted life years 
(QALYs). The UK Social Tariff value set will be used to calculate the quality adjustments (utility). 
SF-12/SF-36 
As described in Section 4.1.1. Both the PCS and MCS components are considered in the quality of 
life measurement. The range of the score is from 0 (substantial limitations/frequent psychological 
distress) to 100 (no physical limitations/absence of psychological distress). 
 
4.5.2 Mapping SF-12/36 to EQ-5D 
Mapping is an approach to derive an estimate of health state utility for one survey from scores elicited 
using another survey. The EQ-5D will be the primary instrument used to estimate utility. For trials 
with no EQ-5D data, the SF-12/36 will be used and a mapping process applied to convert the SF-
12/36 results to EQ-5D dimension scores and utility estimates. 
 
It is possible to use an algorithm (Sheffield) to convert the SF-12/36 into an SF-6D and assign utility 
values, however studies (Brazier and Roberts, 2004) have demonstrated these may not be directly 
comparable with those from the EQ-5D tariff. 
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There are several methods available to map the SF-12/36 to the EQ-5D. Firstly, a choice must be 
made to map the SF-12/36 to the EQ-5D index score, or to map to the EQ-5D individual dimensions.  
The advantage of mapping to the dimension score is that the data used to define the mapping 
algorithm is not country specific, whereas the index score is based on the country specific tariffs and 
limits the generalizability of the algorithm. This will not be an issue, as we are only considering utility 
from a UK valuation perspective. The disadvantage of mapping to the individual dimensions is added 
complexity without necessarily increased predictive power (Rowen et al., 2009).  
 
Once we have decided whether to map to the index value or the dimension score, we have our 
dependant variable.  Second there is a choice as to how we estimate the relationship between the SF-
12/36 (our explanatory variable) and the EQ-5D (dependant variable). The first choice is to use 
existing estimates generated from existing algorithms based on large national datasets. The alternative 
is to generate our own estimates of the relationship using the trials with SF-12/36 data and EQ-5D 
data. We would generate these estimates using an existing, validated econometric approach.  
Literature has shown (Rowen et al., 2009) that heterogeneity across populations can lead to different 
mapping estimates being generated. This suggests applying existing estimates to our trial data may not 
be appropriate if the characteristics of our trial data differ from the original study. However, the 
differences in estimates may be small and outweighed by the added simplicity of the approach. 
 
In addition, for the benefits of generating new mapping estimates to be realised, those studies used to 
generate the new estimates (studies with both SF-12/36 & EQ-5D data) must be of a large sample 
which is homogenous with the studies the mapping is applied to (studies with only SF-12/36 data). If 
new estimates are generated to support the mapping process, there is the added complexity of suitable 
validation of the estimates and approach. This is required as advised by the NHS DSU TSD guidelines 
(Longworth and Rowen, 2013). With an existing algorithm and estimates, this validation should have 
already occurred. 
 
With each of the mapping approaches discussed there exists the risk of bias being introduced into the 
results. Rowen et al. (2009) found each of these methods would overestimate the Health State Utility 
for patients with worse health states. For this reason, which ever approach is used, validation against 
those trials with both SF-12/36 and EQ-5D data is paramount to minimize this risk of bias.  
 
In the first instance a simple approach will be applied using existing estimates and mapping algorithm 
to estimate the EQ-5D utility index for the trials with only SF-12/36 data. For validation purposes this  
will also be applied to trials with both SF-12/36 & EQ-5D. The accuracy of the estimates can then be 
compared directly. More complex mapping methods, as described, will be explored as necessary. 
 
4.5.3 Derivation of QALYs 
Quality adjusted life years (QALYs) are a standardized measure of a patient’s health status. The EQ-
5D is a method of estimating a patient’s utility level at a given point in time. In order to turn this into 
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a QALY it must be integrated over time. For example, an EQ-5D utility score of 1, held by a patient 
for a 6 month period would equate to a QALY of 0.5. In this way QALYs can be calculated as the 
area under the curve (AUC), where time is on the horizontal axis and utility is measured on the 
vertical axis. Where EQ-5D data is not directly available, the mapped EQ-5D scores will be used and 
an AUC will be generated from the mapped utility scores. The AUC will be calculated for each 
patient, providing a QALY score as measured over a 1 year time horizon. 
 
Under perfect conditions an exact continuous curve could be estimated for each patient, giving an 
unbiased estimate of their QALY score over 1 year.  In practice this is not feasible.  As an alternative,  
a discrete approximation method is used, called discrete or numerical integration. The AUC is divided 
up into a series of trapezoids from which the area is then calculated.  For a curve concave to the origin  
this has the effect of slightly underestimating the true area, for a convex function the area will be 
slightly overestimated. 
 
The more data points (in our case EQ-5D follow up points) the better the accuracy of the numerical 
estimation method. This does lead to a further issue. The trials within this study have different 
numbers of follow up points. This suggests that for those with more follow up points a more accurate 
(less biased) estimate of their QALYs will be achieved. In practice this is unlikely to cause a material 
difference. 
  
4.6 Cost-effectiveness 
4.6.1 Cost 
Cost of treatment is made up of the cost of the intervention and the cost of healthcare resource use 
following the intervention. Unit costs will be identified for all healthcare resource use items from 
English national sources (NHS reference costs, PSSRU). The trials included in this study have 
varying levels of detail on healthcare resource usage. For trials with recorded resource use data, total 
costs per patient will be generated by multiplying the amount of resource use by its associated unit 
cost and adding the cost of the intervention itself. Costs will be calculated over a 1 year time horizon.  
Costs will be presented as a total cost per patient from an NHS perspective. 
Primary analysis will include trials with both health outcomes and resource use data from which a 
cost of treatment can be estimated.  Trials with extensive missing resource use data may also need to 
be excluded if the missing data cannot be imputed in a robust and stable way (see Section 8.3). 
 
For trials lacking resource use data, costs cannot be calculated directly. Where this is the case, costs 
will be estimated indirectly as a function of the health outcomes. Using data from trials with both 
resource use and health outcome a regression model will be estimated. The specification of the model 
will be dictated by the data.  A mixed effects model controlling for clustering by trial and intervention 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
236
   
Statistical Analysis Plan for the Low Back Pain Repository 
 
Effective: 9 December 2013 Version 1.0 
with costs as the dependant variable will be assumed. Health outcomes will be the main independent 
variable, with demographics and baseline data included as covariates to control for heterogeneity 
across trial.  The purposes of the model will be to estimate the relationship between the health 
outcomes, other covariates (primarily demographic data) and the total cost of treatment.  If the model 
does not have suitable predictive power it will not be appropriate to include those trials without 
resource use in the full economic analysis.  
 
4.6.2 Net monetary benefit 
Using the methods described above, QALYs/effects (E) and costs (C) will be estimated for each 
patient over a 1 year time horizon. The cost effectiveness analysis will be formed of three parallel 
streams. Firstly, to maximize QALYs (irrespective of costs), secondly to minimize costs (irrespective 
of QALYs) and finally to maximize expected net monetary benefit (NMB). The expected NMB is 
calculated as a function of the QALYs, costs and the societal willingness to pay per QALY gained (λ) 
as shown above.  In this way, the expected NMB accounts for both costs and QALYs simultaneously. 
The NMB will be calculated using a threshold willingness to pay of £30k per QALY gained, as per 
National Institute for Health and Clinical Excellence (NICE) guidelines. 
 
5. Moderator variables 
This section defines the explanatory variables that may potentially be treatment moderators. The 
moderators are made up of participant characteristics/demographics (Section 5.1), employment and 
work status (Section 5.2), and baseline clinical data (Sections 4.1, 4.2, 4.3, 4.4 and 5.3). 
 
5.1 Participant characteristics and demographic data 
Variables collected at baseline: 
• Age 
• Sex 
• Ethnicity 
• Education 
• BMI 
• Previous treatment(s) 
•  
5.2 Employment and work status 
The employment and work status are collected at baseline. 
 
5.3 Baseline clinical data  
This section describes the derivations of the scoring and scales of the instruments used to measure 
clinical outcomes at baseline. The outcomes are classified broadly into disability (Section 4.1), pain 
(Section 4.2), psychological distress (Section 4.3), quality of life (Section 4.4), fear avoidance and 
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beliefs (Section 5.3.1), catastrophizing (Section 5.3.2), coping (Section 5.3.3), sensory and affective 
perception (Section 5.3.4) and benefits of treatment (Section 5.3.5). 
 
5.3.1 Fear avoidance and beliefs 
Acute Low Back Pain Screening Questionnaire 
The Acute Low Back Pain Screening Questionnaire (ALBPSQ) is a biopsychosocial screening 
instrument with 24 items (Linton and Hallden, 1998). Three items asked for year of birth (age), sex 
and nationality, and the other 21 are scored from 0 to 10 that contribute to the ALBPSQ score. 
ALBPSQ score = sum of all items. 
The total score ranges from 0 to 210. However, only the following three items are used to measure the 
fear-avoidance beliefs: 
• Physical activity makes my pain worse. 
• An increase in pain is an indication that I should stop what I am doing until the pain 
decreases. 
• I should not do my normal work with my present pain. 
The scores for these items will be summed up. 
 
Back Beliefs Questionnaire 
The Back Beliefs Questionnaire (BBQ) is an instrument that measures a participant’s beliefs about 
their LBP and the inevitable future as the consequence of LBP (Symonds et al., 1996). It consists of 
nine inevitability statements and five “distracting” statements. Participant is to rate each item with 
score from 1 (completely disagree) to 5 (completely agree). The BBQ scale is computed by reversing 
the scoring for items 1, 2, 3, 6, 8, 10, 12, 13, and 14 (the inevitability statements), and then, summing 
them up. The total score ranges from 9 to 45 with a higher score indicates a more positive attitudes 
and beliefs. 
 
Fear-Avoidance Beliefs Questionnaire 
The fear-avoidance beliefs questionnaire (FABQ) is an instrument to measure participant’s beliefs 
about how physical activity and work affect their low back pain (Waddell et al., 1993). The physical 
component consists of four 7-level items and the work component consists of seven 7-level items. The 
individual item score ranges from 0 (completely disagree) to 6 (completely agree). 
FABQphysical = sum(of items 2, 3, 4, and 5). 
FABQwork = sum(of items 6, 7, 9, 10, 11, 12 and 15). 
Thus, the total score for physical component ranges from 0 to 24 and for work component ranges 
from 0 to 42. 
 
Tampa Scale for Kinesiophobia 
The original Tampa Scale for Kinesiophobia (TSK) developed by Miller, Kopri and Todd was 
unpublished but was later published with permission in Vlaeyen et al. (1995). It consists of 17 items 
and aims to measure the fear of movement or (re)injury. Each item is scored from 1 (strongly 
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disagree) to 4 (strongly agree). For the computation of the total score, scores for items 4, 8, 12, and 16 
are reversed. 
TSK score = sum of all items. 
The total score ranges from 17 to 68 with higher score indicates higher degree of kinesiophobia. 
 
5.3.2 Catastrophizing 
Coping Strategies Questionnaire 
The Coping Strategy Questionnaire (CSQ) is a 48-item instrument that assesses the cognitive and 
behavioural pain coping strategies of participants with chronic LBP (Rosenstiel and Keefe, 1983). The 
48 items summarize into six different cognitive coping strategies, namely, diverting attention (DA), 
reinterpreting pain sensations (RS), coping self-statements (CSS), ignoring pain sensations (IS), 
praying and hoping (PH) and catastrophizing (CAT), and two behavioural coping strategies, namely, 
increasing behavioural activity (IBA) and increasing pain behaviours (IPB).  However, some 
subscales may have lower internal reliability and other shorter versions of the CSQ are sometimes 
used (see, for example, Harland and Georgieff, 2003).  
 
Regardless of the version, each item in the CSQ is scored on a 7-point Likert scale from 0 (never do 
that) to 6 (always do that). Items that correspond to each of the subscale are summed up. Generally, 
six items from the CSQ sum up each subscale. Hence, the range of score for each subscale is from 0 
to 36. The higher score means a more frequently used strategy in coping chronic pain. 
 
Only the catatrophizing (CAT) dimension of the CSQ is used. 
 
Pain-Related Self Statement 
The Pain-Related Self Statement (PRSS) scale assesses participant’s cognitive coping with pain (Flor 
et al., 1993). It consists of two subscales; “catastrophizing” and “coping”. Each subscale is 
summarized by nine items. Participant is to rate on a 6-point Likert scale of how often the statement 
entered their mind when they experienced severe pain. The score ranges from 0 (almost never) to 5 
(almost always). 
PRSS-catastrophizing = sum of even numbered items. 
PRSS-coping = sum of odd numbered items. 
The total score for both subscales ranges from 0 to 45 with the higher score indicates more positive 
self-statements. 
 
5.3.3 Coping 
Coping Strategies Questionnaire 
See section 5.3.2. Only the coping subscale of the CSQ (CSS) is used. 
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Pain-Related Self Statement 
See section 5.3.2. Only the coping subscale of the PRSS (PRSS-coping) is used. 
 
Pain Self-Efficacy Questionnaire 
The Pain Self-Efficacy Questionnaire (PSEQ) is an instrument aims to measure the confidence of the 
participant in performing a particular behaviour or task despite of their pain (Nicholas, 2007). There 
are 10 items in the questionnaire and each item is made up of seven levels, ranging from 0 (not at all 
confident) to 6 (completely confident). 
PSEQ score = sum of all items. 
The total score ranges from 0 to 60 where the higher score reflects stronger self-efficacy beliefs. 
 
5.3.4 Sensory and affective perception 
McGill Pain Questionnaire 
The long (Melzack, 1975) and short (Melzack, 1987) forms of the McGill Pain Questionnaire aim to 
quantify the sensory, affective and evaluative dimensions of pain experience and are commonly used 
in diagnosis. In the short form, there are 11 items associated with sensory dimension of pain 
experience and four items associated with affective dimension. Participant is to rate the intensity of 
each pain descriptor as “none” (score, 0), “mild” (score, 1), “moderate” (score, 2) or “severe” (score, 
3). 
Sensory index = sum of all 11 items associated with sensory perception. 
Affective index = sum of all 4 items associated with affective perception. 
The range of sensory index is from 0 to 33 and the range of affective index is from 0 to 12 where 
higher score indicates severe intensity. 
 
 
Modified Somatic Perception Questionnaire 
The Modified Somatic Perception Questionnaire (MSPQ) is an instrument that measures somatic and 
autonomic perception for chronic back pain patients (Main, 1983). It consists of 13 symptoms (items) 
and participant is to rate the extent of how they have felt over the past week for each item. The 
scoring ranges from 0 (not at all) to 3 (extremely). 
MSPQ score = sum of all items. 
The range of the score is from 0 to 39 where higher score indicates more marked general somatic 
symptoms. 
 
 
Pain Experience Scale (Schmerzempfindungsskala) 
The Pain Experience Scale (SES) is an instrument with 24 items that measures sensory and affective 
characterization of pain (Geissner, 1995). It is usually used as a diagnostic tool and has been proven to 
be suitable in different psychological pain management approaches, physio-therapeutic prevention 
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and a multimodal treatment programme of a specialized pain clinic. Participant is asked to rate the 
appropriateness of each item, from fully appropriate (score, 4) to not appropriate (score, 1).  
Affective score = sum of 14 items associate with affective characterization of pain. 
Sensory score = sum of 10 items associate with sensory characterization of pain. 
 
The range of affective score is from 14 to 56 and the range of sensory score is from 10 to 40. The 
higher score indicates severe pain experienced. 
 
Table 6.1 Grouping of treatment arms. 
Parent group Subgroup Subtype 
Intervention 
Active physical Exercise 
 Graded activity 
Passive physical Acupuncture  
 Manual therapy 
 Individual physiotherapy 
Psychological Advice/education  
 Psychological (cognitive behavioural) 
Sham control 
 Sham acupuncture 
 Sham electrotherapy 
 Mock transcutaneous electrical nerve stimulation   (TENS) 
 Sham advice/education 
Control GP/usual care 
General practitioner (GP) 
Waiting list 
 
 
5.3.5 Selection of instrument 
All of the instruments will be mapped into a single ordinal categorical variable. The scores 
will be categorized by the 33.33rd and 66.67th percentile or by the instrument’s cut-off that 
discriminate the low and high risk from the moderate risk group. 
 
6. Treatment arms 
The therapist delivered interventions are broadly classified into intervention, sham control 
and control. The intervention grouping may be further classified into three broad categories, 
namely, active physical, passive physical and psychological (Table 6.1). 
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7. Follow-up time points 
Due to the design of individual trial’s protocol, the follow-up time points are inherently 
different between trials. The follow-up times are classified broadly into short-term, mid-term 
and long-term (Table 7.1). 
Table 7.1 Follow-up time points. 
Follow-up Definition 
Short-term Between baseline and anytime from 8 weeks to 3 months from randomization or start 
of first day of treatment. 
Mid-term Between baseline and 6 months from randomization or start of first day of treatment. 
Long-term Between baseline and 12 months from randomization or start of first day of treatment. 
 
 
8. Datasets 
8.1 Complete case analysis 
The main analysis is to confirm proof of concept and hence will be based on complete case analysis.  
 
8.2 Missing data 
Missing data may be due to non-responders/withdrawals or missing items. Missingness due to non-
responders or withdrawals will not be imputed. Missing items (at each follow-up time point) may be 
imputed and the method for imputation is as described in Section 8.3. 
 
8.3 Imputed dataset 
Instruments that have a standardize method to impute missing items will be followed. For example, 
imputation for items in SF-12 and SF-36 will be according to the algorithm detailed in the manual 
(Ware et al., 2000, 2002). 
 
For other instruments that do not provide any recommendation, multiple imputation (MI) will be used. 
The standard implementations of MI assume that data are missing at random (MAR) but it can also be  
implemented under the assumption of missing not at random (MNAR). Thus, MI will be used to 
handle missing items. Imputation will only be performed if the fraction of missing items for an 
instrument is less than 30 per cent (White et al., 2011) for that particular follow-up time point. The 
method(s) and model(s) used will be according to the recommendations given by Little and Rubin 
(2002) and White et al. (2011).  
 
Imputation will not be performed on summary/composite-level for clinical outcomes as it is 
impossible to infer whether the participant was a non-responder or had withdrawn from the trial.   
However, for some of the economic variables used to estimate health utility and costs, it may be 
necessary to impute on a summary/composite-level. 
Missing data for economic health outcomes will fall into 3 categories:   
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1. Individual dimensions missing for an outcome at a specific time-point. 
2. Entire response for a health outcome missing from one or more time-points. 
3. Entire response missing from a specific time-point forward to the end of the trial, where it is 
unknown if this is non-response or censoring due to drop out or death. 
 
Category 1 is unlikely to be present, however if found will be dealt with via MI for that time-point 
alone and performed at the level of the individual dimension. For category 2, MI will be used to 
estimate the missing data-point as a summary/composite index score. A suitable regression equation 
will be specified for each trial and MI will be performed for each trial separately. Each of the 
variables to be imputed will be left-hand side dependent variables, estimated simultaneously to 
preserve covariance between them. Baseline index score, demographics and all other relevant 
covariates with complete data will be right-hand side independent variables. The model specification 
will be adjusted to find the best predictors and a model that leads to a stable convergent MI process.  
Individuals with no baseline data are unlikely to occur, however if they occur those individuals may 
have to be excluded from the analysis. 
 
For individuals that fall into category 3, the process will be the same as for 2, however if a censored 
individual is known to have died this will be controlled for using a categorical dummy variable and 
they will be given a health utility value of 0 beyond the time of death. If the reason for censoring is 
not known for a particular trial/individual, the data will still be imputed. However, we will need to be 
mindful of the potential bias in the result. Due to the nature of the conditions being explored in these 
trials death is unlikely to have occurred over and above the national average rate, so should not be a 
concern for this process. 
 
Truncated regression techniques will be used to constrain imputation results between the accepted 
ranges, for example, EQ-5D index scores can only lie between -0.59 and 1.0. 
 
Costs as described in Section 4.6.1 will be calculated from the underlying resource use. The 
imputation of missing data will be performed as part of the same process as the missing health 
outcomes, with resource use items/costs being estimated simultaneously with the missing health 
outcomes data to preserve the underlying relationship (assuming correlation between healthcare 
resource use and health outcomes is present). 
 
Specifically for costs, if some resource use has been captured for an individual at a time-point, any 
blanks at that time-point will be considered 0 rather than missing.  Only resource items explicitly 
coded as missing in the original trial data, or where there is no resource use information for an entire 
time-point will be treated as missing. Resource use will, therefore, be imputed at a 
composite/summary level for each time-point.  In this case total costs may be used as the dependent 
variable to be imputed.  As with health outcomes this will be conditional on being able to specify a 
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suitable model that leads to a robust and stable MI solution. Censoring will be dealt with in the same 
manner as for health outcomes. 
 
Sensitivity analysis will be performed to check the validity of the assumptions. 
 
9. Statistical Analysis 
9.1 Descriptive summary 
The baseline information for each RCT and treatment arm will be summarized. The continuous data 
will be summarized as mean, standard deviation, median and interquartile range. The categorical data 
will be summarized as the number of participants and percentage within each category. 
 
9.2 Meta-analysis 
A one step individual patient data meta-analysis will be performed to explore the efficacy between 
intervention against control (sham treatment and GP/usual care). Trials will be modelled as random 
effect (Riley et al., 2010). 
 
9.3 ANCOVA analysis 
An individual patient data or summary/composite meta-analysis will be performed to identify any 
covariates that predict outcomes. Continuous covariate will be analysed with analysis of covariance 
(ANCOVA) method with trials as the random effect. Categorical covariate will be analysed with 
logistic regression. Variables are statistically significant at a two-sided 0.05 level.  
 
9.4 Clinical and health economic prediction rule and identification of 
subpopulations 
The construct of a clinical and health economic prediction rule and the identification of a 
subpopulation that may benefit from different treatment modalities will be as detailed below. Only 
two treatment arms will be compared at each construction. For example, intervention arm against 
control arm, active physical arm against control arm, and others (see Table 6.1 for the grouping of 
treatment arms). Results from each construction will be collated and report together. 
 
Table 9.1 Moderators identified from literature review (Gurung et al. 2013). 
Age 
Sex 
Employment status 
Education 
Use of narcotic 
Back pain status (baseline RMDQ) 
Treatment expectations 
Quality of life 
Psychosocial status (baseline anxiety and/or depression) 
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Stage 1: Interaction with treatment 
All covariates that are potential moderators will be tested for interaction treatment effects. Linear 
models will be used to test the moderator-by-treatment interaction effects. In the event that the 
assumed linear relationships between the covariate and outcome are not appropriate then an 
alternative non-linear functional forms will be explored, e.g. through fractional polynomials (Royston 
and Sauerbrei, 2008). As model selection can lead to overoptimistic results, shrinkage methods will be 
applied to correct for such bias (Tibshirani, 1996). Covariate is declared as statistically significant at 
the 20% level. This will ensure that covariates that approach statistical significance will not be missed 
and not to overwhelm the pool of potential moderators for Stage 2. 
Stage 2: Construction of clinical/health economic prediction rule 
2.1 Modelling 
Treatment moderators identified in Stage 1 and those that have been identified in the systematic 
review (see Table 9.1; Gurung et al., 2013) will make up the list of covariates to be considered for the 
clinical/health economic prediction rules analysis.  
There is no standard method that can be readily applied to this IPD subgroup identification. As such, 
we will explore and adapt two methods that are commonly used in identifying subgroups of poor 
prognosis in cohort studies. The first method, the Adaptive Risk Group Refinement (LeBlanc et al., 
2005) that identifies subgroups by a greedy algorithm “peeling” of fractions of the total data in a 
series of steps. The second method is based on recursive partitioning that, as the name suggests, 
recursively partition the covariate space to identify subgroups of patients who most (or least) benefit 
from treatment (see, for example, Dusseldorp et al., 2010; Lipkovich et al., 2011; and Su et al., 2009). 
 
Issues such as the splitting of a continuous variable or grouping of a categorical variable into fewer 
levels/groups, multiplicity adjustment and internal validation (e.g. cross-validation) will be handled 
within each method.  
 
2.2 Minimum subgroup size 
In splitting the covariate into two or more parts, it may be possible that the sample size of a 
subpopulation for a treatment arm (Table 6.1) may be very small. Prediction rules based on a very 
small sample size may produce unreliable and very poor estimates. As there is no clear threshold as to  
what is considered as a reasonable size, two proportions, namely, 1/10 and 1/20, of the population will 
be explored. The reliability of the estimates for each minimum size will be reported. 
 
2.3 Formulation of economic prediction rule 
The primary objective function for the economic prediction rule will be maximizing the expected net 
monetary benefit (NMB) as NMB combines both cost and effects simultaneously. We will also run 
parallel streams of analysis to maximise the sum of QALYs and minimise the total costs 
independently. 
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 The NMB will be estimated for each patient and substituted for the clinical outcome indicator in the 
prediction rule algorithm. Within this algorithm, a regression approach will be used to estimate the 
mean difference in outcome between one intervention and some comparator, in a sequence of 
subgroups defined by specified moderators and of varying size. By substituting the NMB as the 
dependent variable within the prediction rule algorithm, we can estimate the Incremental Net 
Monetary Benefit (INMB) for the intervention (relative to the comparator), for each of the subgroups 
tested. The optimum subgroup will be that which maximises the sum of INMB for all of the 
individuals in the subgroup.   
 
Alternative regression specifications may be more robust to potential bias from endogeniety between 
costs and effects, skew in the distribution of costs (Nixon and Thompson, 2005), and ultimately lead 
to more efficient estimates than this simple NMB approach. This will be explored within the 
analysis. We will also investigate the possibility of using a two-equation model (Willan, et al. 2004) 
to estimate the two related dependent variables of cost and QALYs, and to control for factors that 
might confound the treatment effects and potential heterogeneity between trials. 
 
 
For a specific treatment j, the expected NMB per individual can be expressed as: 
 
Two comparators, treatment A vs. B 
In the simple case, one treatment of interest (B) will be compared to a control of usual care (or best 
current practice) (A).  Let Pj denote the proportion of the total population P treated with intervention j 
(j = A, B), ranging from 0 to 1. The treatment options are considered exhaustive and mutually 
exclusive. Therefore, the subsets of the population given each treatment can be defined in terms of 
one another;   PB = P − PA.  There will be a minimum sample size equal to 10% of P, denoted by P10%.   
 
Let us consider the peeling algorithm to maximize expected NMB across the total population P. The 
starting case is that the maximum number patients receive treatment B. Based on the moderators of 
interest, the peeling algorithm will iteratively reduce the sample receiving treatment B provided a 
higher expected NMB across the whole population (P) can be achieved. This process will continue 
until the expected NMB can no longer increase, or the minimum sample size of PB = P10% is reached. 
 
As the algorithm reduces the size of the subgroup (PB) for treatment B by 10%, the subgroup (PA) for 
treatment A will be increased in size by 10%. The 10% will be made up of patients with the same 
characteristics as those removed from B, defined by the treatment modifier criteria. By weighting the 
E(NMB) by Pj for each treatment a representative total E(NMB) across the total population is 
estimated. 
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The objective function being maximized can therefore be expressed as 
 
provided PA and PB satisfied these conditions; PA ≥ P10%, P − PA ≥ P10% and PB = (1 − PA). Note that 
both proportions, PA and PB change as a function of the moderators of interest. 
 
Three comparators A vs. B vs. C 
At the next level of complexity, three comparators are introduced; A (usual care), treatment B and 
treatment C.  The same constraints of mutual exclusivity and exhaustiveness apply, thus each patient 
in the population P must receive one and only of treatments A, B or C. In this case the process can be 
considered as a network, or series of sequential optimizations. 
 
Firstly, the optimal allocation of patients between treatment B and treatment A is assessed exactly as 
before. We are left with two subgroups of size PA and PB = (P − PA). In the second phase we must 
identify if anyone in the two subgroups PA and PB would yield a better result if they were moved to 
treatment C.  Here we define a new subgroup PC where 
 
 
We now have a series of three optimization problems.  
 
Optimization 1 
The first being identical to our two-treatment scenario but with treatment C included and explicitly 
constrained to a sample set of 0. Thus, the expected NMB is expressed as 
 (1) 
where PA and PB satisfied these conditions; PA ≥ P10%, PB ≥ P10%, PC = 0, and PA + PB + PC = 1. 
 
At this point the optimal subgroup between PA and PB has been determined excluding treatment C.  
This has determined the starting subgroups for the next round of optimization. 
 
 
 
Optimization 2 
Now we will identify if anyone from subgroup PB should be moved to treatment C. In this case 
subgroup PA will be held constant at . The expected NMB is as expressed as equation (1) but PA is 
fixed at  whilst PB and PC satisfied these conditions;   and PC ≥ P10%. 
 
The output of this optimization will determine the final optimal solution for treatment B, designated 
as the subset  where treatment B is preferred over treatment A and C. There will also be those 
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allocated to treatment C where we know treatment C is preferred to A and B, these will be designated 
as .  
 
Optimization 3 
We will now conduct the same process for subgroup , as identified in Optimization 1.  However, 
for treatment B subgroup  will be held constant at  and subgroup  will start at . The 
expected NMB is as expressed as equation (1) but PB is fixed at  whilst PA and PC satisfied these 
conditions;  and . 
 
Table 10.1 Items to be included in the statistical and health economic reports. 
Section and topic Description 
Methods  
Statistical method The statistical methods used for analyses as described in Sections 9.1 to 9.3. 
The statistical models used for analyses as described in Section 9.4 with 
references and a detailed description of changes made on the cited models so 
that they can be used in this project specifically. 
The validation methodology 
Results (for each clinical and health economic outcomes described in Section 4) 
Trials (participants) The trials involved. 
Interventions The interventions involved. 
Outcomes The specific instruments that have been selected for analysis. 
Discussion  
Interpretation Interpretation of the results. 
Generalizability/overall 
evidence 
General interpretation and recommendation to the community based on the 
current evidence. 
 
 
The output of this final optimization will yield subgroups  and . From Optimization 2 we know 
. By construction,  always. 
 
As can be seen, as this process expands beyond three comparators, the number of optimization 
problems will increase as a function of the number of treatment options. However the approach will 
be the same. The order in which the alternative treatments are compared should not influence the 
result of the peeling algorithm.  However, for completeness the algorithm will be run on treatment 
comparisons in different orders to verify the result. 
 
The same process will be followed for the purpose of maximizing total QALYs and for costs, simply 
substituting these measures for NMB. 
 
10. Reporting of the Results 
The statistical and health economics reports will consist of the features shown in Table 10.1. 
The reports will also be supported by figures and tables as appropriate. 
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5.1. The mapping instructions are written in the XML language and the program for it is 
<oXygen/>. 
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SPSS syntax (example): 
GET file="O:\Temporary\Trial01\Example01.sav" . 
SORT CASES by ID . 
DATASET NAME Base1 . 
GET file=" O:\Temporary\Trial01\Example02.sav" . 
SORT CASES by ID . 
DATASET NAME Month3 . 
GET file=" O:\Temporary\Trial01\Example03.sav" . 
SORT CASES by ID . 
DATASET NAME Month12 . 
MATCH FILES 
        / FILE = "Base1" 
        / FILE = "Month3" 
        / FILE = "Month12" 
        / BY ID . 
EXECUTE . 
 
 
SPSS syntax (example): 
See section 6.6 
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Stata syntax (example): 
 
* There are two dates of interview: "var1" and "var2" and they are 
mutually exclusive 
* Combine these two into one variable "interview" 
GENERATE interview = . 
REPLACE interview = var1 
REPLACE interview = var2 if var1 == . 
FORMAT interview %td 
 
 
 
SPSS syntax (example): 
* The original date of assessment was in a string format thus,  
* need to extract the dates, months and years (that is, split  
* the original variable into three variables before merging them 
* into one . 
* Define the variables . 
STRING assess_dd assess_mm assess_yy (A2) . 
* Extract the first two characters and assign it as date . 
COMPUTE assess_dd = CHAR.SUBSTR(string_assess,1,2) . 
* Extract the 3rd and 4th characters and assign them as month . 
COMPUTE assess_mm = CHAR.SUBSTR(string_assess,3,2) . 
* Extract the last two characters and assign them as year . 
COMPUTE assess_yy = CHAR.SUBSTR(string_assess,5,2) . 
EXECUTE . 
STRING assess_dttemp (A8) . 
COMPUTE assess_dttemp = CONCAT(rtrim(assess_dd),"-", 
rtrim(assess_mm),"-", 
rtrim(assess_yy)) . 
EXECUTE . 
COMPUTE assess_date = number(assess_dttemp, date) . 
FORMATS assess_date (date11) . 
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SPSS syntax (example): 
DO REPEAT var = var1 var2 var3 . 
IF (char.index(var,",") GE 1)  var = REPLACE(var,",",";") . 
END REPEAT . 
EXECUTE . 
where var1 var2 and var3 are the short names of the string variables. 
 
Stata syntax (example): 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', ",", ";", .)  
} 
where the notation (`) before CHVAR is the grave accent and not a single quotation ('). 
 
 
 
Stata syntax (example): 
* "new line" (ASCII dec 10) 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(10)'", ";", .)  
} 
* "vertical tab" (ASCII dec 11) 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(11)'", ";", .)  
} 
* "form feed/new page" (ASCII dec 13) 
FOREACH CHVAR OF var1 var2 var3 { 
REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(12)'", ";", .)  
} 
* "carriage return" (ASCII dec 13) 
FOREACH CHVAR OF var1 var2 var3 { 
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REPLACE `CHVAR' = SUBINSTR(`CHVAR', "`=char(13)'", ";", .)  
} 
 
 
SPSS syntax (example): 
SAVE TRANSLATE outfile = 'O:\Processed\LisetPengel\FullDat.csv' 
/ TYPE = CSV 
/ FIELDNAMES  
/ MISSING = RECODE 
/ CELLS = values 
/ RENAME = (Envelope_number=ID) . 
 
Stata syntax (example): 
RENAME PTID ID 
OUTSHEET USING “O:\Processed\BeST\BeST.csv”, COMMA NOLABEL QUOTE 
REPLACE 
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Example 1:  
 
To select only subjects from the Kennedy trial, the values to be entered in “Expression 1”, 
“Relation” and “Expression 2” are: 
 
 EXPRESSION 1 RELATION EXPRESSION 2  
 prms_TrialName = 'Kennedy'  
 
Note that the string value (e.g. Kennedy) is enclosed in single quote. 
 
Example 2: 
To select only subjects over 50 years old, the values to be entered in “Expression 1”, “Relation” 
and “Expression 2” are: 
 
 EXPRESSION 1 RELATION EXPRESSION 2  
 Age > 50  
 
 
• 
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Figure A.1 The screenshot of the ETL program. 
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Figure B.1 Screenshot of steps (a) – (b) to access Repository data with SPSS as given in Section 7.4. This page 
has been left intentionally blank. For a copy of the screenshots, please contact the corresponding author.
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Figure C.1 Screenshots of step (a) – (c) to access Repository data with STATA given in Section 7.5. This page 
has been left intentionally blank. For a copy of the screenshots, please contact the corresponding author.
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